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Wastewater-based epidemiology (WBE) is an innovative tool that, unlike 
traditional epidemiological approaches, is capable of providing real-time profiling 
of community health and lifestyle along with emerging trends and changes in 
pattern usage of drugs in wastewater. By using human urinary excreted indicators, 
so-called “biomarkers”, WBE provides estimates at population level. Therefore, the 
choice and the evaluation of suitable biomarkers of exposure to drugs is of 
fundamental importance for the public health monitoring. Moreover, since many 
drugs are chiral, the investigation on enantiomeric profiling of chiral biomarkers 
provides a new dimension to WBE. To aid enantiomeric profiling in WBE, sensitive 
enantioselective methodologies are required. 
In this thesis, two novel multiresidue analytical methods based on chiral liquid 
chromatography coupled to mass spectrometry were developed and validated. 
The first method investigated the main human biomarkers for the detection of illicit 
drugs of abuse and potentially abused licit drugs. New biomarkers were 
investigated, such as mephedrone, PMA and all MDMA’s metabolites. 
Furthermore, a case study on mephedrone posed the basis for a novel approach 
towards biomarker selection in estimation of human exposure to chiral drugs with 
limited metabolism data. As a result, mephedrone was a suitable biomarker due to 
its stability in wastewater. In addition, some of its metabolites were also proposed 
as potential candidates for mephedrone use. 
The second method explored biomarkers of quinolones’ use, as they represent one 
class of antibiotics with rising concern in antibiotic resistance. The most 
comprehensive panel of quinolones’ biomarkers was considered for the first time 
in WBE studies. 
Both methodologies were applied to wastewaters from eight locations in Europe 
allowing the first pan-European studies on enantiomeric profiling of chiral 
biomarkers. Key findings of this research included: the detection of high 
mephedrone loads only in the UK, thus indicating human consumption; the 
detection of HMMA, a MDMA metabolite, as a suitable indicator of MDMA 
consumption and the determination of different synthetic production routes of 
methamphetamine across Europe. With regards to quinolones’ biomarkers, higher 
ofloxacin loads were found in Southern European cities along with differences in 
 
 ii 
enantiomeric fraction with respect to Northern ones. Moreover, ofloxacin’s 
metabolites showed ofloxacin use and ulifloxacin was found as a result of 
prulifloxacin consumption.  
Therefore, enantiomeric profiling led to an understanding of: (i) new patterns of 
emerging drugs of abuse, (ii) changes in patterns of classical illicit drugs and (iii) 
quinolones with the verification of the origin of drug residue, potency of abused 
drug and its synthetic route and (iv) quinolones’ metabolic profiles.  
Moreover, the simultaneous determination of quinolones’ biomarkers in European 
samples allowed for the verification of spatial and temporal trends of quinolones’ 
use and the occurrence of their resistance genes. This proof-of-concept research will 
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Chapter 1: Introduction 
 
1.1 Wastewater Analysis for Human Health Biomarkers Detection 
Determinants of health-related states are generally investigated through 
epidemiologic methodologies, such as population surveys and surveillance studies, 
which allow for a comprehensive evaluation of community-wide status. However, 
these methods are associated with a significant time lag, so that there is a need for 
real-time profiling assessment of community health and lifestyle, especially in the 
case of outbreaks and hot points. For this reason, a lack of real-time data has been 
the causa movens for a new monitoring program capable of guaranteeing an 
integrated approach to the current monitoring techniques. Such a program consists 
of real-time measurements of human health indicators through wastewater analysis. 
Testing wastewater for obtaining information at community level is a 
pioneering approach. Although still in its initial stages, it is currently used as a 
complementary tool in the determination of illicit drug use trends at community 
level through the analysis of human urinary biomarkers in wastewater. 
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In this context the research project SEWPROF, funded by the European 
Commission, Marie Curie Actions, Seventh Framework Programme, Initial 
Training Network (ITN), aimed at developing inter-disciplinary and cross-sectorial 
research capabilities in the newly-emerging field of wastewater-based 
epidemiology (WBE).  
 
1.2 The SEWPROF project 
SEWPROF project provided an integrated approach towards public health 
monitoring based on innovative WBE techniques. It involved 14 researchers 
working on 12 different countries and it operated on four research streams, which 
contributed to depict the Europe-wide monitoring of societal health and lifestyle 
through WBE. These addressed new developments on: 
1. Robust sampling techniques and assessment of biomarker transformation in 
sewers. Areas of investigation were focused on: passive samplers for wastewater 
biomarkers, adaptation of traditional sampling devices for WBE and new models 
for estimating in-sewer transformation of biomarkers. 
2. Methods for targeted analysis and screening of biomarkers. Research was 
dedicated to provide novel methods for the detection of biomarkers by using 
hyphenated analytical and bioanalytical techniques. In particular, specific health-
related biomarkers in wastewater were targeted for their analysis by 
chromatography coupled with mass spectrometry. These included new 
drugs/psychoactive compounds and their transformation products (TPs), illicit 
drugs, F2-isoprostane, urinary metabolites of pesticides, antibiotic residues, 
phosphodiesterase type 5 inhibitors and their metabolites. By using enantioselective 
analysis, other health-related biomarkers were chiral illicit drugs, chiral potentially 
abused drugs and chiral antibiotics. Cocaine and prostate specific antigen were 
targeted by employing newly developed multichannel biosensors. 
3. Estimation of community wide-health and lifestyle. It provided real-time 
monitoring of the selected biomarkers along with identification of new illicit drug 
trends, estimates of population habits and comparison with social studies. 
4. Europe-wide wastewater epidemiology monitoring. It provided spatial and 
temporal variations of the above-mentioned biomarkers across several European 
locations. 
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Interlinked research was carried out through secondments and visits among the 
institutions involved along with an international training program on main WBE 
topics. 
 
1.3 PhD aims and objectives 
This PhD was part of the second macro-area of research within SEWPROF 
project. It aimed at developing and validating new analytical methodologies capable 
of determining the enantiomeric profiling of chiral biomarkers in wastewater as an 
aid to understand human exposure to chiral xenobiotic substances. It also 
contributed to the fourth area as novel developed methods were applied to the 
Europe-wide environmental monitoring. 
The objectives of this PhD were the following: 
 To develop and validate a robust, multi-residue and sensitive methodology for 
the analysis of chiral biomarkers for illicit drug use at enantiomeric level in 
wastewater. This was because the analysis of human biomarkers could give 
invaluable information regarding the pathways of human exposure due to 
stereoselective metabolism of some chiral illicit drugs. 
 To investigate enantiomeric profiling in estimation of illicit and potentially 
abused drug use via WBE for the (i) verification of their potency, origin and 
route of administration; (ii) monitoring of changing patterns of their use; (iii) 
legal and illicit use distinction and (iv) identification of metabolic pathways of 
drugs of abuse in wastewater. 
 To develop and validate a chiral analytical method for the determination of 
biomarkers for chiral antibiotics’ use. 
 To explore the enantiomeric profiling of chiral antibiotics (i.e. quinolones) in 
wastewater by applying the WBE approach. 
 To perform target and untargeted screening of unknowns, metabolites and 
transformation by-products at enantiomeric level.  
Finally, my PhD contributed to the identification of biomarkers of exposure to 
antibiotics in wastewater and to their analysis along with the biomarkers of 
microbial resistance. 
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1.4 Secondments 
In order to accomplish the above mentioned objectives of this PhD, as 
established by the SEWPROF project, a number of secondments at European 
academic institutions was carried out. These are as follows: 
 Secondment at the Universitat des Saarlandes (USAAR), Dept. of 
“Experimentelle und Klinische pharmakologie und Toxikologie” (Homburg, 
Germany). In order to investigate the enantiomeric profiling of an emerging 
drug of abuse, mephedrone, a number of experiments was performed to support 
the study on biomarkers of mephedrone intake. These were aimed at (i) studying 
differences in enantiomeric fractions of mephedrone and normephedrone in 
biological matrices (i.e. rat urine and pooled human liver microsomes) and (ii) 
looking at the presence of other mephedrone metabolites in incubated 
wastewater through high resolution mass spectrometry (HRMS). 
 Secondment at “Istituto di Ricerche Farmacologiche Mario Negri” (IRCCS) 
(Milan, Italy). A preliminary investigation on biomarkers of exposure to 
antibiotics was performed through a method in HPLC-MS (QqQ). These were 
24 antibiotics belonging to several classes, such as quinolones, 
fluoroquinolones, cephalosporins, macrolides, carbapenems, sulphamidics, 
tetracyclines, broad-spectrum penicillins, urinary-tract infections and 
glycopeptides. 
 Secondment at “Institut Catala’ de Recerca de l’Aigua” (ICRA) (Gerona, 
Spain). In-sewer stability and transformation study on pharmaceuticals and 
illicit drugs in a pressurized sewer under anaerobic conditions was performed. 
This enabled (i) the targeted screening of compounds in wastewater through the 
usage of advanced analytical methodologies, based on UPLC-Q-Trap analysis; 
(ii) the screening of suspected compounds in wastewater through UHPLC-HR-
MS/MS analysis for investigating the presence of nitro transformation products 
of selected compounds and (iii) the study of in-sewer stability of illicit drugs 
present in the samples. 
 
1.5 Thesis Outline 
The first chapter presents an introduction about the needs for real-time 
monitoring of human health biomarkers through wastewater analysis and the 
Chapter 1: Introduction 
 5 
contribution of the SEWPROF project to enhance the knowledge on WBE field 
through the investigation areas. It also reports the aims and objectives of this PhD 
and the topics of the secondments planned in the European institutions. 
The second chapter shows an overview on human health biomarkers and 
methodologies used for testing wastewater from the scientific literature, 
highlighting their benefits and current limitations. WBE approaches in the context 
of multi-scale communities are reported along with a discussion on the contribution 
from enantiomeric analysis.  
The methodologies and results sections are presented and discussed in two 
main parts: 
 Part A. Biomarkers for illicit drugs’ use. 
The third chapter is dedicated to a novel multiresidue method developed for 
the simultaneous detection and the quantification of 56 achiral and chiral 
biomarkers in wastewater. These are illicit drugs and potentially abused drugs. 
Method development phase is reported in details. The methodology was applied to 
a week monitoring campaign in the UK. Results on in-sewer stability and 
transformation study in a pressurized sewer under anaerobic conditions were also 
discussed. 
After finding a new emergent drug from the monitoring campaign at 
consistent levels in the wastewater, chapter four poses the basis for a new approach 
towards biomarker selection in estimation of human exposure to chiral drugs with 
limited metabolism data. Particularly, a case study on mephedrone is discussed 
here. 
Chapter five shows the results from the first enantiomeric profiling of illicit 
drugs in a pan-European study, giving a massive contribute to the Europe-wide 
WBE monitoring. 
 Part B. Biomarkers for antibiotics’ use. 
The sixth chapter explores a new multi-residue stereoisomeric analysis of 
human and veterinary chiral quinolones drugs (including an antifungal drug) in 
wastewater using chiral liquid chromatography coupled with tandem mass 
spectrometry. Method development is largely discussed. 
Chapter seven covers the first study on enantiomeric profiling of quinolones 
and monitoring in European wastewaters along with a first attempt to correlate 
WBE to the occurrence of quinolones resistance gene. 
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Finally, the conclusions of this thesis are reported in chapter eight. In 
particular, a summary of the results, highlights and novel contributions achieved in 
the previous chapters are shown. This thesis concludes with an outlook on future 
research activities and directions based on the outcomes of this PhD. 
Appendixes are provided as supplementary materials to the thesis. For 
clarity reasons, tables and figures are reported under their corresponding chapters 
throughout text. 
  




















Chapter 2: Background and Literature Review 
 
2.1 Monitoring and Evaluation of Human Health State 
Health information is the result of several multi-integrated monitoring 
indicators and their measurement strategies. Its comprehensive assessment for the 
public health decision making is generally provided by the World Health 
Organization (WHO) through analytical and descriptive studies, surveillance and 
statistics on health themes [1]. This institution is the directing and coordinating 
authority for health within the United Nations System [2]. Health data are published 
regularly in annual reports and they are available online. The drawback of this 
assessment is represented by the delay in information flows from the population to 
the policies’ makers, which can affect the progress and performance of strategies. 
Therefore, real time profiling of community-wide health and lifestyle is necessary 
for the investigation of determinants of health-related states. 
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Among many approaches, an innovative one is the wastewater analysis. The 
novelty is represented by the possibility to evaluate population health through the 
study of biomarkers. In this manner, a newly-emerging field of wastewater-based 
epidemiology (WBE) has been developed, with the purpose of estimating 
population habits (e.g. consumption or exposure to xenobiotics). The research 
strategy for obtaining epidemiological information from wastewater was initially 
applied only to a restricted class of compounds such as drugs of abuse, in order to 
determine community-wide illicit drug use trends. This is accomplished via the 
analysis of urinary drug biomarkers in wastewater with the usage of analytical 
methodologies, including hyphenated mass spectrometry (MS) techniques. This 
original approach towards WBE profiling area, once extended to other health 
biomarkers, will be able to take an instantaneous picture of a community by 
describing aspects and behaviours in real-time, through a wider range of techniques 
including bioanalytical tools and real-time sensors. 
 
2.1.1 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) 
The European centre for the monitoring of drugs and drug addiction 
provides a surveillance activity through several networks cooperating together. 
These include reitox focal points, key epidemiological indicators, Early Warning 
System (EWS) network and legal correspondents [3]. In addition, new 
developments, such as supply indicators and European School Survey Project on 
Alcohol and Other Drugs (ESPAD), are also involved in order to draw the complex 
picture of drug use. Typical key epidemiological indicators are listed below: 
 treatment demand, which consists of the number of people that require a 
therapeutic treatment after drug use; 
 general population surveys; 
 problem drug use; 
 drug related deaths, coming from hospitals’ reports; 
 infectious diseases. 
Along with these more traditional tools, new complementary monitoring 
approaches are expanding their reliability in giving information on drugs use: trend 
spotter methods, internet surveys and wastewater monitoring. Especially the latter 
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tool has seen a growing interest in the scientific public. In occasion of the 
conference “Testing the waters”, held in Lisbon in May 2013, the state-of-the-art 
of this emerging field was presented through a multidisciplinary and international 
approach. In the report “EMCDDA insights-Assessing illicit drugs in wastewater” 
[4], an overview on community drug use information achievable through 
wastewater analysis was presented. The most recent developments of wastewater 
analysis were shown at the 2nd international conference “Testing the Waters 2015” 
last October and published in “Assessing illicit drugs in wastewater: advances in 
wastewater-based drug epidemiology” by EMCDDA last March as a demonstration 
of how WBE field is rapidly growing. 
 
2.2 Human Health Biomarkers: Definition 
Biomarkers in health field are defined “(…) as indicators of normal 
biological processes, pathogenic processes or pharmacological responses to a 
therapeutic intervention” (Biomarkers Definition Working Group, (2001) [5]). 
There are two major types of biomarkers: biomarkers of exposure, which are used 
in risk prediction, and biomarkers of disease, which are used in screening, diagnosis 
and monitoring of disease progression [6]. The application of the biomarkers 
concept is mainly associated to the clinical field. However, as humans are subjected 
to a range of chemical exposures from the environment, it is possible to define 
biomarkers of exposure as indicators of daily life exposure to chemicals in air, 
water, soil, food and lifestyle factors [7]. Exposure to chemicals can be either 
voluntary such as food, pharmaceuticals and illicit drugs, or involuntary such as 
personal care products absorbed through the body, pollutants and contaminants 
present in the air and in the food, inhaled or ingested. Biomarkers of exposure can 
also be useful indicators about lifestyle and human habits. For instance, they can be 
indicators of intake of alcohol, consumption of food, but also chemicals such as 
prescribed pharmaceuticals [8, 9]. In particular, the rationale behind the assessment 
of biomarkers of exposure is that chemicals once in the body undergo absorption, 
distribution, metabolism and excretion, as in the case of pharmaceuticals, before 
they are found in the sewage system.  
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2.3 Wastewater Analysis 
As stated by the EMCDDA’s report [4], a “wastewater system contains 
information about the society that serves and reflects the behaviours of that 
population”. As highlighted by Bohannon (2007) [10], a wastewater treatment plant 
(WWTP) has many advantages. In fact, it can be intended as an “accessible, 
economical source of real-time and pooled epidemiologic information” [10]. 
Moreover, the research on drugs in wastewater analysis can be intended as the 
means to provide so-called “drug consumption index”, that is more appropriate for 
drug surveillance purposes [4]. Indeed, it can provide a “screening tool for 
communities” served by the WWTP monitored. 
Daughton in his work [11] showed that if an excretion product remains constant in 
wastewater and during the transport to the WWTP, the quantity excreted by a 
community is roughly correspondent to that found in the wastewater system. In this 
way, the criteria for the assessment of a biomarker were posed. Examples of 
suggested and existing biomarkers in wastewater are reported in Table 2-1. 
The step from the wastewater analysis to a more comprehensive and systematic 
approach able to assess the collective exposure of the population of a community 
to any sort of chemicals was called wastewater-based epidemiology. 
 
Table 2-1 Potential and existing wastewater biomarkers of human health (modified from Thomas 
and Reid (2011) [12]). 
Health parameter Biomarkers 
Lifestyle Alcohol consumption Ethyl sulphate 
Tobacco consumption Cotinine, tobacco specific nitrosamines, menthol 
Drug consumption Drugs and their urinary metabolites (i.e. cocaine, 
benzoylecgonine, ecgonine methyl ester, 
tetrahydrocannabinol (THC), 11-nor-9-carboxy-
THC, synthetic cannabinoids, amphetamine, 
methamphetamine, cathine, cathinone, MDMA, 
6-monoacetylmorphine (6-MAM), together with 
the new and emerging synthetic drug classes, etc.) 
Anabolic steroid abuse Synthetic steroids and their metabolites 
Diet  Urinary sugars 
Synthetic sweeteners 
Phytoestrogens 
Fruit and vegetable intake Flavonoids 
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Soya Iso-flavonoids 
Caffeine consumption Caffeine 
Meat consumption Creatinine, taurine, 1-methylhistidine, 3-
methylhistidine 
Health Illness and disease Specific pharmaceuticals and their metabolites 
Oxidative stress F2-isoprostanes, 8-hydroxydeoxyguanosine 
Pregnancy Human chorionic gonadotropin 
Allergy Antihistamines 
Cancer Hepatoma, testicular, 
colon, breast, pancreatic 










Environment PAH exposure Phenanthrol and other PAH metabolites 
Aflatoxin exposure Aflatoxin N(7)-guanine 
 
2.3.1 Critical Steps in Wastewater Analysis: Sample Preparation 
Wastewater is a very complex and dynamic environmental matrix. It 
contains lots of contaminants able to compete and interfere with the investigated 
target compounds. So, “cleaning” the wastewater sample with an adequate sample 
preparation is crucial. The following aspects need to be considered: 
 Pre-treatment of the collected sample and/or adoption of precautions in 
order to not degrade the analytes of interests. 
 Choice of sample volume, which often is a compromise between large 
volumes (able to permit good recoveries and low limits of detection and 
quantification) and small volumes (representing a good starting point for the pre-
concentration step, but more negatively influenced by the matrix effect).  
 Removal of solid part of the wastewater sample by one or more filtration 
steps. 
 Pre-concentration of the analytes through mainly solid phase extraction 
(SPE) in order to get concentration range of microgram/liter (μg/L) or 
nanogram/liter (ng/L). 
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A good compromise in the number of the steps in the sample preparation is also 
required. Indeed, many steps may cause either the partial loss of the analyte with a 
consequent decrease in recovery or the complete absence. 
One of the first papers, which highlighted the discrepancies in misreporting data of 
wastewater analysis, was written by Baker et al. (2011) [13]. They drew attention 
to critical steps during the analytical methodologies used in sample collection, 
storage and preparation for the analysis of pharmaceuticals and illicit drugs. As 
mentioned, they pointed out the importance of: (i) the effect of evaporation 
temperature and solvent with regards to the SPE extracts; (ii) the effect of silanising 
glassware; (iii) the recovery of analytes during vacuum filtration through glass fibre 
filters and the pre LC–MS filter membranes and (iv) stability data of analytes. Van 
Nuijs et al. (2012) [14] emphasised that in most cases degradation of the analytes 
occurred after few hours the collection. One of the most updated review on stability 
of abused drug biomarkers was recently published by McCall et al. (2015) [15]. 
 
2.3.2 Critical Steps in Wastewater Epidemiology: Uncertainties 
Understanding the main uncertainties related to WBE approach is crucial in 
the wastewater analysis. The lack of biodegradation data on biomarkers is still an 
area of further investigation. Stability is linked to the fate of a drug from the 
excretion step to the wastewater flow, but other parameters are involved in a fate of 
a drug. Degradation, partitioning and sorption of drug target residues (DTRs) are 
also important variables to consider [16], [17]. 
Among these sources of uncertainty, special attention was drawn to the estimation 
of the population size served by a WWTP as an essential component for comparing 
results from different sites. Ort et al. (2010) [18] showed how to maximise the 
sampling procedure in order to avoid evaluation errors associated to the catchment 
size, sewer type, sampling setup, substance of interest and accuracy of analytical 
method. The authors emphasised that sampling, chemical analysis, flow 
measurement, excretion fraction and estimated number of people that contributed 
to the wastewater are components of uncertainty. Lai et al. (2011) [19] illustrated 
that differences or changes in drug loads lower than 20-30% of uncertainty were 
not significant. This enabled to define when real changes in mass loads occurred. 
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2.4 Wastewater-based Epidemiology 
WBE is a new methodology for estimating the mass load of human 
biomarkers (detected in wastewater) in a population [20]. Its concept, originally 
developed by Zuccato et al. (2005) [21], consists of determining the levels of illicit 
drugs and their metabolites in wastewater and back-calculating the mass loads of 
the parent drugs associated with the population under investigation. Once the drug 
metabolisms and the excretion patterns are known, these loads can then be used to 
evaluate the consumption of drugs in g day-1 or doses day-1. A schematic overview 















Figure 2-1 Overview of the WBE approach (modified from Van Nuijs et al.[22]) (N: nitrogen, P: 
phosphorus, BOD: Biochemical Oxygen Demand, COD: Chemical Oxygen Demand). 
 
As highlighted by Zuccato et al. (2008) [16], the first step of a WBE approach is 
the selection of a major and exclusive excretion product, named drug target residue 
(DTR), that ideally needs to satisfy the criteria of stability in wastewater. The DTRs 
are urinary metabolites or unchanged parent compounds (see Table 2-2). For some 
compounds, the metabolites are more reliable DTRs, as in the case of 
benzoylecgonine, the major cocaine metabolite, whilst for others the parent 
compound works better, as in the case of methamphetamine. During the 
metabolism, many compounds are excreted as glucuronides, but these conjugates 
are very unstable in wastewater [23] as they are deconjugated by faecal bacteria 
Multiplying with the flow rate of the wastewater stream (L/day) 
Multiplying with correction factor that takes possible degradation during 
transport of wastewater to WWTP into account 
Measured concentration of 
compounds 
Mass-loads of compounds (mg/day) 
Corrected concentration of 
compounds 
Amount of use illicit drug (mg/day) 
Amount of use illicit drug (mg/day 
per 1000 inhabitants) 
Multiplying with correction factor that takes excretion pattern of illicit 
drugs into account 
Dividing with amount of inhabitants that is present in the catchment area 
of the WWTP calculated based on concentrations N, P, BOD and COD in 
the sample. 
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enzymes to the free compound [24]. For this reason, glucuronides are not suitable 
DTRs.  
 
Table 2-2 Examples of DTRs selected for a study in WBE (modified from Zuccato et al. [16]). 
Drug DTR Relation of DTR 
to parent drug 
Percentage 










Major metabolite 45 1.05 2.33 
Cocaine Parent drug 
(minor excretion 
product) 
   
Heroin Morphine Major but 
nonexclusive 
metabolite 
42 1.29 3.07 
 6-MAM Minor but 
nonexclusive 
metabolite 
   
Ampheta
mine 
Amphetamine Parent drug and 
major excretion 
product 





Parent drug and 
major excretion 
product 
43 1.0 2.3 
MDMA MDMA Parent drug and 
major excretion 
product 
65 1.0 1.5 




0.6 0.91 152 
a Average for the most frequent route of intake. 
As reported in Baker et al. (2012) [25], the daily load is determined by the 
following factors: 
 DTR’s concentration (Conc) present in wastewater, expressed in ng L-1. 
  The stability change, intended as a percentage of the change of each 
compound in raw wastewater at a certain temperature and after an estimated time 
(Stab). In Baker and Kasprzyk-Hordern, (2011) [26], this value was positive in the 
case of an increase in DTRs’ concentration or negative in the case of a decrease. 
 DTR’s sorption to suspended particulate matter (SPM) (Sorp), expressed as 
a concentration in ng L-1. As highlighted in Baker et al. (2012) [25], this parameter 
was considered in order not to underestimate the concentration. In literature, data 
on the sorption are still missing for many compounds. 
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 The flow of an influent wastewater system, calculated as a volume of 
wastewater during 24 hours in L day-1 (Flow). 
The daily load, expressed in Eq. (1) as g day-1, is a suitable starting point for the 




































dayg  (1) 
The step from daily load to daily consumption requires other parameters. 
Indeed, in order to determine the daily consumption, the information on the 
population of a wastewater catchment area is needed. Moreover, other parameters 
linked to DTR are involved along with the load data. These are: 
 the percentage of dose excreted as DTR after relevant forms of 
administration (Excretion); 
 the molar ratio between the parent drug and its DTR (MWRatio); 
 the DTR present as contribution from other sources (OS), different from that 
one of the parent compound (expressed in mg day-1 1000 people -1). 































11  (2) 
Through the described approach, it is possible to achieve an evidence-based and 
real-time estimation of drug collective consumption. 
 
2.4.1 Human Indicators 
Human urine indicators play a very important role in drug estimation, 
because they could be potentially used as index mass loads [26]. The population of 
a certain area may vary not only during a year due to immigration flows, but also it 
may fluctuate during the day for work reasons. Also weather conditions, e.g. heavy 
rains or dryness, play a relevant role in determining the volume of wastewater. 
Therefore, all these variables could affect the estimation of the population size and, 
consequently, the back-calculation of drugs use. Along with classical human 
indicators of the wastewater analysis, such as BOD, COD, phosphorus, ammonia 
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[27], other substances were considered. Coprostanol was targeted by Daughton 
[28]. Lai et al. (2011) [19] found acesulfame suitable for estimating population, 
even though the lack of national consumption data was determinant for its 
exclusion. Creatinine was the elected human indicator by Chiaia et al.[29], whilst 
cotinine and 1,7-dimethylxanthine were retained suitable by Baker [26]. Caffeine 
was often considered together with nicotine. The latter compound was also widely 
used as a biomarker for environmental tobacco smoke (ETS) in order to identify 
people at risk and verify the progress of tobacco control strategies resulting in less 
ETS. Recently, a multiple substances panel approach able to give a proper 
assessment of the population was preferred. This was because this approach was (i) 
more robust compared to the singular-substance-based, (ii) statistically framework 
orientated and (iii) more advantageous for larger wastewater catchments. 
Chen et al. (2014) [30] suggested that drug consumption per capita could be 
calculated without an estimation of the population by using a population biomarker 
(PB). The five criteria established for a good PB were defined as follows: 
1. quantification level in wastewater at µg L-1 range; 
2. low affinity for SPM or to filter paper; 
3. stability in wastewater matrix; 
4. constant excretion; 
5. exclusive human excretion in order to have a better correlation with census 
population data. 






















capitapernconsumptioDrug  (3) 
Spatial and temporal differences on occurrence of drug consumption can be 
studied at every community levels. Indeed, its evaluation can be achieved at local, 
national and international level. 
 
2.4.2 Local level 
At local level, many studies were independently performed in several 
countries. As an example, from a study in 2008 in Milan (Italy) [16], it was possible 
to see variations in DTRs from the most investigated illicit drugs through 
wastewater analysis in a two-week time (Figure 2-2). From the obtained profile, it 
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was observed that THC-COOH (metabolite of THC, which is one of the major 
components of cannabis) remained stable as morphine during all the week, ecstasy 
showed a slight increase and cocaine experienced substantial increase during the 
weekend.  
 
Figure 2-2 Drug residue loads for the city of Milan (Italy) in 2008 (from Zuccato et al. 2008 [16], 
reproduced with permission from Environmental Health Perspectives). 
Bones et al. (2007) showed an opposite pattern for cocaine and its metabolite 
(higher for cocaine than for benzoylecgonine) in Dublin (Ireland) [31]. This was 
the only discordant pattern with respect to the results found in other studies as stated 
by Van Nuijs et al. (2011) [32]. 
Weekly variations were studied in Zagreb (Croatia) by Terzic et al. (2010) [33], 
showing an increased heroin drug profile with respect to those observed in western 
European countries and an overall DTRs’ increase during weekend days. Similar 
studies were performed in Paris (France) by Karolak et al. (2010) [34] and in three 
Canadian cities by Metcalfe et al. (2010) [35]. 
A case study by Postigo et al. (2011) illustrated fluctuations in drugs consumption 
in a range time of a week and in few months monitoring in a prison (Figure 2-3) 
[36]. The drug consumption in this particular condition was lower than the 
estimated intake in a nearby city. Methadone, alprazolam and ephedrine were the 
most consumed drugs. A decrease of usage of methadone and alprazolam was noted 
on Sunday, presumably due to the absence of the prisoners for the weekend permits 
and an increase of ephedrine in correspondence of more cases of asthma and 
bronchitis. 
























Figure 2-3 Estimates for cocaine, cannabis, methadone, alprazolam and ephedrine consumption: a) 
use throughout the week and b) use during the studied period, both expressed in doses/day/1000 
inhabitants (reproduced with permission from Fig. 1 in Postigo et al. (2011) [36], Elsevier). 
In order to show patterns of drug usage not only in a week time but also in a day 
time, a study was successfully performed in Oslo (Norway) by Reid et al. [37]. The 
day scale investigation showed how pharmaceuticals and illicit drugs patterns 




Benzoylecgonine Cocaine Methamphetamine 
Figure 2-4 Proportion (mean, n = 26) of the daily mass-load of cocaine (excreted unchanged), 
benzoylecgonine, methamphetamine, cetirizine and metoprolol acid that are excreted at different 
times of the day. Data derived from 6-hourly measurements of sewage in a treatment plant (after the 
primary settling tank) in Oslo throughout the period of 4–30 September 2009. Times are therefore 
off-set by 7 h to account for the average residence time of sewage in the pipe-network (reproduced 
with permission from Fig. 4 in Reid et al. (2011) [37], Elsevier). 
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In particular, it was pointed out that a diurnal trend was present for cetirizine, but 
not for metoprolol acid due to its pharmacokinetics, different doses and the possible 
nocturia once ingested. The stable tendency of methamphetamine was explained 
because of complex combination factors between the half-life excretion and the 
different dosing times. Interesting considerations arose from the cocaine. It was 
mostly consumed during the evening hours as the unchanged excreted cocaine 
showed very high percentages in the proportion of the mass load, whilst its 
metabolite, which has a long excretion half-life, was constant during the day and 
the night. Through the comparison of the cocaine patterns in weekdays and 
weekend days it was possible to observe that its consumption in the weekend was 
later in the evening with respect to weekdays. In fact, the profile of the excreted 
unchanged cocaine culminated between 10 pm and 4 am in weekdays and, later, 
between 4 am and 10 am during the weekend (Figure 2-5). 
 
 
Weekday cocaine Weekend Cocaine 
Figure 2-5 Proportion of the daily mass-load of cocaine (excreted unchanged) with comparison 
between weekday (Monday–Friday) and weekend (Saturday and Sunday) periods. Data derived 
from 6-hourly measurements of sewage in a treatment plant (after the primary settling tank) in Oslo 
throughout the period of 4–30 September 2009. Times are therefore off-set by 7 h to account for the 
average residence time of sewage in the pipe-network (reproduced with permission from Fig. 5 in 
Reid et al. (2011) [37], Elsevier). 
 
Year timescale temporal variations enabled critical considerations on illicit drugs’ 
use trends. Zuccato et al. (2011) [38] showed these differences through wastewater 
analysis. The study proved a significant drop in cocaine and heroin consumption in 
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confirmed by the weekly load profile. The cannabis pattern, instead, seemed to be 
slightly decreased from the beginning of 2005 until March 2009, but an increase 
was observed in September 2009 at level similar to that one seen in 2005. The 
methamphetamine pattern revealed a constant rise from 2005 to 2009. Several 
hypotheses were postulated in order to explain the observed drop in cocaine and 
heroin trends. Along with the decrease of number of consumers and the increase of 
cheaper illicit drugs and interest for NPSs, the economic crisis surely played an 
important role in the cocaine and heroin trends. Wastewater analysis data were also 
confirmed by local and general epidemiological surveys, even though these 
documents were published only few years later in 2011. This case by Zuccato is the 
evidence that WBE can reveal the estimation of illicit drug trends faster than 
traditional methods. 
 
2.4.3 National level 
 At national level, one of the first inter-cities studies was performed by 
Zuccato et al. (2005) [21], in which samples were collected from four medium-
sized Italian cities. In that study, loads measured for cocaine’s DTR were similar in 
Cuneo, Latina and Varese (average 33±3 g day-1), with exception for the largest city 
from Sardinia island, Cagliari (130 g day-1). Although the assessment of cocaine 
load did not include Southern Italian cities, this inter-cities comparison was a first 
attempt in WBE field. With the inclusion of the city of Milan in a later study [16], 
spatial variations were studied about cocaine use in Italy: this illicit drug seemed to 
be used more in the big city with respect to the medium-sized cities as stated by 
Van Nuijs et al. (2011) [39]. The confirmation of this finding arrived from a further 
study conducted in the “Aqua Drugs project”, in which five large-sized, four 
medium-sized, four medium-small-sized and four small-sized Italian cities were 
compared at the same time. Moreover, in this study a more critical evaluation of 
cocaine consumption through the North, the Centre and the South of Italy was 
performed. It showed that the highest cocaine use was in the central part of the 
country, whilst comparable lower trends were observed in the North and in the 
South. 
Van Nuijs et al. [40] collected data from a one-year campaign in Belgium. 
Variations in the number of inhabitants were taken into account for the estimation 
of drug consumption [22]. As before, it was confirmed that cocaine was more 
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consumed in large cities, such as Antwerp, Brussels and Charleroi, than in medium-
sized cities. Seasonality of cocaine consumption was also investigated in Belgium 
[41]. Van Nuijs did not note any statistically significant variations of cocaine usage 
along the seasons. This result was in contrast with findings obtained by Huerta-
Fontela et al. (2008) in surface water from North-East of Spain cities [42]. Van 
Nuijs contested the results obtained from the Spanish study due to a lack of statistics 
and for the chosen matrix. Temporal trends were studied by Postigo et al. (2010) 
[43] in many cities in Ebro river basin area in a year time. Spatial variations were 
investigated also in urban and rural areas in Oregon (USA) by Banta-Green (2009) 
[44]. Urban areas showed higher benzoylecgonine loads than rural ones, whilst for 
methamphetamine the pattern was quite widespread in all the municipalities. 
Spatial and temporal variations were also studied in urban, semi-rural and vacation 
areas in Australia by Lai et al. (2013) [45]. A further example of spatial differences 
at national level was carried out in France by Nefau et al. (2013) [46], where 
geographical significant differences were found due to inhomogeneous drug pattern 
in the country.  
WBE was also applied to investigate illicit drug trends in megacities. Khan et al. 
(2014) [47] studied this approach for the first time in four Chinese megacities 
(Beijing, Guangzhou, Shenzhen, and Shanghai), populated by 11.4 million of 
inhabitants for two-month period (September-October) in 2012. Considered the 
restricted surveillance data in this area of the world, this study showed consistency 
with the United Nations Office on Drugs and Crime (UNODC) report data. In fact, 
higher consumptions in cocaine, ecstasy, methamphetamine and ketamine were 
observed in the southern megacities of Guangzhou and Shenzhen with respect to 
those detected in the northern Beijing and Shanghai. The following patterns were 
reported: methamphetamine was ubiquitous; ketamine was mostly used in the South 
of China; NPSs’ levels were low, presumably indicating a scarce interest for these 
substances, except for benzylpiperazine, meta-chlorophenylpiperazine (mCPP) and 
trifluoro-methylphenylpiperazine (TFMPP) probably used as substitutes of 
MDMA. Cocaine and MDMA were found in lower amount compared to Europe. In 
contrast with Thibault (2012) [48], who stated that the elective drug of abuse for 
“marginalized rural Chinese or migrant workers living on the outskirts of urban 
areas” was heroin, in this study heroin metabolite’s loads in megacities was not 
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statistically relevant [47]. Due to the lack of seasonal prevalence data, WBE 
approach should be more investigated in these areas in future studies. 
 
2.4.4 International level 
At European level, one of the first approaches in using WBE was realised 
by Castiglioni et al. in 2006, in which data obtained from two WWTPs in two 
European countries, Italy and Switzerland, were compared [23]. 
Later, Zuccato et al. (2008) enhanced this process by including data from three big 
cities, Milan (Italy), Lugano (Switzerland) and London (UK) [16]. From Zuccato’s 
work, it was possible to confirm that the trend in illicit drugs use was THC >> 
cocaine > heroin with the exception of Milan, where cocaine use was higher than 
cannabis. The most evident discrepancy observed among these cities was ascribed 
to amphetamine loads which were statistically significant only for London. 
Regarding to ecstasy, slightly higher consumption was detected in Lugano than in 
Milan and London. The measurements performed by wastewater analysis were in 
accordance with UNODC report 2006 at national scale [49]. 
In 2011, Van Nuijs reviewed the most important studies overall Europe performed 
by several research groups [32], emphasising how the need of a procedural 
standardisation should be pursued in order to use WBE for routine drug monitoring. 
The intent of more coordinated studies through an European-wide network (Sewage 
analysis CORE group- SCORE) became tangible with the creation of a “common 
protocol of action”. It also placed the basis for the success of the 19 cities study and 
reinforced a subsequent wider program including 27 cities. In detail, a common 
methodology with a standardisation of procedures of wastewater, named “the best 
practise protocol”, was given by Castiglioni et al. (2014) in order to get more 
homogeneous data for the comparison among countries (Table 2-3) [50].  
 The European study by Thomas et al. 2012 [51], involving nineteen cities 
across the continent, highlighted regional differences in drug usage (Figure 2-6). In 
order to get valid quality assurance data for the analytical methodologies used, an 
inter-laboratories test was performed, for the first time, before the one-week 
campaign. If quality control results failed the attended concentrations for a drug, 
the results obtained for that substance within the monitoring were not included for 
that laboratory.  
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Table 2-3 Summary of the consensus best practice protocol for the sampling, analysis and reporting 
of data elaborated by the SCORE group (modified from Castiglioni et al. 2014 [50]). 
Parameter Agreed procedure Further comment 
Sampling and sampling handling 
Sampling information A questionnaire for each sewer 
network should be completed 
The questionnaire elaborated 
by Ort is available in 
Castiglioni et al. (2013) 
Sampling point 1st routine influent sampling 
location at works 
To be noted in sampling 
questionnaire 
Sample type 24 h composite  
Defined day Start/finish between 8 and 10 
am 
 
Sampling container PET or glass(silanised) Record 
Storage treatment during 
sampling 
<4 ºC Record time and temperature 
in storage 
Storage after sampling Choose based on the available 
options in the following 
preferential order: 
1.On SPE cartridge within 12 h 
with internal standard added. 
2.Freeze preferentially after 
addition of internal standard. 
3.Freeze 
Record period before 
extraction. 
Time in freezer if frozen. 
Filtration Internal standard added before 
filtration. 
Filter type GFC (0.45 µm) 
Record any deviation. 
Additional parameters to be 
recorded in sampling 
questionnaire 
BOD, COD, N, P, flow data, 
type of sewage influent, 
temperature, pH 
Report methods also if 
possible 




All participants are welcome 
to include other compounds 




Internal quality control Use of labelled internal 
standards for each analyte 
Report any deviation 
External quality control Analysis of methanol 
standards and influent samples 
prepared by one laboratory and 
sent to each participant 
Interlaboratory studies 
Data reporting Common procedure to 
calculate limits of detection 
and quantification 
Samples results as a means of 
three individual analyses 
Reporting template is 
provided 
 
Questionnaires were filled providing information about wastewater catchment area 
and details on sample preparation. The sampling campaign took place 
simultaneously for all the laboratories with a sampling time between 8 am and 10 
am. One week in March was chosen, with the exception of only those cities hosting 
particular events or festivals in that week. Composite 24-hours samples were 
collected, stored as according to protocol’s specifications and analysed with internal 
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validated analytical methods. A key step before the analysis was the use of internal 
standard in order to reduce and compensate the errors linked to the matrix effect 
and to the analytical technique. The procedural standardisation of the study 
guaranteed a harmonization of the collected data and enabled comparison of daily 
drug loads, showing interesting trends for cocaine, amphetamine, 
methamphetamine, ecstasy and cannabis across Europe. 
 
Figure 2-6 Average estimates of cocaine consumption (back-calculated from benzoylecgonine BE 
loads) and population-normalized loads of amphetamine (AMP), methamphetamine (METH) in 19 
selected European cities and cannabis (THC-COOH, all in mg/1000 inhabitants/day) in 13 of them 
between the 9th and 15th March 2011 (mean ± SD from all sampling days, n = 7) (reproduced with 
permission from Fig. 2 in Thomas et al. (2012) [51], Elsevier). 
 
Unlike widespread cannabis trends observed in all Europe with no substantial 
differences, geographical variances were noticed. Western and central European 
areas revealed more cocaine consumption than eastern and northern ones. Ecstasy 
was more prevalent in the UK and in Dutch areas, especially due to the presence of 
illicit production sites. Northern Europe showed more consume of 
methamphetamine. For countries with more cities included in the study, such as 
Sweden and Finland, cocaine loads were higher in more urbanised cities than in less 
urbanised ones. Temporal dissimilarities were noticed in cocaine and MDMA 
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especially due to its change in weekend loads. Indeed, this was more evident in 




Figure 2-7 Day-to-day variation of cocaine consumption (based on the loads of the main metabolite 
benzoylecgonine) in 19 cities and ecstasy (MDMA) in 15 cities. Medians are significantly different 
on the weekend compared to weekdays (reproduced with permission from Fig. 3 in Thomas et al. 
(2012) [51], Elsevier). 
 
Despite of general agreement of the results with national prevalence data, an 
increased number of cities involved was highly recommended for further 
monitoring campaigns.  
 In fact, from 14.12 million of people and 19 cities involved in the first 
monitoring campaign in 2011, 11.50 million and 23 cities were in 2012, up to 24.74 
million and 42 cities in 2013. Results were displayed as in the example shown in 
Figure 2-8 [52]. According to that study, in the case of cocaine, WBE data were not 
in fully agreement with the national reports (i.e. constant trend instead of a 
decrease). By including data from Germany, it was possible to better describe the 
cocaine use across Europe. Indeed, cocaine was more highly consumed in western 
Europe than in eastern part. The methamphetamine usage was more an eastern-
northern phenomenon. Cannabis remained used very widespread, with the 
exception of Amsterdam due to a non-resident population consumption. 
Inability in estimating large doses used by few people or vice versa and differences 
linked to the drug purity still remain limitations of wastewater analysis. Several 
suggestions were provided to support data interpretation in future monitoring 
campaigns: 
 demographic data should be taken into account as cities have different 
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drug consumption if high and low prevalence areas are used. Indeed, it would be 
preferable to assess for each country a panel of cities with differences in 
demographics that allows for comparison at international level; 
 monitoring strategies should be improved in terms of logistics, quality 
assurance and representativeness for the whole year. 
An improved systematic WBE approach, including integrated small, medium and 
large-sized cities profile and more monitoring weeks during the year (i.e. seasonal 
drug monitoring) would result in a better contribute for reliable data on the 
assessment of drug consumption. This achievement was realised, for the first time, 
at continental level. 
 
Figure 2-8 Population-normalized benzoylecgonine (BE) loads of a single 1-week period per year 
(extracted from Ort et al. (2014) [52]). 
 
A similar approach is still missing in other areas of the world, where knowledge in 
this field is fragmentary. A detailed geographical and spatial situation is still 
unknown for the poorest area of the world. An estimation of illicit drugs trends in 
some areas of the world was provided only by Khan et al. (2014) [47]. Briefly, 
cocaine, MDMA and amphetamine consumption was higher in America, Canada, 
Australia and Europe than in the mainland China, even if a recent decrease was 
observed in Australia for MDMA [53]. Methamphetamine use was more prevalent 
in America than in Asia and lower in Europe, with the exception of some countries, 
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such as Finland, Norway and Czech Replublic. Ketamine consumption was lower 
in Europe (not including the UK), and in America compared to Asia. Cannabis also 
showed the same trend of cocaine. 
 
2.5 Enantiomeric analysis 
2.5.1 Chirality 
As human pharmacokinetics shows stereoselectivity in the case of many 
chiral xenobiotics, chirality is a relevant topic to investigate. 
According to the IUPAC Recommendations 1997, chirality is defined as “the 
geometric property of a rigid object (or spatial arrangement of points or atoms) of 
being non-superimposable on its mirror image”. Enantiomers are identical in most 
of their chemical-physical properties, except for the ability in rotating the plane-
polarized light. This feature reflects also a different way of interaction between the 
molecule and the biological receptor due to a particular spatial conformation of the 
ligands. In nature, the selector often is a biological molecule with a specific 
conformation able to give not only weak interactions, such as hydrogen bonds and 
dipole interactions, but also steric effects, which can create inclusion or protrusion 
pockets suitable for the molecule fitting. As a consequence, potency and activity of 
enantiomers are highly influenced. In fact, among non-steroidal anti-inflammatory 
drugs (NSAIDs) S-ibuprofen is one hundred times more potent than R-enantiomer, 
whilst among beta-blockers S-enantiomers are highly active in humans [54]. 
In the past, drugs were usually administered as racemate due to the high costs of 
enantioselective syntheses for pharmaceutical companies. Only recently, an 
inversion of the trend has been observed as clinical trials costs are doubled in the 
case of a racemate compared to those for a single enantiomer. 
Different behaviours of enantiomers need to be evaluated during the 
development process of a drug. 
Differences related to the distribution of a drug in tissues may occur. An example 
is given by venlafaxine, which is a drug administered in racemic form. In rats a 
different distribution of R- and S- enantiomer in the serum and in the brain was 
observed [55]. 
Metabolism studies are extremely important. Historically, the under-investigation 
of in vivo metabolism of thalidomide was known for its dramatic consequences in 
foetus [54]. This drug has the tranquilising properties in its R-enantiomer and a 
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dangerous teratogenic activity in S-enantiomer [54]. If administered to women in 
gestation, thalidomide interconverts in the body to the hazardous S-enantiomer. 
Not all the chiral drugs undergo an in vivo interconversion, but many other 
phenomena may also occur [54]:  
 differences in metabolic rate can facilitate the production of a compound 
with a determined stereochemistry with respect to its enantiomer; 
 differences in the metabolic pathway can favour a particular enantiomer; 
 changes in the number of chiral centres, such as introduction of another 
chiral centre (i.e. the product of the R-warfarin, called warfarin alcohol, has two 
chiral centres with respect to the original drug) or removal of the chiral centre (i.e. 
achiral sulfone originated from chiral omeprazole) or conservation of the chiral 
centre (i.e. the hydroxylated metabolites of warfarin, produced by both 
enantiomers, maintain the same chiral centre of warfarin); 
 enzymatic chiral inversion; 
 different stereoselectivity among species (i.e. the clearance of propranolol 
is higher for the S-enantiomer in dogs than in humans). 
Metabolites, coming from a chiral compound, may have only one 
pharmacologically active enantiomer or both active enantiomers with the same 
potency or different activities [54]. 
 
2.5.2 Environmental analysis: chiral chromatography coupled with tandem 
mass spectrometry using protein-based chiral stationary phases  
Chiral liquid chromatography (LC) environmental analysis mainly uses 
macromolecular selectors as stationary phases [56]. The interest on these protein-
based chiral stationary phases (CSPs) arose because chiral distinction capability of 
enzymes and plasma proteins was known as natural chiral pool of selectors [57]. 
Those based on albumins (e.g. human and bovine serum albumins, HSA and BSA), 
glycoproteins [e.g. α1-acid glycoprotein (AGP) and crude ovomucoid (OVM)], 
enzymes, such as cellobiohydrolase I (CBH) belong to this group [57]. Enantiomer 
separation capabilities cover preferably acidic compounds in the case of HSA 
column, basic ones in the case of CBH and a wide range for AGP.  
Since many illicit drugs are basic, the most used for environmental chiral analysis 
of drugs of abuse are CBH and AGP columns. 
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2.5.2.1 CBH and AGP columns 
CBH has a cellobiohydrolase immobilized on spherical 5 μm silica particles 
as chiral selector. Its isoelectric point (pI), defined as the pH at which a substance 
is electrically neutral, is 3.9. According to Henriksson et al. [58], three main active 
chiral-recognition areas are defined in the column: a catalytically active core, a 
connecting area and a cellobiohydrolase domain with 36 aminoacids forming two 
disulphide-bridged loops. The catalytically active core contains the dominating 
chiral binding site, whilst the cellulose one has the other enantioselective site [59]. 
Developed by Hermansson [60], AGP consists of a single peptide chain with 
181 aminoacids and five heteropolysaccaride units, containing 14 residues of sialic 
acid. Due to the presence of this acidic component, AGP has 2.7 as pI [61]. Sugar 
moieties are also present [60]. As the tertiary structure is missing, few information 
are available on the chiral recognition sites and mechanism of AGP, even if it is 
known that hydrophobic, electrostatic and hydrogen bonding interaction play a key 
role in the retention and enantioselectivity of a solute in AGP [62]. 
 
2.5.2.2 Chiral separation and mechanism 
Factors, such as temperature, pH and mobile phase composition, could 
influence the chiral recognition. Changes in temperature were very limited 
especially for CBH because its chiral selectors could be denaturated [63]. Hence, 
pH could be a key parameter along with mobile phase compositions. Both columns 
are positively charged at pH<pI and negatively charged at pH>pI. This means that 
from pH>pI up to neutral conditions, the degree of the net negative charge of the 
chiral selector increases, thus determining ionic bonds between the chiral CSP and 
the positively charged solute (i.e. amine). As a consequence, a high retention time 
(Rt) along with enantioselectivity are expected. Hydrophobic interaction and 
hydrogen bonds are also forces involved in Rt and their influence depends on the 
nature of the solute. The enantioselective retention could be achieved through 
mobile phases containing different organic modifiers, different aqueous-organic 
ratios and different salt concentrations. The most frequently used uncharged organic 
modifiers are methanol, acetonitrile, 2-propanol. Depending on their nature, a 
decreasing modifier concentration will result in a higher Rt and enantioselectivity 
(i.e. amines). The presence of a buffer in a mobile phase can ionise the analytes and 
alter the interactions of the analytes with the stationary phase at molecular level.  
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2.5.2.3 Sample preparation needs and constraints 
In order to study the enantiomeric profiling of illicit drugs in the 
environment, some precautions are required during the sample collection and 
preparation. Indeed, an incorrect assessment of the relative concentration of 
enantiomers could be obtained at this stage due to the activation of enantioselective 
and/or enantiospecific microbial processes [13]. Potentially abused substances such 
as antidepressants were found not stable. In particular, nortriptyline, venlafaxine, 
fluoxetine and norfluoxetine reached half concentration after 24 h at pH 7.4 [13]. 
In that case, time and pH were two factors responsible for the degradation process 
(i.e stability was improved at lower pH). Moreover, enantioselective degradation 
occurred when influent and effluent samples were compared [64, 65]. In order to 
reduce enantioselective degradation, a correct storage protocol is highly 
recommended. The time existing between the sampling and the sample preparation 
needs to be reduced. Samples kept at low temperatures during the transport will 
help in minimizing the microbial activity. 
A controversial question is about the acidification of the sample and the addition of 
sodium azide as the matrix might be subjected to modification [56]. If the advantage 
of both processes relies on stopping the microbial activity, additional errors could 
be inevitably introduced (i.e. at lower pH the percentage of sorption to solids 
components in wastewater can vary considerably for ionisable compounds). In MS 
the most often used source for chiral analysis of drugs of abuse is the electrospray 
ionisation (ESI). Signal suppression may occur in ESI, thus significantly affecting 
the matrix effect and the chiral recognition for the enantiomers [56]. Indeed, 
extreme pH cannot be used due to possible denaturation of the chiral selector itself. 
As a consequence, a key step in chiral method development is the choice of the SPE 
sorbent. The elective choice is represented by Oasis hydrophilic-lipophilic balanced 
(HLB) cartridges. In fact, for amphetamines an Oasis mixed-mode anion exchange 
sorbent (MAX) and HLB were preferred to an Oasis mixed-mode cation exchange 
one (MCX) with a CBH column. This was due to the eluting agent influencing the 
decrease of enantiomeric resolution [65]. 
 
2.5.3 Enantiomeric profiling of illicit drugs in environmental analysis 
The investigation of illicit drugs at enantiomeric level in environmental 
samples was principally performed (i) to remove pharmaceutically active 
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compounds and (ii) to understand the difference between the direct consumption 
and its disposal, as well as the origin of a drug residue in WBE. An indication of 
which enantiomer fraction is predominant is given by the measurement of 
enantiomeric fraction (EF). EF is the ratio between the peak area of the first eluted 
enantiomer (or the (+)-enantiomer, if (-)-enantiomer is used in the numerator, it is 
usually indicated in the equation) and the sum of both enantiomer peak areas (EF= 
(+)/[(+)+(-)]). A chiral CBH column was used to perform environmental chiral 
analysis of amphetamine-like compounds [66]. 
Kasprzyk-Hordern et al. (2010) [65] showed how the enantiomeric composition of 
chiral drugs was altered during the wastewater treatment process, thus determining 
an occurrence of enantioselective processes during wastewater treatment. Indeed, 
venlafaxine was found racemic in influent and enriched of one enantiomer in 
effluent wastewater samples in two WWTPs. 
The hypothesis about the enantioselective degradation of drugs in the WWTP 
process was confirmed in a later study conducted in seven WWTPs in England over 
the period of nine months in 2012 [67]. In raw wastewater, R-(-)-MDMA was found 
predominant with respect to the S-(+)-MDMA due to stereoselective human 
metabolism. EF value increased from 0.68 in raw wastewater to 0.78 in treated 
wastewater due to the treatment of wastewater possibly resulted from the 
stereoselective microbial processes.  
Enantiomer-specific degradation was observed for amphetamine, leading to an 
enrichment of R-(-)-form. In the case of ephedrine, the natural 1R,2S-(-)-enantiomer 
was detected in raw wastewater, whilst the synthetic 1S,2R-(+)-enantiomer was 
found in treated wastewater, thus showing perhaps a chiral inversion process. 
Receiving waters were also enriched of R-(-)-enantiomer for amphetamine (EFs > 
0.80) and MDMA (EF up to 0.80±0.01) and 1S,2R-(+)-ephedrine.  
Microcosm experiment carried out with a CBH column under isocratic conditions 
proved that stereoselective processes leaded to an enrichment of R-(-)-amphetamine 
(EF changed from 0.47 to <0.02) [68]. The enantiomeric fate of MDA changed 
along the treatment of wastewater. Indeed, EF equals to 0.28-0.30 was reported in 
raw wastewater indicating a prevalence of S-(+)-form, a slight enrichment of R-(-)-
MDA during wastewater treatment (EF=0.38-0.40) and finally EF=0.56-0.58 in 
surface waters, thus leading to the R-(-)-enantiomer due to stereoselective removal 
or transformation of S-form [67]. For a potentially abused antidepressant, 
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venlafaxine, removal is problematic in WWTP treatment due to weak 
stereoselective processes. Low venlafaxine degradation was further proved by 
Vazquez-Roig et al. [69]. 
 
2.5.4 Enantiomeric profiling of illicit drugs for WBE purposes 
Only few papers correlated the enantiomeric composition of illicit drugs 
found in wastewater to official statistics. 
Chiral analysis helped in distinguishing the MDMA origin in wastewater 
and clarifying whether it was due to direct disposal or its abuse. All illicit synthesis 
methods produce racemic MDMA (EF=0.5). However, S-(+)-MDMA undergoes 
preferential metabolism over R-(-)-MDMA. This leads to the enrichment of residual 
MDMA excreted in urine (and then found in wastewater) with the R-(-)-enantiomer 
(EF>0.5). This characteristic change in EF of MDMA allows for the verification of 
whether drug residues present in wastewater results from its consumption (EF>0.5) 
or direct disposal of unused drug (EF=0.5). For example, the results of several 
sampling campaigns in England (Figure 2-9) [70] and in the Netherlands [71] 
showed that MDMA is usually present in wastewater due to its consumption 
(EF>0.5; MDMA enriched with R-(-)-enantiomer). However, excessively high 
mass loads of MDMA during one sampling campaign in a WWTP in Utrecht (the 
Netherlands) proved to be racemic, thus indicating direct disposal of unused 
MDMA. This coincided with a police raid earlier at a nearby illegal production 
facility within the catchment (Figure 2-10) [71]. 
The study of the enantiomeric profiling of MDA can also help in 
recognising the origin of a drug residue. The minor metabolic pathway of MDMA 
produces MDA with an enrichment of S-(+)-enantiomer in urine. Differently, if the 
MDA is originated from its direct disposal in the racemic form, the R-(-)-
enantiomer would be prevalent due to the metabolic conversion from S-(+)-MDA 
to R-(-)-MDA [72]. Indeed, it was observed by Kasprzyk-Hordern et al. [70] that 
MDA was detected only in August with an enrichment of its S-(+)-enantiomer. The 
presence of MDA in raw wastewater with EF equals to 0.24 and 0.30 seemed to be 
due to MDMA abuse and not to its intentional consumption. No intentional MDA 
use was also found in Dutch cities. 
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Figure 2-9 Concentrations, loads and enantiomeric fractions found in wastewater for MDMA (left) 
and MDA (right) in the UK (reproduced with permission from Fig. 3-4 in Kasprzyk-Hordern and 










Figure 2-10 (a) Loads of MDMA of wastewater samples in Utrecht collected for the European 
Monitoring campaign in 2010 and 2011, (b) EF of MDMA in Utrecht for those campaigns (modified 












































































Chapter 2: Background and Literature Review 
 34 
For some drugs, such as amphetamine, the contribution from other drugs’ 
metabolism needs to be considerated. Kasprzyk and Baker [67] found that legal 
amphetamine, prescribed in S-(+)-form in England, was in low levels when 
compared to the illegal use. EF average was 0.64 in raw watewater, indicating an 
enrichment of R-(-)-enantiomer. These data were in agreement with human 
consumption as S-(+)-amphetamine is preferentially metabolised after ingestion of 
the racemate. In a monitoring campaign in 2011 in Eindhoven (the Netherlands), 
high amphetamine loads were found 14 times higher than those in 2010 (Figure 
2-11). EF values were 0.52±0.01 and 0.52±0.02 in Eindhoven for the campaign in 
2010 and 2011, respectively. This data did not match with the EFs found in 
England. The enantiomeric profiling of amphetamine and methamphetamine is still 




Figure 2-11 Daily load of amphetamine in Eindhoven for the European Monitoring campaign in 
2010 and 2011 (from Emke et al. 2014 [71]). 
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Chapter 3: Enantiomeric profiling of chiral drug 
biomarkers in wastewater with the usage of 
chiral liquid chromatography coupled with 
tandem mass spectrometry 
 
3.1 Summary 
This chapter proposes a novel multi-residue stereoselective method utilising a CBH 
(cellobiohydrolase) column for the analysis of 56 drug biomarkers in wastewater. 
These are: opioid analgesics, amphetamines, cocaine, heroin, stimulants, 
anaesthetics, sedatives, anxiolytics, designer drugs, phosphodiesterase-5 (PDE5) 
inhibitors, amphetamine and methamphetamine drug precursors. Satisfactory 
enantiomeric separation was obtained for 18 pairs of enantiomers including 
amphetamine, methamphetamine, MDMA (3,4-methylenedioxy-
methamphetamine) and its metabolites HMA (4-hydroxy-3-methoxyamphetamine) 
and HMMA (4-hydroxy-3-methoxy-methamphetamine), PMA (para-
 Chapter 3: Enantiomeric Profiling of Chiral Illicit Drugs Biomarkers 
 43 
methoxyamphetamine), MDA ((±)-3,4-methylenedioxyamphetamine) and 
mephedrone. The method was applied in a one week monitoring study of a large 
wastewater treatment plant in England, UK. Most target drugs were found at 
quantifiable concentrations in analysed samples. Enantiomeric profiling revealed 
that amphetamine, methamphetamine and MDMA were found enriched with R-(-)-
enantiomers, probably due to their stereoselective metabolism favouring S-(+)-
enantiomers. MDA was either enriched with R-(-)- or S-(+)-enantiomer indicating 
that its presence might be due to either abuse of racemic MDA or abuse of MDMA 
respectively. Non-racemic enantiomeric fractions were also observed in the case of 
HMMA and mephedrone suggesting enantioselective metabolism. To the author’s 
knowledge, this is the first time chiral separation and wastewater profiling of 




Wastewater-based epidemiology (WBE) has the potential to inform public health 
via the analysis of human urinary biomarkers in wastewater [1]. WBE is an 
emerging field but it has already found applications in verifying spatial and 
temporal community-wide illicit drug [2, 3], alcohol [4] or tobacco use [5]. 
An understanding of human pharmacokinetics and the selection of potential 
biomarkers informing public health is key to successful application of the WBE 
approach. As human pharmacokinetics shows stereoselectivity in the case of many 
chiral xenobiotics [6], chirality is also important to investigate in WBE.  
In a recent study, the enantioselective separation of common illicit drugs revealed 
changes in enantiomeric composition of chiral drugs during wastewater treatment 
[7, 8]. In particular, it was demonstrated that the type of chiral drug, the treatment 
technology used in a wastewater treatment plant and the season affected the 
stereoselective enrichment or depletion of the enantiomeric composition of a drug. 
In another study, microbial metabolic processes were found to be responsible for 
stereoselective degradation of amphetamine-like compounds in river [9] and 
activated sludge microcosms [10]. 
Unfortunately in WBE, chiral analysis still has limited application despite its high 
potential in helping to understand for example: (i) the different route of synthesis 
of the drugs, (ii) the differentiation between the abuse and the licit use of drugs, (iii) 
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the origin of a drug residue, differentiation between consumption and disposal of 
unused drugs and (iv) and the potency of the abused drug [11]. The concept of 
enantiomeric profiling in WBE has been applied for the first time by Kasprzyk-
Hordern et al. (2012) [11]. In fact, from a study conducted in 7 WWTPs in England 
for 5 months, it was possible to conclude that MDMA was found in the influent 
wastewater samples due to its abuse rather than its direct disposal. Also, the 
presence of MDA was associated with abuse of MDMA and not abuse of MDA. In 
another study by Emke et al. (2014) [12], chiral analysis was key in confirming that 
unexpectedly high loads of MDMA observed in wastewater from one of Dutch 
cities were a result of dumping of MDMA from a local production facility during a 
police raid.  
In order to undertake enantiomeric profiling of wastewater for chiral drug 
biomarkers, robust and multi-residue chiral analytical methods need to be 
developed. Until now, chiral LC-MS (liquid chromatography coupled with tandem 
mass spectrometry) methods were utilised in the investigation of a limited number 
of chiral drugs [11-13]. Therefore, chiral methods were used only as 
complementary tools alongside non-chiral LC-MS methods. Those approaches 
required an ad hoc sample preparation, which meant higher sample volume, more 
time consuming and less cost effective analysis.  
This chapter proposes, for the first time, a multi-residue method utilising a CBH 
(cellobiohydrolase) column for the analysis of 56 drug biomarkers at enantiomeric 
level, including satisfactory enantiomeric separations for 18 pairs of enantiomers. 
To the author’s knowledge, this method is the first to allow for: 
(i) simultaneous and mutiresidue differentiation between the abuse and the licit 
use of drugs (e.g. in the case of amphetamine as illicit amphetamine, as opposed to 
prescribed licit amphetamine, is distributed as racemate),  
(ii) verification of the origin of a drug residue (e.g. methamphetamine as chiral 
signature of methamphetamine is route of synthesis dependent),  
(iii) differentiation between consumption and disposal of unused drugs (e.g. in 
the case of MDMA, fluoxetine and other targeted chiral illicit drugs. This is due to 
the fact that metabolic processes in humans are stereoselective and lead to changes 
of chiral signature of excreted drugs when compared to their unused counterparts) 
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(iv) verification of the potency of the abused drug (e.g. S-(+)- enantiomers of 
amphetamine and methamphetamine are known to be much more potent than R-(-) 
enantiomers of the same drugs). 
The developed and validated method enabled the identification, detection and 
quantification of most targeted human biomarkers in wastewater. The method was 
applied in a one week monitoring study of a large wastewater treatment plant in the 
UK. Wastewater profiling of 56 biomarkers was undertaken. These are: opioid 
analgesics, amphetamines, cocaine, heroin, stimulants, anaesthetics, sedatives, 
anxiolytics, designer drugs, PDE5 inhibitors, amphetamine and methamphetamine 
drug precursors (Table 3-1). To the author’s knowledge, this is the first time chiral 
separation and then wastewater profiling of mephedrone, MDMA and its 
metabolites HMA, HMMA, PMA (para-methoxyamphetamine) using chiral CBH-
HPLC-MS/MS method has been reported. The latter compound is a 
phenylisopropylamine with hallucinogenic properties, responsible, alongside N-
monomethyl analogue (PMMA), for several deaths due to its abuse [14-16]. 
Moreover, the method was applied for investigating the in-sewer stability of the 
targeted biomarkers in a pressurized sewer under anaerobic conditions. This 
stability study was performed for evaluating any alteration in concentration of the 
biomarker during its transport in the sewer system to the collection site. This 
evaluation at enantiomeric level was performed for the first time. 
 
3.3 Experimental 
3.3.1 Chemicals and materials 
The following analytes were selected for the study (Table 3-1): opioid analgesics, 
amphetamines, cocaine, heroin, stimulants, anaesthetics, sedatives, anxiolytics, 
designer drugs, PDE5 inhibitors, amphetamine and methamphetamine drug 
precursors. Table S1 shows all target analytes, their CAS number, molecular 
formula, molecular weight, pKa and supplier information. 
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Table 3-1 Selected chiral drug biomarkers and their pharmacokinetic data. 
Group Drug Metabolite Excretion Source of 
excretion (range) 
Stimulants Cocaine Cocaine 1.0-9.0%, 7.5% [17]; [18] 
Benzoylecgonine 32.5% (nasal) [19] 





Cocaethylene  Drugbank [21], 
[20] 
Stimulants Amphetamine Amphetamine 30.0% in neutral condition of pH, up to 74.0% in acidic and 1.0% in 
alkaline urines 
[17] 
Norephedrine 2.0% in neutral condition of pH [17] 
Stimulants Methamphetamine Methamphetamine 43.0% at pH range between 6 and 8, up to 76.0% in acidic and 2.0% in 
alkaline urines 
[17] 
Amphetamine 4.0-7.0% at pH range between 6 and 8 [17] 
Stimulants Mephedrone Mephedrone Not available data  
Hallocinogens MDA MDA Unchanged (overdose case) [22] 
Hallocinogens MDMA MDMA 15.0% [23] 
MDA 1.5% [23] 
DHMA Minor [24] 
HMMA 20.0% [23] 
HMA 1.0% [23] 
Hallocinogens MDEA MDEA 19.0% [17] 
MDA 28.0% [17] 




Opioids Morphine  Morphine  10.0% [17] 
Morphine-3-glucuronide 75.0% [17] [26] 
Hydromorphone (not targeted) Trace [26] 




Ketamine Ketamine 2.3% [17] 
Norketamine 1.6% [17] 
Stimulants Benzylpiperazine Benzylpiperazine 3.0-6.0% [27] 
Benzodiazepines Temazepam Temazepam 1.5%+73.0% as conjugated [17] 
Oxazepam 1.0%+5.8% as conjugated [17] 
Benzodiazepines Diazepam Diazepam Trace [17] 
Oxazepam gluc 33.0% [17] 
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Temazepam 6.0% [17] 
Nordiazepam Trace (Steven B. Karch, 
2007) 
Benzodiazepines Nitrazepam Nitrazepam trace, 1.0% (in the 7 day urine) [17] 
7-amino-nitrazepam 31.0% (in the 7 day urine) [17] 
Benzodiazepines Oxazepam Oxazepam trace+61.0% as glucuronide [17] 
Benzodiazepines Lorazepam Lorazepam trace as unchanged + 75.0% lorazepam glucuronide [17] 
Population 
biomarkers 
Caffeine Caffeine 0.7-0.9% 
 
1,7-dimethylxanthine 14.0% [28] 
Population 
biomarkers 
Nicotine Nicotine 13.0%, 5.0% [5], [17] 
Cotinine 30.0%, 10.0% [5], [17] 
Population 
biomarkers 
Creatinine    
Opioids Codeine Codeine 10.0%, 32.0-46.0% as glucuronide Drugbank [21], 
[26] 
Morphine 5.0-13.0% [26] 
Opioids Oxycodone  Oxycodone  13.0-19.0%+7.0-29.0% as conjugated [17] 
Oxymorphone 13.0-14.0% as conjugated [17] 
Noroxycodone Trace [17] 
Opioids Hydrocodone Hydrocodone 
  
Hydromorphone (not targeted) 5.0% [26] 
Opioids Dihydrocodeine Dihydrocodeine 31.0%, 28.0% as conjugated [17] 
Dihydromorphine 8.4% as conjugated [17] 
Opioids Methadone Methadone 27.5 (5-50) [22] 
EDDP 3.0-25.0% [17] 
Antidepressants Venlafaxine Venlafaxine 5.0% [17] 
O-desmethylvenlafaxine 29.0-48.0% [17] 
PDE5 Inhibitor Vardenafil Vardenafil <10.0% (Thomas L. 
Lemke, David A. 
Williams  2012)  
Precursors Ephedrine  Ephedrine  70.0-80.0% [17] 
Norephedrine  4.0% [17] 
Pseudoephedrine  Pseudoephedrine  88.0% [17] 
Stimulants PMA    
Opioids Tramadol  Tramadol  29.0% [17] 
O-desmethyltramadol 20.0% as free and conjugated [17] 
Z-drugs Zolpidem  Zolpidem  Nd [17] 
Antidepressants Amitriptyline Amitriptyline Trace Drugbank [21] 
PDE5 Inhibitor Sildenafil Sildenafil 13.0% [17] 
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Z-drugs Zopiclone Zopiclone 4.5 [17] 
Antidepressants Fluoxetine  Fluoxetine  2.5-5.0% [29] 
Norfluoxetine 10.0% [29] 
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The following deuterated analogues of target analytes were used as internal 
standards (IS): cocaine-D3, benzoylecgonine-D8, cocaethylene-D3, ecgonine 
methyl ester-D3, amphetamine-D5, methamphetamine-D5, phencyclidine-D5, 
mephedrone-D3, MDA-D5, MDMA-D5, MDEA-D5, cotinine-D3, EDDP-D3, 
heroin-D9, codeine-D6, oxycodone-D6, hydrocodone-D6, morphine-D6, morphine-
3β-D-glucuronide-D3, methadone-D9, temazepam-D5, diazepam-D5, nordiazepam-
D5, nitrazepam-D5, oxazepam-D4, lorazepam-D4, zopiclone-D4, ketamine-D4, 
norketamine-D4 and 1S,2R-(+)-ephedrine-D3.  
The following analytes were used as racemates: (±)-mephedrone, (±)-4-hydroxy-3-
methoxymethamphetamine (HMMA), (±)-3,4-methylenedioxymethamphetamine 
(MDMA), (±)-4-hydroxy-3-methoxyamphetamine (HMA), (±)-methamphetamine, 
(±)-amphetamine, (±)-3,4-methylenedioxyamphetamine (MDA), (±)-tramadol, (±)-
desmethylvenlafaxine, (±)-venlafaxine, (±)-3,4-methylenedioxy-N-ethyl-
amphetamine (MDEA), (±)-ephedrine, (±)-pseudoephedrine, (±)-para-
methoxyamphetamine (PMA), (±)-norephedrine, (±)-norfluoxetine, (±)-zopiclone, 
(±)-fluoxetine, (±)-3,4-dihydroxymethamphetamine (DHMA), (±)-methadone, (±)-
ketamine, (±)-norketamine, (±)-2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine 
(EDDP), (±)-lorazepam, (±)-temazepam, (±)-oxazepam. Enantiomerically pure 
standard solutions were used for the following analytes: 6-monoacetylmorphine 
with five defined stereocentres; oxycodone with four defined stereocentres, also 
known as (-)-oxycodone; morphine-3β-D-glucuronide with ten defined 
stereocentres; hydrocodone with four defined stereocentres; dihydromorphine with 
five defined stereocentres; codeine, also known as (-)-codeine with five defined 
stereocentres; morphine, also known as D-(-)-morphine with four defined 
stereocentres; normorphine with five defined stereocentres; heroin with five defined 
stereocentres; dihydrocodeine, also known as (-)-dihydrocodeine with five defined 
stereocentres; noroxycodone with four defined stereocentres; oxymorphone, also 
known as (-)-oxymorphone with four defined stereocentres; cocaethylene with four 
defined stereocentres; cocaine, also known as (-)-cocaine with four defined 
stereocentres; benzoylecgonine, also known as (-)-benzoylecgonine with four 
defined stereocentres and anhydroecgonine methyl ester (AEME) with two defined 
stereocentres. All standards and internal standards were of the highest purity 
available (>97%). Stock and working solutions of standards were stored at -20° C. 
Methanol, acetonitrile and ammonium acetate were purchased from Sigma Aldrich, 
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UK. Ultrapure water was obtained from PURELAB UHQ-PS Unit (Elga, UK). The 
deactivation of the glassware was carried out in order to prevent the adsorption of 
polar compounds to the hydroxyl sites on the glass surface. The process consisted 
of the following steps: rinsing of the glassware with 5% dimethyldichlorosilane 
(DMDCS) once, with toluene twice and with methanol thrice. 
 
3.3.2 Sample collection, storage and sample preparation 
24h composite wastewater influent samples were collected in 
polytetrafluoroethylene (PTFE) bottles from a local wastewater treatment plant. In 
details, 10 mL aliquots were taken every 15 minutes by ISCO 3700 device (time-
proportional sampling). They were then transported to the laboratory in cool boxes 
packed with ice blocks and filtered through GF/F 0.7 µm glass fibre filter 
(Whatman, UK). 100 µL of a mixture of internal standard at concentration 1 mg L-
1 were added to 100 mL of a wastewater sample to give final concentration of 1 µg 
L-1. Stability of analytes in wastewater has been already investigated in previous 
works from the group [30, 31]. For the in sewer transport stability study, triplicate 
samples were collected from a real pressurized sewer working under anaerobic 
conditions in the municipality of Palamós in the North-East coast of Catalonia 
(Spain) (Figure 3-1). Sampling was undertaken at the inlet (SP1) and at the outlet 
(SP2) of the pipe for three consecutive days for a total of 6 samples in September 
2015 during dry weather conditions. Samples were collected employing two 
portable automatic refrigerated samplers Hach-Lange Buhler BL 2000 with 24 PE 
containers of 1 L located at SP1 and SP2. Samples were all prepared as discussed 
above. Cartridges were then sent to the laboratory in the UK, where the elution of 
the analytes and their analysis were performed according to the method described 
below. Solid phase extraction (SPE) was carried out using Oasis HLB cartridges 
(60 mg, Waters, UK) and the following procedure. The cartridges were conditioned 
with 2 mL of methanol followed by equilibration with 2 mL of ultrapure water at a 
rate of 3 mL min-1. 100 mL of environmental sample (spiked with ISs at 1 µg L-1) 
were passed through the HLB cartridge at a rate of 8 mL min-1. The cartridges were 
then washed with 3 mL of ultrapure water at a rate of 3 mL min-1 and the analytes 
were eluted with 4 mL of methanol at a rate of 8 mL min-1 into 5 mL silanised glass 
tubes. The extract was transferred to the TurboVap evaporator (Caliper, UK).  
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Figure 3-1 Location and layout of the studied sewer. Point 1: SP1 pump station collecting 
wastewater of the suburb of South-Palamós pushing it to the SP2; point 2: SP2 Palamós wastewater 
treatment plant. 
 
Length of the pipe 4800 m 
Diameter of the pipe 556 mm 
Hydraulic retention time 9-15 hours 
Average daily flow 2812 ± 77m3 sewage/day 
Sampling Composite samples of wastewater collected during 24-hour 
period using a flow-proportional sampling mode following the 
sampling guidelines proposed by Ort et al. (2010). 
 
After evaporation to dryness under nitrogen flow (5-10 psi) at 40°C the samples 
were reconstituted with 0.5 mL 1mM ammonium acetate/methanol 85:15 v/v and 
filtered through 0.2 µm PTFE filters (Whatman, Puradisc, 13mm). The filtered 
samples were transferred to polypropylene plastic vials bonded pre-slit 
PTFE/Silicone septa (Waters, UK) and then 20 µL were directly injected into a 
UHPLC-MS/MS system. Samples from monitoring campaign were prepared in 
duplicate and analysed twice. 
 
3.3.3 Sample analysis with chiral liquid chromatography coupled with 
tandem mass spectrometry 
Separation of all analytes was undertaken with Waters ACQUITY UPLC® system 
(Waters, Manchester, UK). Three chiral columns were evaluated in this study: 
(1) CHIRALPAK® CBH HPLC Column 5 μm particle size, L × I.D. 10 cm × 
2.0 mm (Chiral Technologies, France) with a Chiral-CBH guard column 10 × 2.0 
mm, 5 μm particle size (Chiral Technologies, France); 
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(2) CHIROBIOTIC V column 5 μm particle size, L × I.D. 25 cm × 2.1 mm 
(Sigma Aldrich, UK) with a guard column 2 cm × 4.0 mm, 5 μm particle size (Sigma 
Aldrich, UK); 
(3) CHIROBIOTIC T column 5 μm particle size, L × I.D. 25 cm × 2.1 mm 
(Sigma Aldrich, UK) with a guard column 2 cm × 4.0 mm 5 μm particle size (Sigma 
Aldrich, UK). 
ACQUITY UPLCTM autosampler was kept at 4°C, while the column temperature 
was set at 25°C. The injection volume of the sample was 20 µL. Several mobile 
phase compositions were tested (see for details Tables S2, S3 and S4). Different 
flow rates were also trialled: 0.075 mL min-1 and 0.1 mL min-1. The selected chiral 
column was the CHIRALPAK® CBH HPLC column. The chosen mobile phase 
used in the method was 1mM ammonium acetate/methanol 85:15 v/v at a 0.1 mL 
min-1 under isocratic conditions. 
All analytes were identified and quantified using a triple quadrupole mass 
spectrometer (Xevo TQD, Waters, Manchester, UK) equipped with an electrospray 
ionisation source (ESI). Analyses were performed in positive mode with an 
optimised capillary voltage of 3 kV, source temperature of 150°C, desolvation 
temperature of 265°C and desolvation gas flow of 550 l h-1. Nitrogen, supplied by 
a high purity nitrogen generator (Peak Scientific, UK), was used as a nebulising and 
desolvation gas. Argon (99.999%) was used as a collision gas. MassLynx 4.1 
(Waters, UK) was used to control the Waters ACQUITY system and the Xevo 
TQD. Data processing was carried out on TargetLynx software (Waters, 
Manchester, UK).   
The mass spectrometer was operated in the multiple reaction monitoring (MRM) 
mode measuring the fragmentation of the protonated pseudo-molecular ions of each 
compound. The choice of fragmentation ion for each compound was based on the 
most intense signal. MRM transitions as well as cone voltages and collision 
energies were obtained after direct infusion of each standard at a concentration of 
100 µg L-1 into the mass spectrometer. In the final stage of the method development, 
once CBH column was chosen, cone voltages and collision energies were optimised 
for the chosen MRM transitions through infusion of each standard at 100 μg L-1 
combined with LC using 1mM ammonium acetate/methanol 85:15 v/v as mobile 
phase at 0.1 mL min-1 under isocratic conditions. Two or three MRM transitions 
were selected for each compound. The most abundant transition product ion was 
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typically used for quantification, whilst second and third transitions used for 
confirmation purposes for nearly all compounds. The MRM transitions of the 
studied compounds, cone voltages and collision energies are presented in Table 3-
2. 
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ratio ± SD 
MRM1/MR
M3 ratio ± 
SD 
Internal standard 
Cocaine 40/20 304.2 > 182.1 40/31 304.2 > 82.1 - - 2.8 ± 0.2 - Cocaine-D3 
Benzoylecgonine 38/19 290.2 > 168.1 38/30 290.2 > 105.1 - - 1.9 ± 0.2 - Benzoylecgonine-
D8 
Cocaethylene 38/20 318.2 > 196.2 38/30 318.2 > 82.1 - - 1.9 ± 0.1 - Cocaethylene-D3 
Anhydroecgonine methyl 
ester (AEME) 
39/23 182.1 > 118.0 39/21 182.1 > 122.1 - - 1.2 ± 0.1 - Cocaine-D3 
Amphetamine   18/16 136.16 > 91.1 18/8 136.16 > 119.1 - - 1.2 ± 0.1 -  Amphetamine-D5 
Methamphetamine  24/19 150.2 > 91.1 24/10 150.2 > 119.1 - - 1.8 ± 0.1 - Methamphetamine-
D5 
Benzylpiperazine (BZP) 35/20 177.1 > 91.1 35/15 177.1 > 85.1 - - 6.5 ± 0.6 - PCP-D5 
MDA  21/11 180.0 > 163.1 21/22 180.0 > 105.1 - - 2.6 ± 0.4 - MDA-D5 
MDMA 24/13 194.1 > 163.1 24/24 194.1 > 105.1 - - 2.1 ± 0.1 - MDMA-D5 
MDEA 28/13 208.1 > 163.1 28/27 208.1 > 105.1 - - 2.1 ± 0.2 - MDEA-D5 
HMA 6/14 182.1 > 165.0 6/24 182.1 > 105.0 6/18 182.1 > 133.0 1.8 ± 0.7 2.4 ±1.4 Amphetamine-D5 
HMMA 16/12 196.1 > 165.0 16/26 196.1 > 105.0 16/22 196.1 > 133.0 3.1 ± 0.6 3.8 ±0.6 Methamphetamine-
D5 
DHMA 6/12 182.1 > 151.0 6/18 182.1 > 123.0 6/24 182.1 > 105.0 2.8 ± 0.5 3.2 ±0.7 Amphetamine-D5 
Mephedrone 10/12 178.1 > 160.1 10/22 178.1 > 145.0 10/22 178.1 > 119.0 1.6 ± 0.2 8.5 ±2.1  Mephedrone-D3 
p-Methoxyamphetamine 
(PMA) 
20/20 166.0 > 121.0 20/20 166.0 > 149.0 - - 12.5 ± 1.5 - MDA-D5 
Heroin 51/50 370.2 > 165.1 51/29 370.2 > 268.1 - - 1.5 ± 0.2 - Heroin-D9 
O-6-monoacetylmorphine 
(O-6-MAM) 
52/39 328.1 > 165.1 52/26 328.1 > 211.1 - - 1.4 ± 0.3 - PCP-D5 
Codeine 49/25 300.2 > 215.1 49/57 300.2 > 152.1 - - 1.8 ± 0.1 - Codeine-D6 
Oxycodone 36/29 316.2 > 241.1 36/26 316.2 > 256.1 - - 1.4 ± 0.3 - Oxycodone-D6 
Noroxycodone 22/36 302.1 > 227.0 22/28 302.1 > 187.0 - - 5.5 ± 0.8  Oxycodone-D6 
Hydrocodone 24/34 300.1 > 199.0 24/46 300.1 > 171.0 - - 3.7 ± 0.2 - Hydrocodone-D6 
Oxymorphone 40/19 302.1 > 284.1 40/28 302.1 > 227.1 - - 2.3 ± 0.2 - Oxycodone-D6 
Morphine 53/38 286.1 > 165.1 53/56 286.1 > 152.1 - - 1.2 ± 0.2 - Morphine-D6 
Normorphine 45/43 272.1 > 165.0 45/49 272.1 > 152.1 - - 1.3 ± 0.5 - Morphine-D6 
Dihydromorphine 28/42 288.2 > 185.0 28/32 288.2 > 213.0 28/42 288.2 > 231.0 2.9 ± 0.5 129.6 ±68.4 Morphine-D6 
Dihydrocodeine 53/33 302.1 > 199.1 53/60 302.1 > 128.1 - - 1.9 ± 0.2 - Codeine-D6 
Morphine-3β-D-
glucuronide 
56/44 462.3 > 286.1 56/80 462.3 > 165.0 56/56 462.3 > 201.1 4.7 ± 1.8 9.88 ±3.0 Morphine-3β-D-
glucuronide-D3 
Methadone 31/15 310.2 > 265.1 31/28 310.2 > 105.1 - - 1.6 ± 0.5 - Methadone-D9 
EDDP 50/29 278.2 > 234.1 50/24 278.2 > 249.1 - - 2.3 ± 0.1 - EDDP-D3 
Tramadol 24/17 264.2 > 58.1 24/11 264.2 > 246.3 - - 102.1 ± 3.6 - Methamphetamine-
D5 
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O-desmethyl-tramadol 2/18 250.1 > 58.0 2/20 250.1 > 232.0 2/34 250.1 > 107.0 899.7 ± 14.7 1228.0 
±373.0 
Codeine-D6 
Temazepam 37/21 301.1 > 255.1 37/14 301.1 > 283.1 - - 2.2 ± 0.1 - Temazepam-D5 
Diazepam  54/27 285.0 > 154.1 54/31 285.0 > 193.1 - - 1.2 ± 0.1 - Diazepam-D5 
Nordiazepam  51/29 271.1 > 140.1 51/29 271.1 > 165.0 - - 2.0 ± 0.1 - Nordiazepam-D5 
Nitrazepam 44/24 282.1 > 236.1 44/37 282.1 > 180.1 - - 2.5 ± 0.3 - Nitrazepam-D5 
7-aminonitrazepam 48/25 252.1 > 121.1 48/40 252.1 > 94.1 - - 5.7 ± 0.9 - Nitrazepam-D5 
Oxazepam 38/21 287.1 > 241.1 38/15 287.1 > 269.0 - - 1.3 ± 0. - Oxazepam-D4 
Lorazepam 30/20 321.0 > 275.1 30/33 321.0 > 229.1 - - 3.3 ± 1.4 - Lorazepam-D4 
Zopiclone 22/18 389.1 > 245.0 22/42 389.1 > 217.0 - -   Zopiclone-D4 
Zolpidem 8/36 308.2 > 235.2 8/36 308.2 > 263.0 - - 1.7 ± 0.5  Cocaine-D3 
Amitriptyline 37/26 278.2 > 91.1 37/18 278.2 > 233.2 - - 1.8 ± 0.2 - EDDP-D3 
Fluoxetine 25/8 310.3 > 148.1 - - - - - - MDMA-D5 
Norfluoxetine 17/7 296.2 > 134.1 - - - - - - MDMA-D5 
Venlafaxine 27/12 278.2 > 58.1 27/12 278.2 > 260.1 27/32 278.2 > 121.0 2.7 ± 0.2 4.5 ±0.7 Methamphetamine-
D5 
Desmethylvenlafaxine 25/24 264.0 > 58.1 25/24 264.0 > 107.1 25/20 264.0 > 246.3 12.7 ± 1.8 66.4 ±5.9 Methamphetamine-
D5 
Ketamine  31/27 238.1 > 125.0 31/15 238.1 > 220.1 - - 3.3 ± 0.5 - Ketamine-D4 
Norketamine  23/27 224.0 > 125.0 23/12 224.0 > 207.1 - - 1.1 ± 0.1 - Norketamine-D4 
Sildenafil 60/28 475.3 > 100.2 68/50 475.3 > 283.2 68/36 475.3 > 311.2 28.6 ± 8.6  17.3 ±4.0 PCP-D5 
Vardenafil 74/68 489.3 > 151.0 74/48 489.3 > 321.1 - - 7.2 ± 3.0 - Methadone-D9 
Ephedrine  23/12 166.1 > 148.1 23/21 166.1 > 133.0 - - 7.4 ± 0.8 - 1S, 2R-(+)-
ephedrine-D3 
Pseudoephedrine 23/12 166.1 > 148.1 23/21 166.1 > 133.0 - - 6.9 ± 0.6 - 1S, 2R-(+)-
ephedrine-D3 
Norephedrine 23/10 152.1 > 134.1 23/16 152.1 > 117.1 - - 3.1 ± 0.4 - 1S, 2R-(+)-
ephedrine-D3 
Caffeine 38/15 195.1 > 138.0 38/23 195.1 > 110.0 - - 2.5 ± 0.3 - Cotinine-D3 
1,7-dimethylxanthine 54/21 181.0 > 124.1 - - -  
 
- - - Cotinine-D3 
Nicotine 37/20 163.1 > 130.0 37/24 163.1 > 117.0 - - 1.4 ± 0.1 - Cotinine-D3 
Cotinine 34/21 177.1 > 80.0 34/22 177.1 > 98.1 - - 2.8 ± 0.2 - Cotinine-D3 
Creatinine 31/11 114.0 > 86.1 31/16 114.0 > 72.1 - - 21.9 ± 4.2 - Cotinine-D3 
aCV, cone voltage (V); CE, collision energy (eV) 
 
  
 Chapter 3: Enantiomeric Profiling of Chiral Illicit Drugs Biomarkers 
 56 
Selection of ISs (see Table 3-3) for those compounds for which deuterated or C13 
analogues were not available commercially or in our laboratory was based on 
structural similarity and elution time to account for possible signal 
suppression/enhancement of studied analytes in ESI. 
 
Table 3-3 MRM transitions selected for IS standards used in the method. 
ISs CV/CEa MRM1 (quantification) Supplier 
Cocaine-D3 40/20 307.2 > 185.1 Cerilliant 
Benzoylecgonine-D8 38/19 298.2 > 171.1 Cerilliant 
Cocaethylene-D3 42/20 321.2 > 199.1 Cerilliant 
Ecgonine methyl ester-D3 44/22 203.2 > 185.2 Cerilliant 
Amphetamine-D5 22/16 141.0 > 92.9 Cerilliant 
Methamphetamine-D5 28/12 155.1 > 121.0 Cerilliant 
PCP-D5 18/14 249.2 > 164.1 Cerilliant 
Mephedrone-D3 30/22 181.1 > 163.1 Cerilliant 
MDA-D5 21/11 185.1 > 168.1 Cerilliant 
MDMA-D5 26/13 199.1 > 165.1 Cerilliant 
MDEA-D5 28/13 213.1 > 163.0 Cerilliant 
Cotinine-D3 44/24 180.1 > 80.0 Cerilliant 
EDDP-D3 50/29 281.2 > 234.1 LGC Standards 
Heroin-D9 51/50 379.2 > 165.8 Cerilliant 
Codeine-D6 52/28 306.2 > 218.1 Cerilliant 
Oxycodone-D6 36/29 322.2 > 247.1 Cerilliant 
Hydrocodone-D6 64/32 306.2 > 202.0 Cerilliant 
Morphine-D6 53/38 292.2 > 153.1 Cerilliant 
Morphine-3β-D-
glucuronide-D3 
52/36 465.2 > 289.1 Cerilliant 
Methadone-D9 31/15 319.3 > 268.2 Cerilliant 
Temazepam-D5 37/21 306.7 > 260.1 Cerilliant 
Diazepam-D5 54/27 290.1 > 154.1 Cerilliant 
Nordiazepam-D5 48/36 276.1 > 140.1 Cerilliant 
Nitrazepam-D5 52/42 287.1 > 185.0 Cerilliant 
Oxazepam-D4 38/21 292.0 > 246.0 Cerilliant 
Lorazepam-D4 25/29 325.0 > 279.2 Cerilliant 
Zopiclone-D4 24/16 393.1 > 245.0 Cerilliant 
Ketamine-D4 31/27 242.1 > 129.1 Cerilliant 
Norketamine-D4 32/28 228.1 > 128.9 Cerilliant 
1S,2R-(+)-Ephedrine-D3 23/18 169.2 > 151.0 LGC Standards 
aCV, cone voltage (V); CE, collision energy (eV) 
 
3.3.4 Method Validation 
The developed method was fully validated for wastewater samples. The following 
parameters were studied: instrumental and method limits of detection and 
quantification, linearity, precision and accuracy, ion suppression, resolution of 
enantiomers and enantiomeric fraction. Due to the potential presence of target 
analytes in wastewater deuterated analogues of the targeted analytes were used as 
internal standards and to evaluate method performance. 
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The instrumental limit of detection (IDL) was determined at a concentration value 
giving a signal-to-noise ratio (S/N) ≥ 3 for all the MRM transitions selected for each 









  (4) 
where Rec is the relative SPE recovery of the analyte in the matrix and CF is the 
SPE concentration factor. 
The instrumental limit of quantification (IQL) was determined at the minimum 
concentration value giving S/N ≥ 10 for all the MRM transitions. The method 








  (5) 
The linearity of the method was verified for each compound in the following range: 
IDL - 1000 µg L-1. The individual calibrators were at a concentration of 1000, 800, 
700, 600, 500, 400, 300, 200, 100, 50, 10, 5, 1, 0.5, 0.25, 0.1, 0.05, 0.025, 0.01, 
0.005 and 0 µg L-1. 
For some compounds, especially human indicators, such as caffeine and creatinine, 
dilution integrity was considered as these substances are present at high 
concentrations in wastewater in respect to the illicit drugs concentration range. 
Dilution integrity was assessed through the analysis of two diluted samples 1:10 
and 1:100 at the highest concentration in wastewater spiked with a mixture of ISs. 
If the compound could be quantified with a relative error within the 15% in relation 
to the nominal concentration, the dilution integrity was maintained. 
Precision, expressed as relative standard deviation (RSD) of replicate analysis 
(n=4) at three different concentrations on the same day (intra-RSD%), was 
evaluated as:  
(i) instrumental precision using standard solutions spiked in mobile phase at 
10, 100 and 1000 µg L-1 for (non-chiral/not enantiomerically separated) 
analytes, or at 5, 50 and 500 µg L-1 for individual enantiomers (separated 
from racemic mixture);  
(ii) method precision using standard solutions spiked in 100 mL of influent 
wastewater at 50, 500 and 5000 ng L-1 for (non-chiral/not enantiomerically 
separated) analytes, or at 25, 250 and 2500 ng L-1 for individual enantiomers 
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(separated from racemic mixture). The extraction by SPE of these samples 
followed the same protocol described in 3.3.2. 
Reproducibility (inter-day precision) of the method was determined by replicate 
measurements (n=3) of the same concentrations of analytes as in the case of intra-
day precision on three different days in order to assess the inter-day instrumental 
precision and the inter-day method precision. Precision data were acceptable when 
the RSD% was less than 15% for all the concentrations investigated during the 
different days.  
Accuracy of the method was expressed as percentage of closeness agreement 
between the mean of a set of analytical results and the theoretical value. 
Carryover was studied by injecting a spiked sample at a concentration of 1000 µg 
L-1 followed by three blanks and it was considered insignificant if the concentration 
of the analyte was below the LOQ. 
Ion suppression was calculated for each analyte as a percentage decrease in signal 
intensity in a sample matrix versus in mobile phase (free from analytes). Signal 
suppression was calculated using the following equation: 











  (6) 
where IS was the analyte peak area in wastewater extract (0.5 mL) spiked after 
SPE extraction with 100 ng, I0 was the analyte peak area in unspiked wastewater 
extract, IMP was the analyte peak area in mobile phase (0.5 mL) spiked with 100 
ng of each analyte.  
















  (7) 
where trE1 and trE2 are retention times of the first- and the second-eluted enantiomer 
respectively and wbE1, wbE2 are widths of their responses at a baseline. Rs ≥1.2 
indicates full baseline resolution. Rs =1 indicates 2% overlap which is deemed 
acceptable for quantification purposes. 
Enantiomeric fraction (EF) was calculated using the following equation: 
 
 
    

EF  (8) 
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where (+) is the concentration of (+)-enantiomer or first eluted enantiomer, and (-) 
is the concentration of (-)-enantiomer or second eluted enantiomer. EF equals 1 or 
0 in the case of enantiomerically pure compound and 0.5 in the case of a racemate. 
The assessment of the absolute configuration of the first eluted or second eluted 
enantiomer was achieved through the injection of an enantiomerically pure 
standard (when available). 
Validation protocols were in agreement with European Guidelines concerning the 
performance of analytical methods and the interpretation of results [32]). 
 
3.3.5 Quantification and quality controls 
The identification criteria for each analyte were as follows [32]: 
- %RSD of relative retention time (RRT) should not exceed ±2.5% when 
compared to RRT of standard solution.  
- All selected MRM transitions need to be present.  
- The maximum permitted tolerance for relative ion intensities of MRM 
transitions should not change more than ±20% for ions with relative 
intensities of >50%, ±25% for ions with relative intensities between 20% 
and 50%, 30% for ions with relative intensities between 10% and 20% and 
±50% for ions with relative intensities less than 10%. 
Quality controls at 10, 100 and 1000 µg L-1 were also prepared and injected on 
regular basis to maintain instrument’s performance.  
 
3.4 Results and Discussions 
3.4.1 Choice of Biomarkers 
Fifty six compounds were selected and targeted as potential human biomarkers of 
drug consumption. These are: opioid analgesics, amphetamines, cocaine, heroin, 
stimulants, anaesthetics, sedatives, anxiolytics, designer drugs, PDE5 inhibitors, 
amphetamine and methamphetamine drug precursors (Table 3-1). Multiple human 
urine indicators, such as creatinine, caffeine, nicotine, 1,7-dimethylxanthine, 
cotinine, were also targeted as indicators of population size served by a wastewater 
treatment plant in question. 
The selection process of target drug biomarkers included the investigation of: (i) 
classical drugs of abuse, with good literature based evidence of their detection and 
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quantification in wastewater; (ii) new emerging drugs of abuse for further study, 
even if prevalence data and stability data in wastewater are not well documented, 
and (iii) substances with abuse potential.  
Cocaine, benzoylecgonine, anhydroecgonine methylester and cocaethylene were 
selected as biomarkers of cocaine abuse. Indeed, anhydroecgonine methylester, 
ethylecgonindine and ecgonidine were identified as suitable indicators of crack 
cocaine [33]. Moreover, cocaethylene was chosen as biomarker of co-
administration of cocaine and ethanol [34]. Ecgonidine and norcocaine were not 
included in this study as they were not detected in a previous UK study by Baker et 
al. (2014). Furthermore, cuscohygrine, a marker of coca chewing [35], was also 
included in the method in order to distinguish between chewing of cocoa leaves (the 
“coqueo”, a practise well-known in South America) and illegal abuse of cocaine. 
To the author’s knowledge, no investigation of cuscohygrine and hygrine (cocoa 
chewing markers) has been undertaken to date. It is however worth mentioning that 
the practise of chewing cocaine is a non-European habit. Cuscohygrine was 
included in the method development but not in the method validation due to low 
sensitivity and poor chromatography (results are included in the supplementary 
data). 
 
3.4.2 Method development for the detection of illicit/licit abused drugs in 
wastewater 
3.4.2.1 Chiral-CBH column 
The CHIRAL-CBH column contains a protein cellobiohydrolase (CBH) as the 
chiral selector which is immobilised onto spherical 5 µm silica particles. The 
protein has a molecular weight of 60,000–70,000 and an isoelectric point of 3.9. 
The chiral recognition site is 4Å×7Å×40 Å-long tunnel in the core of the protein. 
The tunnel contains seven acidic amino acid residues, four tryptofan residues and 
also tyrosine, serine, threonine, arginine and histidine. The mechanism of retention 
of analytes in CHIRAL-CBH column can therefore involve a combination of ion 
exchange, hydrogen bonding and hydrophobic interactions. The enantioselectivity 
of the retention is regulated by the pH of mobile phase, the nature and concentration 
of the organic modifier and the aqueous buffer [7]. Therefore, in order to achieve 
the best chiral recognition of target chiral analytes within one analytical run, the 
following parameters were investigated in this study: type and concentration of 
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organic modifier (acetonitrile, methanol an isopropanol) in aqueous mobile phase 
and concentration of ammonium acetate. 
In order to undertake quantitative measurements at enantiomeric level we aimed at 
obtaining enantiomeric resolution with maximum 2% overlap for each pair of 
enantiomers (Rs ≥ 1). Our study revealed that Rs ≥ 1 was achieved only in the case 
of 3 compounds (HMA, fluoxetine and zopiclone) in 1mM ammonium 
acetate/acetonitrile 9:1, 7 compounds in 1mM ammonium acetate/isopropanol 9:1 
and >10 compounds in 1mM ammonium acetate/methanol 8.5:1.5 (Figures S1-3). 
A comparison of mobile phases with the same water content revealed that the 
separation selectivity differed for protic and aprotic solvents. Acetonitrile (an 
aprotic solvent) did not provide an adequate separation selectivity as opposed to 
protic solvents such as methanol and isopropanol (fluoxetine was an exception). 
Moreover, better separation selectivity was observed for more polar methanol than 
isopropanol. Furthermore, the water content in mobile phases containing 
isopropanol or methanol had an impact on enantioselectivity in the case of most of 
the studied analytes. In fact, lower water content provided higher resolution of 
enantiomers for tested mobile phases. 
Additionally, different organic content in aqueous mobile phases affected retention 
times of many compounds as shown in Figure S4. A trend between retention time 
and the methanol content with three different concentrations of ammonium acetate 
was observed. Indeed, higher concentrations of ammonium acetate led to lower 
resolution values and lower retention times. Furthermore, retention times decreased 
with a higher content of methanol. In contrast, retention times increased with an 
increase of concentration of isopropanol (Figure S5). 
The salt concentration plays a key role in controlling the pH of mobile phase, 
ionisation of analytes and resulting interactions between analytes and the stationary 
phase. In this study, ammonium acetate was used. The amphetamine-like 
compounds (except for PMA) showed higher resolution with lower concentration 
of ammonium acetate in the mobile phase. Overall, lower concentrations of 
ammonium acetate were preferred. However, this trend was not observed in the case 
of cyclopyrrolone zopiclone and the substituted cyclohexanone norketamine 
(Figure S3). 
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3.4.2.2 Chirobiotic V and T 
Chirobiotic V and T, two chiral columns having macrocyclic antibiotics as chiral 
selectors, were also tested. In reversed-phase conditions, not only cationic and 
anionic interactions are possible by changing pH of the mobile phase but also 
inclusion of the pocket and hydrogen bonding are favoured. In polar organic mode, 
other interactions are involved, such as dipole stacking and π-π complexation. 
A comparison between CBH and Chirobiotic V columns was performed by Bagnall 
et al. 2012 [36]. Due to the utilisation of a combination of ion exchange, hydrogen 
bonding and hydrophobic interactions, CBH column was more selective in 
providing better enantiomeric resolution (i.e. Rs MDMA CBH 1.9 > Rs MDMA CBV 1.0) 
than Chirobiotic V. In general, CBH column provided good results in terms of 
separation and resolution of amphetamine-like compounds when compared to 
Chirobiotic V.  
Experiments carried out with Chirobiotic T column showed high enantioselectivity 
(Rs ≥ 2.2) for benzodiazepines only, a class of compounds not enantiomerically 
resolved using CBH column (Figure S5). It is worth emphasising that polar organic 
mobile phases, containing only methanol and 99% methanol/0.005% FA/1mM 
ammonium acetate, provided the best chiral recognition for most of the chiral 
benzodiazepines. Furthermore, mobile phases containing comparable quantities of 
an acid as a mobile phase additive provided better chiral recognition at lower 
concentrations of ammonium acetate (Figure S6). 
 
After taking above results into consideration, the best chiral recognition for the 
widest group of analytes, combined with acceptable retention times, was achieved 
with the CBH column and a mobile phase composed of 1mM ammonium 
acetate/methanol 85:15 (pH 6.4). 
 
3.4.3 Method validation for the detection of illicit/licit abused drugs 
3.4.3.1 Solid phase extraction 
Oasis HLB cartridges are the sorbents of choice when utilising chiral separations 
with the CBH column. Relative recoveries data are reported in Table 3-4. 
Recoveries were high (on average > 90%) for all analysed compounds. 
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Table 3-4 SPE recovery for the studied analytes. 
Analyte 
SPE relative recovery % (n=3) 
25 ng/L* 250 ng/L* 2500 ng/L* 
Cocaine 100.0 ± 1.9 91.0 ± 0.7 85.0 ± 1.7 
Benzoylecgonine 76.0 ± 1.4 79.0 ± 1.8 98.0 ± 3.9 
Cocaethylene 102.0 ± 2.6 92.0 ± 0.2 94.0 ± 1.4 
R-(-)-Amphetamine 101.0  ± 6.6 76.0  ± 1.6 82.0 ± 4.7 
S-(+)-Amphetamine 81.0  ± 10.6 99.0  ± 2.0 82.0 ± 4.2 
R-(-)-Methamphetamine 91.0 ± 4.4 113.0 ± 0.7 82.0 ± 5.0 
S-(+)-Methamphetamine 84.0 ± 1.9 86.0 ± 1.2 84.0 ± 7.1 
E1-Mephedrone 109.0 ± 3.2 99.0 ± 4.8 80.0 ± 7.0 
E2-Mephedrone 99.0 ± 8.5 99.0 ± 4.3 87.0 ± 11.5 
R-(-)-MDA 93.0 ± 6.2 94.0 ± 4.2 81.0 ± 1.0 
S-(+)-MDA 110.0 ± 8.5 99.0 ± 1.5 91.0 ± 1.5 
R-(-)-MDMA 91.0 ± 3.7 81.0 ± 7.8 89.0 ± 4.3 
S-(+)-MDMA 93.0 ± 1.7 100.0 ± 0.7 84.0 ± 1.9 
E1-MDEA 102.0 ± 2.0 95.0 ± 8.6 91.0 ± 5.9 
E2-MDEA 99.0 ± 1.8 92.0 ± 1.9 93.0 ± 13.4 
Heroin 86.0 ± 9.4 80.0 ± 5.6 75.0 ± 2.4 
O-6-monoacetylmorphine 108.0 ± 2.3 120.0 ± 1.4 114.0 ± 1.0 
Morphine 98.0 ± 15.2 92.0 ± 1.3 112.0 ± 3.2 
Morphine-3β-D-
glucuronide 99.0 ± 0.5 121.0 ± 2.5 109.0 ± 5.3 
Ketamine 127.0 ± 2.5 100.0 ± 5.7 85.0 ± 6.2 
Benzylpiperazine 112.0 ± 5.3 96.0 ± 13.1 100.0 ± 4.9 
Temazepam 117.0 ± 4.1 117.0 ± 3.0 99.0 ± 4.7 
Diazepam 93.0 ± 3.9 115.0 ± 0.3 95.0 ± 4.9 
Nordiazepam 108.0 ± 9.0 108.0 ± 11.2 96.0 ± 4.7 
Nitrazepam 89.0 ± 3.1 91.0 ± 2.7 89.0 ± 1.5 
Oxazepam 92.0 ± 2.7 117.0 ± 1.4 92.0 ± 1.6 
7-amino-nitrazepam 83.0 ± 6.4 85.0 ± 0.4 80.0 ± 4.1 
Lorazepam 98.0 ± 14.4 108.0 ± 3.4 86.0 ± 3.0 
Anhydroecgonine methyl 
ester 80.0 ± 5.3 102.0 ± 0.1 86.0 ± 0.4 
E1-HMA 97.0 ± 8.7 114.0 ± 0.3 106.0 ± 16.4 
E2-HMA 106.0 ± 4.6 107.0 ± 2.9 120.0 ± 11.5 
E1-HMMA 84.0 ± 8.8 85.0 ± 9.4 100.0 ± 3.3 
E2-HMMA 108.0 ± 7.5 105.0 ± 2.4 118.0 ± 1.7 
DHMA 108 ± 11.9 112 ± 2.4 111 ± 2.8 
Caffeine 80.0 ± 2.5 84.0 ± 2.7 80.0 ± 1.5 
1,7-dimethylxanthine 104.0 ± 0.5 100.0 ± 1.3 106.0 ± 2.4 
Nicotine 97.0 ± 2.5 81.0 ± 6.2 120.0 ± 9.5 
Cotinine 105.0 ± 2.8 93.0 ± 6.1 89.0 ± 3.5 
Creatinine 80.0 ± 4.6 94.0 ± 9.5 109.0 ± 13.3 
Codeine 95.0 ± 6.7 108.0 ± 3.1 107.0 ± 2.1 
Oxycodone 84.0 ± 2.1 91.0 ± 3.8 99.0 ± 3.3 
Noroxycodone 93.0 ± 11.3 80.0 ± 2.8 90.0 ± 3.2 
Hydrocodone 84.0 ± 3.1 104.0 ± 8.9 101.0 ± 10.6 
Oxymorphone 94.0 ± 5.7 87.0 ± 7.7 89.0 ± 1.2 
Dihydrocodeine 98.0 ± 7.3 104.0 ± 2.9 89.0 ± 3.8 
Methadone 95.0 ± 0.9 116.0 ± 0.5 89.0 ± 1.4 
EDDP 90.0 ± 6.5 97.0 ± 3.0 90.0 ± 1.1 
E1-Venlafaxine 83.0 ± 0.6 105.0 ± 6.3 91.0 ± 0.4 
E2-Venlafaxine 91.0 ± 5.8 104.0 ± 5.4 90.0 ± 0.7 
Vardenafil 120.0 ± 0.5 115.0 ± 11.0 100.0 ± 8.8 
E1-Norephedrine 112.0 ± 2.8 117.0 ± 1.1 108.0 ± 1.5 
E2-Norephedrine 115.0 ± 5.9 95.0 ± 2.1 83.0 ± 1.4 
E1-PMA 110.0 ± 8.5 94.0 ± 2.4 80.0 ± 0.7 
E2-PMA 113.0 ± 3.5 118.0 ± 5.9 91.0 ± 0.4 
Normorphine 80.0 ± 8.4 80.0 ± 11.9 111.0 ± 4.0 
Dihydromorphine 106.0 ± 0.5 80.0 ± 2.0 80.0 ± 4.5 
D1-Tramadol 109.0 ± 6.0 111.0 ± 7.2 96.0 ± 10.0 
D2-Tramadol 90.0 ± 7.8 81.0 ± 2.7 80.0 ± 1.1 
O-Demethyltramadol 80.0 ± 6.4 118.0 ± 4.4 80.0 ± 3.3 
Zolpidem 101.0 ± 0.8 96.0 ± 14.0 115.0 ± 1.7 
Amitriptyline 81.0 ± 0.2 82.0 ± 2.9 92.0 ± 2.7 
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Norketamine 89.0 ± 8.2 116.0 ± 2.6 102.0 ± 2.2 
Sildenafil 115.0 ± 0.7 105.0 ± 8.5 96.0 ± 9.0 
(+)-Ephedrine 81.0 ± 9.0 82.0 ± 2.6 91.0 ± 2.1 
(-)-Ephedrine and (-)-
Ψephedrine 112.0 ± 0.6 87.0 ± 2.5 113.0 ± 9.6 
(+)-Ψephedrine 104.0 ± 10.6 83.0 ± 0.3 81.0 ± 1.0 
Desmethylvenlafaxine-E1 91.0 ± 9.8 113.0 ± 14.2 98.0 ± 6.5 
Desmethylvenlafaxine-E2 82.0 ± 1.1 92.0 ± 4.1 99.0 ± 10.7 
E1-Zopiclone 80.0 ± 2.0 82.0 ± 0.7 81.0 ± 3.7 
E2-Zopiclone 80.0 ± 1.2 80.0 ± 6.7 83.0 ± 4.6 
S-(+)-Fluoxetine 100.0 ± 5.5 81.0 ± 3.8 100.0 ± 0.7 
R-(-)-Fluoxetine 97.0 ± 16.6 91.0 ± 5.5 101.0 ± 7.1 
E1-Norfluoxetine 87.0 ± 1.7 80.0 ± 4.6 87.0 ± 5.3 
E2-Norfluoxetine 80.0 ± 0.4 81.0 ± 1.7 84.0 ± 2.6 
*- the following concentrations were used: 50, 500 and 5000 ng L-1 in the case of compounds that 
were not enantioseparated. 
 
3.4.3.2 Instrumental and method validation parameters 
Figure 3-2 shows mass chromatograms of MRM 1 transitions used for 
quantification purposes, for each investigated analyte of a spiked influent 
wastewater sample at a concentration of 500 ng L-1. The developed method allowed 
for identification and quantification of all studied analytes with satisfactory 
sensitivity and specificity. 
Concentrations of compounds were calculated using the standard calibration curves 
which were developed using a detector response defined as the ratio of the peak ion 
(the specific product ion of the highest intensity, MRM1) to the base peak ion of 
the internal standard. The mean correlation coefficients (R2) of the calibration 
curves were on average > 0.997 for the investigated compounds (Table 3-5). 
The linearity ranges varied for different analytes. Most analytes showed linearity 
from 0.25 µg L-1 up to 500 or 1000 µg L-1 (for single enantiomer or racemate 
respectively). Opioids, DHMA, lorazepam, creatinine and 1,7-dimethylxanthine 
showed very good linearity in the range: 1 µg L-1 - 500 or 1000 µg L-1 (for single 
enantiomer or racemate respectively). Amphetamine-like compounds gave linearity 
from 0.125 µg L-1 to 500 or 1000 µg L-1 (for single enantiomer or racemate 
respectively) showing a high level of performance of the CBH column for these 
compounds. Cocaine and its metabolites responded with a linearity range of 0.01 
µg L-1 - 500 or 1000 µg L-1 (for single enantiomer or racemate respectively). In the 
case of compounds present in wastewater at high concentrations exceeding 
accepted linearity ranges, dilution (1:10 or 1:100) of samples was utilised. It was 
maintained with a relative error <15%. 
Good enantiomeric resolution (Rs ≥1.0, allowing for quantification of individual 
enantiomers) was obtained for most analytes (Table 3-6).  
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Figure 3-2 Chromatograms of the quantification MRM transition for each investigated analyte of a 
spiked influent wastewater sample at a concentration of 500 ng L-1with CBH column. 
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Table 3-5 Validation parameters - retention time, relative retention time, linearity range, correlation coefficient obtained from calibration curve and 
instrumental and method limits of detection and instrumental and method limits of quantification (WW means wastewater). 
Compound Rt 
(min) 
Rel. Rt Sample diluent Influent WW 
Linearity 
range (µg/L) 
R2 IDLS/N (µg/L) IQLS/N (µg/L) MDL (µg/L) MQL (µg/L) 
Cocaine 15.7 ±0.4 0.3 0.010-1000 0.9997 0.01 0.05 0.0001 0.0003 
Benzoylecgonine 3.1 ±0.0 0.0 0.005-1000 0.9992 0.01 0.02 0.0001 0.0001 
Cocaethylene 16.0 ±0.7 0.3 0.100-1000 0.9996 0.10 0.25 0.0005 0.0013 
R-(-)-Amphetamine 15.5 ±0.3 0.1 0.125-500 0.9987 0.12 0.50 0.0008 0.0029 
S-(+)-Amphetamine 22.6 ±0.4 0.2 0.125-500 0.9988 0.12 0.50 0.0008 0.0029 
R-(-)-Methamphetamine 14.5 ±0.4 0.3 0.050-500 0.9989 0.05 0.12 0.0003 0.0006 
S-(+)-Methamphetamine 16.5 ±0.4 0.3 0.050-500 0.9994 0.05 0.12 0.0003 0.0007 
E1-Mephedrone 16.5 ±0.4 0.3 0.250-500 0.9990 0.25 0.50 0.0013 0.0026 
E2-Mephedrone 21.0 ±0.5 0.2 0.250-500 0.9993 0.25 0.50 0.0007 0.0026 
R-(-)-MDA 28.1 ±0.5 0.2 0.500-500 0.9991 0.50 2.50 0.0028 0.0140 
S-(+)-MDA 47.4 ±0.8 0.4 0.500-500 0.9980 0.50 2.50 0.0025 0.0124 
R-(-)-MDMA 21.9 ±0.5 0.2 0.050-500 0.9992 0.05 0.25 0.0003 0.0014 
S-(+)-MDMA 32.9 ±0.5 0.1 0.050-500 0.9994 0.05 0.25 0.0003 0.0013 
E1-MDEA 19.0 ±0.5 1.8 0.125-500 0.9994 0.12 0.25 0.0006 0.0013 
E2-MDEA 21.0 ±0.5 0.2 0.125-500 0.9995 0.12 0.25 0.0007 0.0013 
Heroin 22.5 ±0.4 0.5 1.000-1000 0.9946 1.00 5.00 0.0062 0.0312 
O-6-monoacetylmorphine 24.1 ±0.7 1.1 0.250-1000 0.9987 0.25 1.00 0.0011 0.0044 
Morphine 17.4 ±0.8 0.5 0.250-1000 0.9955 0.25 0.50 0.0012 0.0025 
Morphine-3β-D-
glucuronide 
3.3 ±0.0 6.5 0.500-1000 0.9983 0.50 5.00 0.0023 0.0228 
Ketamine 11.6 ±0.2 0.3 0.100-1000 0.9994 0.10 0.25 0.0005 0.0012 
Benzylpiperazine 21.3 ±0.4 1.6 0.500-1000 0.9957 0.50 1.00 0.0024 0.0048 
Temazepam 5.2 ±0.2 1.2 0.250-1000 0.9972 0.25 0.50 0.0011 0.0022 
Diazepam 6.0 ±0.3 0.6 0.250-1000 0.9974 0.25 0.50 0.0012 0.0024 
Nordiazepam 8.9 ±0.2 0.5 0.250-1000 0.9985 0.25 0.50 0.0012 0.0024 
Nitrazepam 7.3 ±0.0 1.4 0.250-1000 0.9984 0.25 0.50 0.0014 0.0027 
Oxazepam 7.0 ±0.2 4.8 0.500-1000 0.9971 0.50 1.00 0.0025 0.0049 
7-amino-nitrazepam 5.3 ±0.1 0.6 0.250-1000 0.9923 0.25 0.50 0.0015 0.0030 
Lorazepam 6.8 ±0.1 1.4 1.000-800 0.9900 1.00 5.00 0.0051 0.0256 
Anhydroecgonine methyl 
ester 
12.4 ±0.2 0.5 0.500-1000 0.9971 0.50 1.00 0.0028 0.0056 
E1-HMA 17.7 ±0.4 0.4 2.500-500 0.9900 2.50 5.00 0.0118 0.0236 
E2-HMA 34.3 ±0.5 0.8 2.500-500 0.9903 2.50 5.00 0.0113 0.0225 
E1-HMMA 15.9 ±0.4 2.5 0.250-500 0.9982 0.25 0.50 0.0014 0.0028 
E2-HMMA 18.6 ±0.5 2.5 0.250-500 0.9974 0.25 0.50 0.0011 0.0022 
DHMA 12.5 ±0.2 4.1 1.000-1000 0.9959 1.00 5.00 0.0045 0.0226 
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Caffeine 6.1 ±0.0 0.8 0.250-1000 0.9981 0.25 0.50 0.0047 0.0259 
1,7-Dimethylxanthine 6.4 ±0.1 0.8 1.000-1000 0.9983 1.00 5.00 0.0048 0.0241 
Nicotine 12.5 ±0.1 2.6 0.250-1000 0.9964 0.25 0.50 0.0013 0.0025 
Cotinine 3.4 ±0.0 0.5 0.010-1000 0.9988 0.01 0.02 0.0001 0.0001 
Creatinine 3.0 ±0.0 2.0 1.000-1000 0.9943 1.00 5.00 0.0053 0.0265 
Codeine 15.8 ±0.4 0.3 0.500-1000 0.9980 0.50 1.00 0.0024 0.0048 
Oxycodone 16.1 ±0.7 0.3 0.250-1000 0.9977 0.25 1.00 0.0014 0.0054 
Noroxycodone 20.7 ±0.3 0.6 1.000-1000 0.9991 1.00 5.00 0.0057 0.0285 
Hydrocodone 19.2 ±1.1 0.4 1.000-1000 0.9987 1.00 5.00 0.0052 0.0259 
Oxymorphone 18.7 ±0.5 0.3 1.000-1000 0.9976 1.00 5.00 0.0056 0.0278 
Dihydrocodeine 14.0 ±0.5 0.6 0.500-1.000 0.9985 0.50 1.00 0.0026 0.0051 
Methadone 21.3 ±1.3 0.3 0.250-1000 0.9992 0.25 0.50 0.0012 0.0025 
EDDP 19.7 ±0.5 0.2 0.025-1000 0.9993 0.02 0.10 0.0001 0.0005 
E1-Venlafaxine 12.5 ±0.5 0.6 0.125-500 0.9980 0.12 0.25 0.0007 0.0013 
E2-Venlafaxine 15.6 ±0.5 2.9 0.125-500 0.9971 0.12 0.25 0.0007 0.0013 
Vardenafil 24.7 ±1.3 2.8 1.000-1000 0.9911 1.00 5.00 0.0045 0.0223 
E1-Norephedrine 13.6 ±0.3 0.4 0.125-500 0.9981 0.12 0.25 0.0006 0.0011 
E2-Norephedrine 15.1 ±0.4 2.2 0.125-500 0.9983 0.12 0.25 0.0006 0.0012 
E1-PMA 21.3 ±0.5 0.5 0.125-500 0.9964 0.12 0.25 0.0007 0.0013 
E2-PMA 36. 8 ±0.4 1.4 0.125-500 0.9994 0.12 0.25 0.0006 0.0011 
Normorphine 20.0 ±0.6 0.8 1.000-800 0.9905 1.00 5.00 0.0055 0.0276 
Dihydromorphine 15.1 ±0.5 0.5 1.000-800 0.9915 1.00 5.00 0.0056 0.0282 
D1-Tramadol 12.6 ±0.4 0.6 0.500-500 0.9985 0.50 1.00 0.0024 0.0047 
D2-Tramadol 13.7 ±0.5 0.7 0.500-500 0.9989 0.50 1.00 0.0029 0.0059 
O-Demethyltramadol 13.5 ±0.4 0.8 0.500-1000 0.9921 0.50 1.00 0.0027 0.0053 
Zolpidem 15.1 ±0.6 2.3 0.025-1000 0.9924 0.02 1.00 0.0001 0.0047 
Amitriptyline 55.3±3.1 2.9 5.000-1000 0.9950 5.00 10.00 0.0294 0.0588 
Norketamine 8.5 ±0.3 0.6 0.500-1000 0.9986 0.50 1.00 0.0024 0.0048 
Sildenafil 17.7 ±1.0 3.8 1.000-1000 0.9911 1.00 5.00 0.0047 0.0237 
(+)-Ephedrine 12.3 ±0.3 0.6 1.000-500 0.9974 1.00 5.00 0.0059 0.0295 
(-)-Ephedrine and (-)-
Ψephedrine 
13.4 ±0. 0.5 0.500-1000 0.9975 0.50 1.00 0.0024 0.0048 
(+)-Ψephedrine 32.94 ±0.8 1.9 1.000-500 0.9903 1.00 5.00 0.0056 0.0280 
Desmethylvenlafaxine-E1 15.8 ±0.4 0.7 5.000-500 0.9941 5.000 10.000 0.0249 0.0497 
Desmethylvenlafaxine-E2 17.2 ±0.4 0.6 5.000-500 0.9973 5.000 10.000 0.0275 0.0550 
E1-Zopiclone 32.7 ±0.3 4.6 10.000-500 0.9903 10.000 50.000 0.0285 0.3125 
E2-Zopiclone 59.8 ±0.4 5.2 10.000-500 0.9909 10.000 50.000 0.0326 0.3208 
S-(+)-Fluoxetine 43.2 ±1.8 3.1 10.000-500 0.9915 10.000 50.000 0.0533 0.2664 
R-(-)-Fluoxetine 57.2 ±2.1 3.3 10.000-500 0.9907 10.000 50.000 0.0517 0.2588 
E1-Norfluoxetine 81.3 ±6.0 14.4 10.000-500 0.9916 10.000 50.000 0.0589 0.2945 
E2-Norfluoxetine 87.8 ±3.5 12.9 10.000-500 0.9921 10.000 50.000 0.0612 0.3061 
  
 Chapter 3: Enantiomeric Profiling of Chiral Illicit Drugs Biomarkers 
 68 
Table 3-6 Validation parameters - enantiomeric fraction (EF) and enantiomeric resolution (Rs) of 
compounds, which enantiomers were separated under studied conditions.  
Analyte Structure Rs EF (n=9) 








1.0±0.0 0.50±0.00 0.49±0.00 0.49±0.00 
Mephedrone 
 
1.4±0.1 0.50±0.01 0.50±0.00 0.48±0.01 
MDA 
 
1.8±0.2 0.47±0.01 0.48±0.01 0.50±0.00 
MDMA 
 
1.2±0.1 0.51±0.00 0.50±0.00 0.51±0.00 
MDEA 
 
0.8±0.3 0.50±0.01 0.51±0.01 0.50±0.01 
HMA 
 
2.7±0.3 0.54±0.08 0.47±0.00 0.49±0.05 
HMMA 
 
0.8±0.1 0.48±0.01 0.43±0.01 0.40±0.00 
Tramadol 
 
0.9±0.0 0.46±0.01 0.46±0.02 0.49±0.03 
Fluoxetine 
 
0.6±0.2 0.51±0.03 0.50±0.02 0.51±0.04 











1.0±0.1 0.50±0.04 0.49±0.01 0.50±0.01 
(+)-Ephedrine 
 
0.9±0.1 0.40±0.03 0.50±0.1 0.49±0.16  
    
(+)-ephedrine 
 
2.2±0.2 0.52±0.01 0.45±0.03 0.42±0.02 
Norephedrine 
 
0.9±0.1 0.50±0.04 0.46±0.01 0.47±0.00 
Zopiclone 
 




0.9±0.1 0.42±0.04 0.43±0.03 0.40±0.03 
PMA 
 
2.7±0.2 0.48±0.02 0.47±0.01 0.41±0.00 
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The following analytes: MDEA, HMMA, tramadol, fluoxetine, ephedrine, 
norephedrine and desmethylvenlafaxine showed lower enantiomeric resolution and 
therefore results for single enantiomers of these compounds should be considered 
on a semi-quantitative basis.  
Enantiomeric fractions for those analytes which were injected as racemates, were 
on average 0.49 and were reproducible across different concentration ranges (Table 
3-6).  
The instrumental limits of detection and quantification ranged from 0.005 to 10 µg 
L-1 and from 0.050 to 50 µg L-1, respectively (Table 3-5). The method limits of 
detection and quantification ranged from 0.03 to 61 ng L-1 and from 0.130 to 
320.870 ng L-1 (Table 3-5). The instrumental and method precision was on average 
<5% and <10% respectively (Tables 3-7 and S5). 
Ion suppression studies showed how the presence of the internal standard deuterates 
compensated the ion suppression in the matrix, even for those compounds that had 
not its corresponding deuterated analogue. (Table S6). 
 
3.4.4 Analysis of wastewater samples 
The developed and validated method was applied in a one-week monitoring 
campaign of a wastewater treatment plant serving a large city in the UK. The results 
are provided in Table 3-8. 
Most target drugs were found at quantifiable concentrations in analysed samples. 
The results for several drugs such as cocaine and MDMA and their metabolites 
show a clear trend of increased concentration during weekends. Other target drugs 
showed constant concentrations across the sampling week. These are for example: 
morphine, ketamine, benzylpiperazine, dihydrocodeine, methadone, amphetamine 
and methamphetamine. These results will be used in further study to estimate drug 
use via wastewater-based epidemiology. It is worth noting that despite suspected 
high usage of zopiclone, fluoxetine and norfluoxetine, these drugs were not detected 
in analysed wastewater samples. This is probably because of relatively high MDL 
values for zopiclone, fluoxetine and its metabolite norfluoxetine in the developed 
method. Amphetamine and MDMA were found enriched with R-(-)-enantiomers, 
probably due to their stereoselective metabolism favouring S-(+)-enantiomers. 
MDA was either enriched with R-(-)- or S-(+)-enantiomer indicating that its 
presence might be due to either abuse of racemic MDA (excess of R-(-)-enantiomer 
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should be observed if administered as racemate) or abuse of racemic MDMA 
(excess of S-(+)-enantiomer should be observed).  
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Table 3-7 Validation parameters - method precision 

























D 1* D 2 D 3 D 1 D 2 D 3 D 1 D 2 D 3 
   
Cocaine 6.5 2.7 5.2 0.5 4.8 3.4 4.7 1.9 1.5 4.8 2.9 2.7 
Benzoylecgonine 2.3 7.5 10.2 5.3 4.6 6.6 14.4 2.5 4.9 6.6 5.5 7.3 
Cocaethylene 3.5 5.1 5.4 6.4 3.8 3.8 6.1 2.0 4.3 4.7 4.7 4.2 
R-(-)-Amphetamine 3.3 2.5 4.6 5.2 14.7 10.8 6.2 3.9 6.2 3.5 10.2 5.4 
S-(+)-Amphetamine 3.1 4.3 12.6 1.4 6.5 4.7 3.8 7.0 7.3 6.7 4.2 6.0 
R-(-)-Methamphetamine 8.9 6.7 9.3 3.4 7.0 8.3 4.8 5.2 5.4 8.3 6.2 5.1 
S-(+)-Methamphetamine 6.8 3.6 15.4 1.2 5.5 4.0 2.7 2.9 4.2 8.6 3.6 3.3 
E1-Mephedrone 9.8 13.7 14.1 3.6 6.8 14.6 3.7 10.0 5.6 12.5 8.3 6.4 
E2-Mephedrone 10.7 12.0 4.6 5.2 12.9 8.4 9.2 3.7 2.8 9.1 8.8 5.2 
R-(-)-MDA 1.7 6.6 9.7 3.0 3.4 5.7 0.1 7.7 1.1 6.0 4.0 3.0 
S-(+)-MDA 4.4 3.8 7.8 2.6 6.7 5.3 7.2 3.7 4.5 5.3 4.9 5.1 
R-(-)-MDMA 7.0 1.8 4.0 5.8 4.6 3.9 3.4 1.5 6.5 4.3 4.8 3.8 
S-(+)-MDMA 1.0 1.9 6.9 0.6 3.1 2.9 1.2 2.8 0.7 3.3 2.2 1.6 
E1-MDEA 6.9 6.2 3.0 5.1 8.5 7.8 4.7 2.2 4.3 5.4 7.1 3.7 
E2-MDEA 6.0 6.3 2.8 1.4 9.2 4.9 8.3 1.4 1.7 5.0 5.2 3.8 
Heroin 17.3 12.0 1.1 4.4 6.8 6.4 10.5 5.2 12.2 10.1 5.9 9.3 
O-6-monoacetylmorphine 3.3 6.9 12.1 4.2 6.6 5.7 5.8 3.8 6.3 7.4 5.5 5.3 
Morphine 17.8 0.8 0.8 8.8 4.5 6.7 6.7 7.2 14.2 6.5 6.7 9.4 
Morphine-3β-D-glucuronide 18.2 3.7 23.2 27.1 10.4 4.8 18.6 19.4 4.2 15.0 14.1 14.1 
Ketamine 8.3 2.2 3.9 2.0 5.2 3.9 1.9 1.6 2.0 4.8 3.7 1.8 
Benzylpiperazine 4.4 1.0 9.4 4.3 7.1 5.2 1.9 4.8 2.1 5.0 5.5 2.9 
Temazepam 25.9 16.4 5.5 6.7 8.7 8.5 4.1 3.8 2.7 15.9 8.0 3.5 
Diazepam 2.1 5.4 5.8 5.0 9.5 8.4 1.8 3.9 2.7 4.4 7.6 2.8 
Nordiazepam 3.1 19.8 7.0 4.7 5.5 5.6 15.7 5.1 6.1 9.9 5.3 9.0 
Nitrazepam 9.0 1.2 18.7 9.2 4.5 5.2 6.2 5.1 1.9 9.6 6.3 4.4 
Oxazepam 13.7 10.0 10.7 3.9 8.3 5.6 3.4 5.3 7.9 11.4 5.9 5.5 
7-amino-nitrazepam 0.0 4.5 5.0 3.4 5.8 2.0 0.0 2.1 5.2 3.2 3.7 2.4 
Lorazepam 4.4 10.6 6.7 9.9 3.9 2.4 3.9 6.8 3.3 7.2 5.4 4.7 
Anhydroecgonine methyl 
ester 
5.3 9.3 3.6 1.4 5.6 5.7 3.0 3.2 1.0 6.1 4.2 2.4 
E1-HMA 4.4 5.1 1.6 7.6 1.1 4.4 6.4 6.0 5.9 3.7 4.4 6.1 
E2-HMA 5.2 4.8 12.6 3.8 2.0 5.0 7.0 6.5 6.0 7.5 3.6 6.5 
E1-HMMA 7.4 7.6 7.5 2.8 3.8 6.0 4.1 2.7 0.3 7.5 4.2 2.4 
E2-HMMA 4.7 6.4 3.6 2.1 2.1 6.2 2.9 3.1 3.6 4.9 3.5 3.2 
DHMA 8.9 9.1 1.2 6.1 2.5 9.0 3.2 6.9 4.6 6.4 5.9 4.9 
Caffeine 2.2 5.6 2.2 5.1 7.3 3.8 9.5 0.9 1.9 3.3 5.4 4.1 
1,7-Dimethylxanthine 6.0 4.0 5.7 4.5 0.0 4.7 2.7 3.5 5.8 5.2 3.1 4.0 
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(-)-Nicotine 3.7 4.0 8.5 6.6 1.8 4.0 1.6 5.5 5.4 5.4 4.1 4.1 
Cotinine 3.0 8.1 6.8 4.4 4.0 4.8 3.2 6.1 4.7 6.0 4.4 4.7 
Creatinine 18.3 1.0 9.7 2.7 14.9 8.8 0.7 7.6 4.4 9.6 8.8 4.2 
Codeine 2.9 4.5 4.9 2.1 5.7 7.8 6.4 2.7 9.0 4.1 5.2 6.0 
Oxycodone 10.5 4.2 16.8 2.3 4.4 8.6 3.3 7.0 7.6 10.5 5.1 6.0 
Noroxycodone 19.3 9.2 14.1 2.6 9.3 7.4 4.9 8.3 5.4 14.2 6.4 6.2 
Hydrocodone 4.7 1.1 1.9 3.8 9.2 7.1 1.4 5.5 7.8 2.6 6.7 4.9 
Oxymorphone 5.3 2.1 6.7 3.7 0.6 3.5 4.9 3.5 6.7 4.7 2.6 5.0 
Dihydrocodeine 0.3 7.6 4.7 1.0 7.0 1.7 5.6 3.9 3.7 4.2 3.2 4.4 
Methadone 7.8 0.0 7.3 2.1 4.4 6.5 5.9 2.8 5.7 5.0 4.4 4.8 
EDDP 3.1 5.3 6.2 3.9 9.4 5.3 5.1 1.1 2.9 4.9 6.2 3.0 
E1-Venlafaxine 9.1 1.5 5.7 5.5 5.2 7.5 5.3 7.1 5.6 5.4 6.1 6.0 
E2-Venlafaxine 0.0 4.8 3.1 4.9 1.4 7.6 1.5 4.0 5.2 2.6 4.6 3.6 
Vardenafil 9.4 11.0 10.6 5.6 9.2 13.0 14.6 9.0 5.2 10.3 9.3 9.6 
E1-Norephedrine 7.3 3.8 1.3 2.8 3.0 7.3 4.4 3.0 7.4 4.1 4.3 5.0 
E2-Norephedrine 5.7 4.6 6.3 3.1 3.9 6.1 2.2 2.1 3.5 5.5 4.3 2.6 
E1-PMA 7.7 4.8 8.3 1.4 4.4 3.7 3.8 4.3 5.3 6.9 3.2 4.5 
E2-PMA 6.2 8.8 11.6 7.8 4.6 6.6 1.7 3.9 2.9 8.9 6.3 2.8 
Normorphine 11.4 2.9 4.6 2.7 12.6 5.5 12.0 3.6 7.8 6.3 6.9 7.8 
Dihydromorphine 1.5 13.4 4.1 10.1 14.9 1.4 9.8 2.6 11.3 6.3 8.8 7.9 
D1-Tramadol 4.9 7.0 6.6 6.1 5.7 3.9 6.5 1.7 0.5 6.2 5.3 2.9 
D2-Tramadol 6.2 9.7 6.1 4.2 3.2 4.0 2.5 3.7 2.5 7.3 3.8 2.9 
O-Desmethyltramadol 4.8 8.7 0.0 15.7 16.0 4.6 12.2 16.2 11.5 4.5 12.1 13.3 
Zolpidem 18.2 7.0 0.6 5.5 3.4 4.8 0.6 9.1 6.9 8.6 4.5 5.5 
Amitriptyline 8.0 7.3 1.1 10.9 7.3 8.7 2.7 6.7 0.1 5.5 9.0 3.1 
Norketamine 9.6 7.6 11.2 7.7 8.0 8.3 6.5 5.8 3.6 9.5 8.0 5.3 
Sildenafil 20.1 5.9 20.8 1.2 13.3 10.1 5.6 3.5 6.8 15.6 8.2 5.3 
(+)-Ephedrine 5.3 16.5 9.8 5.0 4.5 6.6 7.2 2.8 3.3 10.5 5.4 4.4 
(-)-Ephedrine and (-)-
Ψephedrine 
8.3 14.8 5.2 1.8 0.8 5.4 5.7 1.0 3.3 9.4 2.7 3.3 
(+)-Ψephedrine 2.8 2.5 6.2 5.8 1.3 9.4 2.9 2.0 1.7 3.8 5.5 2.2 
Desmethylvenlafaxine-E1 8.7 7.4 2.3 8.4 3.7 9.5 2.7 5.0 3.7 6.2 7.2 3.8 
Desmethylvenlafaxine-E2 6.4 8.7 7.4 3.8 2.8 5.3 2.3 4.9 8.2 7.5 4.0 5.1 
E1-Zopiclone 20.0 17.8 19.5 14.5 13.2 19.2 12.6 7.9 5.6 19.1 15.6 8.7 
E2-Zopiclone 18.7 18.2 20.4 17.6 14.8 6.9 11.4 5.8 9.8 19.2 13.1 9.0 
S-(+)-Fluoxetine 19.3 14.2 1.1 12.9 18.2 14.0 3.5 5.4 2.9 11.5 15.0 4.0 
R-(-)-Fluoxetine 19.2 2.7 20.7 6.2 3.8 0.5 0.3 2.7 14.5 14.2 3.5 5.8 
E1-Norfluoxetine 17.6 15.1 9.7 6.6 3.8 9.6 2.5 7.9 13.5 14.1 6.7 8.0 
E2-Norfluoxetine 1.9 6.8 10.7 20.3 10.5 3.4 0.7 10.7 7.3 6.5 11.4 6.2 
*-D indicates day 
**- the following concentrations were used: 10, 100 and 1000 ng L-1 in the case of compounds that were not enantioseparated 
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As MDA is a minor and not exclusive metabolite of MDMA, other metabolites 
(HMMA, HMA, and DHMA) were targeted for the first time in wastewater. The 
trend observed for HMMA in terms of concentration was similar to the parent drug 
MDMA, whilst for HMA and DHMA the trends were not “superimposable” to that 
one of MDMA. Among the metabolites of MDMA investigated, this was the first 
time that the enantiomeric profiling of HMA and HMMA was studied in 
wastewater. In the developed method, the enantiomers of DHMA were not 
separated so evaluation of its enantiomeric profiling was not possible. Significant 
changes in enantiomeric fractions (between 0.40 and 0.58) were noticed in the case 
of HMMA suggesting enantioselective metabolism. The enantiomeric profiling of 
PMA was not undertaken as PMA was not detected in wastewater. Even though 
PMA is a minor metabolite of PMMA, as reported by Lin et al.2007, most PMMA 
is excreted unchanged in the urine. So, PMA could be a suitable biomarker only for 
PMA intake [37]. 
Temporal changes in mephedrone concentrations were observed with noticeable 
increase of mephedrone levels during weekends. This is the first time mephedrone 
was detected and quantified in wastewater in the UK. Mephedrone was also found 
to be enriched with E1 enantiomer, which suggests enantioselective metabolism in 
humans. Further work is needed to support the above hypothesis.  
Moreover, the method was applied for investigating the in-sewer stability of the 
targeted biomarkers in a pressurized sewer under anaerobic conditions ( see Figure 
3-1). As WBE relies on the quantification of a DTR and a DTR may undergo 
degradation during the transport in the sewer until the collection of the wastewater 
sample, in-sewer stability studies are required. Indeed, they can evaluate any 
alteration in its concentration avoiding any under- or over-estimations of the 
targeted drug in WBE. This study was performed for the first time at enantiomeric 
level. Nearly 44% of the compounds were highly stable (changes in concentrations 
were within 20%), 10% had medium stability (variations were between 20 and 
40%), 3% had low stability (alterations >40%). 43% of the compounds were <MDL 
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Table 3-8 Concentrations of targeted compounds in wastewater samples during one week monitoring campaign.  
 Concentration [ng L-1]  
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Cocaine 403 ± 28 449 ± 60 420 ± 13 397 ± 28 452 ± 22 694 ± 23 634 ± 23 
Benzoylecgonine 997 ± 150 754 ± 90 788 ± 26 864 ± 112 950 ± 43 1604 ± 129 1537 ± 95 
Cocaethylene 4 ± 0 2 ± 0 2 ± 1 2 ± 0 4 ± 0 10 ± 1 9 ± 1 
R-(-)-Amphetamine 241 ± 62 169 ± 8 207 ± 39 202 ± 14 204 ± 10 224 ± 17 192 ± 11 
S-(+)-Amphetamine 171 ± 12 122 ± 7 154 ± 7 152 ± 14 140 ± 28 170 ± 17 147 ± 3 
R-(-)-Methamphetamine 6 ± 1 3 ± 11  6 ± 1 6 ± 2 6 ± 1 5 ± 1 4 ± 1 
S-(+)-Methamphetamine 2 ± 2 3 ± 5 6 ± 1 6 ± 4 3 ± 1 3 ± 2 4 ± 1 
E1-Mephedrone 42 ± 7 18 ± 6 32 ± 10 18 ± 3 22 ± 7 67 ± 15 53 ± 11 
E2-Mephedrone 29 ± 2 14 ± 5 28 ± 3 14 ± 6 18 ± 5 47 ± 6 44 ± 5 
R-(-)-MDA 7 ± 7 3 ± 4 10 ± 11 N.D. N.D. 4 ± 3 7 ± 2 
S-(+)-MDA N.D. N.D. 2 ± 4 3 ± 4 4 ± 8 13 ± 5 14 ± 7 
R-(-)-MDMA 109 ± 7 68 ± 5 45 ± 3 34 ± 2 45 ± 4 133 ± 9 186 ± 10 
S-(+)-MDMA 43 ± 4 26 ± 2 23 ± 2 19 ± 2 32 ± 1 84 ± 4 110 ± 6 
E1-MDEA N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
E2-MDEA 1 ± 0 1 ± 1 N.D.  N.D. 8 ± 16 N.D. 1 ± 1 
Heroin N.D. 26 ± 52 112 ± 223 68 ± 78 50 ± 64 147 ± 24 16 ± 32 
O-6-monoacetylmorphine 7 ± 4 2 ± 2 5 ± 4 2 ± 2 4 ± 4 7 ± 5 2 ± 2 
Morphine 653 ± 29 643 ± 65 713 ± 40 514 ± 18 640 ± 27 591 ± 63 595 ± 46 
Morphine-3β-D-glucuronide N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
Ketamine 274 ± 17 235 ± 9 284 ± 22 250 ± 14 254 ± 8 287 ± 23 281 ± 14 
Benzylpiperazine 9 ± 7 65 ± 6 9 ± 3 9 ± 2 7 ± 1 7 ± 3 8 ± 3 
Temazepam 269 ± 78 320 ± 116 408 ± 55 233 ± 125 224 ± 133 256 ± 134 255 ± 119 
Diazepam 3 ± 6 2 ± 5 3 ± 3 41 ± 10 22 ± 6 3 ± 6 3 ± 4 
Nordiazepam 18 ± 11 9 ± 7 14 ± 11 12 ± 12 12 ± 10 4 ± 8 9 ± 8 
Nitrazepam 3 ± 5 29 ± 24 N.D. 4 ± 3 1 ± 2 2 ± 2 4 ± 8 
Oxazepam N.D. N.D. 184 ± 123 281 ± 198 73 ± 147 98 ± 195 83 ± 96 
7-amino-nitrazepam 2 ± 3 28 ± 28 1 ± 1 5 ± 8 5 ± 6 2 ± 3 13 ± 4 
Lorazepam 59 ± 59 N.D. 28 ± 35 9 ± 18 33 ± 27 N.D. 5 ± 9 
Anhydroecgonine methyl ester 5 ± 1 8 ± 2 8 ± 2 9 ± 2 8 ± 2 12 ± 1 12 ± 1 
E1-HMA 43 ± 29 N.D. N.D. N.D. N.D. 13 ± 26 45 ± 35 
E2-HMA 46 ± 4 11 ± 22 N.D. N.D. N.D. 12 ± 24 32 ± 22 
E1-HMMA 27 ± 7 14 ± 2 9 ± 1 7 ± 1 10 ± 2 23 ± 2 35 ± 3 
E2-HMMA 21 ± 5 12 ± 3 10 ± 1 9 ± 1 10 ± 2 27 ± 4 33 ± 2 
DHMA N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
Caffeine 184819 ± 14657 135883 ± 11735 173852 ± 8241 171064 ± 8077 171958 ± 5199 169130 ± 5162 151231 ± 5249 
1,7-Dimethylxanthine 107717 ± 4786 85882 ± 2418 137196 ± 28326 114869 ± 46279 75413 ± 6759 107717 ± 12820 106272 ± 31432 
(-)-Nicotine 6152 ± 4540 3340 ± 653 7810 ± 4460 8562 ± 7806 6375 ± 3844 4872 ± 244 5549 ± 1807 
Cotinine 2137 ± 324 1882 ± 202 2116 ± 35 2071 ± 83 2194 ± 67 2266 ± 115 2437 ± 114 
Creatinine 679 ± 51 326 ± 87 355 ± 53 379 ± 124 338 ± 79 250 ± 58 330 ± 59 
 Chapter 3: Enantiomeric Profiling of Chiral Illicit Drugs Biomarkers 
 76 
Codeine 2475 ± 56 1914 ± 269 2235 ± 247 1984 ± 195 2079 ± 134 1964 ± 184 1929 ± 257 
Oxycodone 11 ± 2 33 ± 30 16 ± 6 14 ± 8 15 ± 4 11 ± 3 18 ± 7 
Noroxycodone 21 ± 18 33 ± 23 13 ± 16 15 ± 10 33 ± 5 35 ± 12 25 ± 6 
Hydrocodone N.D. 22 ± 26 14 ± 29 10 ± 20 11 ± 22 38 ± 45 10 ± 20 
Oxymorphone 14 ± 12 46 ± 35 20 ± 4 18 ± 2 18 ± 12 12 ± 9 19 ± 3 
Dihydrocodeine 449 ± 37 437 ± 83 442 ± 19 380 ± 40 427 ± 36 419 ± 61 406 ± 59 
Methadone 54 ± 6 50 ± 11 54 ± 2 53 ± 2 56 ± 4 59 ± 4 51 ± 5 
EDDP 126 ± 13 105 ± 10 117 ± 11 106 ± 6 123 ± 16 112 ± 18 122 ± 8 
E1-Venlafaxine 94 ± 9 74 ± 12 86 ± 9 92 ± 12 94 ± 9 102 ± 3 105 ± 3 
E2-Venlafaxine 122 ± 3 88 ± 8 102 ± 11 97 ± 11 101 ± 12 109 ± 3 92 ± 7 
Vardenafil 7 ± 9 N.D. N.D. N.D. N.D. N.D. N.D. 
E1-Norephedrine N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
E2-Norephedrine N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
E1-PMA N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
E2-PMA N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
Normorphine 148 ± 23 131 ± 79 154 ± 16 181 ± 69 193 ± 52 152 ± 30 145 ± 27 
Dihydromorphine 23 ± 5 43 ± 4 25 ± 10 27 ± 3 32 ± 15 15 ± 5 24 ± 5 
D1-Tramadol 704 ± 17 720 ± 30 740 ± 48 766 ± 12 692 ± 32 772 ± 40 798 ± 39 
D2-Tramadol 640 ± 2 666 ± 21 678 ± 13 621 ± 65 672 ± 26 651 ± 37 595 ± 22 
O-Desmethyltramadol 836 ± 76 873 ± 25 950 ± 21 882 ± 20 801 ± 16 849 ± 3 860 ± 9 
Zolpidem 1 ± 1 1 ± 2 N.D. N.D. N.D. N.D. N.D. 
Amitriptyline 234 ± 40 126 ± 17 257 ± 29 227 ± 13 232 ± 59 218 ± 6 245 ± 22 
Norketamine 47 ± 10 39 ± 9 32 ± 4 57 ± 1 50 ± 14 45 ± 7 37 ± 8 
Sildenafil 30 ± 9 3 ± 0 21 ± 7 13 ± 0 12 ± 2 11 ± 2 20 ± 7 
(+)-Ephedrine N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
(-)-Ephedrine and (-)-Ψephedrine 23 ± 10 21 ± 3 28 ± 4 24 ± 3 27 ± 3 18 ± 7 17 ± 2 
(+)-Ψephedrine 201 ± 15 191 ± 10 169 ± 22 163 ± 20 160 ± 19 136 ± 13 153 ± 3 
Desmethylvenlafaxine-E1 291 ± 2 296 ± 13 292 ± 14 289 ± 10 315 ± 7 269 ± 15 305 ± 15 
Desmethylvenlafaxine-E2 250 ± 6 233 ± 9 235 ± 8 191 ± 4 225 ± 15 211 ± 12 215 ± 26 
E1-Zopiclone N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
E2-Zopiclone N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
S-(+)-fluoxetine N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
R-(-)-fluoxetine N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
E1-Norfluoxetine N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
E2-Norfluoxetine N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
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Table 3-9 In-sewer stability of illicit drugs and potentially abused licit drugs through chiral HPLC-MS/MS (QqQ) analysis (n.d. means <MDL). 
Analyte 
Day-to-day variation in 
concentrations % (n=3) In-sewer stability 
Day 1 [%] ± SD 
In-sewer stability 
Day 2 [%] ± SD 
In-sewer stability 
Day 3 [%] ± SD 
In-sewer stability 
(Average [%] ± SD) 
Inlet Outlet 
Cocaine 29.5 33.3 31.4 11.0 21.8 21.4 ± 10.2 
Benzoylecgonine 24.0 27.8 10.6 6.9 21.7 13.0 ± 7.7 
Cocaethylene 20.6 16.1 20.1 7.6 34.6 20.8 ± 13.5 
R-(-)-Amphetamine 13.6 31.6 4.9 7.9 38.0 13.7 ± 22.0 
S-(+)-Amphetamine 10.7 22.6 2.2 5.5 44.3 13.7 ± 26.8 
R-(-)-Methamphetamine 113.9 109.6 18.7 15.6 61.3 31.9 ± 25.5 
S-(+)-Methamphetamine 22.8 33.5 21.8 17.8 4.7 11.6 ± 14.3 
E1-Mephedrone n.d. n.d. n.d. n.d. n.d. n.d. 
E2-Mephedrone n.d. n.d. n.d. n.d. n.d. n.d. 
R-(-)-MDA 28.2 33.6 62.8 1.5 16.5 16.0 ± 41.6 
S-(+)-MDA 31.5 34.1 14.8 10.7 21.4 15.6 ± 5.4 
R-(-)-MDMA 52.6 44.1 7.2 4.0 14.4 3.7 ± 10.8 
S-(+)-MDMA 57.9 38.5 13.8 7.1 43.5 7.5 ± 31.3 
E1-MDEA n.d. n.d. n.d. n.d. n.d. n.d. 
E2-MDEA n.d. n.d. n.d. n.d. n.d. n.d. 
O-6-monoacetylmorphine n.d. n.d. n.d. n.d. n.d. n.d. 
Benzylpiperazine n.d. n.d. n.d. n.d. n.d. n.d. 
Temazepam 10.9 3.6 26.3 22.3 14.6 21.1 ± 6.0 
Diazepam 13.2 19.2 24.2 0.0 29.6 1.8 ± 27.0 
Nordiazepam 32.4 14.5 35.9 19.6 7.9 8.1 ± 27.8 
Nitrazepam n.d. n.d. n.d. n.d. n.d. n.d. 
Oxazepam 4.2 19.1 6.0 0.3 32.6 12.8 ± 17.5 
7-amino-nitrazepam n.d. n.d. n.d. n.d. n.d. n.d. 
Lorazepam 1.9 7.8 14.9 10.4 26.3 17.2 ± 8.2 
E1-HMA n.d. n.d. n.d. n.d. n.d. n.d. 
E2-HMA n.d. n.d. n.d. n.d. n.d. n.d. 
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DHMA n.d. n.d. n.d. n.d. n.d. n.d. 
Caffeine 14.1 22.7 39.2 29.2 51.9 40.1 ± 11.4 
1,7-dimethylxanthine 4.9 9.6 46.4 34.8 50.6 44.0 ± 8.2 
Nicotine 16.8 21.7 20.0 4.5 34.9 19.8 ± 15.2 
Cotinine 3.1 2.5 0.1 0.5 1.3 0.6 ± 0.7 
Creatinine 23.9 5.3 24.0 1.2 6.4 6.3 ± 15.8 
Codeine 13.6 21.8 9.5 6.0 13.1 3.2 ± 11.5 
Oxycodone 4.8 12 1.2 7.5 23.9 10.1 ± 12.7 
Noroxycodone 2.7 26.7 7.4 24.4 44.4 25.4 ± 18.6 
Hydrocodone 22.2 20.4 27.3 34.8 3.2 3.6 ± 31.0 
Oxymorphone 15.9 18.9 13.3 13.0 37.0 12.4 ± 25.0 
Dihydrocodeine 26.4 31.0 10.5 3.1 0.0 4.6 ± 5.4 
Methadone 13.2 13.0 22.1 0.9 14.3 11.8 ± 11.7 
EDDP 22.5 28.7 8.9 1.1 4.0 2.0 ± 6.5 
E1-Venlafaxine 3.6 18.8 1.2 13.4 27.7 14.1 ± 13.3 
E2-Venlafaxine 7.1 21.2 10.0 16.5 33.3 19.9 ± 12.1 
Vardenafil n.d. n.d. n.d. n.d. n.d. n.d. 
E1-Norephedrine 20.9 26.4 76 9.8 18.8 22.4 ± 48.6 
E2-Norephedrine 28.5 31.1 22.7 7.8 1.3 9.7 ± 12.1 
E1-PMA n.d. n.d. n.d. n.d. n.d. n.d. 
E2-PMA n.d. n.d. n.d. n.d. n.d. n.d. 
Dihydromorphine n.d. n.d. n.d. n.d. n.d. n.d. 
Zolpidem n.d. n.d. n.d. n.d. n.d. n.d. 
Amitriptyline n.d. n.d. n.d. n.d. n.d. n.d. 
Sildenafil n.d. n.d. n.d. n.d. n.d. n.d. 
E1-Zopiclone n.d. n.d. n.d. n.d. n.d. n.d. 
E2-Zopiclone n.d. n.d. n.d. n.d. n.d. n.d. 
S-(+)-Fluoxetine n.d. n.d. n.d. n.d. n.d. n.d. 
R-(-)-Fluoxetine n.d. n.d. n.d. n.d. n.d. n.d. 
E1-Norfluoxetine n.d. n.d. n.d. n.d. n.d. n.d. 
E2-Norfluoxetine n.d. n.d. n.d. n.d. n.d. n.d. 
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3.5 Conclusions 
 Understanding patterns of drug use is of key importance in public health 
monitoring. WBE, a new non-intrusive tool, provides significant advances in the 
field. It allows for multiple temporal and spatial drug use estimates in near-real 
time. Enantiomeric profiling provides a new dimension to WBE as it can help with 
the verification of the origin of drug residue, potency of abused drug and its 
synthetic route. To aid enantiomeric profiling in WBE, a new analytical method 
utilising a CBH column and liquid chromatography coupled with tandem mass 
spectrometry was developed. The method showed very good performance: >90% 
SPE recoveries, very good sensitivity (MDLs and MQLs at ppt levels), high 
linearity range and method precision <10%. The method allowed for the analysis 
of 56 drug biomarkers in wastewater. These are: opioid analgesics, amphetamines, 
cocaine, heroin, stimulants, anaesthetics, sedatives, anxiolytics, designer drugs, 
PDE5 inhibitors, amphetamine and methamphetamine drug precursors. Satisfactory 
enantiomeric separation was obtained for 18 pairs of enantiomers including 
amphetamine, methamphetamine, MDMA and its metabolites HMA and HMMA, 
PMA, MDA and mephedrone. The method was applied in a one week monitoring 
study of a large wastewater treatment plant in the UK. Most target drugs were found 
at quantifiable concentrations in analysed samples. The results for several drugs 
such as cocaine and MDMA and their metabolites showed a clear trend of increased 
concentrations during weekend. Enantiomeric profiling revealed that amphetamine, 
methamphetamine and MDMA were found enriched with R-(-)-enantiomers, 
probably due to their stereoselective metabolism favouring S-(+)-enantiomers. 
MDA was either enriched with R-(-)- or S-(+)-enantiomer indicating that its 
presence might be due to either abuse of racemic MDA or abuse of racemic 
MDMA. Non-racemic enantiomeric fractions were also observed in the case of 
HMMA and mephedrone suggesting enantioselective metabolism. To the author’s 
knowledge, this is the first time chiral separation and wastewater profiling of 
mephedrone, PMA, MDMA and its metabolites HMA and HMMA is reported. In-
sewer stability study performed in a pressurized sewer under anaerobic conditions 
showed that nearly 44% of the compounds were highly stable with changes in 
concentrations within 20%. 
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3.6 Contributions 
In-sewer stability study was carried out by Dr. Oriol Gutierrez and Olga Auguet. 
 
3.7 Supplementary Data 
The following supplementary data are contained in Appendix 1: 
Table S1 Selected analytes and their properties. 
Table S2 Studied mobile phase compositions with CHIRALPAK® CBH HPLC. 
Table S3 Studied mobile phase compositions with CHIROBIOTIC V. 
Table S4 Studied mobile phase compositions with CHIROBIOTIC T. 
Table S5 Validation parameters -instrumental precision. 
Table S6 Validation parameters- ion suppression. 
Figure S1 CBH column - enantiomeric resolution of studied analytes in a mobile 
phase containing acetonitrile as organic modifier (mobile phase composition: 1mM 
ammonium acetate/acetonitrile 9:1). 
Figure S2 CBH column - enantiomeric resolution of studied analytes in a mobile 
phase containing isopropanol as organic modifier (mobile phase composition: (a) 
1mM ammonium acetate/isopropanol 9:1 and (b) 1mM ammonium 
acetate/isopropanol 9.5:0.5). 
Figure S3 CBH column - enantiomeric resolution of studied analytes in mobile 
phases containing: (a) 1 mM ammonium acetate/methanol 9.5:0.5, (b) 1 mM 
ammonium acetate/methanol 9:1, (c) 2.5 mM ammonium acetate/methanol 9:1, (d) 
5 mM ammonium acetate /methanol 9:1, (e) 10 mM ammonium acetate /methanol 
9:1 and (f) 1 mM ammonium acetate /methanol 8.5:1.5. 
Figure S4 CBH column - Impact of different percentanges of modifiers on retention 
time of analytes. 
Figure S5 Chirobiotic T column - overview of the separation for the targeted 
analytes 
Figure S6 Chirobiotic T column - separation of oxazepam and lorazepam. 
 
3.8 References 
1. Castiglioni, S., et al., Testing wastewater to detect illicit drugs: State of the 
art, potential and research needs. Sci Total Environ, 2014. 487(0): p. 613-
620. 
 Chapter 3: Enantiomeric Profiling of Chiral Illicit Drugs Biomarkers 
 81 
2. Thomas, K.V., et al., Comparing illicit drug use in 19 European cities 
through sewage analysis. Sci Total Environ, 2012. 432: p. 432-439. 
3. Ort, C., et al., Spatial differences and temporal changes in illicit drug use 
in Europe quantified by wastewater analysis. Addiction, 2014. 109(8): p. 
1338-52. 
4. Reid, M.J., et al., Analysis and interpretation of specific ethanol 
metabolites, ethyl sulfate, and ethyl glucuronide in sewage effluent for the 
quantitative measurement of regional alcohol consumption. Alcohol Clin 
Exp Res, 2011. 35(9): p. 1593-9. 
5. Castiglioni, S., et al., A novel approach for monitoring tobacco use in local 
communities by wastewater analysis. Tob Control, 2014. 
6. Petrie, B., Camacho-Muñoz, D., Castrignanò, E., Evans, S., Kasprzyk-
Hordern, B., Chiral Liquid Chromatography Coupled with Tandem Mass 
Spectrometry for Environmental Analysis of Pharmacologically Active 
Compounds. LCGC Europe, 2015. 28(3). 
7. Kasprzyk-Hordern, B., V.V. Kondakal, and D.R. Baker, Enantiomeric 
analysis of drugs of abuse in wastewater by chiral liquid chromatography 
coupled with tandem mass spectrometry. J Chromatogr A, 2010. 1217(27): 
p. 4575-4586. 
8. Kasprzyk-Hordern, B. and D.R. Baker, Enantiomeric Profiling of Chiral 
Drugs in Wastewater and Receiving Waters. Environ Sci Technol, 2012. 
46(3): p. 1681-1691. 
9. Bagnall, J., et al., Stereoselective biodegradation of amphetamine and 
methamphetamine in river microcosms. Water Res, 2013. 47(15): p. 5708-
5718. 
10. Evans, S.E., et al., Determination of chiral pharmaceuticals and illicit drugs 
in wastewater and sludge using microwave assisted extraction, solid-phase 
extraction and chiral liquid chromatography coupled with tandem mass 
spectrometry. Anal Chim Acta, 2015. 882(0): p. 112-126. 
11. Kasprzyk-Hordern, B. and D.R. Baker, Estimation of community-wide 
drugs use via stereoselective profiling of sewage. Sci Total Environ, 2012. 
423: p. 142-150. 
 Chapter 3: Enantiomeric Profiling of Chiral Illicit Drugs Biomarkers 
 82 
12. Emke, E., et al., Enantiomer profiling of high loads of amphetamine and 
MDMA in communal sewage: a Dutch perspective. Sci Total Environ, 2014. 
487: p. 666-72. 
13. Vazquez-Roig, P., et al., Stereoisomeric profiling of drugs of abuse and 
pharmaceuticals in wastewaters of Valencia (Spain). Sci Total Environ, 
2014. 494-495: p. 49-57. 
14. Ling, L.H., et al., Poisoning with the recreational drug 
paramethoxyamphetamine ("death"). Med J Aust, 2001. 174(9): p. 453-455. 
15. Kraner, J.C., et al., Fatalities caused by the MDMA-related drug 
paramethoxyamphetamine (PMA). J Anal Toxicol, 2001. 25(7): p. 645-648. 
16. Martin, T.L., Three cases of fatal paramethoxyamphetamine overdose. J 
Anal Toxicol, 2001. 25(7): p. 649-651. 
17. Baker, D.R. and B. Kasprzyk-Hordern, Critical evaluation of methodology 
commonly used in sample collection, storage and preparation for the 
analysis of pharmaceuticals and illicit drugs in surface water and 
wastewater by solid phase extraction and liquid chromatography–mass 
spectrometry. J Chromatogr A, 2011. 1218(44): p. 8036-8059. 
18. Baker, D.R., et al., Drugs of abuse in wastewater and suspended particulate 
matter—Further developments in sewage epidemiology. Environ Int, 2012. 
48: p. 28-38. 
19. Commission, E. Commission decision 2002/657/EC concerning the 
implementing Council Directive 96/23/EC concerning the performance of 
analytical methods and the interpretation of results. 2002 [cited 2002]. 
20. Castiglioni, S., E. Zuccato, and R. Fanelli, Illicit drugs in the environment: 
occurrence, analysis, and fate using mass spectrometry. Vol. 48. 2011: John 
Wiley & Sons. 
21. Farooq, M.U., A. Bhatt, and M.B. Patel, Neurotoxic and cardiotoxic effects 
of cocaine and ethanol. J Med Toxicol, 2009. 5(3): p. 134-138. 
22. Rubio, C., et al., Hygrine and cuscohygrine as possible markers to 
distinguish coca chewing from cocaine abuse in workplace drug testing. 
Forensic Sci Int, 2013. 227(1): p. 60-63. 
23. Bagnall, J.P., et al., Using chiral liquid chromatography quadrupole time-
of-flight mass spectrometry for the analysis of pharmaceuticals and illicit 
 Chapter 3: Enantiomeric Profiling of Chiral Illicit Drugs Biomarkers 
 83 
drugs in surface and wastewater at the enantiomeric level. J Chromatogr A, 
2012. 1249: p. 115-29. 
24. Lin, D.L., H.C. Liu, and H.L. Yin, Recent paramethoxymethamphetamine 
(PMMA) deaths in Taiwan. J Anal Toxicol, 2007. 31(2): p. 109-13. 
25. Baselt, R.C., Disposition of Toxic Drugs and Chemicals in Man. 5th edition 
ed., Chemical Toxicology Institute, Foster City, CA. 
26. Lai, F.Y., et al., Profiles of illicit drug use during annual key holiday and 
control periods in Australia: wastewater analysis in an urban, a semi-rural 
and a vacation area. Addiction, 2013. 108(3): p. 556-565. 
27. Khan, U. and J.A. Nicell, Refined sewer epidemiology mass balances and 
their application to heroin, cocaine and ecstasy. Environ Int, 2011. 37(7): 
p. 1236-1252. 
28. Goldstein, R.A., et al. Cocaine: history, social implications, and toxicity: a 
review. in Seminars in diagnostic pathology. 2009. Elsevier. 
29. http://www.drugbank.ca/. 
30. Baselt, R., Disposition of Toxic Drugs and Chemicals in Man Chemical 
Toxicology Institute, Foster City, USA, 2008. 
31. Abraham, T.T., et al., Urinary MDMA, MDA, HMMA, and HMA excretion 
following controlled MDMA administration to humans. J Anal Toxicol, 
2009. 33(8): p. 439-446. 
32. Schwaninger, A.E., et al., Stereoselective urinary MDMA (ecstasy) and 
metabolites excretion kinetics following controlled MDMA administration 
to humans. Biochem Pharmacol, 2012. 83(1): p. 131-138. 
33. Smith, S., E. Scarth, and M. Sasada, Drugs in anaesthesia and intensive 
care. 2011: Oxford University Press. 
34. Gary M. Reisfield, Elaine Salazar, and A.R.L. Bertholf, Rational Use and 
Interpretation of Urine Drug Testing in Chronic Opioid Therapy Ann Clin 
Lab Sci, (37): p. 301-314. 
35. Dargan, P. and D. Wood, Novel psychoactive substances: classification, 
pharmacology and toxicology. 2013: Academic Press. 
36. Andersson, H.C., H. Hallström, and B.A. Kihlman, Intake of caffeine and 
other methylxanthines during pregnancy and risk for adverse effects in 
pregnant women and their foetuses. Vol. 565. 2005: Nordic Council of 
Ministers. 
 Chapter 3: Enantiomeric Profiling of Chiral Illicit Drugs Biomarkers 
 84 
37. Taylor, D., C. Paton, and R. Kerwin, The Maudsley 2003 prescribing 
guidelines. 2003: CRC Press. 
 
 




















Chapter 4: A new approach towards biomarker 
selection in estimation of human exposure to 
chiral drugs with limited metabolism data: a 
case study of mephedrone 
 
4.1 Summary 
WBE is an innovative approach that utilises biomarker analysis in 
wastewater with the aim of estimating public health status. A new compound 
detected in wastewater can be a potential biomarker and an indicator of a new 
emerging trend in public health. However, it is currently very difficult to select and 
validate new biomarkers for NPSs use mainly due to limited or unavailable human 
metabolism data. This chapter presents a new framework that enables the 
identification and selection of new biomarkers of human exposure to drugs with 
limited or unknown human metabolism data. Mephedrone was chosen as a target 
compound in this study to elucidate the assessment of biomarkers for a new 
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emerging drug of abuse using a multi-step analytical procedure. The developed 
framework consists of four steps: (i) the identification of possible metabolic 
biomarkers present in wastewater using in-direct in-vivo study; (ii) the verification 
of chiral signature of the target compound; (iii) the confirmation of human 
metabolic residues in in-vivo and in-vitro studies and (iv) the verification of stability 
of possible biomarkers in wastewater. Mephedrone was selected as a suitable 
biomarker due to high stability profile in wastewater. Its enantiomeric profiling was 
studied for the first time in several biological and environmental matrices, showing 
that chiral analysis was fundamental in order to distinguish human consumption 
from possible direct disposal of unused mephedrone. Further biomarker candidates 
for WBE approach were also proposed for future studies. These are: 4’-carboxy-
mephedrone, 4’-carboxy-normephedrone, 1-dihydro-mephedrone, 1-dihydro-
normephedrone and hydroxyl-tolyl-normephedrone. 
 
4.2 Introduction 
WBE is a new approach that uses biomarker analysis in wastewater with the 
aim of understanding, estimating and monitoring population health and lifestyle. 
WBE is being currently applied to monitor spatial and temporal illicit drug usage at 
local, national and international scale [1-12]. A wider list of biomarkers including 
cocaine, benzoylecgonine, amphetamine, methamphetamine, MDMA, 11-nor-9-
carboxy-delta(9)-tetrahydrocannabinol and other compounds (e.g. heroin, 6-MAM, 
morphine, mephedrone, ketamine, GHB) has been recently proposed in order to 
achieve a more comprehensive estimation of drug abuse at community level [13]. 
A new compound that was detected for the first time in wastewater via non-target 
high resolution mass spectrometry (HRMS) screening can be considered as a 
potential biomarker and an indicator of a new emerging trend in public health and 
lifestyle. This is of particular importance in the identification and monitoring of the 
emergence of new psychoactive substances (NPSs). Unfortunately, it is very 
difficult to validate new biomarkers mainly due to limited or unavailable human 
metabolism data. This chapter presents a new framework that enables the 
identification and selection of new biomarkers of human exposure to drugs with 
limited or unknown human metabolism data. Mephedrone was chosen in this study 
to elucidate the assessment of biomarkers for a new emerging drug of abuse using 
a multi-step analytical procedure. 
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Mephedrone is a stimulant semisynthetic derivative of cathinone. It was first 
synthesised in 1929 by Saem de Burnaga Sanchez but its abuse has been 
documented for the first time only in 2007 [14]. Abuse of mephedrone was reported 
in several European countries. Recently, several mephedrone abuse associated 
deaths were reported in the UK [15]. In response to this, several modified 
cathinones were included in the UK Misuse Drugs Act (in category class B) in April 
2010. Four fatalities due to mephedrone intake were confirmed in Scotland between 
February and May 2010 [16]. 
Mephedrone is a chiral compound. It contains one chiral carbon and it exists 
in two enantiomeric forms as R-(+)-mephedrone and S-(-)-mephedrone. 
Mephedrone can be synthesised via both non-stereoselective and stereoselective 
methods as shown in Figure S1, but, as reported by EMCDDA [17], ‘street 
mephedrone’ is most probably distributed as racemate. Routes of administration 
include oral administration, snorting, rectal or intravenous administration. 
Metabolism of mephedrone in humans and rats was investigated by several research 
groups [18] [14] [19] [20]. The metabolism in humans was verified by Pozo et al. 
2015 [21] using an in vivo study in two volunteers. Six phase I and four phase II 
metabolites were reported in urine (Figure S2). Normephedrone and 4-
hydroxytolylmephedrone, which are two phase I metabolites, showed biological 
activity serving as substrates at monoamine transporters [22]. Stereoselectivity of 
mephedrone was hardly investigated. Stereospecific effects of mephedrone 
enantiomers in rats were reported by Gregg et al. [23]. R-(+)-mephedrone showed 
predominant dopaminergic action and more stimulant-like properties than S-(-)-
mephedrone [24].  
Mephedrone was reported by EMCDDA (EU Early Warning System) to 
have increased usage in the UK in 2014 [25]. Its purity showed a decreasing trend 
in South Wales since its ban in the UK (68.2%± 24.9% as mean value ± SD) [26]. 
It was also detected and quantified in wastewater in Cambridge (UK) [27] and 
during a week monitoring campaign in the UK in 2014 [28]. There is very limited 
information regarding mephedrone in wastewater. It was found in wastewater of 
ten Chinese megacities at levels < 2.8 mg/1000 inhabitants day-1 [19] and in only 
two Italian cities over a four-year monitoring study, which confirms its low use in 
Italy [29]. In all studies, the drug target residue (DTR) for WBE estimations was 
the parent compound mephedrone due to very limited information on human 
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metabolism. This constitutes an issue for the WBE approach, as lack of metabolic 
DTRs does not allow for accurate verification of drug use (e.g. distinction between 
drug consumption and disposal of unused drug). To solve this problem, this chapter 
proposes a novel comprehensive framework that enables biomarker selection in 
WBE for new drugs of abuse with limited knowledge of human metabolism. 
 
4.3 Experimental 
4.3.1 Chemical and Materials 
Table S1 shows target analytes, their CAS number, molecular formula, 
molecular weight, log P, purity and supplier information. The deuterated analogue 
mephedrone-D3 was used as internal standard (IS). All standards and IS were of the 
highest purity available (≥98%). Stock and working solutions of standards were 
stored at -20° C. Methanol, acetonitrile and ammonium acetate were purchased 
from Sigma Aldrich, UK. Ultrapure water was obtained from PURELAB UHQ-PS 
Unit (Elga, UK). The deactivation of the glassware was carried out in order to 
prevent the adsorption of mephedrone and its metabolites to the hydroxyl sites of 
the glass surface. The process consisted of the following steps: rinsing of the 
glassware with 5% DMDCS once, toluene twice and methanol thrice. Glucuronic 
acid (CAS 6556-12-3, Sigma Aldrich, UK) and active sulphate adenosine 3′-
phosphate 5′-phosphosulfate lithium salt hydrate, known as PAPS (CAS 109434-
21-1, Sigma Aldrich, UK), were used as substrates for the investigation of the phase 
II metabolism of mephedrone. 
 
4.3.2 Sample collection, storage and sample preparation 
4.3.2.1 Street mephedrone samples 
Eight street mephedrone powder samples were collected from amnesty bins 
at one of the festivals in the UK in 2014. Methanolic solutions were prepared and 
stored in a freezer at -20°C. Diluted solutions in 1 mM ammonium acetate/methanol 
85:15 v/v were spiked with a solution of mephedrone-D3 at 1 μg mL
-1 and injected 
in the chiral liquid chromatograph coupled with triple quadrupole system (chiral 
LC TQD). 
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4.3.2.2 Rat urine samples 
Metabolism of mephedrone in rats was investigated at Saarland University. 
20 mg kg-1 body mass dose of (±)-mephedrone was administered orally to a male 
Wistar rat (Charles River, Sulzfeld, Germany) for toxicological diagnostic reasons 
according to the corresponding German law (http://www.gesetze-im-
internet.de/tierschg/). The rat was kept in a metabolism cage for a day having water 
ad libitum. Rat faeces and urine samples were separated during the 24 hours of 
collection time and stored at -20 °C in a freezer. Blank rat urine samples collected 
before drug administration were used as control samples. Collected urine samples 
were diluted 100-fold and directly injected into high performance liquid 
chromatography coupled to high resolution mass spectrometry (HPLC-HRMS) 
system: an Orbitrap Q-Exactive (LC Q-E). Acetylation of rat urine sample was 
carried out in order to verify the presence of an acetyl group in a mephedrone 
metabolite. Experimental settings and procedure are described in the appendix 2 
(S1). In order to undertake chiral LC TQD analysis, samples were reconstituted in 
100 μL of 1 mM ammonium acetate/methanol 85:15 v/v. Two standard addition 
curves for the quantification of mephedrone and normephedrone in rat urine 
samples were prepared at seven concentration levels. 
 
4.3.2.3 Pooled urine samples 
Seven pooled urine samples were collected in August 2014 from a UK 
festival event. They came from five different urinals sampled on three different 
days. 3 mL of each sample were spiked with 50 μL of mephedrone-D3 at 1 μg mL
-
1 and underwent SPE using Oasis HLB cartridges (60 mg, Waters, UK) as described 
in paragraph 4.3.2.4 (for “Monitoring campaigns”). Liquid-liquid extraction (LLE) 
was then performed using ethyl acetate and sodium phosphate at pH 8-9. Samples 
were centrifuged for 5 minutes at 5000 rpm. The supernatant was evaporated to 
dryness under nitrogen flow at 40°C and reconstituted in 250 μL of 1mM 
ammonium acetate/methanol 85:15 v/v. After being filtered through 0.2 µm PTFE 
filters (Whatman, Puradisc, 13mm), 20 μL were injected into the chiral LC TQD 
system. 
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4.3.2.4 Wastewater samples 
Monitoring campaigns  
24h time-proportional (10 mL every 15 minutes) composite wastewater influent 
samples were collected in PTFE bottles from a local wastewater treatment plant. 
They were then transported to the laboratory in cool boxes packed with ice blocks 
and filtered through GF/F 0.7 µm glass fibre filter (Whatman, UK). 100 µL of a 
mixture of IS at concentration 1 mg L-1 were added to 100 mL of a wastewater 
sample to give final concentration of 1 µg L-1.  
SPE was carried out using Oasis HLB cartridges (60 mg, Waters, UK). The 
cartridges were conditioned with 2 mL of methanol followed by equilibration with 
2 mL of ultrapure water at a rate of 3 mL min-1. 100 mL of wastewater (spiked with 
IS at 1 µg L-1) were passed through the HLB cartridge at a rate of 8 mL min-1. The 
cartridges were then washed with 3 mL of ultrapure water at a rate of 3 mL min-1 
and the analytes were eluted with 4 mL of methanol at a rate of 8 mL min-1 into 
5mL silanised glass tubes. The extract was transferred to the TurboVap evaporator 
(Caliper, UK). After evaporation to dryness under nitrogen flow (5-10 psi) at 40 °C 
the samples were reconstituted in 0.5 mL 1 mM ammonium acetate/methanol 85:15 
v/v and filtered through 0.2 µm PTFE filters (Whatman, Puradisc, 13mm). The 
filtered samples were transferred to polypropylene plastic vials bonded pre-slit 
PTFE/Silicone septa (Waters, UK) and then 20 µL were directly injected into the 
chiral LC TQD system. 
 
Stability of mephedrone in wastewater 
Stability of mephedrone and normephedrone in wastewater was investigated in dark 
biotic reactors (containing wastewater spiked with the analyte) at 4°C and 17°C for 
a duration of 48 hours. 500 mL of wastewater were spiked in duplicate with 1 μg L-
1 of mephedrone or normephedrone. Unspiked wastewater reactors were also 
included as controls. 50 mL of wastewater samples were collected at 0, 12, 24 and 
48 hours, and spiked with IS. pH and temperature were constantly monitored. 
Samples were filtered through GF/F glass fiber filters and solid-phase extracted as 
described in the section above (paragraph 4.3.2.4-“Monitoring campaigns”). 
Samples were eluted with 4 mL of methanol, dried under nitrogen flow at 40 °C 
and reconstituted in 0.5 mL of 1 mM ammonium acetate/methanol 85:15 v/v for the 
chiral LC TQD analysis and in 0.5 mL of methanol for their LC Q-E analysis. 
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Incubation of mephedrone in wastewater and formation of metabolites 
Mephedrone was incubated in the following reactors: biotic (containing wastewater 
spiked with the analyte), abiotic (containing the wastewater spiked with the analyte 
and sodium azide for quenching any bacterial growth), clean (containing 
demineralised water spiked with the analyte and sodium azide) and control (only 
wastewater) (Table S2a). 4 mL NaN3 solution (50 g L
-1) were added to clean and 
abiotic reactors (containing 400 mL of wastewater each) yielding a concentration 
of 0.2% v/v NaN3. Sampling was performed at time 0, 4 and 7 days. The sample 
preparation was performed using the procedure with the QuEChERs devices 
published elsewhere [30]. Briefly, 1.6 g MgSO4, 0.4 g NaCl and 4 mL IS (in this 
case 250 μL of 10 μg mL-1 mephedrone-D3 were diluted in 50 mL of acetonitrile) 
were mixed. 4 mL from incubated reactors were added and shaken vigorously. After 
centrifugation at 5 °C for 5 minutes at 1200 rpm, 1.5 mL of supernatant were 
transferred to the QuEChERs kit. Samples were centrifuged again for 5 minutes at 
14680 rpm. 1 mL was evaporated to dryness under nitrogen flow at 40 °C. Samples 
were then injected in the LC Q-E system. In order to detect and identify 
biotransformation products of the incubated wastewater, SPE was performed using 
Biotage HCX cartridges, previously conditioned with 1mL of methanol followed 
by 1mL of deionised water. 3 mL of filtered and spiked with mephedrone-D3 
wastewater from each reactor were loaded into the cartridges. 1mL of deionised 
water followed by 1mL of 0.01 M HCl and 1mL deionised water were used for 
washing the cartridges. 2 mL of methanol were used for eluting the neutral fraction, 
whilst 1mL methanol/NH3 33% mix 98:2 v/v for the basic fraction. Analysis of data 
dependent MS/MS fragmentation (ddMS2) was performed. The software used were 
EAWAG-BBD Pathway Prediction System (http://eawag-bbd.ethz.ch/predict/) and 
XCMS Online by the Scripps Research Institute (https://xcmsonline.scripps.edu/). 
 
4.3.2.5 Pooled human liver microsomes (pHLM) experiments 
Two experiments were performed for the in vitro metabolism studies of 
mephedrone. The first one (A) was focused only on metabolites from phase I 
metabolism, whilst the second (B) also took into account phase II conjugated 
metabolites. 
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Experiment A. (±)-Mephedrone was incubated at a final concentration of 2.5 µM 
over 60 minutes in biological triplicate reactors. The reactors are described in Table 
S2b. 100 μL of each reactor contained 90 mM of phosphate buffer at pH 7.4, 25 μM 
of substrate solution, 20 U mL-1 of Superoxide Dismutase (SOD). Apart from “No 
HLM” reactor, 1 mg mL-1 of pooled human liver microsomes (pHLM) (BD 
Biosciences, Heidelberg, Germany) was added to all reactors. The regenerating 
system consisted of isocitrate, MgCl2 and NADP
+ (Biomol, Hamburg, Germany). 
Sampling points were set at 0, 10, 20, 30 and 60 minutes. Time 0 was set when ice 
cold pHLM was added in the reactors for starting the reaction, whilst at time 60 
minutes ice cold acetonitrile was added to stop the reaction. Mephedrone-D3 was 
also added in ice cold acetonitrile to all the incubated samples at a concentration of 
100 ng mL-1. Samples were shaken thoroughly and left in the freezer for 5 minutes. 
pHLM samples were liquid-liquid extracted (LLE) with 300 μL ethyl acetate (pH 
8-9 adding sodium phosphate). Samples were then centrifuged for 5 minutes at 
14680 rpm. The supernatant was gently evaporated to dryness under nitrogen flow. 
Finally, samples were reconstituted in 55 µL of 1mM ammonium acetate/methanol 
85:15. Five microliters were injected in chiral LC VP system. 
Experiment B. Mephedrone was incubated at a final concentration of 10 µM over 
180 minutes in biological duplicates. A single reactor was made of: analyte 
solution, a buffer solution, containing 50 mM KH2PO4 and 5 mM MgCl2 at pH 7.4, 
a NADPH 50 mM solution and pHLM. Glucuronic acid and PAPS were used as 
substrates for the investigation of Phase II metabolism reactions, such as 
glucuronidation and sulfation respectively. Sampling points were set at 0, 10, 20, 
30, 60 and 180 minutes for mephedrone incubation and at 180 minutes for phase II 
metabolism investigation. In this experiment, the blank contained the analyte but 
not the pHLM. Mephedrone-D3 was also added in ice cold acetonitrile to all the 
incubated samples for stopping the reaction. Samples were shaken thoroughly and 
centrifuged for 10 minutes at 12000 rpm. Samples for the investigation of the phase 
II metabolism were evaporated at 40 °C and reconstituted in 100 µL of 
water/methanol 8:2. Ten microliters were injected in liquid chromatography 
coupled with quadrupole time-of-flight (LC QTOF) system. LLE of the pHLM 
samples incubating normephedrone was performed with 300 μL ethyl acetate (pH 
8-9 adding sodium phosphate). Samples were then centrifuged for 5 minutes at 
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14680 rpm. The supernatant was evaporated to dryness under nitrogen flow. 
Samples were reconstituted in 500 µL of 1mM ammonium acetate/methanol 85:15 
v/v. 20 µL were injected in chiral LC TQD system. 
 
4.3.3 Sample analysis with liquid chromatography coupled with tandem 
mass spectrometry 
4.3.3.1 Quantification of mephedrone and its metabolites using targeted 
quantitative analysis utilising chiral liquid chromatography coupled 
with triple quadrupole (chiral LC TQD) 
Separation of all the analytes was undertaken with the validated 
methodology using chiral LC TQD according to [28]. Briefly, a Waters ACQUITY 
UPLC® system (Waters, Manchester, UK), a cellobiohydrolase column (CBH) 
CHIRALPAK® CBH HPLC Column 5 μm particle size, L × I.D. 10 cm × 2.0 mm 
(Chiral Technologies, France) with a Chiral-CBH guard column 10 × 2.0 mm, 5 μm 
particle size (Chiral Technologies, France) coupled with a triple quadrupole mass 
spectrometer Xevo TQD (Waters, Manchester, UK) equipped with an electrospray 
ionisation source (ESI) were used. ACQUITY UPLCTM autosampler was kept at 4 
°C, while the column temperature was set at 25 °C. The injection volume of the 
sample was set at 20 µL. The mobile phase was 1mM ammonium acetate/methanol 
85:15 v/v at a 0.1 mL min-1 under isocratic conditions. The system operated in 
positive mode with a capillary voltage of 3 kV, source temperature at 150 °C, 
desolvation temperature at 265 °C and desolvation gas flow at 550 l h-1. Nitrogen, 
supplied by a high purity nitrogen generator (Peak Scientific, UK), was used as a 
nebulising and desolvation gas. Argon (99.999%) was used as a collision gas. 
MassLynx (Waters, UK) was used to control the Waters ACQUITY system and the 
Xevo TQD. Data processing was carried out on TargetLynx 4.1 software (Waters, 
Manchester, UK). MRM transitions of the studied compounds, cone voltages and 
collision energies are summarised in Table S3. In Table S4 are shown validation 
parameters, such as instrumental and method limits of detection and quantification, 
linearity (Table S4a), SPE recovery (Table S4b), method precision (Table S4c), 
instrumental precision (Table S4d), resolution of enantiomers and enantiomeric 
fraction (Table S4e). The mean correlation coefficients (R2) of the calibration 
curves were ≥ 0.9990 for the investigated compounds. The analytes showed 
linearity from 0.25 µg L-1 up to 500 µg L-1 for single enantiomer highlighting the 
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high level of performance of the CBH column for these compounds. The 
instrumental and method limits of detection were respectively 0.25 µg L-1 for both 
analytes and nearby 1 ng L-1, whilst instrumental and method limits of 
quantification were in both cases lower for mephedrone than for normephedrone. 
The identification criteria for each analyte were in accordance to European 
guidelines [31]. 
 
4.3.3.2 Identification of metabolites using targeted and non-targeted analysis 
with high performance liquid chromatography coupled with high 
resolution mass spectrometry (HPLC-HRMS) 
The analyses were performed using three different HRMS systems: LC VP, 
LC Q-E and LC QTOF respectively. 
Orbitrap system Velos Pro (LC-VP). The separation of the analytes was undertaken 
with UltiMate 3000 HPLC system (Thermo Scientific, Germany) and a 
CHIRALPAK® CBH HPLC Column 5 μm particle size, L × I.D. 10 cm × 2.0 mm 
(Chiral Technologies, France) with a Chiral-CBH guard column 10 × 2.0 mm, 5 μm 
particle size (Chiral Technologies, France). UltiMate 3000 HPLC autosampler was 
kept at 4 °C, while the column compartment at 25 °C. The injection volume of the 
sample was 20 µL. The chosen mobile phase used for the method was 1 mM 
ammonium acetate/methanol 85:15 v/v at a 0.1 mL min-1 under isocratic conditions. 
The optimisation of the sensitivity for mephedrone and normephedrone standard 
solutions was carried out at different source positions, heater temperatures and 
values of sheath and auxiliary gases. All analytes were detected using a mass 
spectrometer (Orbitrap system Velos Pro, Thermo Scientific, Germany) equipped 
with a heated electrospray ionisation source (H-ESI) operating in positive mode. It 
operated measuring the transition of the isolated protonated molecular ions of each 
compound in full scan mode and scanning the product ions spectra at m/z required 
at unit resolution in the full-scan MS/MS mode. ChromeLeon software was used to 
control both systems. Data processing was carried out on Xcalibur 2.1 software 
(ThermoFisher Scientific Inc., San Jose, CA, USA). 
Orbitrap Q-Exactive (LC-Q-E). The LC–HRMS system was composed of a 
ThermoFisher Scientific (Dreieich, Germany) Accela LC system consisting of a 
degasser, a quaternary pump and an HTC PAL autosampler (CTC Analytics AG, 
Zwingen, Switzerland), an Accucore™ Phenyl-Hexyl HPLC Column 2.6 μm 
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particle size, L × I.D. 10 cm × 2.1 mm (Thermo Scientific, Germany) coupled to a 
ThermoFisher Scientific Q-Exactive system (ThermoFisher Scientific, Dreieich, 
Germany). Mobile phase A was a solution of 2 mM aqueous ammonium formate 
plus 0.1% formic acid at pH 3, whilst mobile phase B was a solution of 2 mM 
aqueous ammonium formate with acetonitrile:methanol (50:50, v/v; 1% water) plus 
0.1% formic acid. The sample injection volume was 10 μL. The flow rate was set 
at 0.5 mL min-1 for 10 min and at 0.8 mL min-1 from 10 to 13.5 min. Mobile phase 
gradient was as follows: 0–1.0 min 99% A, 1–10 min to 1% A, 10–11.5 min hold 
1% A, 11.5–13.5 min hold 99% A. The ThermoFisher Scientific Q-Exactive system 
equipped with a heated electrospray ionization (HESI)-II source operated in 
positive and negative ion modes. Source spray voltage was at 3.00 kV (positive 
polarity) and at −4.00 kV (negative polarity); heater temperature and ion transfer 
capillary temperature were set both at 320 °C; S-lens RF level was at 60.0; sheath 
and auxiliary gases were 60 and 10 arbitrary units, respectively. Data were acquired 
in full scan mode and a subsequent data dependent acquisition (DDA) mode over a 
mass range of 130–1000 m/z with a resolving power of 35000 FWHM, microscans 
of 1, automatic gain control (AGC) target at 1e6, maximum injection time (IT) of 
120 ms. Data processing was carried out on ThermoFisher Xcalibur Qual Browser 
software version 3.0.63 software. 
QTOF system (LC-QTOF). MaXis High-Definition (HD) Q-TOF system (Bruker, 
Coventry, UK) was equipped with an ESI source operating in positive and negative 
mode. It was coupled to a UltiMate 3000 HPLC system (Thermo Scientific, UK) 
and an ACQUITY UPLC BEH C18 Column 5 cm 2.1 mm × 1.7 µm particle size 
(Waters, UK). UltiMate 3000 HPLC autosampler was kept at 4°C, while the column 
compartment at 40 °C. The injection volume of the sample was 10 µL. The chosen 
mobile phases delivered at 0.4 mL min-1 were: A – 1mM NH4F in MilliQ-water; B 
– MeOH. The gradient was set as follows: 0-3 min 5% B, 3-4 min 5-60% B, 4-14 
min 60% B, 14-14.1 min 60-98% B, 14.1-17 min 98% B, 17-17.1 min 98-5% B, 
17.1-20 min 5% B. The mass spectrometer measured the m/z transition of the 
isolated protonated molecular ions in full scan mode, whilst it provided all MS and 
MS/MS information independently of the precursor in broadband CID (bb-CID) 
acquisition switching between high and low collision energies. For source settings, 
capillary was set at 4500 V, the nebulizer gas at 3.0 bar, the dry gas at 11.0 L min-
1 and the dry temperature at 220°C. HRMS data processing was carried out on 
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ACD/Labs Metabolite Identification software (Met-ID). It allowed the research of 
metabolites generated by the regioselectivity algorithms of ACD/Percepta, 
matching with those present in the experimental dataset and identifying them 
through IntelliTarget Algorithm. 
4.3.4 Absolute configuration determination of mephedrone using circular 
dichroism (CD) and computational study 
Absolute configuration determination of mephedrone was undertaken using 
a Perkin Elmer Series 200 HPLC system (equipped with a temperature controlled 
autosampler and column compartment, pump and a UV/VIS detector) coupled with 
a Chirascan Circular Dichroism Spectrometer (Applied Photophysics) equipped 
with a quartz spectrophotometer cell type 585.3/Q/10 cuvettes with a path length of 
10 mm for micro flow (Starna scientific). The operating conditions are given in 
Table S5. Separation of mephedrone enantiomers was achieved using a CBH 
column at 0.1 mL min-1 under isocratic conditions using 1 mM ammonium 
acetate/methanol 85:15 v/v as a mobile phase. The background, represented by the 
mobile phase was subtracted from CD spectra. UV absorbance and CD spectra were 
acquired simultaneously at λmax= 265 nm [30] (Figure S3). The predicted UV 
spectrum obtained from the computational study was slightly shifted due to 
solvation effects on the electronic transitions when compared with the UV 
mephedrone spectrum reported by Maskell et al. (2011) [32]. Computational study 
gave predicted CD spectra for (+)- and (-)-mephedrone (Figure S4a) and for (+)- 
and (-)-normephedrone (Figure S4b). In correspondence of the first maximum 
absorbance peak at 265 nm the first eluting mephedrone enantiomer rotated the 
plane of polarized light with a negative Cotton effect, whilst the second peak with 
a positive effect. Combining the information obtained from the experimental 
spectrum and the modelling study, it was possible to establish that R-(+)-
mephedrone eluted as the first enantiomer, while S-(-)-mephedrone as the second. 
Due to similar behaviour of the metabolite, also R-(+)-normephedrone and S-(-)-
normephedrone were assessed as the first and second eluting enantiomers under the 
chromatographic conditions used. 
 
4.3.5 Statistical analysis 
Statistical analysis of the obtained ER values was performed with Data 
Analysis from Excel 2013. Statistical evaluation was done with an unpaired t-test 
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by comparing EFs from wastewater analysis and EFs from the analytical standards 
injected during the validation. T-test and p-value were considered for all wastewater 
samples in both sampling campaigns and excluding outliers, such as Wednesday in 
2014 and Monday in 2015, in which EF was equal and below 0.5. F-test was also 
performed for assessing if variances were equal/unequal for the application of the 
t-test used. A significance level of p < 0.05 was initially set, then levels up to p < 
0.001 were also tested. Paired t-test was used for comparing two datasets of 
wastewater samples, whilst an unpaired t-test for verifying any significant 
difference between EFs from illegal mephedrone samples and EFs from the 
analytical standards in the validation. All t-tests and p-values can be found in 
appendix 2 (S2).  
 
4.4 Results and Discussions 
Two sampling campaigns undertaken in the UK in years 2014 and 2015 
confirmed the presence of mephedrone in wastewater. Its concentrations varied 
from 32 to 114 ng L-1 in 2014 and from 65 to 192 ng L-1 in 2015 (Figure 4-1 and 
Table S6).  
Population-normalised mass loads were calculated as described elsewhere [6]. 
Briefly, daily mephedrone loads (g day-1) were obtained by multiplying measured 
concentrations (ng L-1) in daily samples with the corresponding wastewater 
volumes (L day-1). Mephedrone loads were then normalized by the population size 
of the catchment (mg 1000 people-1 day-1). Loads ranged from 7.6 to 26.3 mg 1000 
people-1 day-1, with a mean value of 14.7 ± 7.2 mg 1000 people-1 day-1 in 2014, 
whilst they ranged from 14.9 to 47.7 mg 1000 people-1 day-1 with a mean value of 
25.6 ± 12.0 mg 1000 people-1 day-1 in 2015 (Table S6). The trend observed for the 
population-normalised mass loads throughout a week showed the highest loads 
during the weekend, which suggests its recreational use. As stated by EMCDDA 
[17], mephedrone is probably consumed in multiple doses of 0.5-2 g per session by 
users rather than single dose of 5-250 mg due to short-lived effects. Even if a mean 
dose value of 1.25 g was considered, daily doses could not be back-calculated due 
to missing DTR excretion data. Furthermore, enantioselective analysis revealed that 
mephedrone present in wastewater was enriched with R-(+)-mephedrone, except 
for the racemate found on Saturday in 2015 and on Wednesday in 2014 and 2015. 
  




Figure 4-1 Mephedrone in a week monitoring program. Results are displayed as concentrations 
(columns), population normalised-loads (columns) and enantiomeric fractions (symbols). Results 
obtained by applying the unpaired t-test showed “t Stat > t Critical one-tail” for all wastewater 
samples excluding Wednesday in 2014 (8.80 > 4.78), p one-tail (0.000024) < 0.001 and for all 
wastewater samples excluding Monday in 2015 (2.83 > 2.01), p one-tail (0.018) < 0.05. Therefore, 
EFs from wastewater samples were significant different (EF>0.5) from EF=0.5 during validation. 
Paired t-test results showed “t Stat <  t Critical one-tail” (1.14 < 1.94), p one-tail (0.15) > 0.05, so 
two datasets of wastewater samples were not significant different from each other. All t-tests and  P-
values can be found in Appendix 2 (S2). 
 
As reported by EMCDDA [17], mephedrone is distributed in Europe as racemate. 
Therefore, the presence of racemate in wastewater may indicate direct disposal. 
Enrichment of mephedrone with R-(+)-enantiomer can indicate stereoselective 
metabolism in humans and/or stereoselective microbial metabolic processes 
occurring in wastewater. However, due to lack of data on metabolism of 
mephedrone in humans and its fate in wastewater, no definite conclusions could be 
drawn regarding mephedrone abuse in the studied population. 
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Therefore, in this chapter, a robust analytical framework to enable accurate drug 
abuse estimation using WBE was proposed (Figure 4-2). The framework consists 
of four steps: 
Step 1: Identification of possible metabolic biomarkers of mephedrone present 
in wastewater using LC-HRMS (in-direct in-vivo study). 
Step 2: Verification of chiral signature of mephedrone using chiral liquid 
chromatography coupled with tandem mass spectrometry (LC-MS/MS). 
Step 3: Confirmation of metabolic residues in in-vivo (human and rat) and in-
vitro (pHLM) studies. 
Step 4: Microbial degradation in wastewater and verification of stability of 
possible mephedrone biomarkers in wastewater. 
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Figure 4-2 Analytical framework proposed for the identification of suitable biomarkers of new occurring compounds for WBE approach (MEPH = 
mephedrone).  
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4.4.1 Step 1: Identification of possible metabolic biomarkers of mephedrone 
present in wastewater using LC-HRMS 
Non-targeted analysis using MetID software enabled the prediction and the 
detection of the following metabolites: dihydro-mephedrone and N-sulfo-
normephedrone, hydroxy-tolyl-normephedrone, 4’-carboxy mephedrone and 4’-
carboxy normephedrone (Table 4-1 and S7, Figure 4-3). Target screening analysis 
in wastewater by using LC-QTOF did not confirm the presence of normephedrone 
as shown in Table S8. Non-targeted screening analysis allowed the detection of 1-
dihydro-normephedrone with good mass accuracy for the precursor and the 
daughter ion with mass error <5ppm, one further daughter ion with an error <10ppm 
(Table S9). The precursor ion of the 4’-hydroxymethyl-mephedrone was detected 
at 6.2 min with -3.1 mass error. Through pHLM experiment, it was detected at 2.4 
min with good mass accuracies for both the parent compound and the daughter ions. 
Even if the analytical standard of 4’-hydroxymethyl-mephedrone was not available 
for the final confirmation of the retention time, it was possible to state that 4’-
hydroxymethyl-mephedrone was likely confirmed in the pHLM samples rather than 
in wastewater. 4’-carboxy-mephedrone was also found in wastewater, albeit it was 
not detected in the pHLM. Further work is, however, needed to verify whether any 
of the above biomarkers is a suitable DTR for estimation of mephedrone abuse via 
WBE. 
 
4.4.2 Step 2: Verification of chiral signature of mephedrone with LC-TQD 
Chiral signature of chemicals has already been proven invaluable in WBE 
in confirming consumption of MDMA [33], atenolol [34] and fluoxetine [35] vs 
their direct disposal. Chiral signature could also prove invaluable in the verification 
of potency of ‘street drugs’ as well as their synthetic routes. However, in order to 
apply such approach, the following two aspects need to be verified: (i) enantiomeric 
signature of distributed drug and (ii) possible changes in its enantiomeric signature 
during human metabolism. 
 
4.4.2.1 Step 2(a): ‘Street’ mephedrone 
Chiral LC TQD analysis of the eight illegal mephedrone samples resulted in EF 
averaging at 0.50 ± 0.01 (Figure 4-4), which indicates non-stereoselective method 
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of synthesis. This confirms the conclusions of Gibbons and Zloh [36] and the 
EMCDDA report on mephedrone [17]. 
 
4.4.2.2 Step 2(b): Metabolism of mephedrone in humans 
As can be seen in Figure 1, mephedrone quantified in wastewater (with chiral LC 
TQD) was enriched with R-(+)-mephedrone. Knowing that mephedrone is 
distributed as racemate, it suggests that the presence of mephedrone in wastewater 
must have been subject to metabolic processes either in humans or other species 
such as microbes. 
Unfortunately, as there is very limited knowledge of stereoisomerism of 
mephedrone, no conclusions can be drawn without any further studies. I therefore 
applied a multi-step approach in order to verify (a) the stereoselective metabolism 
of mephedrone in humans and (b) the stereoselective microbial metabolic processes 
occurring in wastewater (see Step 3). As it is difficult to undertake in vivo 
metabolism studies of new abused drugs in humans, I tested if in vitro experiments 
utilising pHLM represented a valid and alternative method for metabolism 
investigation, especially for new designer drugs [31]. I therefore compared pHLM 
results with biological samples from animal samples (rat urine) and pooled human 
urine samples collected at festivals. 
 
4.4.3 Step 3: Confirmation of metabolic residues in in-vivo and in-vitro 
studies 
4.4.3.1 Step 3(a): In vitro metabolism of mephedrone using pHLM 
In vitro experiments were performed by incubating pHLM to verify the formation 
of phase I (experiment A in section 4.3.2.5) and phase II (experiment B in section 
4.3.2.5) metabolites. Microsomes were previously used by Pedersen et al. [14] 
indicating the involvement of the isoenzyme CYP2D6 in the in vitro metabolism 
studies. In this study, the results obtained using chiral LC-TQD revealed a 
stereoselective metabolism of mephedrone leading to an enrichment with R-(+)-
enantiomer (Figure 4-5) and formation of two metabolites: normephedrone and 
hydroxytolyl-mephedrone enriched with S-(-)-enantiomers. 
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a Metabolites mentioned in Pedersen et al. 2013 
b Metabolites producted by incubation of pHLM using set A experiment (Phase I) 
c Metabolites producted by incubation of pHLM using set B experiment (Phase I and II) 
d Metabolites not previously published 
e Metabolites mentioned in Linhart et al. 2016 
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Figure 4-3 (±)-Mephedrone metabolites detected in the investigated matrices and proposed scheme 
of metabolism (A Metabolites found in rat urine, B Metabolites found in pHLM study, C Metabolites 
found in wastewater). 
 
 
Figure 4-4 Enantiomeric fraction of mephedrone in illegal samples of mephedrone. Results obtained 
by applying the unpaired t-test showed “t Stat < t Critical one-tail” (1.78 < 2.16), p two-tail (0.097) 
< 0.05. Therefore, EFs from street mephedrone samples were not significant different from EF=0.5 
during validation. All t-tests and P-values can be found in Appendix 2 (S2). 
 
  
























Figure 4-5 Stereoselective metabolism of mephedrone and formation of metabolites in in vitro pHLM study. 
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LC QTOF non-targeted screening enabled the prediction and the detection 
of normephedrone and a new phase I metabolite, 4’-carboxy-normephedrone, by 
the use of MetID software. Dihydromephedrone, 4’-hydroxymethyl-mephedrone, 
4’-carboxy-mephedrone and a new phase II metabolite normephedrone-N-
glucuronide were predicted with a mass error <10 ppm for the precursor (for this 
reason they were not displayed in this paper) (Table 4-1 and S7, Figure 4-3). 
Regarding the latter metabolite, glucuronic acid was found to be conjugated to 
normephedrone N- group, in contrast to the 3O-glucuronide observed in Pozo et al. 
2015 [21]. Target screening analysis by using LC-QTOF confirmed the presence of 
normephedrone (Table S8). 
 
4.4.3.2 Step 3(b): In-vivo metabolism of mephedrone in rat urine 
The following mephedrone metabolites were detected in rat urine samples 
using LC Q-E (Table S10): normephedrone, hydroxy-tolyl-mephedrone, 4’-
carboxy-mephedrone, 4’-carboxy-normephedrone, hydroxyl-mephedrone-3O-
glucuronide. Chiral LC VP analysis of mephedrone excreted in the rat urine 
revealed that mephedrone undergoes stereoselective metabolism. 
Both mephedrone and formed metabolites were not racemic in excreted urine: 
normephedrone (Figure S6), hydroxytolyl-mephedrone (Figure S7) and nor-
hydroxytolyl-mephedrone (Figure S8). Diastereoisomers of dihydro-
normephedrone were also found (Figure S7) and a predominance of one 
diastereoisomer with respect to the other was observed in this study. Linhart et al. 
(2016) observed a ratio for erythro- and threo- dihydro-normephedrone of 3:1 [20]. 
This ratio might also be confirmed in this study by assuming the same eluting 
profile as described in [20], although their analytical standards were not available. 
Indeed, EFs were 0.49 ± 0.0 and 0.47 ± 0.0 for mephedrone and normephedrone in 
spiked control rat urine, respectively, whilst a dramatic decrease in EF (0.44 ± 0.0 
and 0.22 ± 0.0 for mephedrone and normephedrone respectively) was observed in 
positive rat urine (Figure 4-6). 
This data shows stereoselective metabolism of both compounds favouring S-(-)-
enantiomer. This is in contrast to pHLM studies and human pooled urine. This study 
indicates that mephedrone metabolism in humans and rats might follow different 
stereoselective patterns. 
 




Figure 4-6 Enantiomeric fraction of mephedrone in’ positive’ and in ‘control’ rat urine samples. 
 
A possible hypothesis for this finding might be the hydroxylation reaction of R-(+)-
normephedrone which lead to enrichment of mephedrone with S-(-)-
normephedrone enantiomer. This also indicates that rat metabolism studies might 
not be indicative for human biomarker selection in WBE. 
It is interesting to note that in the case of nor-hydroxytolyl-mephedrone, although 
this molecule has one chiral centre, four peaks showing the same fragmentation 
patterns were found (Figure S8). It was therefore hypothesised that the metabolic 
hydroxylation reaction may have occurred at different sites of the molecule. For 
this purpose, acetylated rat urine was injected in LC VP and GC-MS systems for 
suspected acetylated metabolites. Due to the presence of co-eluting interferences 
with some matrix compound, no distinguishable peaks for the enantiomers were 
found. No spectra corresponding to the (1-2 acetyl) hydroxyl-nor-mephedrone were 
found. Further work needs to be undertaken to explain this phenomenon. 
 
4.4.3.3 Step 3(c): Mephedrone in pooled urine 
Chiral LC TQD analysis of pooled human urine samples confirmed predominance 
of R-(+)-mephedrone (Figure 4-7), hence its stereoselective metabolism. This is in 
agreement with wastewater samples and the pHLM study, indicating that 
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Figure 4-7 Enantiomeric fraction of mephedrone in pooled human urine samples. Results obtained 
by applying the unpaired t-test showed “t Stat > t Critical one-tail” (4.88 > 1.89 for α=0.05; 4.88 > 
4.78 for α=0.001), p one-tail (0.00089) < 0.001. Therefore, EFs from pooled human urine samples 
were significant different from EF=0.5. All t-tests and P-values can be found in Appendix 2 (S2). 
 
Non-targeted screening with LC-QTOF and LC Q-E confirmed the presence 
of several metabolites that we found in wastewater, rat urine and in pHLM samples. 
These are: 4’-carboxy-mephedrone, 4’-carboxy-normephedrone, 1-dihydro-
mephedrone (not in urine), 1-dihydro-normephedrone and hydroxyl-tolyl-
normephedrone (not in pHLM). Interestingly, normephedrone was not detected in 
wastewater and in pooled urine samples. 
 
4.4.4 Step 4: Microbial degradation in wastewater and verification of 
stability of possible biomarkers of mephedrone in wastewater 
Incubation of mephedrone in wastewater over a duration of 24h did not lead 
to degradation and formation of by-products. Wastewater spiked with mephedrone 
was also incubated in a week long experiment. No formation of by-products was 
observed. 
Stability of DTRs in wastewater is critical if low uncertainty measurements 
of community-wide drug abuse using WBE are to be undertaken. Good biomarkers 
need to be stable for at least 24 hours (so to ensure stability during 24-h composite 
sampling time). As recommended by the consensus best practise protocol for 
sampling and storage in Castiglioni et al. 2014 [13], low temperature settings reduce 
the degradation of biomarkers and help the preservation of the analytes in the 
samples. Indeed, our results after incubation of wastewater at differing 
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reduces degradation of mephedrone with only approximately 10% change at 4oC 
when compared to up to 50% change at 17oC (Table 4-2, Figure S9). Furthermore, 
no formation of new metabolites was observed, which confirms stability of 
mephedrone in wastewater over a time of 24h at 4oC. In contrast, normephedrone 
was found to degrade at temperature settings. 
 
Table 4-2 Stability of targeted compounds in influent wastewater samples stored over a 48 hours. 
Analyte Stabilitya [%] 
Raw (unfiltered) wastewater, pH 
7.4, stored at 17◦C 
Raw (unfiltered) wastewater, pH 7.4, 
stored at 4◦C 
12 h 24 h 48 h 12 h 24 h 48 h 
R-(+)-
Mephedrone 
-23.4 ± 2.7 -29.3 ± 4.7 -48.5 ± 5.0 -9.5 ± 2.7 -10.9 ± 3.5 -10.1 ± 6.3 
S-(-)-
Mephedrone 
-7.1 ± 4.8 -10.2 ± 7.0 -34.4 ± 10.1 -4.0 ± 4.0 -11.9 ± 17.1 -23.9 ± 7.1 
R-(+)-
Normephedrone 
-19.0 ± 13.6 -48.2 ± 73.2 -39.2 ± 10.2 18.0 ± 95.3 -19.9 ± 25.7 -41.7  ± 15.1 
S-(-)-
Normephedrone 
-6.9 ± 0.0 1.5 ± 5.1 -56.1 ± 17.8 -5.1 ± 45.0 -11.1 ± 1.0 -10.1 ± 4.2 
a Expressed as difference in percentage from to time-point 0 ± SD 
 
4.5 Conclusions 
This chapter proposes a new investigative framework for the selection and 
validation of metabolic biomarkers of abused drugs (such as NPSs) with limited 
information on their human metabolism with the ultimate goal of their application 
in WBE to estimate community-wide drug use. Mephedrone was chosen as a target 
chemical due to its widespread abuse in the UK and common presence in 
wastewater but little understanding of its metabolic profile. 
The developed framework consisted of four steps and resulted in the following 
conclusions: 
Step 1: Identification of possible metabolic biomarkers of mephedrone 
present in wastewater using LC-HRMS (in-direct in-vivo study). 
Several metabolites of mephedrone and potential metabolic biomarkers were 
identified in wastewater. These are: dihydro-mephedrone, N-sulfo-normephedrone, 
hydroxy-tolyl-normephedrone, 4’-carboxy mephedrone, 4’-carboxy 
normephedrone, 1-dihydro-normephedrone. 
Step 2: Verification of chiral signature of mephedrone using chiral LC-
MS/MS. 
 ‘Street’ mephedrone was found to be distributed in the UK as racemate.  
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Step 3: Confirmation of human metabolic residues in in-vivo (pooled urine) 
and in-vitro (pHLM) studies. 
Stereoselective metabolism of mephedrone favouring R-(+)-enantiomer was 
observed in pHLM experiments and it was confirmed by pooled urine analysis. 
Interestingly, in-vivo rat metabolism studies led to contrasting results where S-(-)-
mephedrone was favoured. This questions rat studies as a viable approach towards 
biomarker selection for WBE. 
In-vitro pHLM experiments lead to identification of several metabolites and 
potential biomarkers of mephedrone abuse. These are: normephedrone, 4’-carboxy-
normephedrone, dihydromephedrone, 4’-hydroxymethyl-mephedrone, 4’-carboxy-
mephedrone, normephedrone-N-glucuronide. Interestingly, normephedrone formed 
via stereoselective metabolism of mephedrone in in-vitro pHLM studies was not 
identified in pooled urine samples. This might be due to dilution of pooled urine 
samples with urine from non-abusers. 
Step 4: Microbial degradation in wastewater and verification of stability of 
possible biomarkers of mephedrone in wastewater. 
Wastewater simulating microcosms revealed high stability of mephedrone with up 
to a week long incubation time at 4°C.  
In the light of the above evidence, the following conclusions were drawn: 
a. Mephedrone is a suitable candidate as a biomarker, because of its high 
stability in wastewater and stereoselective metabolism in humans. 
b. Chiral analysis is fundamental in the enantiomeric profiling of mephedrone, 
especially in distinguishing between human consumption and direct disposal of 
unused drug. 
c. Despite stereoselective formation of normephedrone in in vitro pHLM 
studies, this metabolite was found to be unsuitable as a biomarker of mephedrone 
consumption as (i) it was not detected in pooled human urine and in wastewater and 
(ii) due to its low stability in wastewater. 
d. Possible biomarker candidates (apart from mephedrone) for future 
investigations are: 4’-carboxy-mephedrone, 4’-carboxy-normephedrone, 1-
dihydro-mephedrone, 1-dihydro-normephedrone and hydroxyl-tolyl-
normephedrone. 
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4.6 Contributions 
Erika Castrignanò and Barbara Kasprzyk-Hordern planned and designed the study. 
Marie Mardal contributed to the experiments on the incubation wastewater study, 
pHLM study for phase I, rat urine analysis and their data analysis at the University 
of Saarland, Homburg, Germany. Markus R. Meyer supervised the experiments 
carried out at the University of Saarland, Homburg, Germany. At the University of 
Bath, Dr. G.Dan Pantos performed computational study and Axel Rydevik helped 
in interpreting LC-HRMS data. “Street” mephedrone samples (collected at 
Glastonbury Festival) and pooled urine samples were kindly provided by Bram 
Miserez, John Ramsey and Trevor Shine at TICTAC Communications Ltd, St. 
George's University of London, UK. Wastewater samples were provided by Wessex 
Water, UK. 
 
4.7 Supplementary Data 
The following supplementary data are contained in Appendix 2: 
Figure S1 Synthesis of (±)-mephedrone (a, b) (modified from Schifano et al. (2010) 
[24]) and of S-(-)-mephedrone (c) (modified from Osorio-Olivares et al. (2003) 
[38]). 
Figure S2 Proposed mephedrone metabolism in humans (modified from Pozo et al. 
(2014)). 
Table S1 Selected analytes and their properties (MW molecular weight, Exp 
experimental, Pred predicted, a predicted using ACD/labs software 
(http://www.chemspider.com). 
S1-Experimental settings and procedure for acetylation of rat urine sample. 
Table S2 Experimental set up of the reactors used for (a) incubating wastewater and 
(b) pHLM. 
Table S3 MRM transitions in chiral LC-TQD method. 
Table S4 Method validation parameters (chiral LC-TQD) for mephedrone and 
normephedrone. 
Table S5 Operating conditions for the absorbance and CD spectra of (±)-
mephedrone (4-MMC) 
Figure S3 CD and absorbance spectra of (±)-mephedrone (4-MMC) (a,b). UV 
spectra of (±)-mephedrone from the computational study (c). 
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Figure S4 Predicted CD spectra for (±)-mephedrone (a) and for (±)-normephedrone 
(b). 
Table S6 Mephedrone concentrations and population-normalised mass loads in 
wastewater samples during one week monitoring campaign in 2014 and in 2015 in 
the UK. 
Table S7 Non-targeted analysis by LC Q-TOF: mephedrone metabolites predicted 
in wastewater and in pHLM by using MetID software (Theor means theorethical 
and Exp. experimental). 
Table S8 Target screening analysis in wastewater and in pHLM by using LC-
QTOF. 
Table S9 Untarget screening analysis in wastewater and in pHLM by using LC-
QTOF. 
Table S10 ddMS2 spectra of mephedrone metabolites detected in rat urine sample 
using LC Q-E. 
Figure S6 MS2 chromatogram of mephedrone and normephedrone in rat urine 
sample using chiral LC VP. 
Figure S7 Full scan chromatograms and spectra of mephedrone metabolites in rat 
urine sample using chiral LC VP. Dihydro-nor-mephedrone diastereoisomers are 
shown in (a), whilst the partial separation of hydroxytolyl-mephedrone enantiomers 
in (b). 
Figure S8 Mephedrone metabolites in rat urine sample identified with chiral LC-
VP: nor-hydroxytolyl-mephedrone and its two enantiomers (note: the presence of 
another minor mephedrone metabolite was observed). 
Figure S9 Mephedrone and normephedrone concentrations and enantiomeric 
fraction in wastewater stability study. Picture of experimental settings. 
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Chapter 5: Enantiomeric profiling of illicit drugs 
in a pan-European study 
 
5.1 Summary 
The aim of this chapter is to present a first study on enantiomeric profiling 
of chiral drugs of abuse and potentially abused drugs in several European locations. 
WBE approach and chiral analysis were combined together, enabling the estimation 
of illicit drug usage at community level and the evaluation of their enantiomeric 
composition. This allowed extrapolating information on the nature of the drug 
residues by distinguishing between human consumption and direct disposal and on 
their synthesis routes. 
Mephedrone was found in the UK with population-normalised mass loads 
up to 47.7 mg 1000 people-1 day-1, enriched with one enantiomer. This finding 
suggests a stereoselective metabolism in humans or stereoselective microbial 
metabolic processes occurring in the environment. A spatial trend was observed 
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between Northern and Southern European cities in the case of amphetamine loads 
with a slight enrichment of R-(-)-amphetamine in wastewater for the majority of 
sampling sites. Methamphetamine loads over the average were detected in Norway. 
This could be motivated by the high number of seizures occurred in this country as 
reported by the EMCDDA. The presence of the predominant S-(+)-
methamphetamine enantiomer in wastewater samples from other European cities 
could be ascribed to its stereoselective synthesis in the illicit manufacturing market. 
The prevalence of R-(-)-MDMA in wastewater indicated that MDMA was present 
because of its consumption rather than its direct disposal. This was also observed 
in cities where previous monitoring campaigns revealed direct disposal of MDMA 
tablets. The enantiomeric profiling of MDMA showed an interesting metabolic 
pattern. In particular, S-(+)-MDA originated from MDMA metabolism rather than 
MDA itself, especially for MDA loads found during weekends. HMMA was more 
suitable as a MDMA biomarker than HMA, which was a good indicator of high 
abused MDMA levels only. Indeed, a slight enrichment of S-(+)-HMMA would 
mean MDMA abuse. Other biomarkers were also investigated such as precursors, 
MDEA, PMA, zopiclone, fluoxetine, norfluoxetine, venlafaxine, 
desmethylvenlafaxine and tramadol. The presence of precursors was reasonably 
ascribed to their medical use. MDEA and PMA were not found. Although high 
usage of zopiclone, fluoxetine and norfluoxetine were suspected, these drugs were 
lower than the method quantification limit (MQL). Venlafaxine: 
desmethylvenlafaxine ratio was 1:2 for the majority of countries. Controversial is 
the interpretation of the enantiomeric composition of both compounds due to 
different EF values. Very high tramadol loads were found in Brussels. Its chiral 
analysis showed an EF range between 0.53 and 0.61, indicating the predominance 
of the first eluting enantiomer. 
 
5.2 Introduction 
Since the first study by Zuccato et al. (2011) [1] on WBE to estimate 
community-wide illicit drug use trends, WBE has proven to provide valuable and 
complementary information to the traditional epidemiological strategies on public 
health [2, 3]. Indeed, the analysis of carefully selected biomarkers, which are often 
unique human urinary metabolic excretion products, allowed for near real-time 
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profiling of population health. Examples include the usage of illicit drugs [4, 5], 
legal highs [6, 7], alcohol [8] and tobacco [9]. 
WBE was utilised by several research groups to verify community-wide 
drug use [10-16]. The first European study in 2011 led by the Sewage Analysis 
CORe group Europe (SCORE) (www.score-cost.eu) involved 19 cities and 
estimated temporal and spatial drugs use trends across Europe [4]. This was 
followed by Europe-wide monitoring of 23 cities in 2012 [5] and then 42 cities in 
2013 [17].There are several key stages in WBE: (i) biomarker selection; (ii) 
collection of representative wastewater samples; (iii) measurement of biomarkers 
in wastewater; (iv) calculation of the normalised-mass loads and, finally, (v) 
estimation of the drug consumption pro capita. Biomarker selection is considered 
to be of critical importance. This cannot be limited to the parent drug itself if 
determination of drug consumption estimate is the aim, since bias coming from 
disposal of unused drug might take place. A biomarker should be uniquely formed 
in the body (such as metabolite), be stable and present in wastewater at quantifiable 
concentrations. Unfortunately, as it is not always possible to select a unique 
metabolic biomarker, different solutions need to be sought. One of the innovative 
approaches focuses on enantiomerism of chiral drugs and their stereoselective 
metabolism. 
Enantiomeric profiling can supplement WBE data with valuable 
information on abuse trends and potency of chiral drugs. It can also help with 
distinguishing between legal and illicit use of drugs as well as providing an 
indication of actual consumption as opposed to disposal of non-consumed drugs 
[2]. This is because drug synthesis is associated with different chiral signatures that 
depend on synthetic routes. Furthermore, chiral drugs undergo stereoselective 
disposition in humans leading to changes in the chiral signature (EF, enantiomeric 
fraction) [18]. For example, MDMA is produced as racemate but it undergoes 
stereoselective metabolism leading to enrichment of MDMA excreted in urine with 
R-(-)-enantiomer due to its longer elimination rate with respect to S-(+)-isomer [19]. 
The potential in using enantioselective analysis for WBE purposes was 
demonstrated in several studies, even though the main investigation of illicit drugs 
at enantiomeric level was focused on understanding the fate of chiral drugs during 
wastewater treatment and in the environment [20]. Kasprzyk-Hordern and Baker 
[19] confirmed that amphetamine found in wastewater in the UK was from illicit 
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use (and not from medical use) and that MDA was present in wastewater as a result 
of MDMA consumption rather than MDA use. Vázquez-Roig et al. reported usage 
patterns of chiral drugs in the catchment area of Valencia (Spain) [21], by linking 
selective enrichment of MDMA with R-(-)-enantiomer in wastewater to human 
consumption. Enantioselective analysis also helped in understanding that the 
unexpectedly high quantity of MDMA detected during a monitoring campaign in 
2011 in Utrecht was due to direct disposal of unused MDMA as a consequence of 
a police raid at a nearby illegal production facility [22]. Similarly, Petrie et al. linked 
high levels of fluoxetine in wastewater with disposal of unused drug rather than its 
consumption [23]. Recently developed by Castrignanò et al., a multi-residue 
enantioselective method enabled simultaneous analysis of 56 biomarkers allowing 
for the first time the detection of mephedrone enantiomers in wastewater samples 
in the UK [24]. 
Despite these findings, a limited number of studies correlated the 
enantiomeric composition of chiral biomarkers to official statistics [20]. Hence, this 
is the first pan-European study aimed at investigating enantiomeric profiling of 
“common” drugs of abuse, new synthetic drugs and chiral pharmaceuticals in eight 
cities from eight different countries (i.e. a population equivalent of 4942979). The 
focus of this research was to: 
• quantify selected drugs in wastewater from eight European locations, 
• verify if drug residues in wastewater were originated from direct disposal 
of unused drug or their consumption, 
• verify new emerging trends and any changes in drug usage across Europe. 
 
5.3 Experimental 
5.3.1 Chemicals and Materials 
The following chiral analytes were selected in this study (Figure 5-1): (±)-
mephedrone, (±)-4-hydroxy-3-methoxymethamphetamine (HMMA), (±)-3,4-
methylenedioxymethamphetamine (MDMA), (±)-4-hydroxy-3-
methoxyamphetamine (HMA), (±)-methamphetamine, (±)-amphetamine, (±)-3,4-
methylenedioxyamphetamine (MDA), (±)-tramadol, (±)-desmethylvenlafaxine, 
(±)-venlafaxine, (±)-3,4-methylenedioxy-N-ethyl-amphetamine (MDEA), (±)-
ephedrine, (±)-pseudoephedrine, (±)-para-methoxyamphetamine (PMA), (±)-
norephedrine, (±)-norfluoxetine, (±)-zopiclone, (±)-fluoxetine.   




Figure 5-1 Chiral analytes selected in the study. 
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Table S1 shows all analytes, their CAS number, molecular formula, molecular 
weight, pKa and supplier information. Amphetamine-D5, methamphetamine-D5, 
mephedrone-D3, MDA-D5, MDMA-D5, MDEA-D5, zopiclone-D4 and 1S,2R-(+)-
ephedrine-D3 were used as internal standards (IS). All standards and ISs were of 
the highest purity available (>97%). Stock and working solutions of standards were 
stored at -20° C. Methanol, acetonitrile and ammonium acetate were purchased 
from Sigma Aldrich, UK. Ultrapure water was obtained from PURELAB UHQ-PS 
Unit (Elga, UK). Deactivation of the glassware was carried out with 5% DMDCS 
followed by washing with toluene and methanol in order to prevent the adsorption 
of basic analytes to the hydroxyl sites on the glass surface.  
 
5.3.2 Sample collection, storage and sample preparation 
24-hours composite wastewater influent samples were collected over seven 
consecutive days in March 2015 from several wastewater treatment plants across 
Europe using best practice sampling protocol [25]. The week in March was chosen 
as a “routine week”, in which no national and local festivities were taking place. 
Sampling sites were in Oslo (Norway), Bristol (United Kingdom), Lyngby 
(Denmark), Utrecht (The Netherlands), Brussels (Belgium), Zurich (Switzerland), 
Milan (Italy) and Castellon (Spain) (Figure 5-2). 
 
Figure 5-2 Sampling sites. 
 Chapter 5: Enantiomeric profiling of illicit drugs in a pan-European study 
 124 
Table 5-1 provides information on population and flow for the selected cities in the 
study. After collection, samples were transported to the local laboratory in 
refrigerated conditions and shipped on ice blocks to the UK within 24 hours. A fully 
validated analytical method was used for the detection and quantification of chiral 
drugs of abuse in wastewater as described elsewhere [24]. Briefly, the samples were 
filtered through GF/F 0.7 µm glass fibre filter (Whatman, UK). 100 µL of IS mix 
(concentration 1 mg L-1) were added to 100 mL of a wastewater sample. 
 
Table 5-1 Selected cities in the study, population and flow data. 
City Bristol Oslo Milan Utrecht Castellon Brussels Zurich Copenhage
n 
Country UK Norway Italy The 
Netherland
s 





886650 580639 1100000 300000 180690 954000 410000 531000 



































































SPE was carried out using Oasis HLB cartridges (60 mg, Waters, UK) and the 
following procedure. The cartridges were conditioned with 2 mL of methanol 
followed by equilibration with 2 mL of ultrapure water at a rate of 3 mL min-1. The 
wastewater sample was passed through the HLB cartridge at a rate of 8 mL min-1. 
The cartridges were then washed with 3 mL of ultrapure water at a rate of 3 mL 
min-1 and the analytes were eluted with 4 mL of methanol at a rate of 8 mL min-1 
into 5 mL silanised glass tubes. The extract was transferred to the TurboVap 
evaporator (Caliper, UK). After evaporation to dryness under nitrogen flow (5-10 
psi) at 40 °C the samples were reconstituted with 0.5 mL 1mM ammonium 
acetate/methanol 85:15 v/v and filtered through 0.2 µm PTFE filters (Whatman, 
Puradisc, 13mm). The filtered samples were transferred to polypropylene plastic 
vials bonded pre-slit PTFE/Silicone septa (Waters, UK) and then 20 µL were 
directly injected into a chiral HPLC-MS/MS. 
 Chapter 5: Enantiomeric profiling of illicit drugs in a pan-European study 
 125 
5.3.3 Sample analysis 
Samples were analysed in triplicate using HPLC-MS/MS system. Separation of all 
chiral analytes was undertaken with a CHIRALPAK® CBH HPLC Column 5 μm 
particle size, L × I.D. 10 cm × 2.0 mm (Chiral Technologies, France) with a chiral-
CBH guard column 10 × 2.0 mm, 5 μm particle size (Chiral Technologies, France) 
using a Waters ACQUITY UPLC® system (Waters, Manchester, UK) under 
isocratic conditions at a 0.1 mL min-1. The mobile phase was made of a solution 1 
mM ammonium acetate/methanol 85:15 v/v. The temperature was kept at 4 °C in 
the ACQUITY UPLCTM autosampler, whilst at 25 °C in the column compartment. 
The injection volume was set at 20 µL. 
A triple quadrupole mass spectrometer (Xevo TQD, Waters, Manchester, UK) 
equipped with an electrospray ionisation source was used in positive mode 
operating in the multiple reaction monitoring (MRM) mode. Table S2 shows MRM 
transitions used for selected analytes. MassLynx 4.1 (Waters, UK) was used to 
control the Waters ACQUITY system and the Xevo TQD. Data processing was 
carried out using TargetLynx software (Waters, Manchester, UK). Method 
validation data are provided in Tables S3-S7. 
 
5.3.4 Calculations 
Enantiomeric fractions (EF) were calculated using equation (7) reported in chapter 
3. In order to obtain daily mass loads, the concentrations of analytes expressed in 
ng L-1 were multiplied by the flow rate (L day-1) and then normalised by the 
population size of the catchment area. This was essential for comparing data coming 
from different cities involved in the study. Figure 5-3 shows the trend of the 
population-normalised loads and the EF along the monitoring week, whilst Figure 
5-4 shows the average weekly population- normalised loads and their weekly 
average EF. Estimated community-wide consumption was calculated using 
population-normalised mass loads and correction factors for excretion pattern (CF) 
of 3.3, 2.3 and 1.5 for amphetamine, methamphetamine and MDMA respectively 
[26, 27]. Estimated data for amphetamine, methamphetamine and MDMA usage 
are shown in Tables S8-S10. 
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5.4 Results and Discussions 
For simplicity, in the graphics results are referred and shown with the fullnames of 
the countries (and not with those of the cities). 
5.4.1 Amphetamine and Methamphetamine 
Data on amphetamines consumption reported by the European drug report 
2015 showed that 1.3 million of Europeans within a range age of 15 - 34 years old 
used amphetamines in the last year [28]. This data was obtained by EMCDDA’s 
five key epidemiological indicators, which consist of “estimates of recreational use 
(based mainly on surveys), estimates of high-risk use, drug-related deaths, 
infectious diseases and drug treatment entry” along with Reitox focal points and 
other sources [28]. In this work, we applied WBE approach to estimate 
amphetamine and methamphetamine use in eight European cities. Unfortunately, 
no metabolic biomarkers of amphetamine and methamphetamine exist that can be 
reliably used to estimate their abuse via WBE. Therefore, amphetamine and 
methamphetamine itself are commonly used as biomarkers. This constitutes a 
problem as the analysis of parent drugs does not usually allow for distinction if 
(meth)amphetamine residue present in wastewater comes from direct disposal of 
unused drug or its consumption. 
Additionally, amphetamine is also a metabolite of other (prescription) drugs, such 
as fenethylline, fenproporex, methamphetamine [29] and selegiline [5]. Moreover, 
the percentage of the unchanged amphetamine fraction in urine can change due to 
changes in urine pH: at neutral pH 30% of amphetamine is found unchanged in 
urine within 24 hours [29], acid urine may contain up to 74% of amphetamine, while 
alkaline urine only 1%. This could lead to high uncertainty of calculations and 
possible over or underestimation of amphetamine use. 
The awareness of this uncertainty is well recognised in the scientific community 
studying amphetamine abuse through WBE [30], [31], [32], [26]. As reported by 
Ort et al. (2014) [5], the evaluation of an effective consumption of amphetamine 
has to be carried out along with methamphetamine data to distinguish between drug 
consumption from its metabolism. However, as in the case of amphetamine, 
methamphetamine excretion is pH of urine dependent. For example, at pH 6-8, the 
unchanged methamphetamine is present at 43% in urine in 24 h, while its 
pharmacologically active metabolite amphetamine at only 4-7%. At acidic pH, up 
to 76% of unchanged methamphetamine can be excreted in urine in 24h.   





































































































Figure 5-3 Population-normalised mass loads and enantiomeric fraction values in a week monitoring campaign. Here, results are shown with the fullnames of the 
countries (and not with those of the cities). For HMMA: EF values displayed in the graphics are reported using the equation E2/(E1+E2), assuming that E1 is R-
(-)-HMMA and E2 is S-(+)-HMMA.  


















































































































































































































































Figure 5-4 Average population-normalised mass loads and average enantiomeric fraction values in a week monitoring campaign. Here, results are shown with 
the fullnames of the countries (and not with those of the cities). For HMMA: EF values displayed in the graphic are reported using the equation E2/(E1+E2), 
assuming that E1 is R-(-)-HMMA and E2 is S-(+)-HMMA. Statistical evaluation obtained by applying the unpaired t-test to amphetamine showed that “t Stat > t 
Critical one-tail” for all wastewater samples excluding Switzerland (8.25 > 1.81 for α=0.05, 8.25 > 4.14 for α=0.001), p one-tail < 0.001. Therefore, EFs from 
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On the other hand, at alkaline urine only around 2% of methamphetamine will be 
excreted [33]. Furthermore, verification of amphetamine/methamphetamine ratio 
cannot provide comprehensive information on drug consumption against direct 
disposal of unused drug. Additional evidence is therefore needed to distinguish 
between amphetamine abuse from its direct disposal or its formation as a metabolite 
of other drugs. The phenomenon of enantiomerism of amphetamines may 
contribute in helping with it. 
Amphetamine has one chiral centre and exists in two enantiomeric forms. 
Amphetamine’s enantiomers have different activity: S-(+)-amphetamine is more 
potent than the R-(-)-enantiomer in eliciting Central Nervous System (CNS) effects, 
whilst R-(-)-amphetamine in cardiovascular effects [34]. Synthesis of racemic 
amphetamine is commonly performed via the Leuckart method, which uses 1-
phenyl-2-propanone, formic acid, ammonium formate or formamide as reagents 
[35]. A stereoselective method, which involves the reduction of appropriate 
diastereoisomers of norephedrine or norpseudoephedrine [36], is much less 
common [37]. In Europe, licit amphetamine is prescribed as enantiomerically pure 
S-(+)-amphetamine formulations (e.g. dexamfetamine sulphate known with trade 
name Dexamed, Attentin, Tentin) in the UK, Denmark, Finland, Ireland, 
Luxembourg, the Netherlands, Norway, Spain, and Sweden [38] and as racemate in 
prescriptions drugs only under the Medicines Act. The prodrug lisdexamfetamine 
in the form of dimesylate salt is completely metabolised to S-(+)-amphetamine and 
it is also available in the European market [39, 40]. Pharmaceuticals, such as 
fenproporex [41] and clobenzorex [42], are metabolised to 25-35% and 5% of 
racemic amphetamine, respectively [43]. If excreted as metabolite of selegiline, 
which intake is only R-(-)-enantiomer, it is enriched with R-(-)-amphetamine along 
with R-(-)-methamphetamine [44]. Amphetamine undergoes enantioselective 
metabolism by favouring S-(+)-enantiomer (elimination half-life of S-(+)-
amphetamine is slightly shorter than R-(-)-amphetamine [45]) and leading to 
enrichment of amphetamine with R-(-)-enantiomer when excreted in urine. 
Therefore, if racemic amphetamine is consumed, it will be found in wastewater 
enriched with R-(-)-enantiomer. 
Similarly to amphetamine, methamphetamine enantiomers are known to 
have different activity. The S-(+)-enantiomer has a central stimulant activity. It is 
used in the treatment of obesity and it is also abused as illicit drug. The R-(-)-
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enantiomer has a prominent peripheral sympathomimetic activity and for this 
reason it is used as a nasal decongestant in non-prescription inhalers in the 
American market [29]. On the illicit market, methamphetamine is synthesised in 
two ways. The first starts from the reactions of phenylacetone (i.e. the Leuckart 
route and reductive amination) giving a racemic mixture of methamphetamine, 
whilst the other starts from (1R,2S)-(-)-ephedrine [or (1S,2S)-(+)-pseudoephedrine] 
that is reduced with red phosphorus and hydriodic acid giving a stereoselective 
synthesis of the S-(+)-isomer. EMCDDA reports indicate that methamphetamine 
commonly found in Europe is primarily enantio-enriched [46]. However, the 
synthesis with phenylacetone as precursor is preferred in Lithuania. Similarly to 
amphetamine, methamphetamine undergoes stereoselective metabolism in humans 
by favouring S-(+)-enantiomer [43] and leading to the enrichment of 
methamphetamine in urine with R-(-)-enantiomer with a changing enantiomeric 
ratio over the time. Controlled pharmaceuticals, such as mefenorex, produce 
racemic methamphetamine as metabolite, whilst others containing famprofazone as 
active compound are converted to 30% S-(+)-methamphetamine and 70% R-(-)-
enantiomer [43]. Therefore, if racemic methamphetamine is consumed, it will be 
found in urine enriched with R-(-)-enantiomer. Additionally, generated 
amphetamine will be enriched with S-(+)-enantiomer. If enantiomerically pure S-
(+)-methamphetamine is consumed, it will be excreted with urine as 
enantiomerically pure S-(+)-methamphetamine and enantiomerically pure S-(+)-
amphetamine. This is because chiral inversion does not take place during human 
metabolism of methamphetamine. 
In this study population normalised mass-loads of amphetamine ranged 
from <MQL in Castellon to a maximum weekly average value of 122.3 mg day-1 
1000 people-1 in Oslo. In particular, the weekly average values were the following:  
• 122.3 mg day-1 1000 people-1 in Oslo (twice as low amount was reported in 
2013 [17]) with loads below 100 mg day-1 1000 people-1 only in two days over a 
week-sampling campaign. R-(-)-enantiomer was mainly predominant across the 
monitoring week (EF<0.5) with an exception on Sunday in which EF was 0.52. 
• 82.6 mg day-1 1000 people-1 in Bristol (exactly the same amount was 
reported in 2014 [17]) with a higher value only on Saturday of 89.6 mg day-1 1000 
people-1 with a predominance of R-(-)-enantiomer. EF values were lower than 0.5 
apart for three days in which EF were about 0.5 (Tuesday, Wednesday and Friday). 
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• 76.5 mg day-1 1000 people-1 in Lyngby (lower amount was found in 2013 
in Copenhagen [17]) with higher loads during the weekend and an EF average value 
lower than 0.5 for all the week. 
• 36.4 mg day-1 1000 people-1 in Utrecht (46.5 and 111.1 mg day-1 1000 
people-1 [17] were reported in 2013 and in 2014 respectively) with higher loads 
from Tuesday to Saturday. EF values were always just slightly below 0.5. 
• 58.3 mg day-1 1000 people-1 in Brussels (24.8 mg day-1 1000 people-1 was 
reported in 2013 [17]) with a clear weekend trend and EF values always lower than 
0.5. 
• 29.3 mg day-1 1000 people-1 in Zurich (42.7 and 25.7 mg day-1 1000 people-
1 were reported in 2013 and in 2014 respectively [17]) with a slight tendency in 
higher loads in the weekend. The average EF was 0.5, but fluctuating values above 
and below 0.5 were found throughout the week. 
• 2.9 mg day-1 1000 people-1 in Milan (values were below limit of 
quantification (LOQ) since 2012 [17]) with no trend observed during the weekend. 
EF values were reported even though high error bars are displayed due to low 
concentrations. 
The average population-normalised amphetamine loads showed a decreasing 
amphetamine usage from Northern to Southern cities. Oslo shows higher 
amphetamine prevalence among Northern European cities. Indeed, only Italian and 
Spanish cities were notably below the overall mean loads 34-28 mg day-1 1000 
people-1 reported in the 2013 European study [5] (the first value is referred to the 
cities participating in all 3 years study, the second to all cities participating in the 
corresponding year). Temporal trends show that amphetamine loads increased in 
Oslo, Lyngby, Brussels and Milan, even if they are very low for the latter city. They 
remained stable in Bristol and decreased in Zurich and in Utrecht. 
However, results on amphetamine are in line with previous monitoring studies 
undertaken in years 2012-15 [5]. Furthermore, enantiomeric profiling revealed that 
amphetamine in wastewater is enriched with R-(-)-enantiomer in most European 
cities. This could indicate the consumption of racemic amphetamine. Interestingly, 
amphetamine was found to be enriched with S-(+)-enantiomer in Zurich and Milan. 
This suggests either usage of S-(+)-amphetamine (prescribed or illicit) or its 
formation as a result of metabolism of methamphetamine. This is very likely as 
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methamphetamine in both cities was found to be enriched with S-(+)-enantiomer 
(see discussion below). 
Population normalised mass-loads of methamphetamine ranged from 
<MQL in Utrecht and Castellon to a maximum value of 172.4 mg day-1 1000 
people-1 in Oslo. According to the EMCDDA Report [28], high methamphetamine 
seizures were seen in Norway and this could explain the high loads detected. In 
details, the results were the follows: 
• 172.4 mg day-1 1000 people-1 as weekly average value in Oslo. This value 
is definitely lower than 237.4 mg day-1 1000 people-1 reported in 2014 but still 
higher than 107.9 in 2013 [17]. The highest amount was found on Monday (318.5 
mg day-1 1000 people-1) and EF values were close or below 0.5. 
• 1.2 mg day-1 1000 people-1 in Bristol (a similar amount was reported in 2014 
[17]). EF values were not displayed because of the proximity of the concentrations 
to the LOQ. 
• Weekly average 6.6 mg day-1 1000 people-1 in Lyngby (<LOQ and 9.8 mg 
day-1 1000 people-1 were reported for the Danish capital respectively in 2014 and 
in 2013 [17]). Due to the presence of only S-(+)-enantiomer in the samples, EF 
values were equal to 1. The loads were quite uniform during all the week. 
• 3.7 mg day-1 1000 people-1 as weekly average value in Brussels (1.7 mg day-
1 1000 people-1 was reported in 2013 [17]) with a very steady trend in the weekend. 
EF values were always equal to 1 because of the presence of one enantiomer only. 
• 20.2 mg day-1 1000 people-1 as weekly average value in Zurich (16.7 and 
21.8 mg day-1 1000 people-1 were reported in 2013 and in 2014 [17]) with a slight 
tendency in higher loads in the weekend. S-(+)-enantiomer was the only enantiomer 
found, so the average EF was 1. 
• 10.3 mg day-1 1000 people-1 in Milan (values were 5.9 and 5.4 mg day-1 
1000 people-1in 2013 and 2014 respectively [17]). 
The overall mean value ranged from 17 to 33 mg day-1 1000 people-1 in 2013 [5] 
(as before, the first value is referred to the cities participating in all 3 years study, 
the second to all cities participating in the corresponding year). Zurich was found 
to have the second high methamphetamine loads of 20.2 mg day-1 1000 people-1 as 
weekly average. Estimates in Lyngby and Brussels were below the overall mean 
value. Other European locations showed low levels. Despite being below the 
European average, Italian data showed doubled amount of methamphetamine load 
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when compared to data from the same area in 2013-14 and reaching 2012 loads 
[17]. 
Enantiomeric profiling of European wastewater samples revealed that 
methamphetamine distributed in most European locations is enantiomerically pure 
of S-(+)-methamphetamine. Norwegian wastewaters were an exception as they 
contained either racemic methamphetamine, which indicated direct disposal of 
unused racemic methamphetamine, or methamphetamine enriched with R-(-)-
enantiomer, which indicated consumption of racemic methamphetamine. This data 
can be confirmed by the fact that racemic methamphetamine, produced in 
Lithuania, is exported to Norway (and Sweden). Therefore, this synthetic route is 
different from that one observed in Central Europe. Interestingly, as S-(+)-
methamphetamine is the most potent psychotropic enantiomer [47] than racemic 
methamphetamine, one can conclude that despite lower usage of methamphetamine 
in Zurich, Lyngby, Brussels and Milan, potency of the drug is much higher than in 
Oslo. 
 
5.4.2 MDMA and MDA 
Data on ecstasy consumption reported by the European drug report 2015 
assessed that 1.8 million of Europeans with a range age from 15 and 34 years old 
used ecstasy in the last year, with a low and stable prevalence trends [28]. MDMA 
is the main ingredient of ecstasy tablets. It was suggested that there is an increased 
availability of high-content MDMA tablets, powder and crystals in Europe [28]. 
Europe-wide MDMA usage was also estimated using WBE [4, 5]. Unfortunately, 
estimations are based on quantification of MDMA as a DTR in wastewater. Such 
an approach does not allow for accurate evaluation of MDMA consumption against 
the direct disposal of unused drug. There are two possible solutions: (1) specific 
metabolic biomarkers should be sought as MDMA is known to extensively 
metabolise to MDA, DHMA and HMMA (Figure 5-5) and (2) enantiomeric 
profiling should be implemented as MDMA undergoes stereoselective metabolism 
leading to the formation of chiral metabolites. 
MDMA has one chiral centre and as a result it exists in two enantiomeric 
forms. MDMA enantiomers have different activity: S-(+)-enantiomers are more 
amphetamine-like stimulants and R-(-)-enantiomers are more hallucinogenic [48].  
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Figure 5-5 Expected EF values in wastewater for MDMA consumption using the analytical conditions described in Castrignanò et al. EF was calculated by dividing the 
concentration of (+)-enantiomer and the sum of the concentrations of both enantiomers. DHMA, DHMA sulphate, HMMA glucuronide and HMMA sulphate were never 
detected in wastewater. The hypothesis is that HMMA glucuronide is hydrolysed by bacteria, giving HMMA enriched of the S-enantiomer. 
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Synthesis of MDMA follows many illicit syntheses pathways, such as 
Leuckart method or reductive aminations reactions, using safrole, isosafrole, 
piperonal and 3,4-methylenedioxyphenyl-2-propanone as starting reagents (these 
precursors are all listed). These methods produce racemic MDMA [49] and, 
therefore, they are not stereoselective [50]. 
This means that MDMA is illegally distributed as racemate. Consequently, if 
directly disposed of, it will be quantified as racemate in wastewater. Furthermore, 
MDMA is stereoselectively metabolised with preferential metabolism of S-(+)-
MDMA, which is also eliminated faster than R-(-)-MDMA [51], and formation of 
MDA enriched with S-(+)-enantiomer [50]. Hence, if found in wastewater after 
consumption, MDMA will be enriched with R-(-)-enantiomer. 
In the current study, population-normalised MDMA loads ranged from a 
minimum average value of 3.2 mg day-1 1000 people-1 in Castellon to a maximum 
value of 62.0 mg day-1 1000 people-1 in Utrecht. Increasing MDMA loads were 
found during weekend in all of the countries involved, with the exception of the 
Dutch city that had also high MDMA load on a weekday. The weekly average 
values were as follows: 
• 37.7 mg day-1 1000 people-1 in Oslo. This value is half of 76.1 mg day-1 
1000 people-1 reported in 2014, but still higher of the loads in 2012 and 2013 (10.6 
and 7.4 mg day-1 1000 people-1 respectively) [17]. R-(-)-enantiomer was the 
predominant in wastewater samples (EF<0.5). 
• 53.1 mg day-1 1000 people-1 in Bristol, almost doubled respect to 31.4 mg 
day-1 1000 people-1 reported in 2014 [17]. Wastewater samples were enriched with 
R-(-)-enantiomer (EF<0.5). 
• 32.0 mg day-1 1000 people-1 in Lyngby. This data is in agreement with the 
amount found in 2014 in Copenhagen (28.2 mg day-1 1000 people-1 [17]). EF values 
were always below 0.5. 
• 62.0 mg day-1 1000 people-1 in Utrecht. This amount was lower respect to 
those ones found in the last two years in Utrecht (83.1 and 86 mg day-1 1000 people-
1 in 2013 and in 2014) and in 2012 (161.9 mg day-1 1000 people-1) [17]. EF values 
were below 0.5. 
• 21.9 mg day-1 1000 people-1 in Brussels (15.3 and 13.0 mg day-1 1000 
people-1 were reported in 2013 and 2012 [17]). EF values always lower than 0.5. 
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• 43.5 mg day-1 1000 people-1 in Zurich (42.9 and 55.4 mg day-1 1000 people-
1 were reported in 2013 and in 2014 [17]). The average EF was below 0.5 
throughout all the week. 
• 6.8 mg day-1 1000 people-1 in Milan (less amounts were detected in 2013-
14 [17]). The average EF was above 0.5 (high error bars were displayed). 
• 3.2 mg day-1 1000 people-1 in Castellon. Values were below LOQ in 2012, 
6.4 mg day-1 1000 people-1 in 2013 and 4.1 mg day-1 1000 people-1 in 2014 [17]. 
EF values were < 0.5. 
The overall MDMA weekly mean in 2013 was between 25 and 18 mg day-1 1000 
people-1 [5] (the first value corresponds to cities participating in all 3 years study, 
whilst the second one to all cities participating in 2013). A geographical trend of 
MDMA loads from North to South was also found. Indeed, Northern European 
cities (except for Brussels) were mostly above the average. Enantiomeric profiling 
revealed that MDMA in wastewater is enriched with R-(-)-MDMA (EF: 0.32 - 
0.40). This indicates that MDMA retrieved in wastewater comes from consumption, 
due to stereoselective metabolism of MDMA in humans. Figure 5-5 shows expected 
EF values in wastewater for MDMA consumption using the analytical conditions 
described in Castrignanò et al [24]. Although illicit MDMA production sites are 
presumably mainly in the Netherlands and in Belgium (as mentioned in the 
EMCDDA report [28]), MDMA loads in these countries seem to be linked to a 
human consumption rather than its direct disposal. This is in contrast to a previous 
study in Utrecht, were high loads of racemic MDMA were recorded as indication 
of disposal of unconsumed drug [22]. The estimates of MDMA usage corrected by 
the CF ranged from the average of 93.0 mg day-1 1000 people-1 in Oslo to 3.5 mg 
day-1 1000 people-1 in Castellon. 
The hypothesis that MDMA was present in European wastewaters as a result 
of its consumption was further evidenced by the study of MDA and its chiral 
signature. MDA can be a drug of abuse itself or a metabolite of MDMA and MDEA 
(3,4-methylenedioxyethylamphetamine). It is therefore of utmost importance to 
verify the origin of MDA. MDA does not have any medical applications and is 
available on the illicit marked as racemate [52]. This is due to non-stereoselective 
synthetic route. Similarly to MDMA, MDA’s metabolism favours S-(+)-enantiomer 
[53]. Therefore, if MDA is consumed, it will be excreted in urine enriched with R-
(-)-enantiomer. On the other hand, if MDA is formed as a result of the metabolism 
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of MDMA or MDEA, it will be present in urine (and in wastewater) enriched with 
S-(+)-enantiomer [54, 55]. In this study, MDEA was not detected in any European 
locations. The highest loads of MDA were recorded in Utrecht with 3.2 mg day-1 
1000 people-1, followed by Bristol with 1.9 mg day-1 1000 people-1 and in Oslo with 
0.5 mg day-1 1000 people-1 at average weekly loads (Table S11). Interestingly, these 
countries have also high MDMA use, which led us to the conclusion that MDA 
could be present in wastewater due to consumption of MDMA. MDA was detected 
one day only in Brussels and Lyngby, respectively enriched of the S-(+)-form and 
R-(-)-form. Furthermore, enantioselective analysis revealed that MDA quantified in 
wastewater was, in most cases, enriched with S-(+)-enantiomer. This indicates that 
its presence is associated with the consumption of MDMA rather than the abuse of 
MDA. However, on two occasions, MDA was found enriched with R-(-)-
enantiomer. This could indeed indicate an abuse of MDA. In the case of racemic 
MDA, this could indicate a combination of either the consumption of MDA and 
MDMA or simply the direct disposal of non-consumed MDA. 
As MDA is a minor and not exclusive metabolite of MDMA, other 
metabolites were also considered as possible DTRs for MDMA consumption: HMA 
and HMMA. 
HMA was detected at 3.4 mg day-1 1000 people-1 as weekly average in three 
days of the monitoring week in the Dutch city (Saturday, Sunday and Monday) and 
at 7.4 mg day-1 1000 people-1 in two days in Bristolian samples (Sunday and 
Monday) (Table S12). Because of the percentage of excretion of HMA after a dose 
of MDMA is 1.3%, its choice as MDMA DTR could be considered only in the case 
of high amount of MDMA intake. Indeed, it was found only in those places 
reporting the highest levels of MDMA. EF showed values close to 0.5 when high 
HMA loads were detected. However, the relevance of enantiomeric significance is 
difficult to comment because of the low number of positive samples. 
HMMA, on the other hand, was found in wastewater at nanogram per litre 
level in six cities out of eight studied (i.e. no HMMA was detected in Oslo and 
Milan) (Table S13). HMMA’s percentage excretion is 40%, which indicates that 
this metabolite could be used as MDMA’s DTR. Due to stereoselective metabolism 
of MDMA favouring S-(+)-enantiomer, HMMA and its glucuronide derivative are 
formed enriched with S-(+)-enantiomer. Interestingly, HMMA sulphate is formed 
via non-stereoselective route [56]. In this study, HMMA was enriched of the second 
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eluting enantiomer. Assuming the same elution order of MDMA enantiomers for 
HMA and HMMA under the same chromatographic conditions, the second-eluting 
enantiomer could be assigned as S-(+)-enantiomer. The expected EF of HMMA in 
wastewater would be higher than 0.5. Therefore, we hypothesize that if an 
enrichment of R-(-)-MDMA occurred in case of consumption, the presence of S-
(+)-HMMA would be observable along with an EF>0.5. Indeed, the trend observed 




Mephedrone is a stimulant semisynthetic derivative of cathinone. It was first 
synthesised in 1929 by Saem de Burnaga Sanchez but its abuse was documented 
for the first time only in 2007 [57]. Abuse of mephedrone was reported in several 
European countries. Recently, several mephedrone abuse associated deaths were 
reported in the UK [58]. In response to this, several modified cathinones were 
included in the UK Misuse Drugs Act (in category class B) in April 2010. Four 
fatalities due to mephedrone intake were confirmed in Scotland between February 
and May 2010 [59].  
Mephedrone is a chiral compound. It contains one chiral carbon and, thus, it exists 
in two enantiomeric forms as R-(+)-mephedrone and S-(-)-mephedrone. Both 
enantiomers are characterised by different potency: R-(+)-mephedrone shows 
predominant dopaminergic action and stimulant-like properties than S-(-)-
mephedrone [60]. Mephedrone can be synthesised via both non-stereoselective and 
stereoselective methods, but, as reported by EMCDDA [61] and confirmed in our 
previous chapter [24], the ‘street mephedrone’ is distributed as racemate. 
Metabolism of mephedrone is stereoselective favouring R-(+)-enantiomer and 
leading to the enrichment of excreted mephedrone with S-(-)-enantiomer. 
Mephedrone was reported by EMCDDA (EU Early Warning System) to have 
increased usage in the UK in 2014 [28]. Indeed, mephedrone was detected only in 
the UK. Because it has no medical use in Europe [61], its presence in wastewater 
can be attributed only to illegal disposal or consumption. Population-normalised 
mass loads ranged throughout a sampling week from 14.9 to 47.7 mg day-1 1000 
people-1 (Table S14). Increasing loads were found in weekend days rather than 
weekdays with a mean value of 25.6 ± 12.0 mg day-1 1000 people-1. A similar trend 
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was observed in Castrignanò et al. [24]. Furthermore, as mephedrone quantified in 
wastewater was found to be enriched with R-(+)-enantiomer, this indicates that 
mephedrone was consumed rather than directly disposed of.  
 
5.4.4 Other Drugs 
The analyses of precursors, such as norephedrine and ephedrines, were 
performed for Oslo, Bristol, Utrecht (only norephedrine) and Milan. An alternative 
metabolic pathway of the amphetamine produces norephedrine. In neutral condition 
of pH, when amphetamine is found unchanged in urine at 30%, norephedrine is 
present at 2% [19]. Hence, its content could vary in acid and alkaline urine 
conditions. Norephedrine is also used as decongestant. 1R,2S-(-)-ephedrine and 
1S,2S-(+)-pseudoephedrine are a bronchodilator and a decongestant respectively, 
whilst their enantiomers have no medical use. According to the EMCDDA, the 
production based on ephedrine and pseudoephedrine is occurring in Central 
European countries, such as Czech Republic, Slovakia and Germany [18]. 
Unfortunately, no Central European cities were included in the study. Population-
normalised norephedrine loads were 51 mg day-1 1000 people-1 in Oslo, 7.1 mg day-
1 1000 people-1 in Milan and 3.4 mg day-1 1000 people-1 in Bristol (Table S15). In 
Utrecht, norephedrine was not detected. EF were 0.48, 1 and 0.56 respectively. 
Population-normalised 1R,2S-(-)-ephedrine loads were 0.7 mg day-1 1000 people-1 
in Oslo, 3.4 mg day-1 1000 people-1 in Milan and 0.6 mg day-1 1000 people-1 in 
Bristol (Table S16). Population-normalised 1S,2S-(+)-pseudoephedrine loads were 
21.2 mg day-1 1000 people-1 in Oslo, 35.7 mg day-1 1000 people-1 in Milan and 96.4 
mg day-1 1000 people-1 in Bristol (Table S16). EF were 0.48, 1 and 0.56 
respectively. 
PMA, a phenylisopropylamine with hallucinogenic properties, was not 
found in any cities. 
Drugs, such as the narcotic-like pain reliever tramadol and the 
antidepressant venlafaxine, were included as they can be potentially abused. Results 
for venlafaxine (VEN) and its metabolite desmethylvenlafaxine (DMV) are 
displayed in Table S17-S18. VEN has an excretion percentage of 5%, while DMV 
29-48% [29]. The weekly average values were the following:  
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• 58.7 and 98.5 mg day-1 1000 people-1 for VEN and DMV in Oslo. There 
were two weekdays in which DMV was higher in loads respect to the other days. 
EF values were slightly below 0.5 for VEN, while they were also >0.5 for DMV. 
• 41.4 and 82.3 mg day-1 1000 people-1 for VEN and DMV in Bristol. The 
trend was quite constant for both compounds. EF values were just above 0.5 for 
VEN, while there was a predominance of the first eluting DMV enantiomer (EF 
equals to 0.65). 
• 99.6 and 221.6 mg day-1 1000 people-1 for VEN and DMV in Lyngby. The 
trend was rather constant along the week and the enantiomeric composition was 
racemic for both compounds. 
• 54.7 and 93.0 mg day-1 1000 people-1 for VEN and DMV in Utrecht with 
pretty stable loads and EF=0.5. 
• 206.3 and 297.7 mg day-1 1000 people-1 for VEN and DMV in Brussels with 
some high peaks during the week. EF values were near to 0.5 for VEN, whilst 0.58 
indicating a predominance of the first eluting DMV enantiomer. 
• 108.0 and 185.4 mg day-1 1000 people-1 for VEN and DMV in Zurich with 
steady loads and EF=0.5 for both compounds. 
• 27.9 and 60.3 mg day-1 1000 people-1 for VEN and DMV in Milan with 
alternant loads for a couple of days and EF approximately equals to 0.5 even if EF 
varied throughout the weekfor both compounds. 
• 90.3 and 235.9 mg day-1 1000 people-1 for VEN and DMV in Castellon with 
small variation in loads for VEN and EF=0.53 for VEN and EF=0.51 for DMV. 
According to these results, the ratio parent:metabolite was 1:2 for the majority of 
countries, with the exception of Brussels and Castellon. The interpretation of the 
enantiomeric composition was not univocal because of the different EF values 
obtained. 
The population-normalised tramadol loads were rather stable for all the considered 
cities, with the exception of the Belgian city in which a doubled-average peak was 
detected on Saturday (Table S19). High mass loads were found in Bristol and 
Lyngby, whilst the highest value was in Brussels (686.9 mg day-1 1000 people-1). 
EF values ranged from 0.53 to 0.61, showing a predominance of the first eluting 
diastomer. 
Even though high usage of zopiclone, fluoxetine and norfluoxetine were 
suspected, these drugs were not detected in some cases or <MQL in others. This is 
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probably due to the relatively high MDL values for zopiclone, fluoxetine and its 
metabolite norfluoxetine in the developed method. 
 
5.5  Conclusions 
This was the first time that the enantiomeric profiling of several chiral drugs 
was studied in different European cities during a one-week monitoring campaign in 
2015. A new occurring drug of abuse mephedrone was reported in the UK with 
population-normalised mass loads up to 47.7 mg day-1 1000 people-1. Moreover, 
the enrichment of R-(+)-enantiomer in wastewater suggested a stereoselective 
metabolism in humans or stereoselective microbial metabolic processes occurring 
in the environment. Further investigations are needed for looking at additional 
mephedrone biomarkers for WBE approach. A spatial difference in loads was 
observed between Northern and Southern European cities for amphetamine. EF 
values showed a slight enrichment of R-(-)-amphetamine in wastewater with the 
exception for some days in Zurich. Still controversial remains the interpretation of 
enantiomeric composition of amphetamine in wastewater. High methamphetamine 
mass loads were found in Norway, where also high seizures were seen according to 
the EMCDDA. S-(+)-methamphetamine was the predominant enantiomer found in 
wastewater samples probably because its stereoselective synthesis was preferred in 
the illicit manufacturing market in Central Europe. The unique exception was 
represented by Norwegian data that suggested a different illegal synthetic route (e.g. 
racemic methamphetamine produced in Lithuania and exported to Baltic countries). 
The prevalence of R-(-)-MDMA found in the wastewater revealed that MDMA was 
due to its direct consumption, even in those cities where illicit manufacturing sites 
are present. S-(+)-MDA originated from MDMA metabolism (especially during 
weekends) rather than MDA itself. As MDA is a minor MDMA metabolite, other 
metabolites were considered for looking at other possible MDMA DTRs, such as 
HMA and HMMA. The latter compound seemed to be a suitable MDMA DTR. A 
slight preponderance of the S-(+)-HMMA could represent MDMA abuse. The 
investigation of precursors showed that their presence was reasonably ascribed at 
their medical use. The antidepressant venlafaxine gave a ratio “parent 
compound:metabolite” of 1:2 for the majority of the countries. Controversial is the 
interpretation of the enantiomeric composition of both compounds due to different 
EF values. Very high tramadol loads were found in Brussels. Chiral analysis 
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showed an EF range between 0.53 and 0.61, indicating the predominance of the first 
eluting diastomer. 
 
5.6  Contributions 
Erika Castrignanò and Barbara Kasprzyk-Hordern planned and designed the study. 
Richard Bade, Lubertus Bijlsma, J. A. Baz-Lomba, Sara Castiglioni, Erika 
Castrignanò, Ana Causanilles, Adrian Covaci, Emma Gracia-Lor, Barbara 
Kasprzyk-Hordern, Juliet Kinyua, Ann-Kathrin McCall, Alexander L. N. van Nuijs, 
Christoph Ort, Benedek G Plósz, Pedram Ramin, Nikolaos I Rousis, Yeonsuk Ryu, 
Kevin V Thomas, Pim de Voogt, Ettore Zuccato and Felix Hernandez organised the 
collection of the wastewater samples from their local wastewater treatment plant. 
Erika Castrignanò analysed the samples and interpreted the results with 
contribution from Barbara Kasprzyk-Hordern. 
 
5.7  Supplementary Data 
The following supplementary data are contained in Appendix 3: 
Table S1 Selected analytes and their properties (MW molecular weight, Exp 
experimental, Pred predicted, a extracted from (Moffat, Osselton et al. 2004), b 
predicted using ACD/labs software (http://www.chemspider.com). 
Table S2 MRM transitions selected for studied analytes. 
Table S3 Validation parameters - retention time, relative retention time, linearity 
range, correlation coefficient obtained from calibration curve and instrumental and 
method limits of detection and instrumental and method limits of quantification. 
Table S4 Validation parameters - method precision. 
Table S5 Validation parameters -instrumental precision. 
Table S6 Validation parameters –ion suppression. 
Table S7 SPE recovery for the studied analytes. 
Table S8 Amphetamine loads. 
Table S9 Methamphetamine loads. 
Table S10 MDMA loads. 
Table S11 MDA loads. 
Table S12 HMA loads. 
Table S13 HMMA loads. 
Table S14 Mephedrone loads. 
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Table S15 Norephedrine loads. 
Table S16 Ephedrines loads. 
Table S17 Venlafaxine loads. 
Table S18 Desmethylvenlafaxine loads. 
Table S19 Tramadol loads. 
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Chapter 6: Multi-residue stereoisomeric analysis 
of human and veterinary chiral drugs in 
wastewater using chiral liquid chromatography 
coupled with tandem mass spectrometry 
 
6.1 Summary 
Quinolones are broad-spectrum antibacterials with clinical and veterinary 
applications. Their wide use has rapidly brought to an increasing antibiotic 
resistance developed by bacteria. The research on the potential biomarkers for 
quinolones consumption in wastewater-based epidemiology (WBE) could be a 
useful means to understand their inappropriate use in the monitored areas. 
Moreover, there is currently a lack of studies on quinolones enantiomeric profiling 
in the environment, which is important to investigate for understanding the role of 
each enantiomer in the environment and, in some cases, the correlation with their 
human stereoselective metabolism. 
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This chapter proposes a novel multi-residue stereoisomeric analytical 
method for the simultaneous analysis of 16 human and veterinary quinolones drugs 
(including an antifungal drug). For the first time, the investigation of (±)-ofloxacin 
with its main metabolites (±)-ofloxacin-N-oxide and (±)-desmethyl-ofloxacin, (±)-
moxifloxacin, the precursor (±)-prulifloxacin with its active compound (±)-
ulifloxacin, (±)-cis-ketoconazole, (±)-flumequine, (±)-nadifloxacin and R-(+)-
besifloxacin was carried out at enantiomeric level in composite wastewater samples 
along with their chiral separation. Chiral liquid chromatography coupled with 
tandem mass spectrometry was used as a tool of investigation. In particular, 
excellent chiral separation was achieved by using a CHIRALCEL® OZ-RH column. 
Enantiomeric resolution values higher than one (Rs ≥ 1) were reached for six over 
nine chiral drugs enabling quantitative analysis. The overall performance of the 
method was satisfactory for all the targeted analytes with a method precision <20% 
and relative recoveries between 70% and 120%. Method detection limits were at 
nanogram per litre level. The method was applied to 24-hours composite samples 
from a week monitoring campaign of a large wastewater treatment plant in the 
South West of the UK. Many target pharmaceuticals were found at quantifiable 
concentrations in the analysed samples. Enantiomeric profiling revealed that (±)-
ofloxacin was found enriched with S-(-)-enantiomer, due to its higher 
enantiomerically pure usage with respect to its enantiomer. Its urinary metabolites 
were found below the method quantification limit. (±)-cis-Ketoconazole was 
enriched with the first-eluting enantiomer. 
 
6.2 Introduction 
Quinolones are a family of synthetic broad-spectrum antibiotic drugs used 
for clinical and veterinary treatments. They belong to the class of inhibitors of 
bacterial topoisomerases IV [1] and DNA gyrase, the originally recognised drug 
target [2]. They are largely used for infections of urinary tract, bone and soft tissue, 
gastrointestinal tract, respiratory tract and sexually transmitted diseases [3]. Earliest 
members of this group were originally potent against Gram-negative bacteria, 
whilst new generations of fluorinated quinolones enlarged their potency range 
against Gram-positive and anaerobic bacteria [4]. Their wide use has rapidly led to 
an increasing antibiotic resistance developed by bacteria [5]. So far, three 
mechanisms have been described for explaining quinolones resistance: (i) target 
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alterations; (ii) decreased accumulations and (iii) mobile quinolones resistance 
element, such as plasmids, carrying qnr gene (less extent) [5]. Rate of resistance 
may vary by organisms and geographic areas [6]. In order to avoid the spread of 
resistance, a systematic surveillance program on antibiotic consumption and 
antimicrobial resistance (AMR) is essential. At the same time, early monitoring is 
desirable with the aim of getting real-time data. A possible way that enables real 
time estimation of antibiotics consumption can be represented by wastewater-based 
epidemiology (WBE). This approach relies on the detection and quantification of 
indicators, so-called biomarkers, which give a profile in terms of real usage of a 
substance through unique human urinary excretion pattern. Examples of this 
approach are well documented in the spatial and temporal community-wide 
monitoring of drugs of abuse [7, 8], alcohol [9] or tobacco use [10]. Indeed, the 
research on potential biomarkers of quinolones use suitable for WBE application 
can help in finding out their inappropriate use in the monitored areas and, thus, in 
informing the public health. The selection process of potential biomarkers is based 
on a full understanding of human pharmacokinetics along with stability properties 
in the environmental matrix. In addition, as some of these drugs are often 
administered as racemate, stereoselective metabolism and/or stereoselective 
enrichment or depletion of the enantiomeric composition of the drug and/or 
transformation products can occur respectively in humans and in the environment. 
In general, pharmacokinetic parameters, along with antibacterial activity, are 
influenced by the position of the chiral centre with respect to the quinolone ring. 
One of the exceptions is represented by (±)-lomefloxacin, in which the enantiomers 
do not show particularly differences in pharmacokinetics and activity [11]. 
Furthermore, chirality is an important aspect to investigate as it allows: (i) 
differentiating between the use and the misuse, (ii) distinguishing the origin of a 
drug residue through the distinction between consumption and disposal of unused 
drugs. 
Additionally, enantiomeric profiling of quinolones in the environment has 
never been undertaken before. In order to undertake enantiomeric profiling of 
wastewater for chiral drug biomarkers, robust and multi-residue chiral analytical 
methods need to be developed [12]. Chiral LC-MS (liquid chromatography coupled 
with tandem mass spectrometry) methods are preferred methods as they allow 
quantitative as well as sensitive and selective measurements of the chiral drugs at 
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enantiomeric level [13]. Chiral LC-MS/MS methods have the advantage to combine 
the resolving power of HPLC and the features of sensitivity and specificity of MS 
[14]. Furthermore, the choice to use reversed-phase LC with MS detection allows: 
(i) handling the sample easily; (ii) choosing the proper buffer for controlling the 
selectivity and (iii) selecting compatible MS mobile phases [14]. Currently, multi-
residue chiral LC-MS methods in environmental matrices are limited [12, 15-18] 
and, to the authors’ knowledge, no reports are available in literature on the analysis 
and the enantiomeric profiling of quinolones and fluoroquinolones. 
This chapter proposes a novel multi-residue stereoselective method for the 
simultaneous analysis of 16 human and veterinary quinolones drugs (including an 
antifungal drug). For the first time the investigation of (±)-ofloxacin with its main 
metabolites (±)-ofloxacin-N-oxide and (±)-desmethyl-ofloxacin, (±)-moxifloxacin, 
the prodrug (±)-prulifloxacin with its active compound (±)-ulifloxacin, (±)-cis-
ketoconazole, (±)-flumequine, (±)-nadifloxacin and R-(+)-besifloxacin was carried 
out at enantiomeric level in composite wastewater samples along with their chiral 
separation. Moreover, the following achiral quinolones were included for 
monitoring purposes: ciprofloxacin, desethylene-ciprofloxacin, norfloxacin and 
nalidixic acid. Moxifloxacin-N-sulphate (with a defined stereochemistry) was also 
included as part of the urinary excretion profile of S,S-moxifloxacin. 
 
6.3 Experimental 
6.3.1 Chemicals and Materials 
Table 6-1 shows the selection of the analytes considered in this study with 
information on their chemical structure, chirality, marketing, use, metabolic and 
excretion patterns, stereoselective metabolism. 
Table S1 shows CAS number, molecular formula, molecular weight, log P, pKa 
values and supplier information for all targeted analytes. 
High pure grade standard solutions of achiral analytes were as follows: 
ciprofloxacin, desethylene-ciprofloxacin, norfloxacin and nalidixic acid. The 
following analytes were used as racemates: (±)-ofloxacin, (±)-ofloxacin-N-oxide, 
(±)-desmethyl-ofloxacin, (±)-lomefloxacin, (±)-prulifloxacin, (±)-ulifloxacin, (±)-
ketoconazole, (±)-flumequine, (±)-nadifloxacin.  
  
 Chapter 6: Multi-residue stereoisomeric analysis of human and veterinary chiral drugs 
 162 
Table 6-1 Selected chiral drug biomarkers (in italics) and their pharmacokinetic data 
Drug Structure Chirality Marketing Use Metabolite Excretion Reference 
Ciprofloxacin 
 
No Synthetic Human Parent compound 40-50% [19], [20] 
Desethylene-ciprofloxacin   
Sulfo-ciprofloxacin   
Oxo-ciprofloxacin   
(±)-Ofloxacin 
 
Yes, 1*C Synthetic Human Parent compound In urine over 24-48 h 
and between 4-8% 
excreted in faeces 
[21], [22] 
Desmethyl-ofloxacin Small amount of the 
dose 
 









Yes, 1*C Synthetic Human Parent compound In urine (80% to 
85%) and in faeces 
(2%) within 24 h 
[21] 
Desmethyl-levofloxacin 2% of the dose  
Levofloxacine-N-oxide 2% of the dose  
Norfloxacin No Synthetic Human Parent compound 25-40% of the dose is 
excreted in urine, 
30% (range: 10-50%) 
is excreted in feces 
within 48 hours 
[26] 
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Metabolites 5-10% as metabolites 




No Synthetic ? Parent compound 2-3% in the urine [21] 
7-hydroxynalidixic acid 
(active) 
About 80% of a dose 
is excreted in the 








Glucuronide conjugates of 







Yes, 1*C Synthetic Human Parent compound 65% in urine [27], [28] 
Glucuronide 9%  






Yes, 2*C Synthetic, 








Human Parent compound ~20% in urine and 
~25% in feces. 
[19], [29], [30] 
Moxifloxacin acyl 
glucuronide 
14% of the dose in 
urine 
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Moxifloxacin-N-sulphate 35% of the dose in 
faeces 
 






Yes, 1 *C Synthetic 
prodrug, sold 
as racemate 
Human Ulifloxacin 17-23% in the urine 
and 17-29% in the 
faeces 
[31] 






Yes, 2 *C Synthetic, 




Human/Veterinary Parent compound 2-4% in urine of 13% 
excreted in urine 
[33],  




Yes, 1*C Racemic Veterinary [34] Parent compound 81-86% in calves 
urine (after enzyme 
deconjugation) 
[35] 
7-hydroxy-flumequine 12-17% in calves 
urine (after enzyme 
deconjugation) 
 
Glucuronides of flumequine   
Stereoselective 
metabolism in sheep, 




Yes, 1*C Synthetic Human Parent compound 0.09% of the 
administered dose 
was excreted in the 
urine over 48 hours, 
<5% eliminated in the 











Yes, 1*C Synthetic, 
sold in one 
form only 
Human Parent compound 73% in animal feces, 









a http://www.rxlist.com  
 Chapter 6: Multi-residue stereoisomeric analysis of human and veterinary chiral drugs 
 166 
Stereoisomerically pure standard solutions of the following analytes were used: S-
(-)-ofloxacin, also known as levofloxacin, R,R-moxifloxacin, S,S-moxifloxacin and 
S,S-moxifloxacin-N-sulphate with two defined stereocentres and R-(+)-
besifloxacin. 
The following deuterated and isotopic analogues of target analytes were used as 
isotopically-labelled internal standards (ILIS): ciprofloxacin-D8, (±)-ofloxacin-D3, 
(±)-desmethyl-ofloxacin-D8 and (±)-flumequine
13C3. 
Standard stock solutions were prepared at 1 mg mL-1 concentration in methanol for 
all the analytes, except for (±)-prulifloxacin, (±)-ulifloxacin, (±)-ofloxacin-D3 and 
(±)-flumequine13C3 that were dissolved in acetonitrile, (±)-lomefloxacin, 
desethylene-ciprofloxacin, ciprofloxacin-D8 and (±)-desmethyl-ofloxacin-D8 in 
water. 
Working solutions of each stereoisomerically pure standard available were prepared 
at 50 ng mL-1 in methanol and analysed to elucidate the elution order of (±)-
ofloxacin and its metabolites enantiomers, and (±)-moxifloxacin diastereoisomers. 
Mixed working solutions containing all analytes were prepared from stock solutions 
at different concentration levels by dilution with mobile phase. They were used for 
the preparation of the aqueous standard calibration solutions and for spiking 
samples in the validation study. Stock and working solutions of standards were 
stored at -20° C.  
HPLC-grade methanol (MeOH), acetonitrile (ACN), isopropanol (IPA), 
ammonium formate and formic acid (≥96%) were purchased from Sigma Aldrich, 
UK, ethanol (EtOH) from Fluka, UK. Ultrapure water was obtained from a MilliQ 
system, UK. All glassware was deactivated in order to prevent the adsorption of 
polar compounds to the hydroxyl sites on the glass surface. The deactivation 
process consisted of rinsing cycles with 5% DMDCS once, with toluene twice and 
with methanol thrice. 
 
6.3.2 Sample collection, storage and preparation 
24h time-proportional (10 mL every 15 minutes) composite wastewater 
influent samples were collected in PTFE bottles (Fisher, UK) in an autosampler 
ISCO 3700 from a wastewater treatment plant in the South West of the UK during 
one week-monitoring campaign in 2015. They were transported to the laboratory in 
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cool boxes packed with ice blocks and filtered through GF/F 0.7 µm glass fibre 
filter (Whatman, UK). 50 µL of a mixture of ILIS at concentration of 1 mg L-1 were 
added to 50 mL of a wastewater sample to provide final concentration of 1 µg L-1. 
Analytes were extracted using SPE and Oasis HLB cartridges (60 mg, Waters, UK), 
previously conditioned with 3 mL of methanol and equilibrated with 3 mL of 
ultrapure water at a rate of 3 mL min-1. 50 mL of spiked environmental samples 
were passed through the HLB cartridges at a rate of 8 mL min-1. The cartridges were 
then washed with 1 mL of ultrapure water at a rate of 3 mL min-1. The elution was 
carried out with 4 mL of methanol at a rate of 8 mL min-1 into 5 mL silanised glass 
tubes. The extracts were transferred to the TurboVap evaporator (Caliper, UK) and 
completely evaporated to dryness under nitrogen flow (5-10 psi). Samples were 
reconstituted with 0.5 mL of 10 mM ammonium formate/methanol 1:99 v/v with 
0.05% formic acid and filtered through 0.2 µm PTFE filters (Whatman, Puradisc, 
13mm). The filtered samples were transferred to polypropylene plastic vials bonded 
pre-slit PTFE/Silicone septa (Waters, UK) and then 20 µL were directly injected 
into a chiral HPLC-MS/MS system. Samples from the monitoring campaign were 
prepared and analysed in duplicate. 
 
6.3.3 Sample analysis by chiral liquid chromatography coupled with tandem 
mass spectrometry 
Samples were analysed using a Waters ACQUITY UPLC® system (Waters, 
Manchester, UK). 
Chromatographic separation of all the analytes was carried out using a chiral 
CHIRALCEL® OZ-RH column (5 μm particle size, L × I.D. 15 cm × 2.1 mm, 
Chiral Technologies, France) with a 2.0 mm × 2.0 mm guard filter (Chiral 
Technologies, France). The column temperature was set at 30°C. The autosampler 
was kept at 4°C.The injection volume of the sample was set at 20 µL. 
Several mobile phase compositions differing in organic modifier, variable 
percentage of organic modifier used and mixture of organic modifiers were tested 
(Table S2). Different mobile phase flow rates (from 0.05 mL min-1 to 0.2 mL min-
1) were also trialled. The best chiral recognition and chromatographic separation of 
analytes was achieved with a mobile phase composed of 10 mM ammonium 
formate/methanol 1:99 v/v with 0.05% formic acid at a flow rate of 0.1 mL min-1 
under isocratic conditions. 
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The MS system was a triple quadrupole mass spectrometer (Xevo TQD, 
Waters, Manchester, UK) equipped with an electrospray ionisation source (ESI). 
Analyses were performed in positive mode with an optimised capillary voltage of 
3 kV, source temperature of 350°C, desolvation temperature of 350°C and 
desolvation gas flow of 650 l h-1. Nitrogen, supplied by a high purity nitrogen 
generator (Peak Scientific, UK), was used as a nebulising and desolvation gas. 
Argon (99.999%) was used as a collision gas. MassLynx 4.1 (Waters, UK) was used 
to control the Waters ACQUITY system and the Xevo TQD. Data processing was 
carried out on TargetLynx software (Waters, Manchester, UK).   
The mass spectrometer acquired data using MRM mode, which enabled the 
measurement of the fragmentation of the protonated pseudo-molecular ions of each 
compound. The choice of fragmentation ion for each compound was based on the 
most intense signal. Corresponding CVs and CEs were obtained after direct 
infusion of each standard at a concentration of 100 µg L-1 into the mass 
spectrometer. Their optimisation for the chosen MRM transitions was carried out 
using mobile phase facilitating the best analytical performance by infusing each 
standard at 100 μg L-1 combined with LC conditions. Two MRM transitions were 
selected for each compound. The most abundant transition product ion was 
typically used for quantification, whilst the second ion was used for confirmation 
purposes. The MRM transitions, CV and CE values of the studied compounds are 
presented in Table 2. 
Selection of ILIS (see Table 6-2) for those compounds for which deuterated or 13C 
analogues were not available in our laboratory was based on similar chemical 
structure and elution time to account for possible signal suppression or 
enhancement of studied analytes in ESI. The most suitable ILIS was chosen for 
each substance. 
 
6.3.4 Method validation 
The method validation was performed in agreement with European Guidelines 
concerning the performance of analytical methods and the interpretation of results 
[40]. 
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Table 6-2 MRM transitions selected for studied analytes and internal standards. 
Compound CV/CEa MRM1 (quantification) CV/CEa MRM2  
(confirmation) 
MRM1/MRM2 ratio ± SD Internal standard 
Ciprofloxacin 42/40 332.2 > 231.1 42/32 332.2 > 245.1 8.9 ± 2.2 Ciprofloxacin –D8 
Desethylene-ciprofloxacin 40/34 306.3 > 217.1 40/26 306.3 > 268.0 1.4 ± 0.4 Ciprofloxacin –D8 
S-(-)-Ofloxacin (L-Ofloxacin) 20/32 362.2 > 261.2 20/32 362.2 > 318.7 29.6 ± 3.4 S-(-)-Ofloxacin-D3 
R-(+)-Ofloxacin 20/32 362.2 > 261.2 20/32 362.2 > 318.7 30.0 ± 3.0 R-(+)-Ofloxacin-D3 
Norfloxacin 58/26 320.2 > 233.1 58/38 320.2 > 204.9 2.6 ± 0.5 Ciprofloxacin –D8 
S-(-)-Ofloxacin-N-oxide 28/18 378.3 > 316.7 28/44 378.3 > 246.9 2.7 ± 0.2 S-(-)-Ofloxacin-D3 
R-(+)-Ofloxacin-N-oxide 28/18 378.3 > 316.7 28/44 378.3 > 246.9 2.9 ± 0.4 R-(+)-Ofloxacin-D3 
S-(-)-Desmethyl-ofloxacin 50/26 348.2 > 261.0 50/33 348.2 > 221.0 7.1 ± 0.6 S-(-)-Desmethyl-ofloxacin-D8 
R-(+)-Desmethyl-ofloxacin 50/26 348.2 > 261.0 50/33 348.2 > 221.0 7.2 ± 0.7 R-(+)-Desmethyl-ofloxacin-D8 
Nalidixic acid 30/28 233.2 > 187.0 30/28 233.2 > 215.1 5.6 ± 0.3 Ciprofloxacin –D8 
(±)-Lomefloxacin 22/24 352.0 > 265.0 22/22 352.0 > 308.0 3.0 ± 0.2 Ciprofloxacin –D8 
R,R-Moxifloxacin 54/27 402.2 > 364.0 54/23 402.2 > 261.0  S-(-)-Desmethyl-ofloxacin-D8 
S,S- Moxifloxacin 54/27 402.2 > 364.0 54/23 402.2 > 261.0  R-(+)-Desmethyl-ofloxacin-D8 
Moxifloxacin-N-sulphate 54/27 402.2 > 364.0 54/28 402.2 > 341.0 2.8 ± 0.8 S-(-)-Desmethyl-ofloxacin-D8 
Prulifloxacin-E1 42/22 462.2 > 444.1 42/32 462.2 > 360.1 1.2 ± 0.1 S-(-)-Ofloxacin-D3 
Prulifloxacin-E2 42/22 462.2 > 444.1 42/32 462.2 > 360.1 1.2 ± 0.2 R-(+)-Ofloxacin-D3 
Ulifloxacin-E1 42/22 350.2 > 306.4 42/26 350.2 > 263.0 1.2 ± 0.3 S-(-)-Desmethyl-ofloxacin-D8 
Ulifloxacin-E2 42/22 350.2 > 306.4 42/26 350.2 > 263.0 1.2 ± 0.2 R-(+)-Desmethyl-ofloxacin-D8 
(±)-cis-Ketoconazole-E1 60/50 532.0 > 82.0 60/58 532.0 > 112.1 3.3 ± 0.1 S-(-)-Ofloxacin-D3 
(±)-cis-Ketoconazole-E2 60/50 532.0 > 82.0 60/58 532.0 > 112.1 3.4 ± 0.1 R-(+)-Ofloxacin-D3 
Flumequine-E1 28/34 262.2 > 201.9 28/26 262.2 > 244.5 1.7 ± 0.1 Flumequine-13C3-E1 
Flumequine-E2 28/34 262.2 > 201.9 28/26 262.2 > 244.5 1.8 ± 0.2 Flumequine-13C3-E2 
Nadifloxacin-E1 40/38 361.3 > 282.9 40/44 361.3 > 256.8 1.6 ± 0.1 Flumequine-13C3-E1 
Nadifloxacin-E2 40/38 361.3 > 282.9 40/44 361.3 > 256.8 1.6 ± 0.2 Flumequine-13C3-E2 
R-(+)-Besifloxacin 34/14 394.1 > 376.4 34/24 394.1 > 356.0 3.4 ± 0.4 Ciprofloxacin –D8 
Internal Standard CV/CEa MRM1 (quantification)     
Ciprofloxacin –D8 30/26 340.1 > 296.1     
S-(-)-Ofloxacin-D3 47/28 365.2 > 261.0     
R-(+)-Ofloxacin-D3 47/28 365.2 > 261.0     
S-(-)-Desmethyl-ofloxacin-D8 64/32 356.6 > 265.1     
R-(+)-Desmethyl-ofloxacin-D8 64/32 356.6 > 265.1     
Flumequine-13C3-E1 40/24 265.1 > 246.9     
Flumequine-13C3-E2 40/24 265.1 > 246.9     
aCV, cone voltage (V); CE, collision energy (eV) 
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The developed method was fully validated for wastewater samples by 
studying instrumental and method limits of detection and quantification, linearity, 
precision and accuracy, matrix effect. 
IDL and IQL values were determined using a S/N approach at the minimum 
concentration value that provided S/N≥ 3 and S/N ≥ 10 for IDL and IQL 
respectively. MDL was calculated using the equation (4) in chapter 3. In this case, 
CF, that was the SPE concentration factor, was equal to 100. MQL was calculated 
using the equation (5) in chapter 3. 
The linearity of the method was studied from 0 to 2000 µg L-1 through the analysis 
of individual calibrators injected in triplicate. They were prepared in mobile phase 
at several concentration levels: 2000, 1000, 800, 700, 600, 500, 400, 300, 200, 100, 
50, 10, 5, 1, 0.5, 0.25, 0.1, 0.05, 0.025, 0.01, 0.005 and 0 µg L-1. ILIS approach was 
used for quantification purposes and for evaluating method performance. 
Precision was expressed as relative standard deviation (RSD) of replicate analysis 
(n=4) at three different concentrations on the same day (intra-RSD%). In particular, 
instrumental precision was evaluated using standard solutions spiked in mobile 
phase at 10, 100 and 1000 µg L-1 for achiral or not stereoisomerically separated 
analytes, at 5, 50 and 500 µg L-1 in the case of individual enantiomers. Method 
precision was assessed using standard solutions spiked in 50 mL of influent 
wastewater at 50, 500 and 5000 ng L-1 for achiral or not enantiomerically separated 
analytes, at 25, 250 and 2500 ng L-1 in the case of individual enantiomers. Spiked 
wastewater samples were then subject to SPE as discussed in 6.3.2. 
Reproducibility (inter-day precision) of the method was determined by replicate 
measurements (n=3) of the same concentrations of analytes as in the case of intra-
day precision on three different days in order to assess the inter-day instrumental 
precision and the inter-day method precision. Precision data were acceptable when 
the RSD% was less than 20% for all the concentrations investigated during the 
different days. Quality controls at three concentration levels (10, 100 and 1000 µg 
L-1) were also prepared and injected on regular basis to maintain instrument’s 
performance. 
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Method accuracy was expressed as a percentage of closeness agreement between 
the difference from the concentration of a spiked sample before the extraction (with 
the background peak subtracted) and the peak area of a standard. 
Sample carryover was studied by injecting spiked samples at a concentration of 
2000 µg L-1 followed by three blanks and it was considered insignificant if the 
concentration of the analyte was below the LOQ. 















    (9) 
where ASPIKED_AFTER_SPE was the analyte peak area in wastewater extract spiked 
after SPE extraction, A0 was the analyte peak area in the unspiked wastewater 
extract, AAP was the analyte peak area of standard spiked in aqueous phase. In order 
to correct matrix enhancement or suppression in some cases, ME was also 































   (10) 
where AILIS_SPIKED_AFTER_SPE was the ILIS peak area in wastewater extract spiked 
after SPE extraction, AILIS_0 was the ILIS peak area in the unspiked wastewater 
extract and AILIS_AP was the ILIS peak area in the standard spiked in aqueous phase. 
Absolute recovery, expressed as a percentage of the ratio between the peak area of 
analyte spiked before SPE (ASPIKED_BEFORE_SPE) and that one spiked after SPE 
(ASPIKED_AFTER_SPE) (both subtracted of the peak area of the unspiked sample), was 


















   (11) 
where ASPIKED_BEFORE_SPE was the  peak area in wastewater extract spiked after SPE 
extraction, AILIS_0 was the ILIS peak area in the unspiked wastewater extract and 
AILIS_AP was the ILIS peak area in the standard spiked in aqueous phase. 
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Relative recovery was calculated by taking into account the ILIS contribution as 



































   (12) 
where AILIS_SPIKED_BEFORE_SPE was the ILIS peak area in wastewater extract spiked 
before SPE. 
Along with the above-mentioned parameters, resolution of enantiomers and 
stereoisomeric fraction were determined as key parameters for a chiral method. 
Resolution of enantiomers of chiral drugs (Rs) was calculated using equation (7) 
reported in chapter 3. Rs =1 indicates 2% overlap which is deemed acceptable for 
quantification purposes. 
Enantiomeric fraction (EF) was calculated using equation (8) from chapter 3. 
In the case of (±)-moxifloxacin, DF was calculated as follows in equation (13):  
 






   (13) 
EF (or DF) equals 1 or 0 in the case of enantiomerically (or diasteromerically) 
pure compound, and 0.5 in the case of a racemate. 
According to [40], the identification of the analyte was based on the following 
criteria: (i) the presence of all selected MRM transitions and (ii) a maximum 
permitted tolerance for relative ion intensities of MRM transitions not changing 
more than ±20% for ions with relative intensities of >50%, ±25% for ions with 
relative intensities between 20% and 50%, 30% for ions with relative intensities 
between 10% and 20% and ±50% for ions with relative intensities less than 10%. 
 
6.4 Experimental 
6.4.1 Selection of potential biomarkers 
There are twenty-eight quinolones currently included among antiinfectives for 
systemic use [41]. All chiral quinolones were initially considered for the study. 
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However, some quinolones are not marketed in Europe. There are for example:(±)-
gemifloxacin, which is a synthetic broad-spectrum drug developed as racemate, but 
not approved in Europe (Korea only); 
- (±)-gatifloxacin, which is a synthetic racemic drug removed from the 
European market and currently available only in the US and Canada as an 
ophthalmic solution; 
- (±)-danofloxacin,(±)-orbifloxacin, (±)-ibafloxacin and (±)-pradofloxacin, 
which are for veterinary use only; 
- (±)-balofloxacin, which is available only in Korea; 
- (±)-pazufloxacin, (±)-tosufloxacin and (±)-sitafloxacin, which are marketed 
only in Japan; 
- (±)-garenoxacin, which is available in Korea, Japan and China. 
The final list of target quinolones included: ciprofloxacin, desethylene-
ciprofloxacin, (±)-ofloxacin, norfloxacin, (±)-ofloxacin-N-oxide, (±)-desmethyl-
ofloxacin, nalidixic acid, (±)-lomefloxacin, S,S-moxifloxacin, R,R-moxifloxacin, 
moxifloxacin-N-sulphate, (±)-prulifloxacin, (±)-ulifloxacin, (±)-flumequine, (±)-
nadifloxacin and R-(+)-besifloxacin (Table 6-1). (±)-cis-Ketoconazole was the only 
chiral antifungal drug included. 
Ciprofloxacin and its metabolite desethylene-ciprofloxacin were targeted as 
biomarkers of ciprofloxacin use. The choice for indicators of (±)-ofloxacin 
consumption was based on human urinary excretion pattern of (±)-ofloxacin. 
Therefore, (±)-ofloxacin-N-oxide and (±)-desmethyl-ofloxacin were included, 
despite their low excretion factor. Nalidixic acid itself was selected as a biomarker 
for its usage despite the fact that only 2-3% of nalidixic acid is excreted unchanged. 
About 80% of a dose is mainly excreted in the urine as glucuronide conjugates, 
including glucuronides of 7-hydroxynalidixic acid. However, glucuronides of 
nalidixic acid can be hydrolysed by bacteria present in the wastewater, thus 
increasing the levels of nalidixic acid present. In the case of (±)-moxifloxacin, both 
the parent compound and the moxifloxacin-N-sulphate were considered. Since this 
drug is sold as enantiomerically pure S,S-moxifloxacin (Avelox is the trade name 
in the UK), also its impurity R,R-stereoisomer was investigated in order to verify 
any variations in a chiral signature of this compound. To the author’s knowledge, 
no investigation of the enantiomeric profiling in wastewater of (±)-prulifloxacin 
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and (±)-ulifloxacin has been undertaken to date. (±)-Prulifloxacin is a synthetic 
prodrug sold as racemate for oral administration. It is converted in its active 
compound ulifloxacin by hepatic enzyme through the removal of the side chain in 
4' site of piperazinyl, where the chiral centre is not the metabolic site. Only L-
ulifloxacin has the bactericidal effects, but enantiomerically pure L-prulifloxacin is 
not commercially available yet [42]. The veterinary (±)-flumequine was included 
for verifying its presence in the environmental matrix. Racemic (±)-nadifloxacin is 
formulated in topical creams, although the antibacterial activity is higher for the 
isomer S-(-)-nadifloxacin. Even though <5% of nadifloxacin is excreted in urine, 
20% is excreted as sulphate and glucuronides [38], which can be potentially re-
converted to the parent compound in wastewater. R-(+)-besifloxacin is a synthetic 
quinolone sold only in one enantiomeric form that has ophtalmic use. It is 
metabolically stable and it does not go through chiral interconversion to its 
enantiomer after human hepatocytes incubation [39]. (±)-Ketoconazole (the only 
antifungal agent on the list)  has two chiral centres and exists as four enantiomers 
[43]: cis-(2S,4R), cis-(2R,4S), trans-(2R,4R), trans-(2S,4S). Clinically, it is sold and 
administered as racemate of two cis-enantiomers, i.e. (+)-ketoconazole and (−)-
ketoconazole [44].The parent compound itself was considered as biomarker of drug 
consumption for norfloxacin, (±)-lomefloxacin, (±)-nadifloxacin, R-(+)-
besifloxacin and (±)-cis-ketoconazole. 
 
6.4.2 Method development for the detection of quinolones and an antifungal 
drug in wastewater 
6.4.2.1 CHIRALCEL® OZ-RH column 
The CHIRALCEL® OZ-RH column contains a cellulose tris (3-chloro-4-
methylphenylcarbamate) as chiral selector coated on 5μm of silica gel. Its schematic 
structure is presented in Figure 6-1. This cellulose phenylcarbamate derivative 
belongs to the group of polysaccharide derivatives in the chiral stationary phases 
(CSPs) along with amylose phenylcarbamate derivatives [45]. Chiral recognition is 
mainly controlled by the presence of an electron-withdrawing substituent (in this 
case the halogen group) and an electron-donating substituent (the methyl group) in 
position 3 and 4 of the phenyl moiety, respectively [46, 47].   
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Figure 6-1 CHIRALCEL® OZ-RH column – stationary phase modified from instruction manual 
provided by the supplier. 
 
The nature of these substituents on the phenyl group of the polymer, along with 
their position [48, 49], produces an inductive effect on the carbamate group. 
Consequently, the alteration of its polarity influences how cellulose derivatives 
interact with the chiral compound. In previous studies, it was demonstrated that the 
nature and the concentration of acidic additives were essential factors in 
determining the retention time and the enantioresolution of the analytes in polar 
organic solvent chromatography and normal phase liquid chromatography [47]. In 
the current study, reverse phase chromatography was used (see the advantages 
mentioned in paragraph 6.2). 
The purpose of this method development was to investigate 
enantioseparation of the target compounds in order to obtain the best method’s 
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The enantioselectivity of the retention was studied over a range of different organic 
modifiers, ratio organic:aqueous phase compositions, pH values, flow rates and 
percentages of additive. 
The impact of organic content on the separation was evaluated in ACN, EtOH, 
MeOH, IPA and mixtures made of ACN:MeOH and EtOH:MeOH (Figure S1). A 
comparison of the impact of the mobile phases with the same percentage of organic 
on the retention time is shown in Figure S2a. The separation selectivity differed for 
protic and aprotic solvents, thus affecting the retention time of the analytes. Longer 
retention time was observed when the mobile composition consisted of an aprotic 
solvent such as ACN, followed by protic solvents such as IPA. The mixture 
EtOH:MeOH provided an adequate separation selectivity for ofloxacin and its 
metabolites only, but it was insufficient for the other compounds tested. The lowest 
retention times were observed for the mixture ACN:MeOH, but unsatisfactory 
enatioseparation was determined for the majority of the substances. 
The impact of the nature of the organic content in the mobile phase on enantiomeric 
resolution was shown by considering the best performing mobile phases (95:5 5mM 
ammonium formate for IPA and ACN, 99:1 5mM ammonium formate for EtOH, 
99:1 10mM ammonium formate for MeOH). Since enantiomeric resolution values 
preferably higher than one enable quantitative analysis at enantiomeric level, the 
aim of this method development phase was to obtain Rs ≥ 1 for the majority of 
targeted compounds. A summary of the best performing mobile phases in terms of 
capability to enantioseparate the analytes is shown in Figure S2b. The study 
revealed that Rs ≥ 1 was achieved for six compounds (ofloxacin, ofloxacin-N-oxide, 
prulifloxacin, flumequine, nadifloxacin and cis-ketoconazole) , 0.8 <Rs < 1 in the 
case of two (desmethyl-ofloxacin and moxifloxacin) and Rs > 0.6 in one case 
(ulifloxacin) using 10 mM ammonium formate/MeOH 1:99 as mobile phase. Rs ≥ 
1 values were found for three analytes (ofloxacin, flumequine and nadifloxacin) and 
only one (flumequine) when EtOH and IPA were respectively used. For mobile 
phase containing ACN, Rs > 0.6 was obtained in one case only (flumequine). 
Moreover, higher enantioresolution values were observed for protic solvent mobile 
phase composition and they increased with the polarity of the protic solvent. Indeed, 
the highest Rs values were seen with MeOH-based mobile phase with respect to the 
less polar EtOH- and IPA-based. Furthermore, the enantioselectivity was 
 Chapter 6: Multi-residue stereoisomeric analysis of human and veterinary chiral drugs 
 177 
influenced by the water content in mobile phases. In fact, lower water content 
provided higher resolution of enantiomers. The highest Rs values were determined 
for nadifloxacin (Rs = 2.86), followed by flumequine (Rs = 1.91) and ofloxacin-N-
oxide (Rs = 1.71). 
By comparing different flow rates, it was possible to conclude that higher 
enantioseparation was achieved at low flow rates. In this case, the best flow rate 
was found at 0.1 mL min-1 (Figure S3a)., The addition of acid in the mobile phase, 
with consequent lower pH values reached, did not provide any enhancement in 
terms of separation for the majority of compounds (Figure S3b). Moreover, the salt 
concentration was another factor that played a key role in the enantioseparation as 
it modulated the interactions between analytes and the stationary phase. In this 
study, ammonium formate was considered. The study on the impact of the 
percentage of additive added revealed that higher ammonium formate percentages 
corresponded to higher retention of the analytes in the column along with an 
improved enantioseparation (Figure S3c). 
As a result of these findings, the best chiral recognition for the widest group of 
analytes with a run time of only 40 minutes was achieved using a mobile phase 
composed of 10 mM ammonium formate/MeOH 1:99 (pH 6.4). 
 
6.4.3 Method validation for the detection of quinolones and an antifungal 
drug in wastewater 
The developed chiral method enabled the identification and quantification 
of all studied analytes with satisfactory sensitivity and specificity. Figure 6-2 shows 
the comparison of the mass chromatograms of MRM 1 transitions used for 
quantification purposes for each analyte between the standard solution in mobile 
phase and a spiked influent wastewater sample at a concentration of 100 ng L-1. 
Concentrations of compounds were calculated using the standard calibration curves 
which were built using ILIS approach. In general, calibration curves fitted 1/x. The 
mean correlation coefficients (R2) of the calibration curves were on average > 0.99 
for the investigated compounds (Table 6-3). The linearity ranges varied depending 
on the analyte. The lowest IDL values were detected for nadifloxacin and 
flumequine.  
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Figure 6-2 Chromatograms of the quantification MRM transition for each investigated analyte of 
(a) a standard solution and (b) a spiked influent wastewater sample at a concentration of 100 ng L-
1with OZ-RH column. 
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Table 6-3 Validation parameters - retention time, relative retention time, linearity range, correlation coefficient obtained from calibration curve and instrumental and method 





Sample diluent WWTP influent 
Linearity range 
(µg/L) 
R2 IDLS/N (µg/L) IQLS/N (µg/L) MDL (ng/L) MQL (ng/L) 
Ciprofloxacin 8.7 ± 0.1 2.5 0.05-1000 0.9945 0.050 0.100 0.6 1.1 
Desethylene-ciprofloxacin 6.6 ± 1.1 1.3 5.0-1000 0.9906 5.000 5.000 54.3 54.3 
S-(-)-Ofloxacin (L-
Ofloxacin) 
13.1 ± 0.1 0.2 0.25-1000 0.9983 0.250 0.250 
2.2 2.2 
R-(+)-Ofloxacin 18.3 ± 0.5 2.5 0.25-1000 0.9973 0.250 0.250 2.3 2.3 
Norfloxacin 9.0 ± 0.3 4.1 0.25-1000 0.9900 0.250 5.000 3.1 62.6 
S-(-)-Ofloxacin-N-oxide 20.3 ± 0.2 0.5 0.5-1000 0.9981 0.500 1.000 4.8 9.6 
R-(+)-Ofloxacin-N-oxide 29.2 ± 0.5 1.8 0.5-1000 0.9974 0.500 1.000 5.5 10.9 
S-(-)-Desmethyl-ofloxacin 7.8 ± 0.1 0.4 0.125-1000 0.9985 0.125 0.500 1.2 5.0 
R-(+)-Desmethyl-
ofloxacin 
9.9 ± 0.1 0.4 0.125-1000 0.9982 0.125 0.500 
1.3 5.1 
Nalidixic acid 14.5 ± 0.1 2.9 0.01-2000 0.9940 0.010 0.025 0.1 0.3 
(±)-Lomefloxacin 8.8 ± 0.1 2.6 0.25-2000 0.9981 0.250 0.250 2.6 2.6 
R,R-Moxifloxacin 8.3 ± 0.1 0.7 0.5-1000 0.9902 0.500 0.500 4.2 4.2 
S,S- Moxifloxacin 9.0 ± 0.1 0.6 0.5-1000 0.9914 0.500 0.500 6.4 6.4 
Moxifloxacin-N-sulphate 13.6 ± 0.2 1.7 0.5-2000 0.9941 0.500 1.000 5.7 11.3 
Prulifloxacin-E1 23.4 ± 0.9 2.4 0.5-1000 0.9969 0.500 0.500 5.8 5.8 
Prulifloxacin-E2 26.5 ± 0.5 2.5 0.5-1000 0.9966 0.500 0.500 5.1 5.1 
Ulifloxacin-E1 9.0 ± 0.6 6.1 2.5-1000 0.9981 2.500 2.500 23.5 23.5 
Ulifloxacin-E2 11.2 ± 0.9 7.8 2.5-1000 0.9950 2.500 2.500 33.9 33.9 
(±)-cis-Ketoconazole-E1 16.3 ± 0.1 0.4 0.05-1000 0.9986 0.050 0.050 0.5 0.5 
(±)-cis-Ketoconazole-E2 18.1 ± 0.1 2.1 0.05-1000 0.9976 0.050 0.050 0.7 0.7 
Flumequine-E1 12.9 ± 0.1 0.2 0.025-1000 0.9991 0.025 0.500 0.3 5.3 
Flumequine-E2 17.5 ± 0.1 0.1 0.025-1000 0.9978 0.025 0.500 0.3 5.3 
Nadifloxacin-E1 15.2 ± 0.1 0.3 0.025-1000 0.9989 0.025 0.500 0.2 4.3 
Nadifloxacin-E2 22.4 ± 0.2 0.2 0.025-1000 0.9978 0.025 0.500 0.2 5.0 
R-(+)-Besifloxacin 6.4 ± 0.2 3.6 1.0-1000 0.9916 1.000 1.000 11.9 11.9 
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Overall, most analytes showed good linearity ranges, from 0.025 µg L-1 up to 1000 
or 2000 µg L-1 (for single enantiomer or racemate respectively). Nalidixic acid 
showed the lowest IQL (0.025) (Table 6-3). Good enantiomeric resolution (Rs ≥ 
1.0), allowing for quantification of individual enantiomers was obtained for six 
analytes (Table 6-4). Since (±)-desmethyl-ofloxacin and (±)-ulifloxacin showed 
lower enantiomeric resolution, results for their single enantiomers should be 
considered on a semi-quantitative basis. EF values, obtained from racemate 
standard solutions injected across three concentration ranges, were on average 0.50 
and were reproducible (Table 6-4). 
Table 6-4 Validation parameters - enantiomeric fraction (EF) or diastereomeric fraction (DF) and 
enantiomeric resolution (Rs) of compounds, which stereoisomers were separated under studied 
conditions, in mobile phase (MP) and in wastewater (WW). 
Compounds Rs EF (n=9) 
In MP In WW 5 µg/L 50 µg/L 500 µg/L 
(±)-Ofloxacin 1.25 0.89 0.53±0.01 0.49±0.01 0.49±0.00 
(±)-Ofloxacin-N-oxide 1.71 1.07 0.49±0.01 0.48±0.01 0.50±0.01 
(±)-Desmethyl-ofloxacin 0.97 0.56 0.50±0.04 0.51±0.02 0.51±0.01 
(±)-Prulifloxacin 1.06 0.46 0.49±0.04 0.41±0.01 0.47±0.02 
(±)-Ulifloxacin 0.67 0.41 0.51±0.01 0.49±0.01 0.49±0.01 
(±)-Flumequine 1.91 1.10 0.51±0.03 0.50±0.02 0.49±0.02 
(±)-Nadifloxacin 2.86 1.44 0.51±0.02 0.52±0.01 0.50±0.02 
(±)-cis-Ketoconazole- 1.20 1.08 0.51±0.01 0.51±0.01 0.50±0.01 
Compound Rs DF (n=9) 
 In MP In WW 5 µg/L 50 µg/L 500 µg/L 
(±)-Moxifloxacin 0.84 0.21 0.53±0.03 0.50±0.04 0.51±0.01 
 
MDL and MQL ranged from 0.1 (nalidixic acid) to 54.3 ng L-1 (desethylene 
ciprofloxacin) and from 0.3 to 54.3 ng L-1 (Table 6-3). The instrumental and method 
precision was on average <20% (Tables 6-5 and S3). Quantification can be 
misinterpreted by matrix effects, especially when LC-(ESI) MS/MS are used for 
complex matrices. Indeed, ME results can be interpreted as signal enhancement 
over 100% and as signal suppression below 100%. Ion suppression determined by 
calculations without ILIS response showed how the presence of ILIS well 
compensated the ion suppression in the matrix, even for those compounds that had 
not their corresponding isotopically labelled or deuterated analogue. (Table 6-6). 
HLB cartridges were chosen as sorbents of choice for chiral separations of the drugs 
investigated with OZ-RH column. Abs recovery and relative recoveries data are 
reported in Table 6-6. Recoveries were between 70% and 120% for all analysed 
compounds. Relative SPE recovery and ME showed the ability of ILIS to correct 
and compensate for the complexity of the matrix. 
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Table 6-5 Validation parameters - method precision 

























D 1* D 2 D 3 D 1 D 2 D 3 D 1 D 2 D 3 
   
Ciprofloxacin 13.6 1.8 1.4 11.9 14.7 9.4 12.0 8.0 6.2 5.6 12.0 8.7 
Desethylene-ciprofloxacin 13.4 0.8 13.0 3.9 7.1 1.3 14.5 8.9 7.6 9.1 4.1 10.3 
S-(-)-Ofloxacin (L-
Ofloxacin) 9.0 15.5 2.3 1.8 3.5 4.8 0.5 2.7 0.4 8.9 3.4 1.2 
R-(+)-Ofloxacin 10.4 9.6 7.2 4.6 3.0 2.5 6.2 3.2 4.9 9.1 3.4 4.8 
Norfloxacin 5.0 0.0 14.1 14.9 17.2 15.6 10.3 7.6 18.6 6.4 15.9 12.2 
S-(-)-Ofloxacin-N-oxide 16.0 7.8 4.3 9.3 7.0 0.2 2.1 5.0 3.9 9.4 5.5 3.7 
R-(+)-Ofloxacin-N-oxide 6.0 15.6 8.2 3.8 2.9 1.3 6.6 3.2 2.5 9.9 2.7 4.1 
S-(-)-Desmethyl-ofloxacin 3.4 2.7 8.8 5.1 4.9 5.1 2.0 2.3 0.8 5.0 5.0 1.7 
R-(+)-Desmethyl-ofloxacin 3.5 17.1 10.1 1.8 3.2 4.5 0.9 2.1 3.0 10.2 3.2 2.0 
Nalidixic acid 2.9 0.4 2.9 7.6 9.5 12.2 11.4 7.6 17.9 2.1 9.8 12.3 
(±)-Lomefloxacin 5.2 14.1 14.1 2.5 2.7 3.3 1.8 3.8 13.0 11.1 2.8 6.2 
R,R-Moxifloxacin 3.6 17.4 16.8 10.5 13.6 9.4 8.0 8.0 0.9 12.6 11.2 5.6 
S,S- Moxifloxacin 11.7 1.9 9.2 9.3 2.5 0.4 7.2 1.7 3.5 7.6 4.1 4.1 
Moxifloxacin-N-sulphate 8.3 3.2 13.8 5.1 5.4 7.3 6.2 3.5 1.6 8.4 5.9 3.8 
Prulifloxacin-E1 4.5 14.6 18.9 4.1 2.2 2.9 8.3 4.4 4.6 12.7 3.1 5.8 
Prulifloxacin-E2 7.6 17.7 20.2 5.4 0.7 4.7 9.7 2.6 2.6 15.2 3.6 5.0 
Ulifloxacin-E1 17.5 3.2 11.4 12.1 15.8 15.8 2.1 10.1 7.1 10.7 14.6 6.4 
Ulifloxacin-E2 11.9 10.2 1.6 12.2 10.6 1.9 1.3 2.9 6.4 7.9 8.2 3.5 
(±)-cis-Ketoconazole-E1 2.2 16.4 5.3 2.9 2.6 4.0 2.3 2.9 2.1 8.0 3.2 2.4 
(±)-cis-Ketoconazole-E2 2.2 5.0 5.7 4.9 1.6 1.9 2.8 2.8 1.1 4.3 2.8 2.2 
Flumequine-E1 1.3 3.2 3.0 1.2 0.6 0.9 0.2 2.0 1.0 2.5 0.9 1.1 
Flumequine-E2 2.3 4.6 0.0 1.8 3.4 0.1 2.6 4.4 6.6 2.3 1.8 4.5 
Nadifloxacin-E1 1.6 3.4 9.5 5.1 0.5 0.2 6.2 2.4 1.3 4.8 1.9 3.3 
Nadifloxacin-E2 5.8 5.5 12.6 5.9 5.0 1.5 2.9 1.1 13.8 8.0 4.1 5.9 
R-(+)-Besifloxacin 7.2 5.6 9.6 8.0 7.6 11.6 6.4 3.7 9.7 7.5 9.1 6.6 
*-D indicates day 
**- the following concentrations were used: 10, 100 and 1000 ng L-1 in the case of compounds that were not enantioseparated  
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SPE relative recovery % (n=3) 
With ILIS Without ILIS 25 ng/L* 250 ng/L* 2500 ng/L* 
Ciprofloxacin 117.0 46.8 68.2 84.3 ± 5.7  83.8 ± 1.7 101.7 ± 31.7 
Desethylene-ciprofloxacin 74.6 23.1 40.3 83.8 ± 8.9 107.7 ± 3.5 84.9 ± 4.5 
S-(-)-Ofloxacin (L-Ofloxacin) 111.6 81.2 114.8 110.8 ± 9.3 113.6 ± 1.5 111.9 ± 1.1 
R-(+)-Ofloxacin 107.6 78.3 141.5 113.8 ± 1.9 98.9 ± 1.8 106.4 ± 2.5 
Norfloxacin 79.2 15.4 271.7 73.0 ± 3.7 82.0 ± 1.0 84.7 ± 2.6 
S-(-)-Ofloxacin-N-oxide 108.7 79.0 124.3 103.1 ± 5.1 106.7 ± 6.2 103.0 ± 2.1 
R-(+)-Ofloxacin-N-oxide 102.9 75.1 168.0 82.2 ± 11.9 95.2 ± 3.0 96.7 ± 2.0 
S-(-)-Desmethyl-ofloxacin 96.3 37.6 67.8 97.1 ± 9.1 103.1 ± 3.5 101.8 ± 3.9 
R-(+)-Desmethyl-ofloxacin 95.6 32.0 129.8 111.3 ± 11.7 88.8 ± 2.9 92.4 ± 2.2 
Nalidixic acid 98.6 63.8 112.6 89.8 ± 7.9 89.3 ± 10.8 90.1 ± 12.7 
(±)-Lomefloxacin 90.8 36.1 99.6 102.9 ± 6.0 90.4 ± 1.0 97.6 ± 1.2 
R,R-Moxifloxacin 104.0 86.3 70.5 118.0 ± 0.8 118.7 ± 1.4 117.3 ± 0.9 
S,S- Moxifloxacin 90.0 61.1 87.9 78.4 ± 5.6 71.7 ± 6.9 85.7 ± 7.5 
Moxifloxacin-N-sulphate 116.4 45.5 88.8 85.2 ± 4.0 82.5 ± 2.8 96.9 ± 3.6 
Prulifloxacin-E1 109.0 132.4 73.5 73.3 ± 2.8 81.9 ± 8.2 105.1 ± 5.7 
Prulifloxacin-E2 102.2 74.6 144.4 97.8 ± 20.4 96.8 ± 3.8 100.7 ± 3.4 
Ulifloxacin-E1 119.1 47.8 92.5 119.0 ± 0.5 98.6 ± 3.5 101.1 ± 4.5 
Ulifloxacin-E2 73.8 20.8 274.1 80.7 ± 9.3 70.3 ± 0.3 70.5 ± 0.5 
(±)-cis-Ketoconazole-E1 95.5 69.4 120.3 104.8 ± 1.7 107.3 ± 3.6 106.4 ± 0.8 
(±)-cis-Ketoconazole-E2 95.8 69.7 112.1 72.0 ± 4.2 70.0 ± 2.2 71.0 ± 1.6 
Flumequine-E1 98.3 66.5 136.8 90.2 ± 2.7 95.0 ± 1.1 95.9 ± 0.1 
Flumequine-E2 97.8 70.8 155.6 89.3 ± 1.8 96.4 ± 0.3 98.4 ± 0.9 
Nadifloxacin-E1 112.3 75.9 119.3 118.3 ± 0.6 115.6 ± 4.5 116.8 ± 3.0 
Nadifloxacin-E2 111.7 80.9 136.0 94.9 ± 6.8 98.6 ± 4.7 107.0 ± 4.6 
R-(+)-Besifloxacin 85.6 17.4 221.6 106.8 ± 2.7 73.5 ± 5.7 72.0 ± 1.6 
*- the following concentrations were used: 50, 500 and 5000 ng L-1 in the case of compounds that were not enantioseparated 
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6.4.4 Application of the method for the analysis of influent wastewater 
samples 
The developed and validated method was applied in a one-week monitoring 
campaign from a wastewater treatment plant serving a large city in the South West 
of the UK. As shown in the results (Table 6-7), ciprofloxacin was the target drug 
with the highest concentrations found, especially at the beginning of the week. Its 
metabolite desethylene-ciprofloxacin was detected at quantifiable concentrations in 
two samples (just above the MQL), whilst it was present at <MQL across the week 
due to its high MQL value. A predominance of the S-(-)-ofloxacin (L-ofloxacin) in 
terms of concentrations was detected with respect to R-(+)-ofloxacin giving a 
constant ratio 3:1 over the week. 
A confirmation of their ratio can be explained only through calculation of their mass 
loads. This is the first time that a complete investigation of ofloxacin metabolic 
profile was detected in influent wastewater in the UK. Their metabolic pattern was 
reflected by the presence of their metabolites: (±)-ofloxacin-N-oxide and (±)-
desmethyl-ofloxacin. Unfortunately, in this case a ratio could not be calculated as 
they were present at <MQL. Other two chiral drugs were found: (±)-cis-
ketoconazole and (±)-flumequine. Interestingly, (±)-cis-ketoconazole was found 
enriched of the first eluting isomer, which suggests potential enantioselective 
metabolism. It should be noted that Hamdy and Brocks [50] found evidence of non-
linear stereoselective pharmacokinetics in rats, whilst no stereoselective 
metabolism by liver microsomes. Hence, further work is needed to support this 
finding. This was the first time that the enantiomers of (±)-prulifloxacin and (±)-
ulifloxacin were investigated, even though their detection was not expected to be 
found in wastewater in the UK. For this reason, the study on their enantiomeric 
profiling was not possible. In the developed method, the enantiomers of (±)-
lomefloxacin were not separated, so the evaluation of its enantiomeric profiling was 
not possible. The following achiral compounds were also present: norfloxacin and 
nalidixic acid. 
Overall, these results showed constant concentrations across the sampling week for 
all the detected and quantifiable analytes. These results will be used in a further 
study to estimate drug use via WBE. 
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Table 6-7 Concentration of targeted compounds in wastewater samples during one week monitoring campaign in the South West of the UK. 
Analyte Concentration [ng L-1]  
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Ciprofloxacin 175 ± 10 192 ± 7 197 ± 6 149 ± 10 124 ± 6 144 ± 2 144 ± 5 
Desethylene-ciprofloxacin 61 ± 2 58 ± 1 < MQL < MQL < MQL < MQL < MQL 
S-(-)-Ofloxacin (L-Ofloxacin) 50 ± 1 38 ± 6 43 ± 2 32 ± 2 31 ± 1 46 ± 3 45 ± 2 
R-(+)-Ofloxacin 13 ± 1 12 ± 1 15 ± 1 10 ± 1 10 ± 1 14 ± 3 14 ± 3 
Norfloxacin n.d. n.d. n.d. < MQL < MQL n.d. < MQL 
S-(-)-Ofloxacin-N-oxide < MQL < MQL < MQL < MQL < MQL < MQL < MQL 
R-(+)-Ofloxacin-N-oxide < MQL < MQL < MQL < MQL < MQL < MQL < MQL 
S-(-)-Desmethyl-ofloxacin 12 ± 4 < MQL < MQL < MQL < MQL < MQL < MQL 
R-(+)-Desmethyl-ofloxacin < MQL < MQL < MQL < MQL < MQL < MQL < MQL 
Nalidixic acid 5 ± 1 2 ± 1 1 ± 0 < MQL 1 ± 0 1 ± 0 1 ± 0 
(±)-Lomefloxacin 3 ± 1 3 ± 1 < MQL < MQL 3 ± 0 < MQL < MQL 
R,R-Moxifloxacin n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
S,S- Moxifloxacin n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Moxifloxacin-N-sulphate n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Prulifloxacin-E1 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Prulifloxacin-E2 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Ulifloxacin-E1 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Ulifloxacin-E2 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
(±)-cis-Ketoconazole-E1 8 ± 1 9 ± 2 10 ± 1 7 ± 1 6 ± 1 9 ± 1 11 ± 1 
(±)-cis-Ketoconazole-E2 5 ± 1 5 ± 1 6 ± 0 4 ± 0 4 ± 0 6 ± 0 6 ± 0 
Flumequine-E1 < MQL < MQL < MQL n.d. < MQL < MQL < MQL 
Flumequine-E2 n.d. < MQL n.d. n.d. n.d. < MQL < MQL 
Nadifloxacin-E1 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Nadifloxacin-E2 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
R-(+)-Besifloxacin n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
n.d. - not detected 
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6.5 Conclusions 
Monitoring activity of antibiotic consumption is crucial for public health 
monitoring, especially when the spreading of antibiotic resistance is related to an 
extensive use. One of the antibiotic class that has a rising concern in antibiotic 
resistance is the quinolones. A near real-time monitoring tool is provided by WBE 
that can also allow for the determination of quinolones consumption biomarkers via 
analysis of human urinary metabolites. Since many quinolones are distributed as 
racemates, pharmacokinetics and pharmacodynamics differences occur in humans 
and animals, and their effects can be found in the environment. However, analytical 
methods that enable the simultaneous determination of quinolones biomarkers 
along with their chiral composition are missing. To aid enantiomeric profiling of 
quinolones and an antifungal drug in WBE, a novel chiral analytical method based 
on SPE with HLB followed by enantioselective HPLC-MS/MS with the usage of 
an OZ-RH column was developed and fully validated in wastewater. This method 
showed very good performance: >70% SPE recoveries, very good sensitivity 
(MDLs and MQLs at ppt levels), high linearity range and method precision < 20%. 
It allowed for the analysis of 16 human and veterinary quinolones drugs as potential 
biomarkers in wastewater. This method was applied in a one week monitoring 
campaign of a large wastewater treatment plant in the South of the UK, where many 
targeted drugs were found at quantifiable concentrations. When these targeted drugs 
were detected, their concentrations did not vary over the week.  
Enantiomeric profiling study revealed that (±)-ofloxacin was found 
enriched with S-(-)-enantiomer, probably due to higher consumption of the 
enantiomerically pure drug. The detection of (±)-ofloxacin metabolites in 
wastewater indicated that their presence was due to their human origin and, thus, to 
the ofloxacin consumption. A slightly enrichment of the first-eluting enantiomer 
was also observed in the case of (±)-cis-ketoconazole, even though further 
investigation is needed. To the authors’ knowledge, this is the first time that chiral 
separation in reverse phase LC-MS was simultaneously undertaken for (±)-
ofloxacin with its main metabolites (±)-ofloxacin-N-oxide and (±)-desmethyl-
ofloxacin, (±)-moxifloxacin, the prodrug (±)-prulifloxacin with its active 
compound (±)-ulifloxacin, (±)-cis-ketoconazole, (±)-flumequine, (±)-nadifloxacin 
and R-(+)-besifloxacin and their enantiomeric profiling was investigated at 
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enantiomeric level in composite wastewater samples. As achiral quinolones were 
also included, the method is suitable for monitoring purposes. 
 
6.6 Supplementary Data 
The following supplementary data are contained in Appendix 4: 
Table S1 Selected analytes and their properties (MW=molecular weight). 
Table S2 Studied mobile phase compositions with CHIRALCEL® OZ-RH column. 
Table S3 Validation parameters -instrumental precision 
Figure S1 CHIRALCEL® OZ-RH column – impact of the organic content on the 
separation of studied analytes (mobile phases in the legend are referred to the 
organic modifier mentioned in the title of the graphic). 
Figure S2 CHIRALCEL® OZ-RH column – (a) impact of the organic modifiers 
used on the separation of studied analytes. The mobile phase composition was 
constituted by the organic solvent specified in the legend and by 5% of 5mM 
ammonium acetate as aqueous content; (b) Impact of the nature of the organic 
content in the mobile phase on enantiomeric resolution. The mobile phases 
considered were the best performing: 95:5 5mM ammonium formate for IPA and 
ACN, 99:1 5mM ammonium formate for EtOH, 99:1 10mM ammonium formate 
for MeOH. 
Figure S3 CHIRALCEL® OZ-RH column – impact of (a) the flow rate, (b) pH and 
(c) percentage of the additive content on the separation of studied analytes. The 
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Chapter 7: Enantiomeric profiling of quinolones 




The misuse of quinolones and fluoroquinolones represents an increasing 
concern especially due to the spreading of antibacterial resistance. Real-time 
monitoring of antibiotics is, therefore, essential to verify (inappropriate and 
unnecessary) use by humans and in veterinary medicine. Along with surveillance 
and statistics data, a helpful on-time monitoring tool is represented by WBE through 
the identification of biomarkers of exposure to antibiotics. Discussed here is the 
first pan-European study on enantiomeric profiling and monitoring of chiral 
quinolones in wastewater. This study identified several new potential biomarkers 
for quinolones consumption to be used in WBE context. They were: (±)-ofloxacin 
with its main metabolites (±)-ofloxacin-N-oxide and (±)-desmethyl-ofloxacin, (±)-
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moxifloxacin, the precursor (±)-prulifloxacin with its active compound (±)-
ulifloxacin, (±)-cis-ketoconazole (the only antifungal included), (±)-flumequine, 
(±)-nadifloxacin and R-(+)-besifloxacin. The investigation of loads of chiral 
quinolones enantiomers in wastewater and their correlation with their human 
stereoselective metabolism enabled to find out areas where consumption and direct 
disposal of ciprofloxacin and ofloxacin occurred (i.e. southern European locations). 
In northern European cities, S-(-)-ofloxacin loads were predominant with respect to 
R-(+)-ofloxacin. Enantiomerically pure S-(-)-ofloxacin (levofloxacin) was detected 
in wastewaters from southern European cities, showing a stereoselective usage of 
the drug. Nalidixic acid, norfloxacin and lomefloxacin were founds at low 
population-normalised loads. Diastereomerically and enantiomerically S,S-
moxifloxacin and S,S-moxifloxacin-N-sulphate were detected in wastewater 
presumably due to metabolism of moxifloxacin. For the first time, population-
normalised ulifloxacin loads were found in Milan and Castellon with average values 
at 22.3 and 1.5 mg day-1 1000 people-1 respectively as a result of prulifloxacin 
metabolism. No racemic prulifloxacin was detected as a consequence of its direct 
disposal. (±)-cis-Ketoconazole was enriched with the first-eluting enantiomer, thus 
suggesting potential enantioselective metabolism. Enrichment of flumequine with 
first-eluting enantiomer in all the samples was explained as a result of animals’ 
metabolism rather than its direct disposal. Moreover, the occurrence of 
fluoroquinolone resistance genes was investigated in wastewaters from several 
European locations. Interpretation of data was controversial even though the 
approach based on analytical and bioanalytical techniques was a promising means 
for further studies. 
 
7.2 Introduction 
Microorganisms, antimicrobial agents and the geographical region are three 
variables that play a key role in the occurrence of antimicrobial resistance in Europe 
[1]. Geographical gradients, from northern to southern Europe and from northern 
to eastern Europe, were reported for some combinations of antimicrobial agents and 
microorganisms [1]. As geographical differences in antibiotics prescription could 
be the evidence of a different consumption pattern and environmental occurrence, 
it is important to investigate the antimicrobial use and correlate their presence in 
the environment with the occurrence of antimicrobial resistance. Whilst data on 
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antimicrobial agents’ usage are annually collected at a community and hospital 
level and are provided by the European Surveillance of Antimicrobial Consumption 
Network (ESAC-Net), data on antimicrobial resistance are given by the European 
Antimicrobial Resistance Surveillance Network (EARS-Net). These monitoring 
activities are therefore essential for delineating common and prompt directions and 
strategies in order to inform the policy’s makers on antimicrobial resistance 
problems, which require international cooperation. These surveillance systems rely 
on national sales, reimbursement data (or a combination of them) and information 
taken from national drug registers. Unfortunately, a temporal delay of one year (or 
two years) usually occurs since epidemiological data are published. This may affect 
the efficiency of decision-making strategies. A promising monitoring tool, recently 
applied to another class of compounds (i.e. illicit drugs), is based on the WBE 
approach. Since humans can be considered as a source of both antibiotics and 
antibiotic resistance genes [2], they can release them as products of urinary 
excretion in the sewer system. Not all of these excretion products, so-called 
biomarkers, are suitable indicators of human antibiotic intake as some prerequisites 
need to be satisfied. A likely drug biomarker for WBE purposes needs to have also 
good stability in wastewater. A number of studies assessed stability of the targeted 
compounds in several environmental matrices, albeit without considering their 
stereoselectivity. As reported by Kummerer [3], fluoroquinolones are insensitive to 
hydrolysis and elevated temperatures, although they are degraded by UV light. 
Indeed, their stability in wastewater and during wastewater treatment is a concern, 
as these potent chemicals can be found in wastewater and then in receiving 
environment, thus contributing to antimicrobial resistance (AMR). 
A number of studies reported antibiotics in the environmental matrices, 
especially because of their proved risk to the environmental and human health [3]. 
Others demonstrated that resistance genes spreading into the environment 
demonstrate an emergent issue [4, 5]. Only a few reports correlated antibiotic loads 
to the presence of antibiotic resistance gene [2]. None of them investigated 
antibiotic profiling focussing on both metabolic profile and stereochemistry 
dimension. There is therefore a knowledge gap regarding antibiotics in the 
environment and their impacts on AMR. 
Therefore, the aim of this chapter is to: 
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(i) study daily loads of selected antibiotics in wastewaters from several 
European locations, which are known to have increasing resistance 
problem; 
(ii) study the enantiomeric profiling of antibiotics; 
(iii) evaluate the level of its antibiotic gene resistance in the wastewater; 
(iv) analyse quinolones and gene resistance loads in the monitored areas. 
7.3 Experimental 
7.3.1 Chemicals and materials 
The following analytes were selected for the study (Figure 7-1): (±)-ofloxacin, S-(-
)-ofloxacin, (±)-ofloxacin-N-oxide, (±)-desmethyl-ofloxacin, (±)-lomefloxacin, 
(±)-prulifloxacin, (±)-ulifloxacin, (±)-ketoconazole, (±)-flumequine, (±)-
nadifloxacin, R,R-moxifloxacin, S,S-moxifloxacin and S,S-moxifloxacin-N-
sulphate and R-(+)-besifloxacin. The following deuterated and isotopic analogues 
of target analytes were used as ILIS: ciprofloxacin-D8, (±)-ofloxacin-D3, (±)-
desmethyl-ofloxacin-D8 and (±)-flumequine
13C3. Standard stock solutions were 
initially prepared at 1 mg mL-1 by dissolving (±)-ofloxacin-D3 and (±)-
flumequine13C3 in acetonitrile and ciprofloxacin-D8 and (±)-desmethyl-ofloxacin-
D8 in water. A mixture of them was finally prepared from stock solutions at 1 mg 
L-1 by dilution with mobile phase and it was used for spiking samples. CAS number, 
molecular formula, molecular weight, pKa and supplier information for targeted 
analytes is given in Appendix 4 (see Table S1). All standards and internal standards 
were of the highest purity available (>97%). Stock and working solutions of 
standards were stored at -20° C. Methanol, ammonium formate and formic acid 
were purchased from Sigma Aldrich, UK. Ultrapure water was obtained from 
PURELAB UHQ-PS Unit (Elga, UK). 
 
7.3.2 Wastewater sample collection and storage 
24-hours composite wastewater influent samples were collected over a week 
in March 2015 from several wastewater treatment plants across Europe. The used 
sampling protocol is described elsewhere [6].  
 


























Figure 7-1 Chiral and not chiral analytes selected in the study [(±)-cis-ketoconazole was the only antifungal included]. The arrow indicates that the produced analyte is a 
metabolite (to be noticed that not all the metabolites were included in the figure). 
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Sampling locations were in Norway (Oslo), United Kingdom (Bristol), Denmark 
(Lyngby), The Netherlands (Utrecht), Switzerland (Zurich), Italy (Milan) and Spain 
(Castellon) (Figure 7-2). 
 
Figure 7-2 Sampling locations. 
Information on population and flow for cities involved in the study are provided in 
Table 7-1. Once collected, wastewater samples were transported to the local 
laboratory in refrigerated conditions and shipped on ice blocks to the UK within 24 
hours. 
Table 7-1 Selected cities in the study, population and flow data. 
City Bristol Oslo Milan Utrecht Castellon Zurich Lyngby 
Country UK Norway Italy The 
Netherlands 
Spain Switzerland Denmark 
Residential 
population 
886650 580639 1100000 300000 180690 410000 531000 
Day Flow in m3/day 
Monday 197493 254570 597470 45970 37469 177167 148724 
Tuesday 204491 252721 423110 44580 40476 160912 150936 
Wednesday 198950 333480 403240 47740 50228 157084 147175 
Thursday 197523 308279 412310 45030 49161 161005 144840 
Friday 252682 277450 402240 49530 43728 161427 145197 
Saturday 220687 256766 403020 46030 38301 200010 137793 
Sunday 193194 250384 422690 46900 37243 243013 137244 
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7.3.3 Sample preparation and analysis with chiral HPLC-MS/MS 
Samples were prepared by following a validated chiral analytical method 
for the detection and quantification of chiral and achiral quinolones and a chiral 
antifungal drug in wastewater as described in Chapter 6. Briefly, samples were 
filtered through GF/F 0.7 µm glass fibre filter (Whatman, UK) and 50 mL were 
spiked with 50 µL of ILIS mixture at concentration of 1 mg L-1. They were then 
solid-phase extracted by using Oasis HLB cartridges (60 mg, Waters, UK). Before 
the loading of the samples, these cartridges were conditioned with 3 mL of methanol 
and equilibrated with 3 mL of ultrapure water at a rate of 3 mL min-1. The loading 
phase was at a rate of 8 mL min-1. Washing step was carried out with 1 mL of 
ultrapure water at a rate of 3 mL min-1, whilst the elution with 4 mL of methanol at 
a rate of 8 mL min-1 into 5 mL silanised glass tubes. The extracts in the glass tubes 
were then evaporated to dryness under nitrogen flow (5-10 psi) by using a 
TurboVap evaporator (Caliper, UK). Reconstitution of the extracts was performed 
by adding 500 μL of the mobile phase, consisting of 10 mM ammonium 
formate/methanol 1:99 v/v with 0.05% formic acid. Before being transferred to 
polypropylene plastic vials bonded pre-slit PTFE/Silicone septa (Waters, UK), 
samples were filtered through 0.2 µm PTFE filters (Whatman, Puradisc, 13mm). 20 
µL were directly injected into a chiral HPLC-MS/MS. Samples from the monitoring 
campaign were prepared and analysed in duplicate. 
The analysis was undertaken by using a Waters ACQUITY UPLC® system 
(Waters, Manchester, UK) with a chiral CHIRALCEL® OZ-RH column (5 μm 
particle size, L × I.D. 15 cm × 2.1 mm, Chiral Technologies, France) connected 
with a 2.0 mm × 2.0 mm guard filter (Chiral Technologies, France) in the column 
compartment (temperature set at 30°C). The autosampler was kept at 4°C. The flow 
rate was 0.1 mL min-1 under isocratic conditions. A triple quadrupole mass 
spectrometer (Xevo TQD, Waters, Manchester, UK) equipped with an ESI was 
used in positive mode. Instrumental parameters are described in details in Chapter 
6 (see paragraph 6.3.3). Data were acquired in MRM mode. Selected MRM 
transitions, CV and CE values for each compound were presented in Chapter 6 (see 
Table 6-2). 
MassLynx 4.1 (Waters, UK) was used to control both systems, the Waters 
ACQUITY and the Xevo TQD. TargetLynx software (Waters, Manchester, UK) 
was used for data processing. 
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7.3.4 Sample preparation and analysis for qnr gene quantification 
UK wastewater samples were firstly tested on non-selective media plates 
for proving the suitable volume to be used in a further qualitative test. Indeed, the 
test “dry run on non-selective media” was performed by using 100 μL and 200 μL 
of refrigerated wastewater samples (day 6th and 7th). Plates were then incubated at 
37° C overnight. As shown in Figure S1, plates with 100 μL of wastewater 
incubated provided a distinct bacteria growth. 100 μL of wastewater samples from 
all the European sites were therefore incubated in cysteine-, lactose-, and 
electrolyte-deficient (CLED) agar plates. CLED agar (Sigma Aldrich, UK) media 
was prepared as follows. 36.15 g of powder were weighted to make 1 L of CLED 
agar solution and transferred to a sterilised 1 L glass bottle. The bottle was filled 
with 1 L of distilled water. Once it was properly dissolved, it was placed in the 
autoclave for 20 minutes. The CLED agar was then finally poured in sterilised petri 
dishes. ~16 colonies from each plate were isolated and incubated singularly (an 
example is shown in Figure S2). Every single colony was stocked in cryogenic vials 
(2mL, Fisherbrand) containing 500 μL of 30% LB/Glycerol filter-sterilised and 
kept in the freezer -80°C as reference. The plates were stored in the fridge with 
paper-tape. Plates of the incubated wastewater are shown in Figure S3-4. 
 
7.3.4.1 DNA extraction 
Triplicate wastewater samples of 1mL each were centrifuged for 5’ at 3000 
g and the cell pellet was resuspended in 200 μL PBS. 5 μL lysozyme were then 
added, followed by an incubation of 15’ at 37 °C. 200 μL Binding buffer and 40 μL 
proteinase K were added and left in incubation for 10’ at 70 °C. 100 μL IPA were 
added before the filtration in a filter tube and the centrifugation for 1’ at 8000 g. 
The flow in the collecting tube was discarded and 500 μL Inhibitor removal buffer 
was added to the filter tube assembled in a new collecting tube. The sample was 
centrifuged for 1’ at 8000 g and the flow was discarded. 500 μL washing buffer 
were added to the filter tube assembled in a new collecting tube. The sample was 
centrifuged for 1’ at 8000 g and the flow was discarded. This step was repeated and, 
finally, the sample was centrifuged for 10’ at 9000 g. The DNA elution was 
performed by adding 200 μL pre-warmed elution buffer into the High Pure Filter 
Tube. This sample preparation was followed the manufacturer’s instructions (High 
Pure PCR Template Preparation Kit, Roche, Germany). DNA concentrations were 
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determined by QubitTM fluorometer (InvitrogenTM). Measurements of the DNA in 
the samples were undertaken in parallel with known standard solutions. 
 
7.3.4.2 Target quantification using qPCR 
The quantification of qnrS gene was performed through real-time PCR 
(qPCR) system (StepOnePlus, Applied Biosystems). The following primers were 
used for specific amplification of qnrS gene (Eurofins Genomics, Germany) (Table 
7-2). 
Table 7-2 Details of qnrS. 
Gene Primer Sequence (5’ -> 3’) 
qnrS qnrSrtF11 GACGTGCTAACTTGCGTGAT 
qnrSrtR11 TGGCATTGTTGGAAACTTG 
 
The PCR conditions were programmed with an initial denaturation at 95 °C for 10’, 
followed by 40 cycles at the same temperature for 15 seconds and an annealing 
temperature of 60 °C for a minute. A melt curve was successively performed 
starting from 65 °C to end up to 95 °C (Figure S5). qPCR reaction was performed 
in duplicate in a 25 μL volume mixture and conducted in 96 well plates containing 
12.5 μL of SYBR Green Master Mix (Applied Biosystems), 0.1 μM of each primer 
and 5 μL of template DNA. Amplicon cloning was performed by insertion of the 
PCR product into a plasmid pCR™ 2.1-TOPO® TA vector (InvitrogenTM) in the 
cloning reaction. The following equation (14) was used for calculating the copy 
number μL-1 as described elsewhere [2]: 
660length  x  Plasmid






Where Plasmid DNA concentration is expressed in g μL-1 and Plasmid length in bp. 
660 is the average molecular weight of 1 bp [7]. Indeed, by ten-fold dilutions of the 
positive sample, a standard curve was created in order to quantify absolute 
concentration in European wastewater samples (Figure S6). 
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7.3.4.3 Target quantification using Digital PCR 
Digital PCR analysis was performed on the QuantStudio® 3D Digital PCR System 
(Life Technologies, Thermo Fisher Scientific). The digital PCR reaction mixture 
consisted of QuantStudio® 3D Digital PCR Master Mix, 20X SYBR® Green I dye 
in TE buffer at pH 8, each primer and DNA sample. The mixture was loaded in a 
high-density nanofluidic chip to partition the sample in many independent reactions 
and sealed. The thermal cycling program was the same reported for qPCR analysis 
in the previous paragraph. AnalysisSuiteTM software was used to get quantification 
of the targeted gene and statistical analysis of the results. 
 
7.4 Results and Discussion 
7.4.1 Analysis of antibiotics in wastewater 
This study targets an antifungal, quinolones and fluoroquinolones. The latter 
class is a high priority class among antibiotics according to WHO [8]. Reported by 
the European Centre for Disease Prevention and Control (ECDC) in 2014 [9], 
consumption of quinolones for systemic use in the community (primary care and 
hospital sector), expressed in defined daily dose (DDD) per 1000 inhabitants and 
per day in presented in Table 7-3. 
Table 7-3 Community consumption, relative consumption and seasonal variation of quinolones in 











Norway 0.50 0.07 3.2% - 0.57 
UK 0.48 0.11 2.3% 9.8% 0.59 
Denmark 0.50 0.21 3.1% 4.9% 0.71 
The 
Netherlands 
0.79 0.11 7.4% - 0.90 
Switzerland n.a.  n.a. n.a. n.a. 
Italy 3.41 0.41 12.2% 22.0% 3.82 
Spain 2.31 - 10.6% - 2.31 
a 
expressed as DDD per 1000 inhabitants and per day 
b 
Consumption of fluoroquinolones expressed as % of the total consumption of antibacterials for 
systemic use 
c 
expressed as the total of consumption from primary care and hospital sector 
d 
data not provided by ECDC 
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As reported by EFSA [8], the underestimation of the fluoroquinolones consumption 
in humans is less problematic with respect to 3rd- and 4th-generation cephalosporins, 
especially because fluoroquinolones are mostly used in human medicine. Indeed, 
according to ECDC/EFSA/EMA first joint report [8], their consumption in 2012 
was higher in humans than in food-producing animals for most countries with a 
population-weighted mean of 7.04 mg/kg estimated biomass and corresponding 
ranges of 2.24–16.03 mg/kg. Therefore, for the locations involved in that study 
(although no data for Switzerland were available), it was possible to state that: 
 Denmark, Norway and the Netherlands showed similar human consumption 
range (≤5 mg per kg estimated biomass) with negligible income from food-
producing animals. 
 For countries where only community consumption data were available for 
human medicine, such as the UK and Spain, the UK had the lowest 
population-corrected consumption of fluoroquinolones with a slight 
contribution from food-producing animals. Spain had high amount 
population-corrected fluoroquinolones consumption estimates for human 
use (>10 mg per kg estimated biomass) and for food-producing animals (< 
5 mg per kg estimated biomass). 
 Italy had the highest difference between population-corrected 
fluoroquinolones consumption estimates for human use (~15 mg per kg 
estimated biomass) and food-producing animals (<5 mg per kg estimated 
biomass). 
Results on population-mass loads for the studied analytes are shown in Figures 7-
3, 7-5 and 7-6. Table S1 provides concentrantions, daily population-normalised 




Ciprofloxacin is an achiral synthetic drug. In humans 40-50% of 
ciprofloxacin is excreted unchanged and as desethylene-ciprofloxacin and sulfo- 
ciprofloxacin with antibacterial activity 30 times less than ciprofloxacin at 2% and 
4%, respectively, oxo-ciprofloxacin with an activity 10-times lower at 7% and 
sporadically as formylciprofloxacin (a minor metabolite) (Figure 7-4) [10, 11].  




Figure 7-3 Average population-normalised mass loads for ciprofloxacin and its metabolite. Here, 
results are shown with the fullnames of the countries (and not with those of the cities). 
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 Ciprofloxacin is also a metabolite of enrofloxacin, which is a veterinary drug. 
Metabolism of enrofloxacin leads to excretion of 31% as ciprofloxacin, 5% as oxo-
ciprofloxacin and 3% as desethylene-ciprofloxacin [12]. Ciprofloxacin and its 
metabolite desethylene-ciprofloxacin were selected as biomarkers of ciprofloxacin 
use.  
In this study, population-normalised ciprofloxacin loads ranged from a 
minimum average value of 37.6 mg day-1 1000 people-1 in Bristol to a maximum 
value of 409.9 mg day-1 1000 people-1 in Castellon. The metabolite loads varied 
from 9 mg day-1 1000 people-1 in Milan to a maximum value of 23.9 mg day-1 1000 
people-1 in Oslo. The highest intra-week variability was found for ciprofloxacin in 
Zurich, followed by Castellon and Milan, for desethylene-ciprofloxacin in Oslo and 
Milan. Indeed, most of the countries showed stable mass loads over the week (Table 
S1). 
Intra-day variation was observed by Coutu et al. (2013) [13], where a peak was 
found between 7 and 9 a.m. due to accumulation of the excreted drug in urine during 
night-time and posology which caused the increased loads at the first flush in 
wastewater [14]. Because of its therapeutic use, seasonal variations were also found 
by Coutu et al. (2013) in Switzerland [13]. This seasonal trend is most likely in 
central and southern European countries, rather than Northern countries, where a 
drop in use during summer is observed, especially because of high temperatures. 
The ratio between parent compound:metabolite ranged between 3:1 and 8:1 for 
Northern European cities and around 20:1 for Southern ones. According to 
metabolism data, the ratio indicating human consumption is nearly 22.5:1, thus the 
loads of ciprofloxacin from Southern cities may be mainly related to consumption. 
From PCA data available for the UK in March 2015 [15], 510 kg of 
ciprofloxacin were prescribed. Considering 45% as average excretion percentage 
for the parent compound and 2% for the metabolite, the excreted amount was 
calculated as 229.6 and 10.2 kg respectively. According to the available statistics, 
its consumption was estimated at 210 mg day-1 1000 people-1 (Table 7-4). Using an 
average dose of 400 mg from the oral formulations available, the estimates found 
from wastewater analysis were 94.2 and 793.9 mg day-1 1000 people-1 using 
ciprofloxacin and desethylene-ciprofloxacin respectively as DTRs.  
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Table 7-4 Consumption estimates were calculated considering prescriptions data from PCA [15] 




DTR Consumption estimates 












18.6 Ofloxacin 4.2 17.2 
Ofloxacin-N-oxide 45.9 
Desmethyl-ofloxacin 141.8 
Norfloxacin 0.1 Norfloxacin 0.1 2.9 
Nalidixic acid 0.0 Nalidixic acid 0.3 0.9 
Lomefloxacin - Lomefloxacin - 0.8 
Moxifloxacin  
  
3.2 Moxifloxacin 3.0 - 
Moxifloxacin-N-sulphate - 
 
This underestimation in wastewater calculations may be explained because of the 
high adsorption to the particulate phase of wastewater for ciprofloxacin that reaches 
68% according to Petrie et al. 2014 [15]. Indeed, this aspect was also highlighted 
by Petrie et al. 2015 [16]. If the absorption to the suspended particulate matter is re-
considered in loads, estimates in wastewater are 294.5 mg day-1 1000 people-1 using 




After (±)-ofloxacin intake, ofloxacin urinary metabolites are (±)-ofloxacin-
N-oxide and (±)-desmethyl-ofloxacin with a percentage of excretion of 2%, (±)-
ofloxacin-glucuronide along with the parent drug itself at 80-85%.   





Figure 7-5 Average population-normalised mass loads for ofloxacin and its metabolites. Mean EFs were 
shown in the secondary vertical axis. Results are shown with the fullnames of the countries (and not with those 
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Disposition of ofloxacin was found to be stereoselective in humans probably 
due to differences in renal excretion [17]. Stereoselective intake of the S-(-)-
ofloxacin (well known as levo-ofloxacin) is linked to the production of S-(-)-form 
metabolites. 
The selection of ofloxacin biomarkers in wastewater was based on (±)-ofloxacin, 
(±)-ofloxacin-N-oxide and (±)-desmethyl-ofloxacin. This was the first time that a 
complete investigation of ofloxacin metabolic profile was performed in 
wastewaters in a pan-European study. 
In the current study, population-normalised ofloxacin loads ranged from a 
minimum average value of 4.3 mg day-1 1000 people-1 in Utrecht to a maximum 
value of 727.4 mg day-1 1000 people-1 in Milan. The same was found for the 
metabolites, but with lower mass loads due to their low urinary excretion. In fact, 
they ranged between 0.4 and 7.4 mg day-1 1000 people-1 for ofloxacin-N-oxide and 
between 1.8 and 11.8 mg day-1 1000 people-1 for desmethyl-ofloxacin. The highest 
intra-week variability was found for ofloxacin in Milan and Castellon, whilst quite 
stable mass loads were achieved for both metabolites (Table S1). 
The most important considerations came out from the analysis of 
enantiomeric profiling. A predominance of the S-(-)-ofloxacin loads was observed 
with respect to R-(+)-ofloxacin in northern European cities. The contribution of 
only one enantiomer, S-(-)-form, was exclusively found in southern locations, thus 
showing a stereoselective usage of the drug (probably linked with prescriptions of 
S-(-)-enantiomer).  
The investigation of ratios were performed through calculations of their mass loads. 
A constant ratio 3:1 for the two ofloxacin enantiomers was found over the week in 
Bristol, whist 4:1 in Oslo and Utrecht. Ofloxacin:ofloxacin-N-oxide ratio was 10:1 
for northern cities, whilst it was different for the others. Ofloxacin was nearly six 
times higher than desmethyl-ofloxacin in Oslo and Bristol, whilst it was three times 
higher in Lyngby and Utrecht. According to metabolism data, the proposed ratio 
was 41.2:1. In Castellon and Milan, slightly higher ratios were found, thus 
suggesting also disposal of ofloxacin in these cities. 
According to PCA data in March 2015 from the UK [15], 18.6 kg of 
ofloxacin were prescribed. Considering 82.5% as average excretion percentage for 
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the parent compound and 2% for the metabolites, the excreted amount was 
calculated as 15.3 and 0.4 kg respectively. Therefore, on the basis of the available 
statistics, its consumption was estimated at 4.2 mg day-1 1000 people-1 (Table 7-4). 
Using an average dose of 300 mg, the estimates found from wastewater analysis 
were 17.2, 45.9 and 141.8 mg day-1 1000 people-1 using ofloxacin, ofloxacin-N-
oxide and desmethyl-ofloxacin respectively as DTRs. These estimates through 
wastewater analysis do not take into account the influence of the adsorption to the 
suspended particulate matter (63% according to Petrie et al. 2014 [15]). If this 
parameter is considered in the calculations, estimates in wastewater are 46.4 mg 
day-1 1000 people-1 considering ofloxacin as DTR. Despite that, official and 
wastewater analysis did not provide similar estimates. 
 
7.4.1.3 Norfloxacin 
Norfloxacin is an achiral synthetic fluoroquinolone. From 25 to 40% of the 
dose it is excreted as unchaged in urine (30% as average in faeces within 48 hours) 
and as metabolites at 5-10% within 24-48 hours. 
In wastewater, population-normalised loads were <MDL in Lyngby and in 
Utrecht up to a maximum value of 40.2 mg day-1 1000 people-1 in Zurich. As in the 
case of ciprofloxacin and ofloxacin, intra-day variation was observed for 
norfloxacin by Coutu et al. (2013) with a peak load in wastewater at the first flush 
in early morning [13]. 
From the UK, PCA data shows that 0.1 kg were dispensed in March 2015 
[15]. Considering 32.5% as average excretion percentage, the excreted amount 
calculated was 0.04 kg. Hence, its consumption was estimated at 0.1 mg day-1 1000 
people-1 (Table 7-4). Estimates from wastewater analysis were 2.9 mg day-1 1000 
people-1 showing a slight disagreement between two sets of data. 
 
7.4.1.4 Nalidixic acid 
Nalidixic acid is an achiral synthetic quinolone. In humans, only ~2-3% of 
nalidixic acid is excreted unchanged, 80% is metabolised to 7-hydroxy-nalidixic 
acid, which is an active compound, carboxy metabolite, the inactive conjugates (7-
hydroxy-nalidixic acid and nalidixic acid glucuronides). 
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In this study, population-normalised loads were <MDL in Lyngby up to a 
maximum value of 2.5 mg day-1 1000 people-1 in Oslo. PCA data from the UK 
showed that this drug was dispensed in the amount of 0.036 kg only by pharmacies 
and appliance contractors in England. Considering 2% of excretion, the excreted 
amount calculated was very low (0.001 kg). Thus, its consumption was estimated 
at 0.3 mg day-1 1000 people-1. The possible hydrolysis of the glucuronides and, thus, 
the release of free-nalidixic acid can contribute to loads found in wastewater. As 
the excretion of these glucuronides is not an available data, estimates were 
performed considering a total contribution of 40% of the parent compound. 
Estimates from wastewater analysis were 0.9 mg day-1 1000 people-1 using nalidixic 
acid as DTR (Table 7-4). Even if both estimates agreed quite well, other DTRs 
could be still investigated. 
 
7.4.1.5 Lomefloxacin 
(±)-Lomefloxacin is a chiral synthetic fluoroquinolone. Once ingested, 65% 
is found unchanged in the urine and 9% is excreted as glucuronide. To the author’s 
knowledge, information on stereoselective metabolism is not available. 
Unfortunately, under chromatographic conditions used, its enantiomers are not 
resolved. Therefore, analyses of its loads are intended for (±)-lomefloxacin. 
In this study, population-normalised loads ranged from a minimum value of 
0.1 for Utrecht to a maximum value of 2.6 mg day-1 1000 people-1 for Milan. 
Even if (±)-lomefloxacin was not dispensed in England in March 2015 
according to PCA data, population-normalised loads were found in wastewater at 
0.5 mg day-1 1000 people-1 (Table 7-4). Its estimate takes into account also the 
percentage fraction from the glucuronides (assuming that they are hydrolysed in 
wastewater). Considering 74% as the excretion percentage, the consumption was 
estimated at 0.8 mg day-1 1000 people-1.  




















































































































































































































































































































































Figure 7-6 Average population-normalised mass loads for other quinolones investigated and cis-
ketoconazole. For chiral drugs, which enantiomers were separated under chromatographic 
conditions used, mean EF was also shown on the secondary vertical axis. Results are shown with 
the fullnames of the countries (and not with those of the cities). 
 
7.4.1.6 Moxifloxacin 
(±)-Moxifloxacin is a synthetic fluoroquinolone that has two chiral centres. 
It is sold in one form of S,S-moxifloxacin. R,R-moxifloxacin is an impurity of the 
drug, therefore it is unlikely a product of human metabolism. Indeed, S,S-
moxifloxacin is excreted unchanged at about 20% in urine and 25% in faeces, as 
acyl-glucuronide at 14% of the dose in urine and moxifloxacin-N-sulphate at 35% 
of the dose in faeces. In this study, diastereomers of moxifloxacin were separated 
under selected chromatographic conditions. Hence, it was possible to verify 
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microbial conversion of the parent drug. S,S-moxifloxacin and moxifloxacin-N-
sulphate were selected as biomarkers of moxifloxacin human use.  
Here, population-normalised moxifloxacin loads ranged from <MDL to a 
maximum of 21.6 mg day-1 1000 people-1 in Castellon enriched of only one S,S-
enantiomer. Population-normalised moxifloxacin-N-sulphate loads ranged from 
zero to a maximum of 149.8 mg day-1 1000 people-1 in Castellon enriched of only 
one S,S-enantiomer as the parent compound.  
Even if (±)-moxifloxacin was not found in wastewater samples from Bristol, 
PCA data from March 2015 [15] shows that S,S-moxifloxacin was dispensed in the 




(±)-Prulifloxacin is a synthetic prodrug sold as racemate for oral 
administration. It is converted in its active compound, ulifloxacin, by hepatic 
enzyme. The chiral centre is not the metabolic site and there is no stereoselective 
metabolism. Only L-ulifloxacin has the bactericidal effects, but still 
enantiomerically pure L-form is not commercially available yet [18]. Ulifloxacin is 
excreted at 17-23% in the urine and 17-29% in the faeces.  
In the current study, population-normalised ulifloxacin loads were found in 
Milan and Castellon with values at 22.3 and 1.5 mg day-1 1000 people-1 respectively. 
Enrichment of ulifloxacin first-eluting enantiomer was detected through chiral 
analysis in Milan, whilst the opposite was observed in Castellon. (±)-Prulifloxacin 
was expected to be found in the wastewaters only in case of direct disposal. 
However, it was not found in any sample, which indicates that there was no direct 
disposal of this drug. 
 
7.4.1.8 Ketoconazole 
(±)-Ketoconazole is a synthetic antifungal, sold as a racemate of the cis-
configuration, i.e. (+)-ketoconazole and (−)-ketoconazole. It is excreted in a 
percentage of nearly 13% in urine (of which 2-4% as unchanged) [19]. 
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In this study, population-normalised loads were from 2.5 in Utrecht up to 
18 mg day-1 1000 people-1 in Oslo. (±)-cis-Ketoconazole was enriched with the first-
eluting enantiomer, thus suggesting a potential enantioselective metabolism. This 
may be controversial, as Hamdy and Brocks [20] found evidence of non-linear 
stereoselective pharmacokinetics in rats and no stereoselective metabolism by liver 
microsomes. Therefore, further works are needed to support this finding, especially 
in-sewer stability studies for proving no selective enantio-biodegradation. 
According to ECDC in 2014, the consumption of ketoconazole for systemic use in 
the community (primary care and hospital sector), expressed as defined daily dose 
(DDD) per 1000 inhabitants and per day, is reported in Table 7-5 for the countries 
of the selected locations. 
Hence, the loads found in wastewater are more linked to other sources of 
ketoconazole (e.g. topical absorption from anti-infective skin preparations) or to the 
veterinary loads. 
Table 7-5 Consumption and relative consumption of ketoconazole in 2014 according to ECDC (n.a. 
means not available): 
Country Community Consumptiona Hospital sectora 
Norway 0.00 <0.01 
UK n.a. n.a. 
Denmark 0.00 0.00 
The Netherlands <0.01 - 
Switzerland n.a. n.a. 
Italy 0.00 0.00 
Spain n.a. n.a. 
a 
expressed as DDD per 1000 inhabitants and per day 
 
7.4.1.9 Flumequine 
(±)-Flumequine is a racemic drug marketed in the veterinary market. After 
enzyme deconjugation, it is excreted as unchanged 81-86% in calves urine, at 12-
17% as 7-hydroxy-flumequine in calves urine and as glucuronide conjugates. It 
undergoes stereoselective metabolism in sheep, cattle and poultry. 
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Population-normalised loads ranged from 0.4 in Lyngby to 1.2 mg day-1 
1000 people-1 in Zurich. Enrichment of flumequine first-eluting enantiomer was 
detected in all the samples from the locations investigated. 
Its presence in this environmental matrix can be explained as excretion 
product from animals’ metabolism (EF>0.5) or as its direct disposal (EF=0.5). In 
wastewater, EF values ranged from 0.6 ± 0.0 to 0.9 ± 0.1). In this case, the first 
option seems to be the most plausible because of the chiral signature (EF>0.5) in 
all the samples. 
 
7.4.1.10 Other quinolones 
Racemic (±)-nadifloxacin is the active compound in some topical anti-
infective creams. The isomer S-(-)-nadifloxacin has higher antibacterial activity 
with respect to the other enantiomer. Its metabolism produces less than 5% of 
unchanged nadifloxacin excreted in urine and conjugates, such as sulphate and 
glucuronides, at about 20% [21]. In wastewater, glucuronides can be potentially re-
converted to the parent compound after hydrolysis by faecal bacteria. 
R-(+)-besifloxacin is a synthetic quinolone formulated for ophthalmic use. 
It is sold only in one enantiomeric form. After human hepatocytes incubation, it 
does not go through chiral interconversion to its enantiomer [22]. 
As both were not detected at enantiomeric level in composite wastewater samples, 
their enantiomeric profiling could not be investigated. 
 
7.4.2 Qualitative test in selective media 
Wastewater samples were incubated in CLED agar, which is a differential 
culture medium for isolating bacteria from the suspected cases of urinary tract 
infection in urine specimens [23]. From the typical colony morphology on CLED 
agar it was possible to observe several bacteria, such as Escherichia coli with its 
opaque yellow colonies with a deeper yellow centre, Klebsiella, mucoid yellow and 
whitish-blue colonies, Enterococci, characterised by small yellow colonies and 
Staphylococcus aureus with its deep and uniform yellow colonies and Coagulase 
Negative Staphylocci with pale opaque yellow colonies. Results are summarised in 
Table S2. 
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7.4.3 Target qnr gene quantification 
QnrS gene was selected because of its reduced susceptibility to 
fluoroquinolones according to Rodriguez-Mozaz et al. [2] and Marti et al. [25]. 
Target qnrS quantification was performed using two techniques: qPCR and digital 
PCR. 
Standard curve, created through qPCR analysis, was linear in the studied 
range. The PCR efficiencies ranged from 90% to 105%. A good separation between 
amplified and non-amplified reactions was achieved with digital PCR. The 
advantage in using digital PCR was the possibility to quantify the targeted gene in 
the wastewater DNA sample without the use of a standard curve along with the high 
number of independent reactions performed per chip. Results from qPCR analysis 
were expressed as Ct (threshold cycle) values, which are relative measurements of 
the concentration of the target gene. By using the equation from the standard curve, 
they were then quantified as “log qnrS copies μL-1”. Results from digital PCR 
analysis were given directly as copies μL-1 (Figure 7-7). Both sets of results were 
converted in millilitres unit. In order to remove any variation in flow, daily loads 
were calculated starting from “absolute concentration” (this was because results 
were not normalised with 16S rRNA). A comparison of the results with two 
techniques is shown in Figure 7-8. 
A higher absolute copy number of qnrS gene was observed for Italy, the UK and 
Norway by using qPCR, whilst they were in the reversed order according to digital 
PCR. Levels of qnrS gene were negligible for Switzerland through qPCR and nearly 
close to levels detected in Spain through digital PCR. 
 
7.4.4 Analysis of quinolones and qnrS gene loads in wastewater 
In this study, most of the compounds belong to the fluoroquinolones class. As qnrS 
is not specific for any quinolone, a calculation based on the total of the 
concentrations and the population-normalised loads of all studied 
quinolones/fluoroquinolones was performed in order to compare the results with 
findings from PCR data (Figure 7-9). The highest occurrence was found in Italian 
and Spanish samples.  
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 UK Neg I ES NO DK Neg NL CH 
 
Figure 7-7 “Concentration” of qnrS gene through digital PCR in the European wastewater samples. 
These samples were collected on the same day in all the sampling sites across Europe (Two negative 
controls were tested, Neg.). Results are shown with the acronyms of the countries (and not with the 
fullnames of the cities). 
 
Figure 7-8 “Absolute concentration” of qnrS gene obtained with qPCR and digital PCR in the 
European wastewater samples. These were calculated as gene loads. These samples were collected 
on the same day in all the sampling sites across Europe. Results are shown with the acronyms of the 
countries (and not with the fullnames of the cities). 
This data was in accordance with the report by ECDC from 2014 (Table 7-3) [9]. 
A higher amount was expected to be found in Spain from PCR data. Moreover, it 
is also true that the population size of the Spanish city considered in the study was 
the lowest when compared to other European locations (population ≥300000). This 
could mean that population normalised gene loads need to be considered. Moreover, 
a higher absolute copy number in the UK and Norway could be explained by colder 
weather conditions that may have contributed to preserve a higher qnrS copy 














































Figure 7-9 Average concentrations and average population-normalised mass loads calculated from 
quinolones’data in one city for each country. For simplicity acronyms of the countries are used in 
the graphics, instead of the fullnames of cities. 
 
A limitation of both analyses was represented by missing relative quantification 
with 16S rRNA gene copy number, which could have helped in the normalisation 
of the data. Thus, this is highly recommended in future studies. Antimicrobial 
resistance could be enhanced by the spreading of antibiotics level in the 
environment especially when direct disposal of some pharmaceuticals occurred. 
ECDC/EFSA/EMA first joint report worked on the relationship between national 
consumption of fluoroquinolones/quinolones and the risk of reduced susceptibility 
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[8]. According to that, the impact on the contribution of quinolone consumption 
could be explained as follows:  
(i) cross-resistance between quinolones and fluoroquinolones are similarly 
detected by the use of epidemiological cut-off values for ciprofloxacin 
resistance; 
(ii) ciprofloxacin resistance in E. coli is leaded by the selection of 
quinolones for the first mutation step; 
(iii) the dissemination of plasmid-mediated resistance to quinolones 
mediated by qnr genes in Salmonella spp. can provide opportunities for 
co-selection of unrelated antimicrobials. 
On the other hand, it was also known that differences in the occurrence of 
ciprofloxacin resistance were presented in countries with similar low level of 
ciprofloxacin consumption from ciprofloxacin resistance in C. coli data. The 
reasons were ascribed to differences in the fluoroquinolones consumption in years 
previous to this study and in bacteria resistance spreading among countries [8]. For 
this reasons, the fact that qnrS gene was not so high in terms of copy number in the 
analysed samples from Italy and Spain with respect to other northern European 
cities could be probably a matter of time. Despite these findings, a statistical 
approach that enables a systematic investigation on the correlation analysis between 
occurrence of antibiotics and occurrence of their gene resistance is recommended. 
This is also because a demonstration of significant correlation was proved at local 
level by Rodriguez-Mozaz et al. (2015) [2]. 
 
7.5 Conclusions 
In this study, WBE was a powerful tool that enabled the monitoring of 
biomarkers for quinolones, fluoroquinolones and an antifungal drug consumption 
over a week. This monitoring activity was relevant as it allowed to obtain real-time 
information on quinolones’ misuse throughout several European locations. Indeed, 
this class of compounds was targeted as its large use could be associated to a 
spreading of antibacterial resistance. The following biomarkers of exposure to 
antibiotics were studied in this first pan-European study: (±)-ofloxacin with its main 
metabolites (±)-ofloxacin-N-oxide and (±)-desmethyl-ofloxacin, (±)-moxifloxacin, 
the precursor (±)-prulifloxacin with its active compound (±)-ulifloxacin, (±)-cis-
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ketoconazole (the only antifungal included), (±)-flumequine, (±)-nadifloxacin and 
R-(+)-besifloxacin. The investigation on their enantiomeric profiling enabled to 
understand patterns of drug use and spatial drug use estimates in near-real time. 
Indeed, through the investigation of the occurrence of ciprofloxacin and ofloxacin 
metabolites, it was possible to get a urinary excretion profiling reflected in the 
wastewater. Through the calculation of parent:metabolite ratio, it was possible to 
hypothesise that ofloxacin may be disposed in Southern European cities due to 
exceeding parent:metabolite ratio with respect to the proposed metabolism ratio. 
Enantiomeric profiling enabled to distinguish drug residue origin. In fact, an 
exclusive stereoselective use of S-(-)-ofloxacin was observed in Southern cities, 
whilst racemic ofloxacin was more predominant in Northern European ones 
(probably due to a difference in prescriptions of the drug itself). Moxifloxacin 
human intake was demonstrated by the presence of S,S-moxifloxacin and S,S-
moxifloxacin-N-sulphate. Enantiomeric profiling of prulifloxacin showed that only 
its metabolite, ulifloxacin, was found in Milan and Castellon. Therefore, the 
presence of ulifloxacin was related to prulifloxacin metabolism and disposal of 
prulifloxacin did not occur in none of the locations monitored. Potential 
enantioselective metabolism was hypothesised for (±)-cis-Ketoconazole as it was 
enriched with the first-eluting enantiomer. Even if flumequine metabolites were not 
included, the enrichment of its first-eluting enantiomer in all the samples was 
mainly caused by the animals’ metabolism rather than its direct disposal. However, 
the occurrence of quinolones in wastewater reflected the spatial trend from 
estimated quinolones consumption reported by ECDC in 2014 [9]. 
Moreover, the occurrence of fluoroquinolone resistance gene was 
investigated in wastewaters from the same European locations. The approach in 
using simultaneous analytical techniques, such as chiral chromatography and mass 
spectrometry for the detection of quinolones biomarkers in wastewater, and 
bioanalytical techniques, such as qPCR and digital PCR for the detection of 
biomarkers of effect for specific health-related biomarkers, represented a promising 
means for understanding correlations of their occurrence in the monitored areas. 
Furthermore, by this study, it was possible to see the potential in applying the same 
methodologic approach to other classes of antibiotics, which through their 
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Erika Castrignanò and Barbara Kasprzyk-Hordern planned and designed the study. 
Richard Bade, Lubertus Bijlsma, J. A. Baz-Lomba, Sara Castiglioni, Erika 
Castrignanò, Ana Causanilles, Emma Gracia-Lor, Barbara Kasprzyk-Hordern, 
Ann-Kathrin McCall, Christoph Ort, Benedek G Plósz, Pedram Ramin, Nikolaos I 
Rousis, Yeonsuk Ryu, Kevin V Thomas, Pim de Voogt, Ettore Zuccato and Felix 
Hernandez organised the collection of the wastewater samples from their local 
wastewater treatment plant. Erika Castrignanò analysed the samples and interpreted 
the results with contribution from Barbara Kasprzyk-Hordern and Ed Feil. 
 
7.7 Supplementary Data 
The following supplementary data are contained in Appendix 5: 
Table S1 Concentrations (Conc.), daily population-normalised mass loads (Loads) 
and EF values for chiral compounds for the European monitoring campaign across 
Europe (besifloxacin, R,R-moxifloxacin, prulifloxacin, nadifloxacin were not 
reported as all values were <MDL). M., T., W., T., F., S., S. were the initials used 
for indicating the days of the week. 
Figure S1 Test “dry run on non-selective media” performed by using 100 μL (on 
the left) and 200 μL (on the right) of refrigerated wastewater Bristolian samples for 
day 6th and 7th. 
Figure S2 Growth of different colonies from an incubated Bristolian wastewater 
sample (on the left), result of the incubation for colony no. 7 and no.8 (on the 
centre), pointing of the single colony to be used a reference (on the right). 
Figure S3 Result of the incubation for the colonies found from every day of the 
sampling campaign in Bristol. 
Figure S4 Result of the incubation for the colonies found from every day of the 
sampling campaign in Oslo, Castellon, Lyngby, Milan, Utrecht and Zurich. 
Table S2 Results on colony morphology assessment for the selected cities in the 
study. 
Figure S5 qPCR-Melt curve. 
Figure S6 qPCR-Standard curve. 
Chapter 7: Enantiomeric profiling of quinolones and monitoring of resistance genes in EU 
 222 
7.8 References 
1. ECDC, Annual epidemiological report 2014 - Antimicrobial resistance 
and healthcare-associated infections 
http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispFor
m.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1292. 
2. Rodriguez-Mozaz, S., et al., Occurrence of antibiotics and antibiotic 
resistance genes in hospital and urban wastewaters and their impact on the 
receiving river. Water Res, 2015. 69: p. 234-242. 
3. Kümmerer, K., Antibiotics in the aquatic environment - A review - Part I. 
Chemosphere, 2009. 75(4): p. 417-434. 
4. Pruden, A., et al., Antibiotic resistance genes as emerging contaminants: 
studies in northern Colorado. Environ Sci Technol, 2006. 40(23): p. 7445-
7450. 
5. Zhang, X.-X., T. Zhang, and H.H. Fang, Antibiotic resistance genes in water 
environment. Appl Microbiol Biot, 2009. 82(3): p. 397-414. 
6. Castiglioni, S., et al., Testing wastewater to detect illicit drugs: state of the 
art, potential and research needs. Sci Total Environ, 2014. 487: p. 613-20. 
7. Perini, F., et al., New approach using the real-time PCR method for 
estimation of the toxic marine dinoflagellate Ostreopsis cf. ovata in marine 






10. Bergan, T., et al., Elimination of ciprofloxacin and three major metabolites 








Chapter 7: Enantiomeric profiling of quinolones and monitoring of resistance genes in EU 
 223 
13. Coutu, S., et al., Temporal dynamics of antibiotics in wastewater treatment 
plant influent. Sci Total Environ, 2013. 458–460: p. 20-26. 
14. Plósz, B.G., et al., Diurnal variations in the occurrence and the fate of 
hormones and antibiotics in activated sludge wastewater treatment in Oslo, 
Norway. Sci Total Environ, 2010. 408(8): p. 1915-1924. 
15. http://www.nhsbsa.nhs.uk/PrescriptionServices/3494.aspx. 
16. Petrie, B., et al., Obtaining process mass balances of pharmaceuticals and 
triclosan to determine their fate during wastewater treatment. Sci Total 
Environ, 2014. 497–498: p. 553-560. 
17. Petrie, B., R. Barden, and B. Kasprzyk-Hordern, A review on emerging 
contaminants in wastewaters and the environment: Current knowledge, 
understudied areas and recommendations for future monitoring. Water Res, 
2015. 72: p. 3-27. 
18. Okazaki, O., et al., Enantioselective disposition of ofloxacin in humans. 





20. YING, J., et al., Optically active compound of prulifloxacin for treating 
infection and preparation method thereof. 2012, Google Patents 
(US20120302580 A1, PCT number PCT/CN2010/078020). 
21. Hamdy, D.A. and D.R. Brocks, Nonlinear stereoselective pharmacokinetics 
of ketoconazole in rat after administration of racemate. Chirality, 2009. 
21(7): p. 704-712. 







Chapter 7: Enantiomeric profiling of quinolones and monitoring of resistance genes in EU 
 224 
25. Marti, E., E. Variatza, and J. Balcázar, Bacteriophages as a reservoir of 
extended‐spectrum β‐lactamase and fluoroquinolone resistance genes in the 
environment. Clin Microbiol Infec, 2014. 20(7): p. O456-O459. 





















Chapter 8: Conclusions and Future Works 
 
8.1 Conclusions  
WBE is an innovative approach complementary to more traditional 
epidemiological techniques, which provides a real-time profiling of community 
health and lifestyle, through the detection and quantification of biomarkers. Since 
many drugs are chiral, the investigation on enantiomeric profiling of chiral 
biomarkers provides a new dimension to WBE. To aid enantiomeric profiling in 
WBE, the development and validation of two new enantioselective methodologies 
were performed by chiral HPLC-MS/MS and enabled the chemical analysis of 
chiral biomarkers.  
These novel methodologies were applied to Europe-wide environmental 
monitoring for: 
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(1) The estimation of illicit/licit drug use via WBE. The impact of enantiomeric 
analysis was used for verifying potency, origin and route of administration of drugs 
of abuse, monitoring any changes in their pattern of use and distinguishing legal 
from illicit use. 
(2) The estimation of quinolones’ use via WBE. Since their wide consumption 
and misuse rapidly brought to an increasing antibiotic resistance, biomarkers of 
exposure to these antibiotics represented a useful target for understanding any 
possible misuse in the monitored areas. 
 
The first method investigated 56 human biomarkers for the detection of 
illicit drugs and potentially abused licit drugs. These were: opioids, amphetamines, 
cocaine, heroin, stimulants, anaesthetics, sedatives, anxiolytics, designer drugs, 
PDE5 inhibitors, amphetamine and methamphetamine drug precursors. Satisfactory 
enantiomeric separation was obtained in a single chromatographic run using a CBH 
chiral column for 18 pairs of enantiomers including amphetamine, 
methamphetamine, MDMA and its metabolites HMA and HMMA, PMA, MDA 
and mephedrone. The method showed very good performance: >90% SPE 
recoveries, very good sensitivity (MDLs and MQLs at ppt levels), high linearity 
range and method precision <10%. The first application of this methodology was 
in a week monitoring campaign in the UK. To the author’s knowledge, the 
enantiomeric profiling of mephedrone and MDMA metabolites was documented 
for the first time. A predominance of R-(+)-mephedrone was found in 
environmental samples, thus suggesting a possible stereoselective human 
metabolism and excretion profile. As a result of the investigation of the temporal 
trend, mephedrone was defined as a recreational drug of abuse due to high loads in 
the weekend (as in the case of MDMA). A comparable trend was also observed for 
MDMA and its metabolite HMMA. 
After the detection of mephedrone loads in two consecutive sampling campaigns in 
the UK in 2014 and 2015, a case study on mephedrone posed the basis for a novel 
approach towards biomarkers’ selection in estimation of human exposure to chiral 
drugs with limited metabolism data. This newly-developed framework consisted of 
four steps: (i) the identification of possible metabolic biomarkers present in 
wastewater through in-direct in-vivo study using LC-HRMS; (ii) the verification of 
chiral signature of the target compound using chiral LC-MS/MS; (iii) the 
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confirmation of human metabolic residues in in-vivo and in-vitro studies and (iv) 
the verification of stability of possible biomarkers in wastewater. At the end, 
mephedrone was chosen as a suitable biomarker due to its high stability in 
wastewater. Its enantiomeric profiling was studied, for the first time, in several 
biological and environmental matrices and it showed that chiral analysis was 
fundamental for distinguishing between human consumption (favouring R-(+)-
enantiomer) and direct disposal of unused mephedrone (as it was found to be 
distributed as racemate in the UK). Indeed, R-(+)-enantiomer was observed in 
pHLM experiments and in pooled urine analysis, whilst S-(-)-form was favoured 
in-vivo rat metabolism studies. Further biomarker candidates, such as 4’-carboxy-
mephedrone, 4’-carboxy-normephedrone, 1-dihydro-mephedrone, 1-dihydro-
normephedrone and hydroxyl-tolyl-normephedrone, were also suggested for WBE 
approach for future studies.  
 
The second method was developed to undertake wastewater profiling for 
antibiotics in order to understand the spatial and temporal antibiotics’ use and the 
prevalence of resistance genes. In particular, this methodology explored 16 
biomarkers of quinolones’ use, as they represent one class of antibiotics with rising 
concern in antibiotic resistance. With >70% SPE recoveries, very good sensitivity, 
high linearity range and method precision < 20%, it allowed for the analysis of 16 
human and veterinary quinolones drugs as potential biomarkers in wastewater. To 
the author’s knowledge, this was the first time that (i) chiral separation of the 
following biomarkers was simultaneously performed in reverse phase LC-MS/MS 
using an OZ-RH column: ofloxacin with its main metabolites ofloxacin-N-oxide 
and desmethyl-ofloxacin, moxifloxacin, the prodrug prulifloxacin with its active 
compound ulifloxacin, cis-ketoconazole, flumequine, nadifloxacin and R-(+)-
besifloxacin and (ii) their enantiomeric profiling was investigated at enantiomeric 
level in wastewater. As some achiral quinolones were included in this research, the 
proposed method was also suitable for monitoring purposes. Thus, the most 
comprehensive panel of quinolones biomarkers was considered for WBE 
applications. 
 
Both methodologies were applied to wastewaters from eight locations 
across Europe [i.e. Oslo (Norway), Bristol (United Kingdom), Lyngby (Denmark), 
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Utrecht (The Netherlands), Brussels (Belgium), Zurich (Switzerland), Milan (Italy) 
and Castellon (Spain)], thus allowing the first pan-European studies on 
enantiomeric profiling of chiral biomarkers. This led to an understanding of: (i) new 
patterns of emerging drugs of abuse, (ii) changes in patterns of classical illicit drugs 
and quinolones with the verification of the origin of drug residue, potency of abused 
drug and its synthetic route and (iii) quinolones metabolic profiles. The results 
indicated that, a new drug of abuse, mephedrone, was prevalent only in the UK (see 
before). A spatial difference in loads was observed between Northern and Southern 
European cities for amphetamine, with a slight enrichment of R-(-)-amphetamine 
in wastewater (with the exception of some days in Zurich). Still not well assessed 
remained the interpretation of the enantiomeric composition of amphetamine in 
European wastewater samples. High methamphetamine loads were found in 
Norwegian samples; this is relevant as in Norway high seizures were also seen 
according to the EMCDDA. Wastewater was enriched of S-(+)-methamphetamine 
probably due its stereoselective synthesis in the illicit manufacturing market, with 
the exception of Oslo, where a different illegal synthetic route was assumed. The 
prevalence of R-(-)-MDMA in wastewaters was linked to the MDMA consumption, 
even in those cities where illicit manufacturing sites were found in the past. S-(+)-
MDA originated mostly from MDMA metabolism. HMMA appeared to be a 
suitable MDMA’s DTR. It was found enriched of the S-(+)-enantiomer in 
wastewaters, suggesting MDMA abuse. The investigation of precursors showed 
that their presence was reasonably ascribed to their medical use.  
Through the investigation of the occurrence of ciprofloxacin and ofloxacin 
metabolites, it was possible to get a urinary excretion profiling reflected in the 
wastewater. Higher loads were found in Southern European cities than in northern 
ones. Enantiomeric profiling revealed the drug residue origin. Indeed, 
enantiomerically pure S-(-)-ofloxacin was observed in Southern locations, whilst 
racemic ofloxacin was more predominant in Northern European ones. 
Moxifloxacin’s human intake was demonstrated by the presence of S,S-
moxifloxacin and S,S-moxifloxacin-N-sulphate. Enantiomeric profiling of 
prulifloxacin showed that ulifloxacin was present because of prulifloxacin 
metabolism. No disposal of prulifloxacin was observed. Potential enantioselective 
metabolism was hypothesised for (±)-cis-Ketoconazole due to an enrichment of the 
first-eluting enantiomer. The enrichment of the first-eluting flumequine enantiomer 
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was assumed to result from animals’ metabolism rather than its direct disposal. 
Furthermore, the occurrence of quinolones in wastewater was in agreement with 
estimated quinolones use from ECDC in 2014. 
 
In conclusion, once biomarkers of exposure were detected, biomarkers of 
effect were identified for specific health-related biomarkers through the usage of 
bioanalytical techniques, including DNA extraction methods followed by qPCR- 
and digital PCR-based techniques. Thus, this work led to an analysis of biomarkers 
of microbial resistance and biomarkers of bacterial infections loads. 
 
8.2 Future Work 
The results of this research on the determination of wastewater profiling for 
antibiotics led to a better understanding of both spatial and temporal antibiotics’ use 
and prevalence of resistance genes across Europe. This work served as a proof-of-
concept for future research studies aimed at verifying any correlation between the 
occurrence of biomarkers of exposure and the spreading of biomarkers of antibiotic 
resistance at local and national level. This will be in support of monitoring activities 
of antimicrobial resistance. Moreover, as many antibiotics are chiral, further works 
will be focused on the development of antimicrobial resistance at stereoisomeric 
level for other classes of antibiotics. This epidemiological approach has the 
potential to become an early warning system for outbreaks of disease and a unique 
tool for the identification of hot-spots in the context of antimicrobial resistance. 
 
However, there are still many open questions with antibiotic resistance 
genes (ARGs) that need to be addressed. ARGs can persist in the environment for 
an extended period of time and spread among bacteria [1]. Therefore, they can be 
considered to be emerging environmental “contaminants” as defined by Pruden et 
al. [2], and they have the potential to be further distributed to various environmental 
compartment. 
 
Since the antibiotic resistance could spread at every level during the 
wastewater treatment, the proposed methodology, which combines the detection of 
antibiotics through analytical techniques and the occurrence of genes through 
bioanalytical methods, can be applied to other environmental matrices, such as 
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effluent wastewater and receiving waters. This will allow verifying the mechanisms 
of transformation of chiral antimicrobial agents and their metabolites during 
wastewater treatment such as the evaluation of the ofloxacin’s metabolic pattern.  
 
8.3 Publications and PhD activities 
A proven record of the research activities was reflected by a number of peer-
reviewed publications at international journals and presentations at international 
conferences. 
In particular, scientific publications were the following: 
1. Castrignanò E., Lubben A., Kasprzyk-Hordern B. Enantiomeric profiling 
of chiral drug biomarkers in wastewater with the usage of chiral liquid 
chromatography coupled with tandem mass spectrometry. J Chromatogr A, 
1438:84-99 (DOI: 10.1016/j.chroma.2016.02.0150), 2016. 
2. Yang Z., Castrignanò E., Estrela P., Frost C.G. & Kasprzyk-Hordern B. 
Community Sewage Sensors towards Evaluation of Drug Use Trends: Detection of 
Cocaine in Wastewater with DNA-Directed Immobilization Aptamer Sensors. Sci 
Rep (DOI: 10.1038/srep21024), 2016. 
3. Petrie B., Camacho-Munoz D., Castrignanò E., Evans S., Kasprzyk-
Hordern B. Chiral Liquid Chromatography Coupled with Tandem Mass 
Spectrometry for Environmental Analysis of Pharmacologically Active 
Compounds LC GC EUROPE 28 (3), 151-160, 2015. 
4. Camacho-Munoz D., Petrie B., Castrignanò E. and Kasprzyk-Hordern B. 
Enantiomeric Profiling of Chiral Pharmacologically Active Compounds in the 
Environment with the usage of chiral Liquid Chromatography Coupled with 
Tandem Mass Spectrometry. Curr Anal Chem, 12, 2015. 
 
Papers under preparation include (tentative titles are provided): 
1. “Enantiomeric profiling of illicit drugs in a pan-European study” (with 
co-authorship of SEWPROF members),  
2. “A new approach towards biomarker selection in estimation of human 
exposure to chiral drugs with limited metabolism data: a case study of mephedrone” 
(with co-authorship of Mardal M., Rydevik A., Miserez B., Ramsey J., Shine T., 
Pantos G. D., Meyer M. R. and Kasprzyk-Hordern B.) 
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3. “Multi-residue stereoisomeric analysis of human and veterinary chiral 
drugs in wastewater using chiral liquid chromatography coupled with tandem mass 
spectrometry”, 
4. “Enantiomeric profiling of quinolones and monitoring of resistance genes 
in European wastewaters”. 
The author contributed to collaborative work across the SEWPROF network: 
1. Gonzalez-Marino I., Gracia-Lor E., Rousis N., Castrignanò E., Thomas 
K. V., Quintana J. B., Kasprzyk-Hordern B., Zuccato E. and Castiglioni S. 
Wastewater-based epidemiology to monitor synthetic cathinones use in different 
European countries. In: Environ Sci Technol (DOI: 10.1021/acs.est.6b02644). 
2. Bade R., Bijlsma L., Sancho J. V., Baz-Lomba J., Castiglioni S., 
Castrignanò E., Causanilles A., Gracia-Lor E., Kasprzyk-Hordern B., Kinyua J., 
McCall A., van Nuijs A. L. N., Ort C., Plósz B. G, Ramin P., Rousis N., Ryu Y., 
Thomas K. V.; de Voogt P., Zuccato E. and Hernandez F. Liquid chromatography-
tandem mass spectrometry determination of synthetic cathinones and 
phenethylamines in influent wastewater of eight European cities. In: Chemosphere 
(submitted). 
3. Ryu Y., Gracia-Lor E., Bade R., Baz-Lomba J.A., Bramness J. G., 
Castiglioni S., Castrignanò E., Causanilles A., Covaci A., de Voogt P., Hernandez 
F., Kasprzyk-Hordern B., Kinyua J., McCall A., Ort C., Plósz B.G., Ramin P., 
Rousis N. I., Reid M. J. and Thomas K. V. Increased levels of the oxidative stress 
biomarker 8-iso-prostaglandin F2α in a city´s wastewater related to tobacco use. In: 
Sci Rep (submitted). 
4. Baz Lomba J.A., Salvatore S., Gracia Lor E., Bade R., Castiglioni S., 
Castrignanò E., Causanilles A., Hernandez F., Kasprzyk-Hordern B., Kinyua J., 
McCall A., van Nuijs A., Ort C., Plósz B.G., Ramin P., Reid M., Rousis N.I., Ryu 
Y., de Voogt P., Bramness J. and Thomas K. V. Comparison of pharmaceutical, 
illicit drug, alcohol, nicotine and caffeine levels in wastewater with sale, seizure 
and consumption data for 8 European cities. In: BMC Public Health (submitted). 
 
Oral sections at international conferences were as follows: 
1. Castrignanò E. and Kasprzyk-Hordern, B. Enantiomeric profiling of 
chiral drug biomarkers in wastewater with the usage of chiral liquid 
chromatography coupled with tandem mass spectrometry. In: Testing the Waters 
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2015: 2nd International Conference on Wastewater-based Drug Epidemiology, 
2015-10-11 - 2015-10-15, Ascona, Switzerland. 
2. Yang, Z., Kasprzyk-Hordern, B., Angls d’Auriac, M., Goggins, S., 
Castrignanò E., Rice, J., Thomas, K. V., Frost, C. and Estrela, P., 2015. Community 
Sensors for Monitoring of Public Health by Means of Wastewater-Based 
Epidemiology. In: Testing the Waters 2015: 2nd International Conference on 
Wastewater-based Drug Epidemiology, 2015-10-11 - 2015-10-15, Ascona, 
Switzerland. 
3. Kasprzyk-Hordern, B., Castrignanò E., Rydevik, A., Lopardo, L., Rice, 
J. and Yang, Z. Wastewater-based epidemiology and future perspectives: testing 
urban water for community-wide public health assessment. In: 15th EuCheMS 
International Conference on Chemistry and the Environment, 2015-09-20 - 2015-
09-25, Leipzig, Germany. 
4. Yang, Z., Angls d’Auriac, M., Goggins, S., Castrignanò E., Rice, J., 
Estrela, P., Frost, C., Thomas, K. V. and Kasprzyk-Hordern, B. Community Sensors 
for Monitoring Public Health using Wastewater-Based Epidemiology. In: 15th 
EuCheMS International Conference on Chemistry and the Environment, 2015-09-
20- 2015-09-25, Leipzig, Germany. 
5. Yang, Z., Kasprzyk-Hordern, B., Angls d’Auriac, M., Goggins, S., 
Castrignanò E., Rice, J., Thomas, K. V., Frost, C. and Estrela, P. Electrochemical 
Community Sensors for Monitoring of Public Health at Population Level Using 
Wastewater-Based Epidemiology. In: The 15th International Symposium on 
Electroanalytical Chemistry (15th ISEAC), 2015-08-13 - 2015-09-16, Changchun, 
China. 
6. Castrignanò E. Programme Working Group Meetings COST Action 
ES1307. Wastewater-based epidemiology for community-wide antibiotics use 
assessment. “Sewage biomarker analysis for community health assessment”, 27th-
28th October 2014, San Anton, Malta. 
 
Finally, a number of presentations were held at the following SEWPROF training 
courses: 
 2nd SEWPROF training Course Oslo (Norway) in September 2013; 
 3rd SEWPROF training Course in Utrecht (The Netherlands) in April 2014; 
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 4th SEWPROF training Course/Mid-Term Review Meeting in Milan (Italy) 
in September 2014; 
 5th SEWPROF training Course in Castellon (Spain) in March 2015. 
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Appendix 1  
The following supplementary data are contained in Appendix 1: 
Table S1 Selected analytes and their properties. 
Table S2 Studied mobile phase compositions with CHIRALPAK® CBH HPLC. 
Table S3 Studied mobile phase compositions with CHIROBIOTIC V. 
Table S4 Studied mobile phase compositions with CHIROBIOTIC T. 
Table S5 Validation parameters -instrumental precision. 
Table S6 Validation parameters- ion suppression. 
Figure S1 CBH column - enantiomeric resolution of studied analytes in a mobile 
phase containing acetonitrile as organic modifier (mobile phase composition: 1mM 
ammonium acetate/acetonitrile 9:1). 
Figure S2 CBH column - enantiomeric resolution of studied analytes in a mobile 
phase containing isopropanol as organic modifier (mobile phase composition: (a) 
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1mM ammonium acetate/isopropanol 9:1 and (b) 1mM ammonium 
acetate/isopropanol 9.5:0.5). 
Figure S3 CBH column - enantiomeric resolution of studied analytes in mobile 
phases containing: (a) 1 mM ammonium acetate/methanol 9.5:0.5, (b) 1 mM 
ammonium acetate/methanol 9:1, (c) 2.5 mM ammonium acetate/methanol 9:1, (d) 
5 mM ammonium acetate /methanol 9:1 and (e) 10 mM ammonium acetate 
/methanol 9:1. 
Figure S4 CBH column - Impact of different percentanges of modifiers on retention 
time of analytes. 
Figure S5 Chirobiotic T column - overview of the separation for the targeted 
analytes. 




Table S1 Selected analytes and their properties (MW molecular weight, Exp experimental, Pred predicted, a extracted from [38] , b predicted using ACD/labs software 
(http://www.chemspider.com). 
Compound CAS Formula MW pKa  LogP LogDb  Supplier 
        Exp.a Pred.a Exp.a Pred.b pH 5.5 pH 7.4  
Cocaine 50-36-2 C17H21NO4 303.4 
8.6 
(15°) 
8.8 2.3c 3.1±0.4 0.1 1.5 LGC (Cerilliant product) 
Benzoylecgonine 519-09-5 C16H19NO4 289.3 - 3.1, 9.5 - 2.7±0.4 0.2 0.2 Sigma-Aldrich 
Cuscohygrine 454-14-8 C13H24N2O 224.3 - - - 0.7±0.3 -3.4 -3.2 TRC 
Cocaethylene 529-38-4 C18H23NO4 317.4 - - - 2.8 -0.2 1.1 




43021-26-7 C10H15NO2 181.2 - - - 1.7±0.3 -0.7 1.0 
Sigma Aldrich (Cerilliant 
product) 
(±)-Amphetamine 300-62-9 C9H13N 135.2 
10.1 
(20°) 
10.0 1.8 1.8±0.2 -1.3 -0.6 LGC(Cerilliant product) 
(±)-Methamphetamine  4846-07-5 C10H15N 149.2 
9.9 
(25°) 
10.2 2.1 1.9±0.2 -1.1 -0.8 LGC (Cerilliant product) 
S-(+)- Methamphetamine 537-46-2 C10H15N 149.2 
9.9 
(25°) 
10.2 2.1 1.9±0.2 -1.1 -0.8 Cerilliant 




- C11H13F3N2 230.2 - - - 2.4±0.5 -0.4 1.2 LGC 









4764-17-4 C10H13NO2 179.2 
9.7 
(25°) 






















15398-87-5 C10H15NO2 181.2 - - - - - - Kinesis  
Caffeine 58-08-2 C8H10N4O2 194.2 
10.4 
(40°) 
-0.9  -0.1 -0.1±0.4 -0.1 -0.1 Sigma-Aldrich 
1,7-dimethylxanthine 
(Paraxanthine) 
611-59-6 C7H8N4O2 180.2 - -  - -1.6±0.9 -1.6 -1.6 Sigma-Aldrich 
(-)-Nicotine 54-11-5 C10H14N2 162.2 3.1 8.9   1.2 0.7±0.3 -2.1 -0.5 Sigma-Aldrich 
(-)-Cotinine 486-56-6 C10H12N2O 176.2 - - - -0.2±0.4 -0.3 -0.2 
Sigma Aldrich (Cerilliant 
product) 
Heroin 561-27-3 C21H23NO5 369.4 
7.9 
(25°) 
9.1 1.6 1.5±0.7 -0.8 0.9 
Sigma Aldrich (Cerilliant 
product) 
6-acetylmorphine 2784-73-8 C19H21NO4 327.4 - 10.2, 9.1 1.9,1.3 0.4±0.7 -1.7 -0.1 
Sigma Aldrich (Cerilliant 
product) 
Codeine 76-57-3 C18H21NO3 299.4 
8.2 
(25°) 
13.8, 9.2 1.2, 1.3 1.2±0.7 -1.4 0.3 Sigma-Aldrich 
Norcodeine 467-15-2 C17H19NO3 285.3 - 13.8, 10.1 1.0, 1.0 0.9±0.7 -2.1 -1.1 
Sigma Aldrich (Cerilliant 
product) 
Oxycodone 76-42-6 C18H21NO4 315.4 - 13.6, 8.2 1.0, 1.0 1.7±0.6 -0.5 1.2 
Sigma Aldrich (Cerilliant 
product) 
Noroxycodone 52446-25--0 C17H19NO4 301.2 - 13.6, 9.5 -  0.2 -2.7 -1.1 
Sigma Aldrich (Cerilliant 
product) 
(-)-Oxymorphone 76-41-5 C17H19NO4 301.3 -  10.1, 8.2 -  0.9±0.5 -1.1 0.5 
Sigma Aldrich (Cerilliant 
product) 
D-(-)-Morphine 57-27-2 C17H19NO3 285.3 
8.2 
(25°) 
10.3, 9.1 0.9 0.4±0.7 -2.1 -0.4 
Sigma Aldrich (Cerilliant 
product) 
Normorphine 466-97-7 C16H17NO3 271.3 - 10.5, 9.8 - 0.1±0.7 -2.9 -1.8 
Sigma Aldrich (Cerilliant 
product) 
Dihydromorphine 509-60-4 C17H21NO3 287.4 - 10.3, 9.2 - 0.6±0.4 -2.0 -0.4 
Sigma Aldrich (Cerilliant 
product) 
Hydrocodone 125-29-1 C18H21NO3 299.4 - 18.0, 8.6 1.2 1.8±0.5 -0.9 0.7 






20290-09-9 C23H27NO9 461.5 - 12.2, 10.8 - -2.0±0.8 -4.5 -4.6 
Sigma Aldrich (Cerilliant 
product) 
(±)-Methadone 76-99-3 C21H27NO 309.4 
8.9 
(25°) 
18.8, 9.1 3.9 4.2±0.3 1.2 2.6 





66729-78-0 C20H23N 277.4 - 9.6 - 5.4 3.6 4.9 LGC (Cerilliant product) 
(±)-cis-Tramadol 36282-47-0 C16H25NO2 263.4 9.4 13.8, 9.2 2.4 2.5±0.3 -0.5 0.5 Sigma-Aldrich 
N-Desmethyltramadol 1018989-94-0 C15H23NO2 249.4 - 13.8, 9.9 - 1.7 -1.4 -1.1 LGC 
(+)-O-Desmethyltramadol 185453-02-5 C15H23NO2 249.4 - 9.6, 9.0 - 1.7 -1.3 -0.2 LGC 
Temazepam 846-50-4 C16H13ClN2O2 300.7 - 10.7, -1.4 2.2 2.1±0.9 2.1 2.1 
Sigma Aldrich (Cerilliant 
product) 
Diazepam 439-14-5 C16H13ClN2O 284.7 3.4 2.9 2.8 2.9±0.9 2.9 2.9 
Sigma Aldrich (Cerilliant 
product) 
Nordiazepam  1088-11-5 C15H11ClN2O 270.7 -  12.3, 2.8 2.5b 3.1±0.5 3.1 3.1 
Sigma Aldrich (Cerilliant 
product) 
Nitrazepam 146-22-5 C15H11N3O3 281.3 -  11.9, 2.6 2.2 2.2±0.5 2.2 2.2 LGC (Cerilliant product) 
7-aminonitrazepam 4928-02-3 C15H13N3O 251.3 -  -  -  1.1±0.8 1.0 1.1 
Sigma Aldrich (Cerilliant 
product) 
Oxazepam 604-75-1 C15H11ClN2O2 286.7 -  10.6, -1.5 -  2.3±0.5 2.3 2.3 
Sigma-Aldrich (Cerilliant 
product) 
(±)-Lorazepam 846-49-1 C15H10Cl2N2O2 321.2 13 10.6, -2.2 2.4 2.5±0.5 2.5 2.5 
Sigma-Aldrich (Cerilliant 
product) 
Amitriptyline 549-18-8 C20H23N 277.4 9.4 9.8 4.9 4.9±0.6 1.9 3.1 Sigma-Aldrich 
Nortriptyline 894-71-3 C19H21N 263.4 - 10.5 - 5.6±0.3 2.6 3.2 Sigma-Aldrich 
Fluoxetine 59333-67-4 C17H18F3NO 309.3 - 9.8 4.0 4.1±0.4 1.0 1.6 LGC (Cerilliant product) 
R-(-)-fluoxetine 114247-09-5 C17H18F3NO 309.3 - 9.8 4.0 4.1±0.4 1.0 1.6 Sigma-Aldrich 
Norfluoxetine 107674-50-0 C16H16F3NO 295.3 - 9.8 - 4.4±0.4 1.4 2.7 LGC (Cerilliant product) 
(±)-Venlafaxine 99300-78-4 C17H27NO2 277.4 - 14.4, 8.9 - 2.9±0.3 -0.1 1.2 Sigma-Aldrich 
O-Desvenlafaxine 300827-87-6 C16H25NO2 263.0 - 10.1, 8.9 - 2.3±0.3 -0.7 0.5 Sigma-Aldrich 
Zolpidem 
 
99294-93-6 C19H21N3O 307.4 6.2 5.6 1.2 3.1±0.6 1.9 3.0 
Sigma Aldrich (Cerilliant 
product) 
(±)-Zopiclone 43200-80-2 C17H17ClN6O6 388.8 - 13.0, 6.9 0.8 -0.3±1.3 -1.5 -0.4 LGC 
(±)-Ketamine 1867-66-9 C13H16ClNO 237.7 - 18.8, 7.4 2.9 2.2±0.6 1.2 2.1 Sigma-Aldrich 
(±)-Norketamine  79499-59-5 C12H14ClNO 223.7 - 18.7, 7.5 - 1.9±0.5 1.1 1.9 
Sigma Aldrich (Cerilliant 
product) 
Sildenafil 139755-83-2 C22H30N6O4S 474.6 - 7.3, 6.0 1.9 2.3±1.4 1.6 2.2 




Vardenafil 224789-1515-5 C23H32N6O4S 488.6 - 8.0, 6.2 1.4 2.6±1.2 1.0 2.5 
Sigma Aldrich (Cerilliant 
product) 
(±)-Pentobarbital  76-74-4 C11H18N2O3 226.3 
8.1 
(25°) 
8.5 2.1 2.0±0.2 2.0 1.9 
Sigma-Aldrich (Cerilliant 
product) 
Secobarbital 29071-21-4  C12H18N2O3 238.3 7.8 8.5 1.9 2.2±0.2 2.2 2.0 
Sigma-Aldrich (Cerilliant 
product) 
Ephedrine 50-98-6 C10H15NO 165.2 
10.3 
(0°) 
13.9, 9.5 1.1 1.0±0.3 -2.0 -0.9 Sigma-Aldrich 
(1R,2R)-(-)-
Pseudoephedrine 
321-97-1 C10H15NO 165.2 
10.3 
(0°) 
13.9, 9.5 1.1 1.0±0.3 -2.0 -0.9 Sigma-Aldrich 
(±)-Norephedrine 154-41-6 C9H13NO 151.2 
9.4 
(20°) 





Table S2 Studied mobile phase compositions with CHIRALPAK® CBH HPLC  
% MP modifiers Conc. NH4OAc (mM) pH 
10% IPA 1.0 5.0 
10% MeOH 1.0 6.6 
10% ACN 1.0 6.4 
5% IPA 1.0 6.2 
5% MeOH 1.0 6.7 
10% MeOH 5.0 6.8 
10% MeOH 10.0 6.9 
10% MeOH 1.0 6. 7 
10% MeOH 2.5 6.6 
10% MeOH 1.0 6.2 
15% MeOH 1.0 6.4 
 
Table S3 Studied mobile phase compositions with CHIROBIOTIC V 
% H2O %FA Conc. NH4OAc (mM) pH 
1 0.005 4 6.8 
5 0.005 4 6.8 
20 0.005 4 6.5 
80 0.005 4 5.2 
25 - 0 0.005 4   
0 0 0   
1 0.005 1 5.9 
1 0.005 10 7.4 
1 0.001 1 7.3 
 
Table S4 Studied mobile phase compositions with CHIROBIOTIC T (mobile phases with pH<3 
were not tested due to the extreme pH not suitable for the studied chiral column)  
% H2O %FA Conc. NH4OAc (mM) pH 
1 0.005 4 6.8 
0 0 0   
5 0.005 4 6.8 
20 0.005 4 6.5 
80 0.005 4 5.2 
80 0 20 6.7 
0 - 100 0.005 4   
1 0.005 1 5.9 
1 0.005 10 7.4 
1 0.001 1 7.3 
1 0.001 10 7.9 
1 0.001 4 7.6 
1 0.01 1 5.2 
1 0.01 10 6.9 
1 0.01 4 6.4 
1 1 1 2. 9 
1 1 10 3.9 
1 1 4 3.5 
5 0.005 1 5.6 




Table S5 Validation parameters -instrumental precision 
 
Intra-day RSD% (n=4) Inter-day RSD% (n=3)  
5 µg/L** 5 µg/L 5 µg/L 50 µg/L 50 µg/L 50 µg/L 500 µg/L 500 µg/L 500 µg/L 5 µg/L 50 µg/L 500 µg/L 
  D 1* D 2 D 3 D 1 D 2 D 3 D 1 D 2 D 3 
   
Cocaine 1.2 2.3 5.3 2.2 4.0 0.5 3.2 3.7 0.5 2.9 2.3 2.5 
Benzoylecgonine 3.1 4.1 2.6 6.2 2.9 2.7 1.1 1.8 1.7 3.3 3.9 1.5 
Cocaethylene 7.9 3.5 4.8 0.2 0.4 0.6 0.2 3.8 2.4 5.4 0.4 2.1 
R-(-)-Amphetamine 4.8 5.8 3.0 2.3 3.1 0.1 3.9 4.7 3.1 4.5 1.9 3.9 
S-(+)-Amphetamine 3.7 5.3 6.5 4.6 3.3 4.3 3.2 4.1 3.4 5.2 4.1 3.6 
R-(-)-Methamphetamine 6.0 5.8 6.3 3.9 5.5 2.3 3.0 5.1 2.8 6.0 3.9 3.7 
S-(+)-Methamphetamine 2.4 2.3 7.7 2.7 0.7 2.1 1.1 4.8 3.4 4.1 1.8 3.1 
E1-Mephedrone 9.3 6.7 5.5 1.9 5.7 5.4 2.9 5.5 4.4 7.1 4.3 4.3 
E2-Mephedrone 3.5 6.7 1.1 3.6 2.5 2.7 9.3 4.3 2.2 3.8 3.0 5.2 
R-(-)-MDA 6.9 1.3 2.7 0.4 5.6 0.1 1.5 0.3 1.6 3.6 2.1 1.1 
S-(+)-MDA 5.7 3.2 6.4 8.0 8.9 3.1 0.3 1.1 6.1 5.1 6.7 2.5 
R-(-)-MDMA 2.5 5.5 2.0 1.8 6.4 3.9 4.8 3.7 6.1 3.3 4.0 4.9 
S-(+)-MDMA 3.5 1.1 4.3 0.5 1.8 1.3 2.5 1.5 2.7 3.0 1.2 2.3 
E1-MDEA 8.6 5.3 5.9 2.2 3.8 1.1 6.1 4.3 0.1 6.6 2.4 3.5 
E2-MDEA 3.6 2.3 10.3 5.3 1.1 0.4 5.6 1.9 0.7 5.4 2.3 2.7 
Heroin 6.7 17.8 0.0 2.4 11.3 29.2 11.5 13.9 13.4 8.2 14.3 13.0 
O-6-monoacetylmorphine 9.0 9.2 12.4 0.0 1.8 11.0 1.2 10.7 1.4 10.2 4.3 4.4 
Morphine 12.1 4.4 10.6 13.5 5.5 7.9 11.0 1.2 4.4 9.1 8.9 5.5 
Morphine-3β-D-glucuronide 14.8 19.9 2.5 4.6 16.8 20.0 8.3 6.6 13.3 12.4 13.8 9.4 
Ketamine 4.0 5.4 7.1 2.0 1.4 1.9 1.3 1.8 1.6 5.5 1.8 1.5 
Benzylpiperazine 6.8 2.4 2.2 6.6 2.5 10.8 1.1 1.8 3.1 3.8 6.6 2.0 
Temazepam 5.9 7.2 7.9 0.7 2.2 6.4 4.4 4.1 0.3 7.0 3.1 2.9 
Diazepam 4.9 4.8 6.3 1.2 2.8 4.4 2.3 1.7 1.3 5.3 2.8 1.8 
Nordiazepam 7.0 8.4 7.3 5.1 7.5 3.6 2.2 1.6 7.4 7.6 5.4 3.7 
Nitrazepam 7.1 4.2 0.8 7.3 7.8 2.9 8.5 5.6 4.7 4.0 6.0 6.3 
Oxazepam 7.5 7.7 7.3 2.7 5.5 0.0 1.7 1.6 0.6 7.5 2.7 1.3 
7-amino-nitrazepam 3.4 3.6 6.5 4.7 3.3 1.8 4.7 5.0 0.8 4.5 3.2 3.5 
Lorazepam 1.9 8.4 21.2 7.5 6.9 1.6 4.8 6.6 7.2 10.5 5.3 6.2 
AEME 6.8 4.2 2.2 4.4 2.9 4.0 0.7 6.5 2.0 4.4 3.8 3.1 
E1-HMA 11.3 5.6 6.3 5.3 6.7 9.1 7.4 4.9 2.1 7.7 7.1 4.8 
E2-HMA 6.1 1.7 1.1 3.1 0.4 2.5 8.9 6.3 9.0 3.0 2.0 8.1 
E1-HMMA 5.3 8.3 4.1 0.8 6.5 6.6 8.2 4.2 1.7 5.9 4.6 4.7 
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E2-HMMA 6.6 5.7 9.4 2.4 3.3 7.4 3.8 4.0 4.6 7.2 4.4 4.1 
DHMA 8.1 4.5 9.2 3.2 12.3 5.4 3.5 2.6 1.7 7.3 7.0 2.6 
Caffeine 1.9 0.9 4.4 3.0 12.9 4.4 4.5 3.6 1.3 2.4 6.7 3.1 
1,7-dimethylxanthine 1.5 8.0 7.7 2.8 15.3 6.6 0.2 0.3 0.9 5.7 8.2 0.5 
Nicotine 1.6 9.8 8.6 2.7 13.4 2.7 1.7 1.6 1.8 6.7 6.3 1.7 
Cotinine 1.1 2.6 6.5 7.0 11.8 2.4 0.1 1.9 4.1 3.4 7.1 2.0 
Creatinine 5.2 6.0 7.4 2.3 0.1 1.2 1.1 0.8 1.6 6.2 1.2 1.2 
Codeine 11.7 7.3 2.3 7.6 1.7 6.9 6.0 2.6 4.8 7.1 5.4 4.5 
Oxycodone 8.3 7.3 4.0 2.5 10.5 6.6 5.6 8.8 5.3 6.5 6.5 6.6 
Noroxycodone 1.91 3.3 4.0 6.0 2.3 3.8 1.4 5.8 2.0 3.1 4.0 3.1 
Hydrocodone 3.8 5.2 4.7 1.3 7.8 4.1 2.0 0.6 1.3 4.6 4.4 1.3 
Oxymorphone 7.3 6.8 5.5 0.4 4.5 2.8 2.1 5.9 2.1 6.5 2.6 3.4 
Dihydrocodeine 6.8 8.2 7.4 6.6 8.7 3.4 0.5 2.0 0.6 7.4 6.2 1.0 
Methadone 0.6 2.1 1.6 2.5 1.0 3.1 1.3 0.9 0.2 1.4 2.2 0.8 
EDDP 5.8 4.8 5.1 1.7 2.7 2.2 0.5 1.3 1.5 5.2 2.2 1.1 
E1-Venlafaxine 7.1 3.1 7.4 3.4 2.0 0.8 0.4 1.4 0.9 5.9 2.1 0.9 
E2-Venlafaxine 6.1 2.4 0.0 1.9 2.9 3.6 0.5 1.4 0.9 2.8 2.8 0.9 
Vardenafil 25.0 7.3 21.8 5.1 1.1 5.1 0.1 0.8 3.1 18.0 3.8 1.3 
E1-Norephedrine 5.9 7.1 3.1 2.7 6.9 5.7 2.2 1.3 1.1 5.4 5.1 1.5 
E2-Norephedrine 5.4 3.1 4.4 2.4 4.7 3.6 3.4 5.2 2.1 4.3 3.6 3.6 
E1-PMA 2.7 8.4 5.6 1.2 8.6 6.1 2.6 0.3 0.4 5.6 5.3 1.1 
E2-PMA 4.6 5.4 4.5 4.6 3.9 2.6 3.1 1.6 1.1 4.9 3.7 1.9 
Normorphine 4.6 13.3 0.0 20.0 0.5 8.2 3.8 0.1 15.8 6.0 9.5 6.6 
Dihydromorphine 18.1 3.0 5.3 15.7 20.0 4.8 8.9 4.9 11.0 8.8 13.5 8.3 
D1-Tramadol 11.2 7.1 5.6 3.4 4.1 3.6 5.1 0.9 2.5 8.0 3.7 2.8 
D2-Tramadol 2.4 6.8 10.7 13.8 12.4 7.1 2.2 10.0 1.1 6.7 11.1 4.4 
O-desmethyltramadol 12.9 10.9 7.2 6.2 3.0 3.5 8.3 5.2 3.2 10.3 4.2 5.6 
Zolpidem 15.7 16.3 1.6 1.2 0.1 1.1 3.3 3.4 0.2 11.2 0.8 2.3 
Amitriptyline 0.0 10.1 8.3 3.1 6.0 11.3 3.4 3.4 3.4 6.1 6.8 3.4 
Norketamine 2.7 6.9 6.0 3.4 1.1 3.5 2.6 2.4 1.4 5.2 2.7 2.1 
Sildenafil 5.4 15.7 10.9 4.8 15.3 5.7 7.6 0.9 1.5 10.7 8.6 3.3 
(+)-Ephedrine 6.9 3.5 6.5 4.3 5.7 3.2 6.3 1.0 3.4 5.6 4.4 3.6 
(-)-Ephedrine and (-)-Ψephedrine 2.6 2.7 4.1 3.6 3.1 2.3 6.4 0.7 4.4 3.1 3.0 3.8 
(+)-Ψephedrine 10.6 6.2 5.6 5.9 0.5 2.4 3.4 9.1 3.2 7.4 2.9 5.3 
Desmethylvenlafaxine-E1 18.2 7.4 5.2 5.3 7.2 0.7 1.9 8.1 2.0 10.3 4.4 4.0 
Desmethylvenlafaxine-E2 5.4 4.5 4.0 5.7 12.5 6.4 2.8 2.0 3.9 4.7 8.2 2.9 
E1-Zopiclone 18.2 19.7 15.8 14.2 16.2 12.2 11.4 10.7 8.7 17.9 14.2 10.3 
E2-Zopiclone 17.9 19.3 16.7 12.6 18.6 18.0 14.6 13.8 8.5 17.9 16.4 12.3 
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S-(+)-Fluoxetine 18.3 6.9 4.9 6.0 19.0 9.3 13.6 14.4 2.4 10.0 11.4 10.2 
R-(-)-Fluoxetine 16.5 15.9 10.2 13.0 1.3 16.9 1.7 9.3 2.4 14.2 10.4 4.5 
E1-Norfluoxetine 11.5 4.4 18.4 5.9 8.2 0.8 5.1 3.1 3.4 11.4 5.0 3.9 
E2-Norfluoxetine 10.2 14.3 16.6 15.5 9.8 13.8 17.6 8.0 0.5 13.7 13.1 8.7 
*-D indicates day 





Table S6 Validation parameters –ion suppression 
 
Signal suppression (%) (n=4) 
Cocaine -69.0 ± 25.8 
Benzoylecgonine -6.1 ± 1.5 
Cocaethylene -27.5 ± 5.2 
R-(-)-Amphetamine 37.9 ± 9.7 
S-(+)-Amphetamine 53.4 ± 9.4 
R-(-)-Methamphetamine -28.5 ± 12.5 
S-(+)-Methamphetamine -6.4 ± 9.2 
E1-Mephedrone -22.3 ± 11.8 
E2-Mephedrone -40.2 ± 14.0 
R-(-)-MDA -15.3 ± 1.4 
S-(+)-MDA -12.5 ± 1.8 
R-(-)-MDMA -43.9 ± 7.4 
S-(+)-MDMA -57.5 ± 8.2 
E1-MDEA -33.9 ± 2.0 
E2-MDEA -58.1 ± 6.6 
Heroin -5.1 ± 10.3 
O-6-monoacetylmorphine -85.2 ± 18.8 
Morphine -58.1 ± 18.5 
Morphine-3β-D-glucuronide 99.7 ± 0.6 
Ketamine 12.5 ± 11.2 
Benzylpiperazine -50.1 ± 5.3 
Temazepam 21.5 ± 4.3 
Diazepam -37.5 ± 7.7 
Nordiazepam -34.9 ± 1.5 
Nitrazepam 45.7 ± 2.6 
Oxazepam 47.7 ± 4.2 
7-amino-nitrazepam 70.9 ± 6.7 
Lorazepam 49.3 ± 10.5 
Anhydroecgonine methyl ester -90.4 ± 2.9 
E1-HMA -50.4 ± 6.2 
E2-HMA -68.7 ± 13.9 
E1-HMMA -81.5 ± 33.7 
E2-HMMA -76.7 ± 15.0 
DHMA 95.4 ± 10.1 
Caffeine 57.3 ± 12.3 
1,7-dimethylxanthine 59.3 ± 9.4 
Nicotine -9.4 ± 7.1 
Cotinine 49.0 ± 10.9 
Creatinine 70.1 ± 2.3 
Codeine -5.2 ± 7.2 
Oxycodone -58.5 ± 11.5 
Noroxycodone -58.6 ± 7.8 
Hydrocodone -50.8 ± 7.6 
Oxymorphone -74.7 ± 10.5 
Dihydrocodeine -6.6 ± 11.6 
Methadone 37.6 ± 19.9 
EDDP 23.9 ± 1.8 
E1-Venlafaxine -19.3 ± 4.8 
E2-Venlafaxine -12.1 ± 9.5 
Vardenafil 15.7 ± 10.8 
E1-Norephedrine 63.4 ± 2.8 
E2-Norephedrine 21.5 ± 4.6 
E1-PMA -21.7 ± 7.9 
E2-PMA -38.8 ± 4.1 
Normorphine 63.2 ± 11.0 
Dihydromorphine 60.0 ± 10.2 
D1-Tramadol 22.1 ± 1.5 
D2-Tramadol 8.8 ± 6.6 
O-desmethyltramadol 46.7 ± 3.0 
Zolpidem -72.1 ± 3.2 
Amitriptyline -23.5 ± 0.6 
Norketamine -52.1 ± 2.4 
Sildenafil -49.9 ± 11.8 
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(+)-Ephedrine -78.2 ± 4.6 
(-)-Ephedrine and (-)-Ψephedrine -72.3 ± 7.5 
(+)-Ψephedrine -76.7 ± 16.3 
Desmethylvenlafaxine-E1 -6.3 ± 2.0 
Desmethylvenlafaxine-E2 -31.1 ± 16.4 
E1-Zopiclone -33.2 ± 5.6 
E2-Zopiclone -41.0 ± 4.5 
S-(+)-Fluoxetine 1.5 ± 0.1 
R-(-)-Fluoxetine 3.2 ± 2.5 
E1-Norfluoxetine -4.3 ± 0.7 











































































































































Figure S2 CBH column - enantiomeric resolution of studied analytes in a mobile phase containing isopropanol as organic modifier (mobile phase composition: (a) 1mM 





























Figure S3 CBH column - enantiomeric resolution of studied analytes in mobile phases containing: (a) 1 mM ammonium acetate/methanol 9.5:0.5, (b) 1 mM ammonium 
acetate/methanol 9:1, (c) 2.5 mM ammonium acetate/methanol 9:1, (d) 5 mM ammonium acetate /methanol 9:1, (e) 10 mM ammonium acetate /methanol 9:1 and (f) 1 mM 



















































































































































































































































































Figure S4 CBH column – Impact of different percentages of modifiers on retention time of analytes 






Figure S5 Chirobiotic T column - overview of the separation for the targeted analytes (MeOH: 






















100% MeOH 1mM Amm.Acet./MeOH 1:99 0.005% FA
10 mM Amm.Acet./MeOH 1:99 0.005% FA 1mM Amm.Acet./MeOH 1:99 0.001% FA
4 mM Amm.Acet./MeOH 1:99 0.01% FA 10mM Amm.Acet./MeOH 1:99 0.01% FA
10mM Amm.Acet./MeOH 1:99 1% FA 1 mM Amm.Acet./MeOH 5:95 0.005% FA
10 mM Amm.Acet./MeOH 5:95 0.005% FA 1 mM Amm.Acet./MeOH 5:95 0.001% FA
MeOH:Water 2:8 MeOH:Water 8:2




Figure S6 Chirobiotic T column - separation of oxazepam and lorazepam (MeOH: methanol, 

























1mM Amm.Acet./MeOH 1:99 0.005% FA
10 mM Amm.Acet./MeOH 1:99 0.005% FA
1mM Amm.Acet./MeOH 1:99 0.001% FA
4 mM Amm.Acet./MeOH 1:99 0.01% FA
10mM Amm.Acet./MeOH 1:99 0.01% FA
10mM Amm.Acet./MeOH 1:99 1% FA
1 mM Amm.Acet./MeOH 5:95 0.005% FA
10 mM Amm.Acet./MeOH 5:95 0.005% FA



























The following supplementary data are contained in Appendix 2: 
Figure S1 Synthesis of (±)-mephedrone (a, b) (modified from Schifano et al. (2010) 
[24]) and of S-(-)-mephedrone (c) (modified from Osorio-Olivares et al. (2003) 
[38]). 
Figure S2 Proposed mephedrone metabolism in humans (modified from Pozo et al. 
(2014)). 
Table S1 Selected analytes and their properties (MW molecular weight, Exp 
experimental, Pred predicted, a predicted using ACD/labs software 
(http://www.chemspider.com). 
S1-Experimental settings and procedure for acetylation of rat urine sample. 
Table S2 Experimental set up of the reactors used for (a) incubating wastewater and 
(b) pHLM. 
Table S3 MRM transitions in chiral LC-TQD method. 
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Table S4 Method validation parameters (chiral LC-TQD) for mephedrone and 
normephedrone. 
Table S5 Operating conditions for the absorbance and CD spectra of (±)-
mephedrone (4-MMC) 
Figure S3 CD and absorbance spectra of (±)-mephedrone (4-MMC) (a,b). UV 
spectra of (±)-mephedrone from the computational study (c). 
Figure S4 Predicted CD spectra for (±)-mephedrone (a) and for (±)-normephedrone 
(b). 
S2-Statistical tests. 
Table S6 Mephedrone concentrations and population-normalised mass loads in 
wastewater samples during one week monitoring campaign in 2014 and in 2015 in 
the UK. 
Table S7 Non-targeted analysis by LC Q-TOF: mephedrone metabolites predicted 
in wastewater and in pHLM by using MetID software (Theor means theorethical 
and Exp. experimental). 
Table S8 Target screening analysis in wastewater and in pHLM by using LC-
QTOF. 
Table S9 Untarget screening analysis in wastewater and in pHLM by using LC-
QTOF. 
Table S10 ddMS2 spectra of mephedrone metabolites detected in rat urine sample 
using LC Q-E. 
Figure S6 MS2 chromatogram of mephedrone and normephedrone in rat urine 
sample using chiral LC VP. 
Figure S7 Full scan chromatograms and spectra of mephedrone metabolites in rat 
urine sample using chiral LC VP. Dihydro-nor-mephedrone diastereoisomers are 
shown in (a), whilst the partial separation of hydroxytolyl-mephedrone enantiomers 
in (b). 
Figure S8 Mephedrone metabolites in rat urine sample identified with chiral LC-
VP: nor-hydroxytolyl-mephedrone and its two enantiomers (note: the presence of 
another minor mephedrone metabolite was observed). 
Figure S9 Mephedrone and normephedrone concentrations and enantiomeric 










Figure S1 Synthesis of (±)-mephedrone (a, b) (modified from Schifano et al. (2010) (Schifano et al., 2011)) and of S-(-)-mephedrone (c) (modified from Osorio-Olivares et al. 








Table S1 Selected analytes and their properties (MW molecular weight, Exp experimental, Pred predicted, a predicted using ACD/labs software (http://www.chemspider.com). 
Compound CAS Formula MW LogP LogDa  Purity (%) Supplier 
        Exp. Pred.a pH 5.5 pH 7.4   
(±)-Mephedrone 1189726-22-4 C11H15NO 177.7 - 1.86±0.31 -0.03 1.55 99.8 Sigma-Aldrich (Cerilliant product) 
(±)-Nor-mephedrone 6941-17-9 C10H13NO 163.4 - - - - 98.0 Cayman Chemical Company 





S1-Experimental settings and procedure for acetylation of rat urine sample. 
A blank and a positive rat urine sample underwent solid-phase extraction (SPE) 
with Isolute hydrophilic cation exchange (HCX) cartridges (130 mg, 3 mL, Biotage, 
Uppsala, Sweden). Cartridges were conditioned with 1mL methanol and 1mL of 
deionised water. 1 mL of rat urine sample spiked with 10 μL of 1 μg mL-1 of 
mephedrone-D3 was loaded onto the cartridge. The washing step was carried out 
with 1mL of deionised water, 1mL 0.01 M HCl followed by 1mL of deionised 
water. The neutral fraction was obtained after eluting the cartridges with 2 mL of 
methanol, and the basic fraction with 1mL methanol/NH3 33% mix 98: 2 v/v. The 
extracts were evaporated to dryness under nitrogen at 40°C and re-dissolved in 100 
μL of methanol. 50 μL were transferred to other vials and dried under nitrogen flow 
at 40 °C. For the analysis in gas chromatography coupled to mass spectrometry 
(GC-MS), rat urine was acetylated with 100 μL of a mixture acetic acid/pyridine 
3:2 through microwave irradiation for 5 minutes at 450 W. After evaporation, the 
sample was reconstituted in 50 μL of methanol and then injected in a splitless 
injection mode into a GC-MS system. The analysis was performed using a Hewlett 
Packard (HP, Agilent, Waldbronn, Germany) 5890 Series II gas chromatograph 
combined with an HP 5972A MSD mass spectrometer and an HP MS ChemStation 
(DOS series) with HP G1034C software version C03.00. The column was Thermo 
Scientific TG-1MS capillary (12 m × 0.2 mm I.D.), cross-linked methyl silicone, 
330 nm film thickness. The following GC conditions were set: injection port 
temperature at 280 °C, helium as carrier gas, 1mL min-1 as flow rate. The column 
temperature was programmed from 100 to 310 °C at 30 °C min-1, initial time 2 min, 
final time 5 min. The MS conditions were as follows: electron ionization (EI) mode, 
70 eV as ionization energy, ion source temperature at 220 °C and capillary direct 
interface heated at 280 °C. The acquisition was in full scan mode with m/z range 

















































10/12 178.1 > 
160.1 










10/20 164.0 > 
131.0 
10/32 164.0 > 
91.0 




30/22 181.1 > 
163.1 
- - - - - - - 
aCV, cone voltage (V); CE, collision energy (eV) 
 Wastewater reactors 
Biotic Abiotic Clean Control 
Mephedrone (100 ng mL-1) X X X  
NaN3  X X  
Demineralised water   X  
Wastewater X X  X 
 
Biological pHLM reactors 
Incubation NoHLM NoRegSys 
Phosphate buffer pH 7.4 X X X 
Regenerating system (Reg Sys) X X  
Substrate solution X X X 
SOD X X X 
HLM X  X 
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Table S4 Method validation parameters (chiral LC-TQD) for mephedrone and normephedrone. 




Sample diluent WWTP influent 
 Linear range (µg L-1) R2 IDLS/Nb 
(µg L-1) 
IQLS/Nc (µg L-1) MDLd (ng L-1) MQLe (ng L-1) 
 R-(+)-Mephedrone 16.5 ±0.4 0.3 0.25-500 0.9990 0.25 0.50 1.30 2.60 
 S-(-)-Mephedrone 21.0 ±0.5 0.2 0.25-500 0.9993 0.25 0.50 0.66 2.63 
 R-(+)-Normephedrone 44.2 ±0.8 6.5 0.25-500 0.9915 0.25 5.0 1.35 26.9 
 S-(-)-Normephedrone 68.8 ±1.4 6.7 0.25-500 0.9911 0.25 5.0 1.35 27.0 
(b) SPE recovery % (n=3) 
  25 ng/L 250 ng/L 2500 ng/L 
 R-(+)-Mephedrone 109.1 ± 3.2 99.3 ± 4.8 80.7 ± 7.0 
 S-(-)-Mephedrone 99.0 ± 8.5 99.1 ± 4.3 87.2 ± 11.5 
 R-(+)-Normephedrone 72.8 ± 1.3 97.4 ± 9.2 108.5 ± 5.7 
 S-(-)-Normephedrone 79.4 ± 0.8 86.0 ± 2.0 113.2 ± 1.4 
(c) Method precision; D represents day 
  Intra-day RSD% (n=4) 
  5 ng L-1 5 ng L-1 5 ng L-1 50 ng L-1 50 ng L-1 50 ng L-1 500 ng L-1 500 ng L-1 500 ng L-1 
  D 1 D 2 D 3 D 1 D 2 D 3 D 1 D 2 D 3 
 R-(+)-Mephedrone 9.8 13.7 14.1 3.6 6.8 14.6 3.7 10.0 5.6 
 S-(-)-Mephedrone 10.7 12.0 4.6 5.2 12.9 8.4 9.2 3.7 2.8 
 R-(+)-Normephedrone 14.1 20.8 13.3 2.8 13.3 8.3 1.5 5.5 12.8 
 S-(-)-Normephedrone 18.2 11.2 3.2 17.4 18.9 0.5 13.9 7.9 18.5 
  Inter-day RSD% (n=3) 
  5 ng L-1 50 ng L-1 500 ng L-1 
 R-(+)-Mephedrone 12.5 8.3 6.4 
 S-(-)-Mephedrone 9.1 8.8 5.2 
 R-(+)-Normephedrone 10.3 8.1 6.6 
 S-(-)-Normephedrone 11.6 12.3 13.4 
(d) Instrumental precision; D represents day 
  Intra-day RSD% (n=4) 
  5 µg L-1 5 µg L-1 5 µg L-1 50 µg L-1 50 µg L-1 50 µg L-1 500 µg L-1 500 µg L-1 500 µg L-1 
  D 1 D 2 D 3 D 1 D 2 D 3 D 1 D 2 D 3 
 R-(+)-Mephedrone 9.3 6.7 5.5 1.9 5.7 5.4 2.9 5.5 4.4 
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 S-(-)-Mephedrone 3.5 6.7 1.1 3.6 2.5 2.7 9.3 4.3 2.2 
 R-(+)-Normephedrone 24.5 5.4 9.2 11.5 8.0 8.2 3.7 3.0 2.7 
 S-(-)-Normephedrone 27.5 12.4 1.1 5.6 4.5 6.6 4.3 2.1 4.0 
  Inter-day RSD% (n=3) 
  5 µg L-1 50 µg L-1 500 µg L-1 
 R-(+)-Mephedrone 7.1 4.3 4.3 
 S-(-)-Mephedrone 3.8 3.0 5.2 
 R-(+)-Normephedrone 8.5 9.2 3.1 
 S-(-)-Normephedrone 7.6 5.6 3.5 
(e)  Rsf EFg 
   5 μg L-1 50 μg L-1 500 μg L-1 
 Mephedrone 1.4 ±0.1 0.50±0.0 0.50±0.0 0.48±0.0 




Instrumental Limit of Detection (IDL). It was determined at a concentration value giving a signal-to-noise ratio (S/N) ≥ 3 for all the MRM transitions 
selected for cocaine; 
c 
Instrumental Limit of Quantification (IQL). It was determined at the minimum concentration value giving S/N ≥ 10 for all the MRM transitions; 
d 
Method Detection Limit (MDL); 
e 




Table S5 Operating conditions for the absorbance and CD spectra of (±)-mephedrone (4-MMC) 
Wavelength  265 nm 
Spectral bandwidth 1 nm 
Step size 1 nm 
Concentration 170 µg mL-1 
Solvent 1mM ammonium acetate/methanol 85:15 
Time 1000 s 
Points 10000 
Samples 4000 




















Figure S3 CD and absorbance spectra of (±)-mephedrone (4-MMC) (a,b). UV spectrum of (±)-




































































Wastewater samples from 2014 sampling campaign. 
 
F-Test Two-Sample for Variances   
  EF EF of standards from validation 
Mean 0.563687 0.491920235 
Variance 0.000983 0.000119448 
Observations 7 7 
df 6 6 
F 8.232061  
P(F<=f) one-tail 0.010733  
F Critical one-tail 4.283866   
 
Data: 
UK 2014 Validation 











t-Test: Two-Sample Assuming Unequal Variances 
 EF EF of standards from 
validation 
Mean 0.5636866 0.491920235 
Variance 0.000983302 0.000119448 




df 7  
t Stat 5.71783294  
P(T<=t) one-tail 0.000360966  
t Critical one-tail 1.894578605  
P(T<=t) two-tail 0.000721932  




t-Test: Two-Sample Assuming Unequal Variances 
 EF EF of standards 
t Stat 5.71783294  
P(T<=t) one-tail 0.000360966  
t Critical one-tail 4.785289629  
P(T<=t) two-tail 0.000721932  
t Critical two-tail 5.407882521  
 





UK 2014 Validation 











t-Test: Two-Sample Assuming Unequal Variances 
 EF EF of standards 
Mean 0.573260904 0.491920235 
Variance 0.000409957 0.000119448 




df 7  
t Stat 8.802454788  
P(T<=t) one-tail 0.00002464  
t Critical one-tail 1.894578605  
P(T<=t) two-tail 4.92701E-05  




t-Test: Two-Sample Assuming Unequal Variances 
 EF EF of standards 
t Stat 8.802454788  
P(T<=t) one-tail 0.00002464  
t Critical one-tail 4.785289629  
P(T<=t) two-tail 4.92701E-05  
t Critical two-tail 5.407882521  
 
Wastewater samples from 2015 sampling campaign. 
 
F-Test Two-Sample for Variances   
  EF EF of standards from validation 
Mean 0.536691 0.49192 
Variance 0.002805 0.000119 
Observations 7 7 
df 6 6 
F 23.48412  
P(F<=f) one-tail 0.00064  




UK 2015 Validation 













t-Test: Two-Sample Assuming Unequal Variances 
 EF EF of standards 
Mean 0.536690782 0.491920235 
Variance 0.002805128 0.000119448 




df 7  
t Stat 2.19033233  
P(T<=t) one-tail 0.032323525  
t Critical one-tail 1.894578605  
P(T<=t) two-tail 0.06464705  




t-Test: Two-Sample Assuming Unequal Variances 
 EF EF of standards 
t Stat 2.19033233  
P(T<=t) one-tail 0.032323525  
t Critical one-tail 4.785289629  
P(T<=t) two-tail 0.06464705  
t Critical two-tail 5.407882521  
 




UK 2015 Validation 











t-Test: Two-Sample Assuming Unequal Variances 
 EF EF of standards 
Mean 0.548157004 0.491920235 
Variance 0.002261769 0.000119448 






df 5  
t Stat 2.833075718  
P(T<=t) one-tail 0.018271203  
t Critical one-tail 2.015048373  
P(T<=t) two-tail 0.036542405  




t-Test: Two-Sample Assuming Unequal Variances 
 EF EF of standards 
t Stat 2.833075718  
P(T<=t) one-tail 0.018271203  
t Critical one-tail 5.893429531  
P(T<=t) two-tail 0.036542405  
t Critical two-tail 6.868826626  
 
Comparison between wastewater samples in 2014-15 sampling campaigns. 
 
Data:  












t-Test: Paired Two Sample for Means 
 EF EF 
Mean 0.5636866 0.536690782 
Variance 0.000983302 0.002805128 
Observations 7 7 




df 6  
t Stat 1.140299108  
P(T<=t) one-tail 0.148812821  
t Critical one-tail 1.943180281  
P(T<=t) two-tail 0.297625643  
t Critical two-tail 2.446911851  
 
Illegal street mephedrone samples. 
 
F-Test Two-Sample for Variances   
  EF of standards from validation  EF 
Mean 0.491920235 0.500885962 
Variance 0.000119448 0.0000718 
Observations 7 8 
df 6 7 
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F 1.664004881  
P(F<=f) one-tail 0.259739457  




Street mephedrone samples Validation 












t-Test: Two-Sample Assuming Equal Variances 
 EF EF of standards 
Mean 0.500885962 0.491920235 
Variance 7.17834E-05 0.000119448 
Observations 8 7 




df 13  
t Stat 1.788847491  
P(T<=t) one-tail 0.048476721  
t Critical one-tail 1.770933396  
P(T<=t) two-tail 0.096953442  
 
Pooled human urine samples. 
 
F-Test Two-Sample for Variances   
  EF  EF of standards from validation 
Mean 0.587123641 0.491920235 
Variance 0.002536336 0.000119448 
Observations 7 7 
df 6 6 
F 21.23383177  
P(F<=f) one-tail 0.000849547  




Pooled human urine samples Validation 













t-Test: Two-Sample Assuming Unequal Variances 
 EF EF of standards 
Mean 0.587124 0.49192 
Variance 0.002536 0.000119 
Observations 7 7 
Hypothesized Mean 
Difference 0  
df 7  
t Stat 4.887707  
P(T<=t) one-tail 0.000889  
t Critical one-tail 1.894579  
P(T<=t) two-tail 0.001778  




t-Test: Two-Sample Assuming Unequal Variances 
 EF EF of standards 
t Stat 4.887707  
P(T<=t) one-tail 0.000889  
t Critical one-tail 4.78529  
P(T<=t) two-tail 0.001778  







Table S6 Mephedrone concentrations and population-normalised mass loads in wastewater samples during one week monitoring campaign in 2014 and in 2015 in the UK. 
2014 
Day  Flow 
[m3 
day-1] 
PEa R-(+)-Mephedrone S-(-)-Mephedrone (±)-Mephedrone 
Concentration 
[ng L-1] 
Population-normalised mass loads 
[mg 1000 people-1day-1]  
Concentratio
n [ng L-1] 
Population-normalised mass loads 
[mg 1000 people-1day-1]  
Concentratio
n [ng L-1] 
Population-normalised mass loads 















































53 ± 11 11.8 44 ± 5 9.8 96.5 21.6 
Avera
ge 





















Day  Flow 
[m3 
day-1] 
PEa R-(+)-Mephedrone S-(-)-Mephedrone (±)-Mephedrone 
Concentration 
[ng L-1] 
Population-normalised mass loads 
[mg 1000 people-1day-1]  
Concentratio
n [ng L-1] 
Population-normalised mass loads 
[mg 1000 people-1day-1]  
Concentratio
n [ng L-1] 
Population-normalised mass loads 

















































90 ± 6 19.6 58 ± 2 12.5 148 32.1 
Avera
ge 
   14.1  11.5  25.6 
SD    6.8  5.6  12.0 
CV    0.5  0.5  0.5 





Table S7 Non-targeted analysis by LC Q-TOF: mephedrone metabolites predicted in wastewater and in pHLM by using MetID software (Theor means theoretical and Exp. 
experimental). 
Metabolite Formula Ionization 
mode 
Rt Precursor ion 




C11H17NO ESI + 5.50 180.1383 180.1384 0.55 
Hydroxy-tolyl-
normephedrone 
C10H13NO2 ESI - 6.70 178.0874 178.0871 -1.68 
4’-carboxy 
mephedrone 
C11H13NO3 ESI - 5.85 206.0823 206.0822 0.48 
4’-carboxy 
normephedrone 
C10H11NO3 ESI - 6.92 192.067 192.066 0.52 
N-sulfo- 
normephedrone 
C10H13NO4S ESI + 7.15 244.0640 244.0638 0.82 
pHLM 
Normephedrone C10H13NO ESI + 6.18 164.1070 164.1064 3.65 
4’-carboxy-
normephedrone 








Table S8 Target screening analysis in wastewater and in pHLM by using LC-QTOF. 
STANDARD MEPHEDRONE-D3 









































































































































































































































Table S9 Untarget screening analysis in wastewater and in pHLM by using LC-QTOF. 
1-DIHYDRO NORMEPHEDRONE 






























































-8.70 - - 
4’-HYDROXYMETHYL-MEPHEDRONE 







































































































































-2.08 - - 
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Figure S7 Full scan chromatograms and spectra of mephedrone metabolites in rat urine sample 
using chiral LC VP. Dihydro-nor-mephedrone diastereoisomers are shown in (a), whilst the partial 
separation of hydroxytolyl-mephedrone enantiomers in (b).
RT: 5.26 - 41.92















































m/z= 146.0961-146.0975 F: 
FTMS + c ESI Full ms2 
164.11@cid35.00 
[50.00-200.00]  MS  ICIS 
EC_urine_STD_4_INJ_3
NL: 2.88E4
m/z= 160.1118-160.1134 F: 
FTMS + c ESI Full ms2 
178.12@cid35.00 
[50.00-200.00]  MS  ICIS 
EC_urine_STD_4_INJ_3
NL: 6.47E4
m/z= 163.1301-163.1317 F: 
FTMS + c ESI Full ms2 
181.14@cid35.00 
[50.00-250.00]  MS  ICIS 
EC_urine_STD_4_INJ_3
RT: 5.26 - 41.92













































m/z= 146.0961-146.0975 F: 
FTMS + c ESI Full ms2 
164.11@cid35.00 
[50.00-200.00]  MS  ICIS 
EC_urine_STD_4_INJ_3
NL: 2.88E4
m/z= 160.1118-160.1134 F: 
FTMS + c ESI Full ms2 
178.12@cid35.00 
[50.00-200.00]  MS  ICIS 
EC_urine_STD_4_INJ_3
NL: 6.47E4
m/z= 163.1301-163.1317 F: 
FTMS + c ESI Full ms2 
181.14@cid35.00 







Figure S8 Mephedrone metabolites in rat urine sample identified with chiral LC-VP: nor-hydroxytolyl-mephedrone and its two enantiomers (note: the presence of another 
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Appendix 3  
The following supplementary data are contained in Appendix 3: 
Table S1 Selected analytes and their properties (MW molecular weight, Exp 
experimental, Pred predicted, a extracted from (Moffat, Osselton et al. 2004), b 
predicted using ACD/labs software (http://www.chemspider.com). 
Table S2 MRM transitions selected for studied analytes. 
Table S3 Validation parameters - retention time, relative retention time, linearity 
range, correlation coefficient obtained from calibration curve and instrumental and 
method limits of detection and instrumental and method limits of quantification. 
Table S4 Validation parameters - method precision. 
Table S5 Validation parameters -instrumental precision. 
Table S6 Validation parameters –ion suppression. 
Table S7 SPE recovery for the studied analytes. 
Table S8 Amphetamine loads. 
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Table S9 Methamphetamine loads. 
Table S10 MDMA loads. 
Table S11 MDA loads. 
Table S12 HMA loads. 
Table S13 HMMA loads. 
Table S14 Mephedrone loads. 
Table S15 Norephedrine loads. 
Table S16 Ephedrines loads. 
Table S17 Venlafaxine loads. 
Table S18 Desmethylvenlafaxine loads. 





Table S1 Selected analytes and their properties (MW molecular weight, Exp experimental, Pred predicted, a extracted from (Moffat, Osselton et al. 2004), b predicted using 
ACD/labs software (http://www.chemspider.com). 
Compound CAS Formula MW pKa  LogP LogDb  Supplier 
        Exp.a Pred.a Exp.a Pred.b 
pH 
5.5 
pH 7.4  
(±)-Amphetamine 300-62-9 C9H13N 135.2 
10.1 
(20°) 
10.01 1.85 1.81±0.20 -1.28 -0.63 
LGC(Cerilliant 
product) 
(±)-Methamphetamine  4846-07-5 C10H15N 149.2 
9.87 
(25°) 
10.21 2.07 1.94±0.21 -1.15 -0.79 
LGC (Cerilliant 
product) 









4764-17-4 C10H13NO2 179.2 
9.67 
(25°) 






42542-10-9 C11H15NO2 193.2 - 10.143 
-
1.65,1.86 















438625-58-2 C11H17NO2 195.2 - - - 1.41 -1.68 -1.24 Kinesis  
(±)-cis-Tramadol 36282-47-0 C16H25NO2 263.4 9.41 
13.80, 
9.23 
2.4 2.51±0.28 -0.53 0.49 Sigma-Aldrich 
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(±)-Fluoxetine 59333-67-4 C17H18F3NO 309.3 - 9.80 4.05 4.09±0.45 1.00 1.57 
LGC (Cerilliant 
product) 
(±)-Norfluoxetine - C16H16F3NO 295.3 - 9.77 - 4.36±0.42 1.39 2.71 
LGC (Cerilliant 
product) 
(±)-Venlafaxine 99300-78-4 C17H27NO2 277.4 - 
14.42, 
8.91 
- 2.91±0.35 -0.08 1.19 Sigma-Aldrich 
(±)-Desvenlafaxine 300827-87-6 C16H25NO2 263.0 - 
10.11, 
8.87 
- 2.26±0.34 -0.73 0.52 Sigma-Aldrich 
(±)-Zopiclone 43200-80-2 C17H17ClN6O6 388.8 - 
13.04, 
6.89 
0.80 -0.33±1.28 -1.55 -0.41 LGC 
(±)-Ephedrine 50-98-6 C10H15NO 165.2 10.3 (0°) 
13.89, 
9.52 
1.13 1.05±0.27 -1.99 -0.96 Sigma-Aldrich 
























ratio ± SD 
MRM1/MRM3 
ratio ± SD 
IS 
Amphetamine   18/16 136.16 > 91.1 18/8 136.16 > 119.1 - - 1.2 ± 0.1 - Amphetamine-D5 
Methamphetamine  24/19 150.2 > 91.1 24/10 150.2 > 119.1 - - 1.8 ± 0.1 - Methamphetamine-D5 
MDA  21/11 180.0 > 163.1 21/22 180.0 > 105.1 - - 2.6 ± 0.4 - MDA-D5 
MDMA 24/13 194.1 > 163.1 24/24 194.1 > 105.1 - - 2.1 ± 0.1 - MDMA-D5 
MDEA 28/13 208.1 > 163.1 28/27 208.1 > 105.1 - - 2.1 ± 0.2 - MDEA-D5 
HMA 6/14 182.1 > 165.0 6/24 182.1 > 105.0 6/18 182.1 > 133.0 1.8 ± 0.7 2.4 ±1.4 Amphetamine-D5 
HMMA 16/12 196.1 > 165.0 16/26 196.1 > 105.0 16/22 196.1 > 133.0 3.1 ± 0.6 3.8 ±0.6 Methamphetamine-D5 




20/20 166.0 > 121.0 20/20 166.0 > 149.0 - - 12.5 ± 1.5 - MDA-D5 
Tramadol 24/17 264.2 > 58.1 24/11 264.2 > 246.3 - - 102.1 ± 3.6 - Methamphetamine-D5 
Zopiclone 22/18 389.1 > 245.0 22/42 389.1 > 217.0 - -   Zopiclone-D4 
Fluoxetine 25/8 310.3 > 148.1 - - - - - - MDMA-D5 
Norfluoxetine 17/7 296.2 > 134.1 - - - - - - MDMA-D5 
Venlafaxine 27/12 278.2 > 58.1 27/12 278.2 > 260.1 27/32 278.2 > 121.0 2.7 ± 0.2 4.5 ±0.7 Methamphetamine-D5 
Desmethylvenlafaxine 25/24 264.0 > 58.1 25/24 264.0 > 107.1 25/20 264.0 > 246.3 12.7 ± 1.8 66.4 ±5.9 Methamphetamine-D5 
Ephedrine  23/12 166.1 > 148.1 23/21 166.1 > 133.0 - - 7.4 ± 0.8 - 1S, 2R-(+)-ephedrine-
D3 
Pseudoephedrine 23/12 166.1 > 148.1 23/21 166.1 > 133.0 - - 6.9 ± 0.6 - 1S, 2R-(+)-ephedrine-
D3 
Norephedrine 23/10 152.1 > 134.1 23/16 152.1 > 117.1 - - 3.1 ± 0.4 - 1S, 2R-(+)-ephedrine-
D3 
ISs CV/CEa MRM1 
(quantification) 
Amphetamine-D5 22/16 141.0 > 92.9 
Methamphetamine-D5 28/12 155.1 > 121.0 
Mephedrone-D3 30/22 181.1 > 163.1 
MDA-D5 21/11 185.1 > 168.1 
MDMA-D5 26/13 199.1 > 165.1 
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MDEA-D5 28/13 213.1 > 163.0 
Zopiclone-D4 24/16 393.1 > 245.0 
1S,2R-(+)-Ephedrine-
D3 
23/18 169.2 > 151.0 
aCV, cone voltage (V); CE, collision energy (eV) 
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Table S3 Validation parameters - retention time, relative retention time, linearity range, correlation coefficient obtained from calibration curve and instrumental and method 
limits of detection and instrumental and method limits of quantification. 
Compound Rt 
(min) 
Rel. Rt Sample diluent WWTP influent 
Linearity 
range (µg/L) 
R2 IDLS/N (µg/L) IQLS/N (µg/L) MDL (µg/L) MQL (µg/L) 
R-(-)-Amphetamine 15.5 ±0.3 0.1 0.125-500 0.9987 0.12 0.50 0.0008 0.0029 
S-(+)-Amphetamine 22.6 ±0.4 0.2 0.125-500 0.9988 0.12 0.50 0.0008 0.0029 
R-(-)-Methamphetamine 14.5 ±0.4 0.3 0.050-500 0.9989 0.05 0.12 0.0003 0.0006 
S-(+)-Methamphetamine 16.5 ±0.4 0.3 0.050-500 0.9994 0.05 0.12 0.0003 0.0007 
E1-Mephedrone 16.5 ±0.4 0.3 0.250-500 0.9990 0.25 0.50 0.0013 0.0026 
E2-Mephedrone 21.0 ±0.5 0.2 0.250-500 0.9993 0.25 0.50 0.0007 0.0026 
R-(-)-MDA 28.1 ±0.5 0.2 0.500-500 0.9991 0.50 2.50 0.0028 0.0140 
S-(+)-MDA 47.4 ±0.8 0.4 0.500-500 0.9980 0.50 2.50 0.0025 0.0124 
R-(-)-MDMA 21.9 ±0.5 0.2 0.050-500 0.9992 0.05 0.25 0.0003 0.0014 
S-(+)-MDMA 32.9 ±0.5 0.1 0.050-500 0.9994 0.05 0.25 0.0003 0.0013 
E1-MDEA 19.0 ±0.5 1.8 0.125-500 0.9994 0.12 0.25 0.0006 0.0013 
E2-MDEA 21.0 ±0.5 0.2 0.125-500 0.9995 0.12 0.25 0.0007 0.0013 
E1-HMA 17.7 ±0.4 0.4 2.500-500 0.9900 2.50 5.00 0.0118 0.0236 
E2-HMA 34.3 ±0.5 0.8 2.500-500 0.9903 2.50 5.00 0.0113 0.0225 
E1-HMMA 15.9 ±0.4 2.5 0.250-500 0.9982 0.25 0.50 0.0014 0.0028 
E2-HMMA 18.6 ±0.5 2.5 0.250-500 0.9974 0.25 0.50 0.0011 0.0022 
E1-Venlafaxine 12.5 ±0.5 0.6 0.125-500 0.9980 0.12 0.25 0.0007 0.0013 
E2-Venlafaxine 15.6 ±0.5 2.9 0.125-500 0.9971 0.12 0.25 0.0007 0.0013 
E1-Norephedrine 13.6 ±0.3 0.4 0.125-500 0.9981 0.12 0.25 0.0006 0.0011 
E2-Norephedrine 15.1 ±0.4 2.2 0.125-500 0.9983 0.12 0.25 0.0006 0.0012 
E1-PMA 21.3 ±0.5 0.5 0.125-500 0.9964 0.12 0.25 0.0007 0.0013 
E2-PMA 36. 8 ±0.4 1.4 0.125-500 0.9994 0.12 0.25 0.0006 0.0011 
D1-Tramadol 12.6 ±0.4 0.6 0.500-500 0.9985 0.50 1.00 0.0024 0.0047 
D2-Tramadol 13.7 ±0.5 0.7 0.500-500 0.9989 0.50 1.00 0.0029 0.0059 
(+)-Ephedrine 12.3 ±0.3 0.6 1.000-500 0.9974 1.00 5.00 0.0059 0.0295 
(-)-Ephedrine and (-)-
Ψephedrine 
13.4 ±0. 0.5 0.500-1000 0.9975 0.50 1.00 0.0024 0.0048 





15.8 ±0.4 0.7 5.000-500 0.9941 5.000 10.000 0.0249 0.0497 
Desmethylvenlafaxine-
E2 
17.2 ±0.4 0.6 5.000-500 0.9973 5.000 10.000 0.0275 0.0550 
E1-Zopiclone 32.7 ±0.3 4.6 10.000-500 0.9903 10.000 50.000 0.0285 0.3125 
E2-Zopiclone 59.8 ±0.4 5.2 10.000-500 0.9909 10.000 50.000 0.0326 0.3208 
S-(+)-Fluoxetine 43.2 ±1.8 3.1 10.000-500 0.9915 10.000 50.000 0.0533 0.2664 
R-(-)-Fluoxetine 57.2 ±2.1 3.3 10.000-500 0.9907 10.000 50.000 0.0517 0.2588 
E1-Norfluoxetine 81.3 ±6.0 14.4 10.000-500 0.9916 10.000 50.000 0.0589 0.2945 





Table S4 Validation parameters - method precision. 

























D 1* D 2 D 3 D 1 D 2 D 3 D 1 D 2 D 3 
   
R-(-)-Amphetamine 3.3 2.5 4.6 5.2 14.7 10.8 6.2 3.9 6.2 3.5 10.2 5.4 
S-(+)-Amphetamine 3.1 4.3 12.6 1.4 6.5 4.7 3.8 7.0 7.3 6.7 4.2 6.0 
R-(-)-Methamphetamine 8.9 6.7 9.3 3.4 7.0 8.3 4.8 5.2 5.4 8.3 6.2 5.1 
S-(+)-Methamphetamine 6.8 3.6 15.4 1.2 5.5 4.0 2.7 2.9 4.2 8.6 3.6 3.3 
E1-Mephedrone 9.8 13.7 14.1 3.6 6.8 14.6 3.7 10.0 5.6 12.5 8.3 6.4 
E2-Mephedrone 10.7 12.0 4.6 5.2 12.9 8.4 9.2 3.7 2.8 9.1 8.8 5.2 
R-(-)-MDA 1.7 6.6 9.7 3.0 3.4 5.7 0.1 7.7 1.1 6.0 4.0 3.0 
S-(+)-MDA 4.4 3.8 7.8 2.6 6.7 5.3 7.2 3.7 4.5 5.3 4.9 5.1 
R-(-)-MDMA 7.0 1.8 4.0 5.8 4.6 3.9 3.4 1.5 6.5 4.3 4.8 3.8 
S-(+)-MDMA 1.0 1.9 6.9 0.6 3.1 2.9 1.2 2.8 0.7 3.3 2.2 1.6 
E1-MDEA 6.9 6.2 3.0 5.1 8.5 7.8 4.7 2.2 4.3 5.4 7.1 3.7 
E2-MDEA 6.0 6.3 2.8 1.4 9.2 4.9 8.3 1.4 1.7 5.0 5.2 3.8 
E1-HMA 4.4 5.1 1.6 7.6 1.1 4.4 6.4 6.0 5.9 3.7 4.4 6.1 
E2-HMA 5.2 4.8 12.6 3.8 2.0 5.0 7.0 6.5 6.0 7.5 3.6 6.5 
E1-HMMA 7.4 7.6 7.5 2.8 3.8 6.0 4.1 2.7 0.3 7.5 4.2 2.4 
E2-HMMA 4.7 6.4 3.6 2.1 2.1 6.2 2.9 3.1 3.6 4.9 3.5 3.2 
E1-Venlafaxine 9.1 1.5 5.7 5.5 5.2 7.5 5.3 7.1 5.6 5.4 6.1 6.0 
E2-Venlafaxine 0.0 4.8 3.1 4.9 1.4 7.6 1.5 4.0 5.2 2.6 4.6 3.6 
E1-Norephedrine 7.3 3.8 1.3 2.8 3.0 7.3 4.4 3.0 7.4 4.1 4.3 5.0 
E2-Norephedrine 5.7 4.6 6.3 3.1 3.9 6.1 2.2 2.1 3.5 5.5 4.3 2.6 
E1-PMA 7.7 4.8 8.3 1.4 4.4 3.7 3.8 4.3 5.3 6.9 3.2 4.5 
E2-PMA 6.2 8.8 11.6 7.8 4.6 6.6 1.7 3.9 2.9 8.9 6.3 2.8 
D1-Tramadol 4.9 7.0 6.6 6.1 5.7 3.9 6.5 1.7 0.5 6.2 5.3 2.9 
D2-Tramadol 6.2 9.7 6.1 4.2 3.2 4.0 2.5 3.7 2.5 7.3 3.8 2.9 
(+)-Ephedrine 5.3 16.5 9.8 5.0 4.5 6.6 7.2 2.8 3.3 10.5 5.4 4.4 
(-)-Ephedrine and (-)-
Ψephedrine 
8.3 14.8 5.2 1.8 0.8 5.4 5.7 1.0 3.3 9.4 2.7 3.3 
(+)-Ψephedrine 2.8 2.5 6.2 5.8 1.3 9.4 2.9 2.0 1.7 3.8 5.5 2.2 
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Desmethylvenlafaxine-E1 8.7 7.4 2.3 8.4 3.7 9.5 2.7 5.0 3.7 6.2 7.2 3.8 
Desmethylvenlafaxine-E2 6.4 8.7 7.4 3.8 2.8 5.3 2.3 4.9 8.2 7.5 4.0 5.1 
E1-Zopiclone 20.0 17.8 19.5 14.5 13.2 19.2 12.6 7.9 5.6 19.1 15.6 8.7 
E2-Zopiclone 18.7 18.2 20.4 17.6 14.8 6.9 11.4 5.8 9.8 19.2 13.1 9.0 
S-(+)-Fluoxetine 19.3 14.2 1.1 12.9 18.2 14.0 3.5 5.4 2.9 11.5 15.0 4.0 
R-(-)-Fluoxetine 19.2 2.7 20.7 6.2 3.8 0.5 0.3 2.7 14.5 14.2 3.5 5.8 
E1-Norfluoxetine 17.6 15.1 9.7 6.6 3.8 9.6 2.5 7.9 13.5 14.1 6.7 8.0 
E2-Norfluoxetine 1.9 6.8 10.7 20.3 10.5 3.4 0.7 10.7 7.3 6.5 11.4 6.2 
*-D indicates day 
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Table S5 Validation parameters -instrumental precision. 
Analyte Intra-day RSD% (n=4) Inter-day RSD% (n=3)  
5 
µg/L** 






5 µg/L 50 µg/L 500 µg/L 
  D 1* D 2 D 3 D 1 D 2 D 3 D 1 D 2 D 3 
   
R-(-)-Amphetamine 4.8 5.8 3.0 2.3 3.1 0.1 3.9 4.7 3.1 4.5 1.9 3.9 
S-(+)-Amphetamine 3.7 5.3 6.5 4.6 3.3 4.3 3.2 4.1 3.4 5.2 4.1 3.6 
R-(-)-Methamphetamine 6.0 5.8 6.3 3.9 5.5 2.3 3.0 5.1 2.8 6.0 3.9 3.7 
S-(+)-Methamphetamine 2.4 2.3 7.7 2.7 0.7 2.1 1.1 4.8 3.4 4.1 1.8 3.1 
E1-Mephedrone 9.3 6.7 5.5 1.9 5.7 5.4 2.9 5.5 4.4 7.1 4.3 4.3 
E2-Mephedrone 3.5 6.7 1.1 3.6 2.5 2.7 9.3 4.3 2.2 3.8 3.0 5.2 
R-(-)-MDA 6.9 1.3 2.7 0.4 5.6 0.1 1.5 0.3 1.6 3.6 2.1 1.1 
S-(+)-MDA 5.7 3.2 6.4 8.0 8.9 3.1 0.3 1.1 6.1 5.1 6.7 2.5 
R-(-)-MDMA 2.5 5.5 2.0 1.8 6.4 3.9 4.8 3.7 6.1 3.3 4.0 4.9 
S-(+)-MDMA 3.5 1.1 4.3 0.5 1.8 1.3 2.5 1.5 2.7 3.0 1.2 2.3 
E1-MDEA 8.6 5.3 5.9 2.2 3.8 1.1 6.1 4.3 0.1 6.6 2.4 3.5 
E2-MDEA 3.6 2.3 10.3 5.3 1.1 0.4 5.6 1.9 0.7 5.4 2.3 2.7 
E1-HMA 11.3 5.6 6.3 5.3 6.7 9.1 7.4 4.9 2.1 7.7 7.1 4.8 
E2-HMA 6.1 1.7 1.1 3.1 0.4 2.5 8.9 6.3 9.0 3.0 2.0 8.1 
E1-HMMA 5.3 8.3 4.1 0.8 6.5 6.6 8.2 4.2 1.7 5.9 4.6 4.7 
E2-HMMA 6.6 5.7 9.4 2.4 3.3 7.4 3.8 4.0 4.6 7.2 4.4 4.1 
E1-Venlafaxine 7.1 3.1 7.4 3.4 2.0 0.8 0.4 1.4 0.9 5.9 2.1 0.9 
E2-Venlafaxine 6.1 2.4 0.0 1.9 2.9 3.6 0.5 1.4 0.9 2.8 2.8 0.9 
E1-Norephedrine 5.9 7.1 3.1 2.7 6.9 5.7 2.2 1.3 1.1 5.4 5.1 1.5 
E2-Norephedrine 5.4 3.1 4.4 2.4 4.7 3.6 3.4 5.2 2.1 4.3 3.6 3.6 
E1-PMA 2.7 8.4 5.6 1.2 8.6 6.1 2.6 0.3 0.4 5.6 5.3 1.1 
E2-PMA 4.6 5.4 4.5 4.6 3.9 2.6 3.1 1.6 1.1 4.9 3.7 1.9 
D1-Tramadol 11.2 7.1 5.6 3.4 4.1 3.6 5.1 0.9 2.5 8.0 3.7 2.8 
D2-Tramadol 2.4 6.8 10.7 13.8 12.4 7.1 2.2 10.0 1.1 6.7 11.1 4.4 
(+)-Ephedrine 6.9 3.5 6.5 4.3 5.7 3.2 6.3 1.0 3.4 5.6 4.4 3.6 
(-)-Ephedrine and (-)-
Ψephedrine 
2.6 2.7 4.1 3.6 3.1 2.3 6.4 0.7 4.4 3.1 3.0 3.8 
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(+)-Ψephedrine 10.6 6.2 5.6 5.9 0.5 2.4 3.4 9.1 3.2 7.4 2.9 5.3 
Desmethylvenlafaxine-E1 18.2 7.4 5.2 5.3 7.2 0.7 1.9 8.1 2.0 10.3 4.4 4.0 
Desmethylvenlafaxine-E2 5.4 4.5 4.0 5.7 12.5 6.4 2.8 2.0 3.9 4.7 8.2 2.9 
E1-Zopiclone 18.2 19.7 15.8 14.2 16.2 12.2 11.4 10.7 8.7 17.9 14.2 10.3 
E2-Zopiclone 17.9 19.3 16.7 12.6 18.6 18.0 14.6 13.8 8.5 17.9 16.4 12.3 
S-(+)-Fluoxetine 18.3 6.9 4.9 6.0 19.0 9.3 13.6 14.4 2.4 10.0 11.4 10.2 
R-(-)-Fluoxetine 16.5 15.9 10.2 13.0 1.3 16.9 1.7 9.3 2.4 14.2 10.4 4.5 
E1-Norfluoxetine 11.5 4.4 18.4 5.9 8.2 0.8 5.1 3.1 3.4 11.4 5.0 3.9 
E2-Norfluoxetine 10.2 14.3 16.6 15.5 9.8 13.8 17.6 8.0 0.5 13.7 13.1 8.7 
*-D indicates day 




Table S6 Validation parameters –ion suppression. 
Analyte Signal suppression (%) (n=4) 
R-(-)-Amphetamine 37.9 ± 9.7 
S-(+)-Amphetamine 53.4 ± 9.4 
R-(-)-Methamphetamine -28.5 ± 12.5 
S-(+)-Methamphetamine -6.4 ± 9.2 
E1-Mephedrone -22.3 ± 11.8 
E2-Mephedrone -40.2 ± 14.0 
R-(-)-MDA -15.3 ± 1.4 
S-(+)-MDA -12.5 ± 1.8 
R-(-)-MDMA -43.9 ± 7.4 
S-(+)-MDMA -57.5 ± 8.2 
E1-MDEA -33.9 ± 2.0 
E2-MDEA -58.1 ± 6.6 
E1-HMA -50.4 ± 6.2 
E2-HMA -68.7 ± 13.9 
E1-HMMA -81.5 ± 33.7 
E2-HMMA -76.7 ± 15.0 
E1-Venlafaxine -19.3 ± 4.8 
E2-Venlafaxine -12.1 ± 9.5 
E1-Norephedrine 63.4 ± 2.8 
E2-Norephedrine 21.5 ± 4.6 
E1-PMA -21.7 ± 7.9 
E2-PMA -38.8 ± 4.1 
D1-Tramadol 22.1 ± 1.5 
D2-Tramadol 8.8 ± 6.6 
(+)-Ephedrine -78.2 ± 4.6 
(-)-Ephedrine and (-)-Ψephedrine -72.3 ± 7.5 
(+)-Ψephedrine -76.7 ± 16.3 
Desmethylvenlafaxine-E1 -6.3 ± 2.0 
Desmethylvenlafaxine-E2 -31.1 ± 16.4 
E1-Zopiclone -33.2 ± 5.6 
E2-Zopiclone -41.0 ± 4.5 
S-(+)-Fluoxetine 1.5 ± 0.1 
R-(-)-Fluoxetine 3.2 ± 2.5 
E1-Norfluoxetine -4.3 ± 0.7 




Table S7 SPE recovery for the studied analytes. 
Analyte 
SPE relative recovery % (n=3) 
25 ng/L* 250 ng/L* 2500 ng/L* 
R-(-)-Amphetamine 101.0  ± 6.6 76.0  ± 1.6 82.0 ± 4.7 
S-(+)-Amphetamine 81.0  ± 10.6 99.0  ± 2.0 82.0 ± 4.2 
R-(-)-Methamphetamine 91.0 ± 4.4 113.0 ± 0.7 82.0 ± 5.0 
S-(+)-Methamphetamine 84.0 ± 1.9 86.0 ± 1.2 84.0 ± 7.1 
E1-Mephedrone 109.0 ± 3.2 99.0 ± 4.8 80.0 ± 7.0 
E2-Mephedrone 99.0 ± 8.5 99.0 ± 4.3 87.0 ± 11.5 
R-(-)-MDA 93.0 ± 6.2 94.0 ± 4.2 81.0 ± 1.0 
S-(+)-MDA 110.0 ± 8.5 99.0 ± 1.5 91.0 ± 1.5 
R-(-)-MDMA 91.0 ± 3.7 81.0 ± 7.8 89.0 ± 4.3 
S-(+)-MDMA 93.0 ± 1.7 100.0 ± 0.7 84.0 ± 1.9 
E1-MDEA 102.0 ± 2.0 95.0 ± 8.6 91.0 ± 5.9 
E2-MDEA 99.0 ± 1.8 92.0 ± 1.9 93.0 ± 13.4 
E1-HMA 97.0 ± 8.7 114.0 ± 0.3 106.0 ± 16.4 
E2-HMA 106.0 ± 4.6 107.0 ± 2.9 120.0 ± 11.5 
E1-HMMA 84.0 ± 8.8 85.0 ± 9.4 100.0 ± 3.3 
E2-HMMA 108.0 ± 7.5 105.0 ± 2.4 118.0 ± 1.7 
E1-Venlafaxine 83.0 ± 0.6 105.0 ± 6.3 91.0 ± 0.4 
E2-Venlafaxine 91.0 ± 5.8 104.0 ± 5.4 90.0 ± 0.7 
E1-Norephedrine 112.0 ± 2.8 117.0 ± 1.1 108.0 ± 1.5 
E2-Norephedrine 115.0 ± 5.9 95.0 ± 2.1 83.0 ± 1.4 
E1-PMA 110.0 ± 8.5 94.0 ± 2.4 80.0 ± 0.7 
E2-PMA 113.0 ± 3.5 118.0 ± 5.9 91.0 ± 0.4 
D1-Tramadol 109.0 ± 6.0 111.0 ± 7.2 96.0 ± 10.0 
D2-Tramadol 90.0 ± 7.8 81.0 ± 2.7 80.0 ± 1.1 
(+)-Ephedrine 81.0 ± 9.0 82.0 ± 2.6 91.0 ± 2.1 
(-)-Ephedrine and (-)-
Ψephedrine 112.0 ± 0.6 87.0 ± 2.5 113.0 ± 9.6 
(+)-Ψephedrine 104.0 ± 10.6 83.0 ± 0.3 81.0 ± 1.0 
Desmethylvenlafaxine-
E1 91.0 ± 9.8 
113.0 ± 
14.2 98.0 ± 6.5 
Desmethylvenlafaxine-
E2 82.0 ± 1.1 92.0 ± 4.1 99.0 ± 10.7 
E1-Zopiclone 80.0 ± 2.0 82.0 ± 0.7 81.0 ± 3.7 
E2-Zopiclone 80.0 ± 1.2 80.0 ± 6.7 83.0 ± 4.6 
S-(+)-Fluoxetine 100.0 ± 5.5 81.0 ± 3.8 100.0 ± 0.7 
R-(-)-Fluoxetine 97.0 ± 16.6 91.0 ± 5.5 101.0 ± 7.1 
E1-Norfluoxetine 87.0 ± 1.7 80.0 ± 4.6 87.0 ± 5.3 




Table S8 Amphetamine loads. 
R-(+)-Amphetamine 

















































































































Mon 46.2 152.5 70.6 233.0 1.1 3.6 8.8 29.1 - - 39.6 130.7 14.3 47.3 40.5 133.6 
Tue
s 
48.1 158.7 56.4 186.0 - - 30.6 100.9 - - 29.4 97.0 12.7 41.8 41.4 136.7 
Wed 45.3 149.6 76.3 251.7 - - 27.4 90.4 - - 27.6 91.2 13.3 44.0 39.3 129.8 
Thu
r 
42.4 140.0 75.0 247.6 0.7 2.5 16.5 54.3 - - 29.3 96.6 13.2 43.7 46.8 154.3 
Fri 46.6 153.8 76.3 251.9 - - 22.1 73.1 - - 33.8 111.4 14.7 48.6 45.8 151.1 
Sat 50.4 166.3 76.4 252.3 - - 26.6 87.8 - - 36.5 120.5 15.8 52.0 46.4 153.3 
Sun 44.6 147.0 46.8 154.4 1.0 3.2 7.9 25.9 - - 44.1 145.4 19.9 65.5 46.7 154.0 
AV 46.2 152.6 68.3 225.3 0.9 3.1 20.0 65.9 - - 34.3 113.3 14.8 49.0 43.8 144.7 
SD 2.5 8.4 11.9 39.3 0.2 0.6 9.1 30.1 - - 6.1 20.1 2.4 8.1 3.3 10.8 
CV 0.06 0.06 0.17 0.17 0.18 0.18 0.46 0.46 - - 0.18 0.18 0.16 0.16 0.07 0.07 
S-(+)-Amphetamine 



















































































































Mon 34.1 112.5 60.7 200.4 3.5 11.7 7.4 24.4 - - 27.6 91.0 16.5 54.3 32.5 107.2 
Tue 39.3 129.8 32.2 106.3 - - 24.5 81.0 - - 20.5 67.6 12.7 42.0 33.1 109.4 
Wed 38.3 126.2 60.7 200.3 - - 22.0 72.8 - - 19.5 64.3 12.8 42.4 28.4 93.7 
Thu
r 
32.7 108.1 54.0 178.1 1.1 3.7 13.7 45.2 - - 20.1 66.5 12.6 41.7 34.7 114.5 
Fri 39.2 129.3 60.3 199.1 - - 18.3 60.5 - - 22.3 73.6 9.1 29.9 31.8 104.9 
Sat 39.2 129.4 65.7 216.9 - - 22.4 73.9 - - 25.8 85.0 17.5 57.6 33.7 111.2 
Sun 32.0 105.7 44.6 147.3 1.2 3.8 6.7 22.2 - - 31.9 105.3 19.7 64.9 34.5 113.9 
AV 36.4 120.1 54.0 178.3 1.9 6.4 16.5 54.3 - - 24.0 79.0 14.4 47.5 32.7 107.8 
SD 3.3 10.9 11.8 38.8 1.4 4.6 7.3 24.1 - - 4.6 15.3 3.6 11.9 2.2 7.1 
CV 0.09 0.09 0.22 0.22 0.71 0.71 0.44 0.44 - - 0.19 0.19 0.25 0.25 0.07 0.07 
(±)-Amphetamine 

















































































































Mon 80.3 265.0 131.3 433.3 4.6 15.2 16.2 53.6 - - 67.2 221.8 30.8 101.7 73.0 240.9 
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Tue 87.4 288.5 88.6 292.3 - - 55.1 181.9 - - 49.9 164.5 25.4 83.8 74.6 246.0 
Wed 83.6 275.8 137.0 452.0 - - 49.4 163.1 - - 47.1 155.5 26.2 86.4 67.7 223.4 
Thur 75.2 248.1 129.0 425.8 1.9 6.2 30.2 99.5 - - 49.4 163.1 25.9 85.4 81.4 268.8 
Fri 85.8 283.1 136.7 451.0 - - 40.5 133.6 - - 56.1 185.1 23.8 78.5 77.6 256.0 
Sat 89.6 295.7 142.2 469.2 - - 49.0 161.8 - - 62.3 205.5 33.2 109.6 80.1 264.4 
Sun 76.6 252.7 91.4 301.7 2.1 7.0 14.6 48.1 - - 76.0 250.7 39.5 130.5 81.2 267.9 
AV 82.6 272.7 122.3 403.6 2.9 9.5 36.4 120.2 - - 58.3 192.3 29.3 96.5 76.5 252.5 
SD 5.5 18.1 22.5 74.2 1.5 5.0 16.4 54.2 - - 10.7 35.3 5.6 18.6 5.1 16.7 




Table S9 Methamphetamine loads. 
R-(+)-Methamphetamine 

















































































































Mon 0.4 1.0 172.3 396.2 0.0 0.0 - - - - - - - - - - 
Tue 0.7 1.6 113.0 259.8 0.7 1.6 - - - - - - - - - - 
Wed 0.8 1.8 61.4 141.3 0.9 2.0 - - - - - - - - - - 
Thu
r 
0.7 1.5 91.9 211.3 1.4 3.2 - - - - - - - - - - 
Fri 0.0 0.0 60.4 139.0 0.0 0.0 - - - - - - - - - - 
Sat 2.1 4.9 96.1 220.9 0.0 0.0 - - - - - - - - - - 
Sun 0.8 1.8 56.1 129.1 0.0 0.0 - - - - - - - - - - 
AV 0.8 1.8 93.0 214.0 0.4 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SD 0.6 1.5 41.0 94.4 0.6 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
CV 0.83 0.83 0.44 0.44 1.34 1.34 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
S-(+)-Methamphetamine 



















































































































Mon 0.4 1.0 146.3 336.4 8.6 19.9 - - - - 4.0 9.2 21.6 49.6 7.7 17.8 
Tue 0.3 0.8 94.7 217.7 11.9 27.3 - - - - 3.1 7.2 18.1 41.6 6.4 14.7 
Wed 0.4 1.0 53.1 122.2 8.7 20.0 - - - - 3.9 8.9 18.0 41.5 6.7 15.3 
Thu
r 
0.4 1.0 86.8 199.6 8.3 19.0 - - - - 3.3 7.7 15.8 36.4 5.1 11.7 
Fri 0.0 0.0 51.1 117.6 9.5 21.8 - - - - 3.9 9.1 18.3 42.2 5.5 12.7 
Sat 0.6 1.4 79.1 181.8 10.4 23.9 - - - - 3.8 8.7 23.0 52.8 8.1 18.7 
Sun 0.4 1.0 44.3 102.0 11.6 26.6 - - - - 3.6 8.3 26.5 60.9 6.6 15.3 
AV 0.4 0.9 79.3 182.5 9.8 22.6 0.0 0.0 0.0 0.0 3.7 8.4 20.2 46.4 6.6 15.2 
SD 0.2 0.4 35.3 81.2 1.5 3.4 0.0 0.0 0.0 0.0 0.3 0.7 3.7 8.4 1.1 2.5 
CV 0.49 0.49 0.44 0.44 0.15 0.15 0.0 0.0 0.0 0.0 0.09 0.09 0.18 0.18 0.17 0.17 
(±)-Methamphetamine 

















































































































Mon 0.9 2.0 318.5 732.6 8.6 19.9 - - - - 4.0 9.2 21.6 49.6 7.7 17.8 
Tue 1.0 2.4 207.6 477.5 12.6 28.9 - - - - 3.1 7.2 18.1 41.6 6.4 14.7 
Wed 1.2 2.8 114.6 263.5 9.5 22.0 - - - - 3.9 8.9 18.0 41.5 6.7 15.3 
Thu
r 
1.1 2.6 178.7 410.9 9.6 22.2 - - - - 3.3 7.7 15.8 36.4 5.1 11.7 
Fri 0.0 0.0 111.6 256.6 9.5 21.8 - - - - 3.9 9.1 18.3 42.2 5.5 12.7 
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Sat 2.7 6.3 175.1 402.8 10.4 23.9 - - - - 3.8 8.7 23.0 52.8 8.1 18.7 
Sun 1.2 2.8 100.5 231.1 11.6 26.6 - - - - 3.6 8.3 26.5 60.9 6.6 15.3 
AV 1.2 2.7 172.4 396.4 10.3 23.6 0.0 0.0 0.0 0.0 3.7 8.4 20.2 46.4 6.6 15.2 
SD 0.8 1.9 76.2 175.3 1.4 3.2 0.0 0.0 0.0 0.0 0.3 0.7 3.7 8.4 1.1 2.5 




Table S10 MDMA loads. 
R-(-)-MDMA 

















































































































Mon 36.3 54.5 40.3 60.5 4.9 7.3 29.0 43.5 2.3 3.4 19.1 28.6 41.5 62.2 22.4 33.6 
Tue 17.6 26.5 19.0 28.5 0.0 0.0 56.5 84.8 1.8 2.7 7.6 11.3 14.9 22.4 11.9 17.9 
Wed 14.1 21.2 14.1 21.2 1.8 2.7 34.2 51.3 0.0 0.0 6.3 9.5 7.7 11.5 7.2 10.8 
Thu
r 
9.9 14.9 22.7 34.0 0.7 1.1 11.2 16.8 0.0 0.0 5.6 8.5 5.5 8.2 7.6 11.5 
Fri 20.2 30.4 11.3 16.9 2.3 3.5 37.3 56.0 2.0 3.0 6.6 10.0 8.7 13.0 9.0 13.5 
Sat 66.0 98.9 26.8 40.2 7.8 11.7 54.3 81.4 1.5 2.3 15.6 23.4 27.8 41.7 31.1 46.7 
Sun 69.3 103.9 30.7 46.0 13.1 19.7 43.5 65.2 2.4 3.7 35.9 53.8 91.9 137.8 45.2 67.8 
AV 33.4 50.0 23.6 35.3 4.4 6.6 38.0 57.0 2.0 2.2 13.8 20.7 28.3 42.4 19.2 28.8 
SD 24.8 37.3 10.0 15.0 4.7 7.0 15.6 23.3 0.4 1.5 11.0 16.6 30.9 46.3 14.5 21.8 
CV 0.7 0.7 0.43 0.43 1.07 1.07 0.41 0.41 0.18 0.71 0.80 0.80 1.1 1.1 0.8 0.8 
S-(+)-MDMA 



















































































































Mon 14.4 21.6 29.0 43.5 2.4 3.6 15.6 23.4 1.0 1.6 8.5 12.8 16.0 24.0 10.4 15.5 
Tue 7.7 11.6 10.6 15.9 2.8 4.3 30.3 45.4 1.0 1.6 3.3 4.9 5.1 7.7 6.3 9.4 
Wed 8.8 13.1 10.6 15.9 1.2 1.8 17.1 25.6 0.0 0.0 3.3 5.0 2.7 4.0 4.4 6.7 
Thu
r 
6.3 9.5 7.6 11.3 0.7 1.1 8.2 12.3 0.0 0.0 3.2 4.8 3.1 4.7 4.9 7.4 
Fri 14.7 22.0 6.4 9.6 1.2 1.7 25.5 38.3 1.3 2.0 3.7 5.5 5.5 8.3 6.0 9.0 
Sat 45.8 68.7 19.0 28.5 4.3 6.4 36.9 55.4 1.0 1.5 10.2 15.2 16.6 24.9 25.4 38.1 
Sun 40.6 61.0 15.7 23.5 4.6 6.9 34.6 51.9 1.7 2.5 24.8 37.2 57.5 86.2 32.3 48.5 
AV 19.8 29.6 14.1 21.2 2.5 3.7 24.0 36.0 1.2 1.3 8.1 12.2 15.2 22.8 12.8 19.2 
SD 16.4 24.6 7.9 11.8 1.5 2.3 10.7 16.1 0.3 1.0 7.9 11.8 19.5 29.3 11.3 17.0 
CV 0.8 0.8 0.56 0.56 0.63 0.63 0.45 0.45 0.24 0.73 0.97 0.97 1.3 1.3 0.9 0.9 
(±)-MDMA 

















































































































Mon 50.7 76.0 69.3 103.9 7.3 10.9 44.5 66.8 3.3 5.0 27.6 41.4 57.5 86.2 32.8 49.2 
Tue 25.4 38.1 29.6 44.4 2.8 4.3 86.8 130.2 2.9 4.3 10.8 16.3 20.0 30.0 18.2 27.3 
Wed 22.9 34.3 24.7 37.0 3.0 4.6 51.3 76.9 0.0 0.0 9.7 14.5 10.3 15.5 11.6 17.5 
Thu
r 
16.3 24.4 30.3 45.4 1.4 2.1 19.4 29.1 0.0 0.0 8.8 13.2 8.6 13.0 12.5 18.8 
Fri 34.9 52.4 17.7 26.5 3.5 5.2 62.9 94.3 3.3 4.9 10.3 15.5 14.2 21.3 15.0 22.6 
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Sat 111.8 167.6 45.8 68.7 12.0 18.1 91.2 136.8 2.5 3.8 25.7 38.6 44.4 66.6 56.6 84.9 
Sun 109.9 164.9 46.4 69.5 17.7 26.6 78.1 117.1 4.1 6.2 60.7 91.0 149.4 224.0 77.5 116.3 
AV 53.1 79.7 37.7 56.5 6.8 10.3 62.0 93.0 3.2 3.5 21.9 32.9 43.5 65.2 32.0 48.1 
SD 40.9 61.4 17.5 26.2 6.0 9.0 25.7 38.5 0.6 2.5 18.8 28.3 50.2 75.3 25.7 38.5 




Table S11 MDA loads. 
R-(-)-MDA 
  POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
  UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 1.5 0.9 - 1.7 - - - - 
Tuesday 1.0 - - 1.8 - - - - 
Wednesday - - - 1.4 - - - - 
Thursday - - - 0.8 - - - 0.6 
Friday 0.6 - - 0.8 - - - - 
Saturday 1.0 - - 1.3 - - - - 
Sunday 2.1 - - 1.7 - - - - 
AV 0.9 0.1 0.0 1.4 0.0 0.0 0.0 0.0 
SD 0.8 0.3 0.0 0.4 0.0 0.0 0.0 0.0 
CV 0.9 2.6 0.0 0.3 0.0 0.0 0.0 0.0 
S-(+)-MDA 
  POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
  UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 1.6 - - 2.4 - - - - 
Tuesday - - - 2.1 - - - - 
Wednesday - - - 0.6 - - - - 
Thursday - - - 0.8 - - - 0.3 
Friday - - - 1.3 - 1.1 - - 
Saturday 3.2 0.4 - 1.9 - - - - 
Sunday 2.5 2.2 - 3.9 - - - - 
AV 1.1 0.4 0.0 1.9 0.0 0.0 0.0 0.0 
SD 1.4 0.8 0.0 1.1 0.0 0.0 0.0 0.0 
CV 1.3 2.2 0.0 0.6 0.0 0.0 0.0 0.0 
(±)-MDA 
 
POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
 
UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 3.2 0.9 - 4.1 - - - - 
Tuesday 1.0 - - 4.0 - - - - 
Wednesday - - - 1.9 - - - - 
Thursday - - - 1.6 - - - 0.9 
Friday 0.6 - - 2.1 - 1.1 - - 
Saturday 4.2 0.4 - 3.2 - - - - 
Sunday 4.7 2.2 - 5.7 - - - - 
AV 1.9 0.5 0.0 3.2 0.0 0.0 0.0 0.0 
SD 2.0 0.8 0.0 1.5 0.0 0.0 0.0 0.0 




Table S12 HMA loads. 
E1-HMA 
  POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
  UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 17.6 - - - - - - - 
Tuesday - - - - - - - - 
Wednesday - - - - - - - - 
Thursday - - - - - - - - 
Friday - - - - - - - - 
Saturday - - - 6.0 - - - - 
Sunday 15.3 - - - - - - - 
AV 4.7 0.1 0.0 0.9 0.0 0.0 0.0 0.0 
SD 8.0 0.3 0.0 2.3 0.0 0.0 0.0 0.0 
CV 1.7 2.6 0.0 2.6 0.0 0.0 0.0 0.0 
E2-HMA 
 
POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
 
UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday - - - 6.4 - - - - 
Tuesday - - - - - - - - 
Wednesday - - - - - - - - 
Thursday - - - - - - - - 
Friday - - - - - - - - 
Saturday - - - 5.7 - - - - 
Sunday 18.7 - - 5.9 - - - - 
AV 2.7 0.1 0.0 2.6 0.0 0.0 0.0 0.0 
SD 7.1 0.2 0.0 3.2 0.0 0.0 0.0 0.0 
CV 2.6 1.8 0.0 1.3 0.0 0.0 0.0 0.0 
(±)-HMA 
 
POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
 
UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 17.6 - - 6.4 - - - - 
Tuesday - - - - - - - - 
Wednesday - - - - - - - - 
Thursday - - - - - - - - 
Friday - - - - - - - - 
Saturday - - - 11.7 - - - - 
Sunday 34.0 - - 5.9 - - - - 
AV 7.4 0.2 0.0 3.4 0.0 0.0 0.0 0.0 
SD 13.4 0.3 0.0 4.7 0.0 0.0 0.0 0.0 




Table S13 HMMA loads. 
E1-HMMA 
 
POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
 
UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 8.5 - - - 3.8 9.1 8.2 5.3 
Tuesday 8.6 - - - 8.2 6.5 - - 
Wednesday 8.3 - - 6.0 - 4.2 - - 
Thursday - - - 5.8 - 4.5 - 5.0 
Friday 10.5 - - 7.0 - 9.0 - 4.2 
Saturday 9.6 - - 6.4 - 9.2 9.0 4.9 
Sunday 8.5 - - 6.4 3.8 9.3 11.2 4.9 
AV 7.7 0.1 0.0 4.5 2.3 7.4 4.1 3.5 
SD 3.5 0.3 0.0 3.1 3.2 2.3 5.1 2.4 
CV 0.5 2.6 0.0 0.7 1.4 0.3 1.3 0.7 
E2-HMMA 
 
POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
 
UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 13.0 - - 9.3 12.0 7.1 6.3 8.1 
Tuesday - - - 8.9 12.9 5.4 - - 
Wednesday - - - 9.3 - 1.9 - - 
Thursday - - - 8.7 - 7.1 - - 
Friday 13.5 - - 9.6 - 14.2 - 7.9 
Saturday 14.8 - - 9.1 - 14.3 14.2 7.6 
Sunday 13.0 - - 9.8 11.9 14.2 17.5 7.6 
AV 7.8 0.1 0.0 9.2 5.3 9.2 5.4 4.4 
SD 7.3 0.2 0.0 0.4 6.6 5.0 7.5 4.2 
CV 0.9 1.8 0.0 0.0 1.2 0.5 1.4 0.9 
(±)-HMMA 
 
POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
 
UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 21.4 - - 9.3 15.8 16.3 14.5 13.4 
Tuesday 8.6 - - 8.9 21.1 12.0 - - 
Wednesday 8.3 - - 15.4 - 6.1 - - 
Thursday - - - 14.5 - 11.6 - 5.0 
Friday 24.0 - - 16.6 - 23.2 - 12.1 
Saturday 24.4 - - 15.5 - 23.5 23.2 12.5 
Sunday 21.5 - - 16.1 15.7 23.5 28.7 12.5 
AV 15.5 0.2 0.0 13.8 7.5 16.6 9.5 7.9 
SD 9.7 0.3 0.0 3.2 9.5 7.0 12.5 6.1 




Table S14 Mephedrone loads. 
R-(+)-Mephedrone 
  POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
  UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 14.9 - - - - - - - 
Tuesday 8.5 - - - - - - - 
Wednesday 8.5 - - - - - - - 
Thursday 8.2 - - - - - - - 
Friday 12.7 - - - - - - - 
Saturday 26.3 - - - - - - - 
Sunday 19.6 - - - - - - - 
AV 14.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SD 6.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
CV 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
S-(-)-Mephedrone 
  POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
  UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 16.1 - - - - - - - 
Tuesday 6.3 - - - - - - - 
Wednesday 8.5 - - - - - - - 
Thursday 7.4 - - - - - - - 
Friday 8.1 - - - - - - - 
Saturday 21.4 - - - - - - - 
Sunday 12.5 - - - - - - - 
AV 11.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SD 5.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
CV 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
(±)-Mephedrone 
  POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
  UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 31.1 - - - - - - - 
Tuesday 14.9 - - - - - - - 
Wednesday 17.1 - - - - - - - 
Thursday 15.6 - - - - - - - 
Friday 20.8 - - - - - - - 
Saturday 47.7 - - - - - - - 
Sunday 32.1 - - - - - - - 
AV 25.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SD 12.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 




Table S15 Norephedrine loads. 
E1-Norephedrine 
 
POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
 
UK Norway Italy Netherlands 
Monday - 25.0 2.7 - 
Tuesday - 23.1 4.6 -- 
Wednesday - 37.3 3.7 -- 
Thursday - 27.6 3.0 -- 
Friday - 18.6 2.6 -- 
Saturday - 22.6 4.4 -- 
Sunday - 22.9 2.3 -- 
AV 0.0 25.3 3.3 0.0 
SD 0.0 6.0 0.9 0.0 
CV 0.0 0.2 0.3 0.0 
E2-Norephedrine 
  POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
  UK Norway Italy Netherlands 
Monday - 30.3 3.8 - 
Tuesday - 18.3 2.3 - 
Wednesday 7.4 33.9 4.0 - 
Thursday 2.5 24.4 4.1 - 
Friday 5.1 21.0 5.1 - 
Saturday 5.3 26.1 4.0 - 
Sunday 3.6 25.9 3.1 - 
AV 3.4 25.7 3.8 0.0 
SD 2.8 5.3 0.9 0.0 
CV 0.8 0.2 0.2 0.0 
(±)-Norephedrine 
  POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
  UK Norway Italy Netherlands 
Monday - 55.2 6.5 - 
Tuesday - 41.3 6.9 - 
Wednesday 7.4 71.2 7.7 - 
Thursday 2.5 52.0 7.1 - 
Friday 5.1 39.7 7.7 - 
Saturday 5.3 48.6 8.4 - 
Sunday 3.6 48.7 5.4 - 
AV 3.4 51.0 7.1 0.0 
SD 2.8 10.5 1.0 0.0 




Table S16 Ephedrines loads. 
1R,2S-(-)-Ephedrine 
 
POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
 
UK Norway Italy 
Monday - 0.4 0.5 
Tuesday 1.8 - 3.8 
Wednesday 0.3 - 0.7 
Thursday - 1.6 4.5 
Friday 0.4 1.4 - 
Saturday 1.2 0.0 14.3 
Sunday - 1.3 - 
AV 0.6 0.7 3.4 
SD 0.7 0.7 5.1 
CV 1.3 1.1 1.5 
1S,2S-(+)-Pseudoephedrine 
 
POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
 
UK Norway Italy 
Monday 126.7 21.9 36.4 
Tuesday 81.2 20.9 39.6 
Wednesday 98.4 24.1 36.7 
Thursday 55.7 20.7 43.5 
Friday 134.1 24.8 30.4 
Saturday 89.2 18.6 30.4 
Sunday 89.4 17.2 33.0 
AV 96.4 21.2 35.7 
SD 26.9 2.7 4.8 




Table S17 Venlafaxine loads. 
E1-Venlafaxine 
 
POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
 
UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 21.7 25.0 11.9 22.8 45.6 97.7 57.0 46.2 
Tuesday 19.6 31.8 13.5 25.0 47.7 113.9 48.3 53.7 
Wednesday 20.1 26.4 12.5 28.2 30.9 47.9 52.9 45.5 
Thursday 20.6 21.8 11.6 30.3 70.5 117.2 54.6 49.4 
Friday 17.4 21.0 18.6 28.6 50.3 127.5 57.1 52.5 
Saturday 19.7 37.6 13.9 24.1 41.1 127.5 56.1 54.8 
Sunday 17.4 27.2 15.4 26.0 48.2 106.0 55.1 42.9 
AV 19.5 27.2 13.9 26.4 47.8 105.4 54.4 49.3 
SD 1.6 5.8 2.4 2.7 12.0 27.6 3.1 4.6 
CV 0.1 0.2 0.2 0.1 0.3 0.3 0.1 0.1 
E2-Venlafaxine 
 
POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
 
UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 23.9 26.7 14.7 25.3 41.5 88.6 54.9 49.0 
Tuesday 22.8 36.6 13.1 25.3 41.0 106.4 47.9 49.2 
Wednesday 22.3 36.2 14.7 28.3 28.1 52.3 50.2 43.8 
Thursday 19.4 25.5 11.6 37.5 64.5 116.5 54.2 48.6 
Friday 21.5 26.3 15.0 28.6 44.0 124.1 57.5 55.0 
Saturday 22.6 39.4 16.1 25.8 36.0 121.9 53.7 58.4 
Sunday 20.8 29.3 12.7 27.2 42.5 96.1 56.3 48.1 
AV 21.9 31.4 14.0 28.3 42.5 100.8 53.5 50.3 
SD 1.5 5.8 1.6 4.3 11.1 25.1 3.4 4.8 
CV 0.1 0.2 0.1 0.2 0.3 0.2 0.1 0.1 
(±)-Venlafaxine 
 
POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
 
UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 45.7 51.7 26.6 48.1 87.1 186.3 111.9 95.2 
Tuesday 42.4 68.3 26.5 50.2 88.7 220.3 96.2 102.9 
Wednesday 42.4 62.6 27.1 56.5 58.9 100.2 103.1 89.2 
Thursday 40.0 47.3 23.2 67.8 134.9 233.7 108.8 97.9 
Friday 38.9 47.3 33.6 57.1 94.4 251.6 114.6 107.5 
Saturday 42.3 76.9 30.0 49.9 77.2 249.5 109.8 113.1 
Sunday 38.2 56.5 28.1 53.2 90.7 202.1 111.4 91.0 
AV 41.4 58.7 27.9 54.7 90.3 206.3 108.0 99.6 
SD 2.6 11.2 3.3 6.7 23.0 52.5 6.3 8.8 




Table S18 Desmethylvenlafaxine loads.  
E1-Desmethylvenlafaxine 
 
POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
 
UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 56.9 54.4 20.6 60.8 137.9 182.8 118.8 131.4 
Tuesday 60.9 75.7 48.8 60.6 152.5 211.3 114.6 150.1 
Wednesday 56.1 82.1 44.7 56.8 110.1 120.1 116.9 123.6 
Thursday 54.6 52.0 36.0 59.3 179.0 247.0 124.1 142.1 
Friday 42.9 55.4 57.4 62.7 163.4 232.9 105.1 143.3 
Saturday 52.1 54.8 28.2 56.8 130.6 246.3 108.8 139.9 
Sunday 51.1 46.6 28.1 57.5 155.4 198.5 110.2 121.5 
AV 53.5 60.2 37.7 59.2 147.0 205.6 114.1 136.0 
SD 5.7 13.3 13.2 2.3 22.8 44.8 6.5 10.7 
CV 0.1 0.2 0.3 0.0 0.2 0.2 0.1 0.1 
E2-Desmethylvenlafaxine 
  POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
  UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 29.5 35.1 14.1 34.3 87.5 75.3 73.9 84.0 
Tuesday 33.1 49.2 25.8 33.7 96.8 98.1 68.3 93.5 
Wednesday 30.9 52.3 22.4 33.6 67.8 52.5 73.6 76.5 
Thursday 27.3 38.8 25.1 32.3 107.5 110.8 76.2 85.1 
Friday 24.9 31.1 36.6 36.0 94.9 104.2 67.3 92.1 
Saturday 30.1 27.0 20.5 33.4 77.8 113.6 72.2 92.1 
Sunday 25.7 35.4 13.8 33.0 89.9 90.3 67.6 76.0 
AV 28.8 38.4 22.6 33.8 88.9 92.1 71.3 85.6 
SD 2.9 9.2 7.8 1.2 13.0 21.8 3.5 7.4 
CV 0.1 0.2 0.3 0.0 0.1 0.2 0.0 0.1 
(±)-Desmethylvenlafaxine 
  POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
  UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 86.4 89.4 34.8 95.2 225.4 258.2 192.7 215.4 
Tuesday 94.0 124.9 74.6 94.4 249.3 309.4 182.9 243.6 
Wednesday 86.9 134.4 67.1 90.4 177.9 172.6 190.4 200.1 
Thursday 81.9 90.8 61.1 91.6 286.5 357.9 200.3 227.2 
Friday 67.8 86.5 94.0 98.7 258.2 337.1 172.5 235.4 
Saturday 82.3 81.8 48.7 90.2 208.4 359.9 181.0 232.0 
Sunday 76.8 81.9 41.9 90.5 245.3 288.8 177.8 197.5 
AV 82.3 98.5 60.3 93.0 235.9 297.7 185.4 221.6 
SD 8.3 21.7 20.5 3.2 35.5 66.4 9.6 17.8 





Table S19 Tramadol loads. 
D1-Tramadol 
 
POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
 
UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 128.6 67.5 15.8 45.5 104.9 377.3 72.6 162.4 
Tuesday 118.7 76.2 20.4 44.0 118.7 342.2 66.3 188.7 
Wednesday 130.0 95.3 22.4 41.9 86.7 303.3 71.6 155.2 
Thursday 126.9 64.2 21.7 38.1 129.5 385.0 75.0 184.4 
Friday 110.6 64.5 31.8 39.1 121.5 367.1 65.8 178.0 
Saturday 119.2 59.7 18.3 41.1 97.9 891.6 77.1 188.4 
Sunday 109.5 56.5 21.1 44.9 110.7 419.2 85.9 154.3 
AV 120.5 69.1 21.6 42.1 110.0 440.8 73.5 173.1 
SD 8.4 13.1 5.0 2.8 14.7 202.0 6.9 15.4 
CV 0.1 0.2 0.2 0.1 0.1 0.5 0.1 0.1 
D2-Tramadol 
  POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
  UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 104.5 45.6 13.6 35.2 72.8 202.8 57.9 127.2 
Tuesday 108.2 54.8 14.6 33.1 79.3 198.5 48.7 136.2 
Wednesday 111.3 76.4 18.7 37.2 64.2 171.9 55.2 122.0 
Thursday 98.4 51.0 16.9 31.4 93.3 221.1 57.3 135.6 
Friday 105.4 48.7 18.6 32.0 85.2 225.5 52.0 131.0 
Saturday 111.6 45.1 14.7 30.5 64.0 477.9 56.6 147.7 
Sunday 98.3 51.3 15.0 34.2 72.6 224.8 64.6 124.8 
AV 105.4 53.3 16.0 33.4 75.9 246.1 56.0 132.0 
SD 5.5 10.7 2.1 2.3 10.8 104.0 5.0 8.7 
CV 0.1 0.2 0.1 0.1 0.1 0.4 0.1 0.1 
(±)-Tramadol 
  POPULATION-NORMALISED MASS LOADS (mg/1000 people/day) 
  UK Norway Italy Netherlands Spain Belgium Switzerland Denmark 
Monday 233.1 113.1 29.3 80.8 177.7 580.0 130.5 289.6 
Tuesday 226.8 131.0 35.0 77.1 198.0 540.7 115.0 324.9 
Wednesday 241.3 171.7 41.1 79.1 150.9 475.2 126.8 277.2 
Thursday 225.2 115.2 38.6 69.5 222.8 606.1 132.3 320.0 
Friday 216.0 113.2 50.5 71.2 206.7 592.7 117.7 309.0 
Saturday 230.9 104.8 33.0 71.7 161.9 1369.5 133.7 336.0 
Sunday 207.8 107.8 36.1 79.1 183.2 644.0 150.5 279.1 
AV 225.9 122.4 37.7 75.5 185.9 686.9 129.5 305.1 
SD 11.1 23.3 6.8 4.6 25.2 305.7 11.7 23.4 







Wastewater samples from 2015 sampling campaign: amphetamine. 
 
F-Test Two-Sample for Variances   
  EF  EF of standards 
Mean 0.460782672 0.516421 
Variance 0.000181069 0.0001 
Observations 5 7 
df 4 6 
F 1.804179405  
P(F<=f) one-tail 0.246815412  
F Critical one-tail 4.53367695   
 
Data: 
Amphetamine 2015 (no Switzerland) Validation 











t-Test: Two-Sample Assuming Equal Variances 
 EF of standards from 
validation 
EF  
Mean 0.516421 0.460783 
Variance 0.0001 0.000181 
Observations 7 5 
Pooled Variance 0.000133  
Hypothesized Mean 
Difference 0  
df 10  
t Stat 8.250336  
P(T<=t) one-tail 4.49E-06  
t Critical one-tail 1.812461  




t-Test: Two-Sample Assuming Equal Variances 
t Stat 8.250336  
P(T<=t) one-tail 4.49E-06  
t Critical one-tail 4.1437  
P(T<=t) two-tail 8.98E-06  
t Critical two-tail 4.586894  
 
Moffat, A. C., D. M. Osselton and Widdop (2004). Clarke's analysis of drugs and 






















Appendix 4  
The following supplementary data are contained in Appendix 4: 
Table S1 Selected analytes and their properties (MW=molecular weight). 
Table S2 Studied mobile phase compositions with CHIRALCEL® OZ-RH column. 
Table S3 Validation parameters -instrumental precision 
Figure S1 CHIRALCEL® OZ-RH column – impact of the organic content on the 
separation of studied analytes (mobile phases in the legend are referred to the 
organic modifier mentioned in the title of the graphic). 
Figure S2 CHIRALCEL® OZ-RH column – (a) impact of the organic modifiers 
used on the separation of studied analytes. The mobile phase composition was 
constituted by the organic solvent specified in the legend and by 5% of 5mM 
ammonium acetate as aqueous content; (b) Impact of the nature of the organic 
content in the mobile phase on enantiomeric resolution. The mobile phases 
considered were the best performing: 95:5 5mM ammonium formate for IPA and 
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ACN, 99:1 5mM ammonium formate for EtOH, 99:1 10mM ammonium formate 
for MeOH. 
Figure S3 CHIRALCEL® OZ-RH column – impact of (a) the flow rate, (b) pH and 
(c) percentage of the additive content on the separation of studied analytes. The 





Table S1 Selected analytes and their properties (MW=molecular weight). 
Compound CAS Formula MW LogP pKa  Supplier 
         Strongest acidic Strongest basic  
Ciprofloxacin 85721-33-1 C17H18FN3O3 331.3 -0.81a 5.76a 8.68a Fluka 
Desethylene-ciprofloxacin 528851-31-2 C₁₅H₁₇ClFN₃O₃ 341.8 - - - TRC 
S-(-)-Ofloxacin (L-Ofloxacin) 100986-85-4 C18H20FN3O4  0.65a 5.45a 6.20a Sigma Aldrich 
(±)-Ofloxacin 82419-36-1 C18H20FN3O4 361.4 0.65a 5.45a 6.20a Sigma Aldrich 
Norfloxacin 70458-96-7 C16H18FN3O3 319.3 -0.92a 5.77a 8.68a Fluka 
(±)-Ofloxacin-N-oxide 104721-52-0 C₂₀H₂₄FN₃O₇ 437.4 - - - TRC 
(±)-Desmethyl-ofloxacin 82419-52-1 C₁₇H₁₈FN₃O₄ 347.3 - - - TRC 
Nalidixic acid 3374-05-8 C12H11N2NaO3 254.2 1.01a 5.95a 4.68a Sigma Aldrich 
(±)-Lomefloxacin 98079-52-8 C17H19F2N3O3  -0.30e 5.64e 8.70e Sigma Aldrich 
R,R-Moxifloxacin 1346603-25-5 C₂₁H₂₅ClFN₃O₄ 437.9 2.9e 5.69a 9.42a TRC 
S,S- Moxifloxacin 192927-63-2 C₂₁H₂₇ClFN₃O₅ 455.9 2.9e 5.69a 9.42a TRC 
Moxifloxacin-N-sulphate n.a. C₂₁H₂₂FN₃Na₂O₇S 525.5 - - - TRC 
(±)-Prulifloxacin 123447-62-1 C21H20FN3O6S 461.5 2.49b 3.27c 5.85d 6.25d Sigma Aldrich 
(±)-Ulifloxacin 112984-60-8 C₁₆H₁₆FN₃O₃S 349.4 -0.56d 5.85d 8.69d TRC 
(±)-cis-Ketoconazole 65277-42-1 C26H28Cl2N4O4  4.19 a - 6.75e Sigma Aldrich 
(±)-Flumequine 42835-25-6 C14H12FNO3  2.42a 6.00e -4.30e Sigma Aldrich 
(±)-Nadifloxacin 124858-35-1 C₁₉H₂₁FN₂O₄ 360.4 1.87d 5.55d 1.27d TRC 
R-(+)-Besifloxacin 405165-61-9 C₁₉H₂₂Cl₂FN₃O₃ 430.3 0.54a 5.64e 9.67e TRC 
Internal Standard       
Ciprofloxacin –D8      QMX laboratories 
(±)-Ofloxacin-D3      QMX laboratories 
(±)-Desmethyl-ofloxacin-D8      TRC 









Table S2 Studied mobile phase compositions with CHIRALCEL® OZ-RH column.  
% ACN % H2O Amm.Form. 
(mM) 
pH Flow rate  
(ml min-1) 
95 5 5 7.48 0.1 
95 5 5 7.48 0.15 
95 5 5 7.48 0.18 
95 5 5 7.48 0.2 
95 5 5+0.1%FA 5.82 0.05 
95 5 5+0.2%FA 5.34 0.05 
95 5 10 7.03 0.05 
95 5 1 7.41 0.05 
95 5 1 7.41 0.1 
99 1 5 7.49 0.1 
85 15 5 7.06 0.1 
75 25 5 6.47 0.1 
65 35 5 6.88 0.1 
% EtOH % H2O Amm.Form. 
(mM) 
pH Flow rate  
(ml min-1) 
99 1 5 7.51 0.1 
95 5 5 7.39 0.1 
95 5 10 7.49 0.1 
85 15 5 7.09 0.1 
85 15 5 4.82 0.1 
75 25 5 7.04 0.1 
% MeOH % H2O Amm.Form. 
(mM) 
pH Flow rate  
(ml min-1) 
99 1 10+ 0.05%FA 5.50 0.1 
99 1 10 7.27 0.1 
99 1 5 7.24 0.1 
95 5 10+ 0.05%FA 5.38 0.1 
95 5 5+ 0.05%FA 5.14 0.1 
95 5 5 7.21 0.1 
85 15 5 7.04 0.1 
75 25 5 6.74 0.1 
65 35 5 6.6 0.1 
%IPA % H2O Amm.Form. 
(mM) 
pH Flow rate  
(ml min-1) 
95 5 5 7.63 0.1 
% 
ACN/MeOH 
% H2O Amm.Form. 
(mM) 
pH Flow rate  
(ml min-1) 
95 5 5 7.37 0.1 
90 10 5 7.2 0.1 
80 20 5 7.12 0.1 
% 
EtOH/MeOH 
% H2O Amm.Form. 
(mM) 
pH Flow rate  
(ml min-1) 





Table S3 Validation parameters -instrumental precision 
 
Intra-day RSD% (n=4) Inter-day RSD% (n=3)  
5 µg/L** 5 µg/L 5 µg/L 50 µg/L 50 µg/L 50 µg/L 500 µg/L 500 µg/L 500 µg/L 5 µg/L 50 µg/L 500 µg/L 
  D 1* D 2 D 3 D 1 D 2 D 3 D 1 D 2 D 3 
   
Ciprofloxacin 5.3 6.4 13.4 0.8 1.0 3.5 7.9 1.0 5.6 8.4 1.8 4.8 
Desethylene-ciprofloxacin 5.4 6.0 17.6 10.9 14.4 5.7 9.0 3.0 6.5 9.7 10.3 6.2 
S-(-)-Ofloxacin (L-Ofloxacin) 6.8 13.0 3.0 3.7 3.0 4.4 2.4 3.8 0.3 7.6 3.7 2.2 
R-(+)-Ofloxacin 4.6 2.3 10.9 2.8 2.1 5.4 5.9 2.4 2.6 5.9 3.4 3.6 
Norfloxacin 4.6 15.8 19.8 11.6 2.9 4.0 14.4 3.5 2.3 13.4 6.2 6.7 
S-(-)-Ofloxacin-N-oxide 3.3 4.0 3.7 4.6 1.1 9.0 4.7 3.2 2.2 3.7 4.9 3.4 
R-(+)-Ofloxacin-N-oxide 5.2 7.1 19.3 15.2 10.3 12.9 5.2 3.7 1.9 10.5 12.8 3.6 
S-(-)-Desmethyl-ofloxacin 1.1 8.1 4.8 0.9 1.0 4.3 1.0 1.6 2.9 4.7 2.1 1.8 
R-(+)-Desmethyl-ofloxacin 5.9 8.2 18.9 1.6 9.0 5.0 3.2 3.4 1.6 11.0 5.2 2.7 
Nalidixic acid 3.0 8.7 2.7 5.6 4.5 4.9 5.3 1.6 3.4 4.8 5.0 3.4 
Lomefloxacin 7.0 15,5 3.2 2.9 4.4 1.7 3.3 3.3 5.0 5.1 3.0 3.9 
R,R-Moxifloxacin 7.5 19.7 10.0 0.0 10.2 11.9 0.9 1.0 8.0 12.4 7.4 3.3 
S,S- Moxifloxacin 13.2 15.3 7.3 4.1 4.7 3.3 2.7 2.7 5.9 11.9 4.0 3.8 
Moxifloxacin-N-sulphate 4.4 5.4 17.3 12.3 5.8 8.3 4.5 9.6 3.5 9.0 8.8 5.9 
Prulifloxacin-E1 2.3 23.3 15.8 6.9 2.5 0.8 4.9 3.5 0.9 13.8 3.4 3.1 
Prulifloxacin-E2 2.0 7.8 12.6 3.3 1.3 2.1 2.1 6.0 5.5 7.5 2.2 4.5 
Ulifloxacin-E1 14.3 9.6 4.1 0.6 4.5 3.1 1.2 4.6 10.3 9.3 2.7 5.4 
Ulifloxacin-E2 7.2 14.8 8.6 13.3 2.8 3.7 7.0 2.1 10.8 10.2 6.6 6.6 
(±)-cis-Ketoconazole-E1 2.6 5.7 2.2 4.2 3.7 4.0 4.0 2.4 1.5 3.5 4.0 2.6 
(±)-cis-Ketoconazole-E2 2.9 2.0 6.8 0.3 2.2 2.6 2.7 1.4 1.9 3.9 1.7 2.0 
Flumequine-E1 3.8 2.2 4.1 0.7 5.2 1.8 4.7 2.3 0.4 3.4 2.6 2.5 
Flumequine-E2 8.6 11.3 6.8 1.3 2.8 7.7 4.6 5.1 0.9 8.9 3.9 3.5 
Nadifloxacin-E1 2.8 3.1 4.6 2.0 3.2 6.5 3.2 6.5 2.6 3.5 3.9 4.1 
Nadifloxacin-E2 4.3 11.3 10.2 6.3 3.1 5.0 5.9 6.4 8.1 8.6 4.8 6.8 
Besifloxacin 3.0 2.1 8.5 13.2 7.9 2.5 12.4 3.2 2.7 4.5 7.9 6.1 
*-D indicates day 

















ACN: Impact of Organic content on the separation 
99:1 5mM Amm.Formate 95:5 5mM Amm.Formate 95:5 5mM Amm.Formate 0.1%FA pH 5.82
95:5 5mM Amm.Formate 0.2%FA pH 5.34 95:5 10mM Amm.Formate 95:5 1mM Amm.Formate
































MeOH: Impact of organic content on the separation 
99:1 10mM Amm.Formate 0.05%FA pH 5.50 99:1 10mM Amm.Formate 99:1 5mM Amm.Formate
95:5 10mM Amm.Formate 0.05%FA pH 5.38 95:5 5mM Amm.Formate 0.05%FA pH 5.14 95:5 5mM Amm.Formate
















ACN/MeOH: Impact of Organic content on the separation 




Figure S1 CHIRALCEL® OZ-RH column – impact of the organic content on the separation of studied analytes (mobile phases in the legend are referred to the organic modifier 











































Organic modifiers: Impact on the Elution Order












Figure S2 CHIRALCEL® OZ-RH column – (a) impact of the organic modifiers used on the separation of studied analytes. The mobile phase composition was constituted by 
the organic solvent specified in the legend and by 5% of 5mM ammonium acetate as aqueous content; (b) Impact of the nature of the organic content in the mobile phase on 
enantiomeric resolution. The mobile phases considered were the best performing: 95:5 5mM ammonium formate for IPA and ACN, 99:1 5mM ammonium formate for EtOH, 




















Impact of the nature of the organic content in the 
mobile phase on enantiomeric resolution



















Figure S3 CHIRALCEL® OZ-RH column – impact of (a) the flow rate, (b) pH and (c) percentage 
of the additive content on the separation of studied analytes. The mobile phase used for the first 












Flow rate (mL min-1)




















ACN: Impact of the pH on the separation 
95:5 5mM Amm.Formate 95:5 5mM Amm.Formate 0.1%FA pH 5.82
















ACN: Impact of % additive  on the retention time






















Appendix 5  
The following supplementary data are contained in Appendix 5: 
Table S1 Concentrations (Conc.), daily population-normalised mass loads (Loads) 
and EF values for chiral compounds for the European monitoring campaign across 
Europe (besifloxacin, R,R-moxifloxacin, prulifloxacin, nadifloxacin were not 
reported as all values were <MDL). M., T., W., T., F., S., S. were the initials used 
for indicating the days of the week. 
Figure S1 Test “dry run on non-selective media” performed by using 100 μL (on 
the left) and 200 μL (on the right) of refrigerated wastewater Bristolian samples for 
day 6th and 7th. 
Figure S2 Growth of different colonies from an incubated Bristolian wastewater 
sample (on the left), result of the incubation for colony no. 7 and no.8 (on the 
centre), pointing of the single colony to be used a reference (on the right). 
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Figure S3 Result of the incubation for the colonies found from every day of the 
sampling campaign in Bristol. 
Figure S4 Result of the incubation for the colonies found from every day of the 
sampling campaign in Oslo, Castellon, Lyngby, Milan, Utrecht and Zurich. 
Table S2 Results on colony morphology assessment for the selected cities in the 
study. 
Figure S5 qPCR-Melt curve. 




Table S1 Concentrations (Conc.), daily population-normalised mass loads (Loads) and EF values for chiral compounds for the European 
monitoring campaign across Europe (besifloxacin, R,R-moxifloxacin, prulifloxacin, nadifloxacin were not reported as all values were <MDL). M., 
T., W., T., F., S., S. were the initials used for indicating the days of the week. 
CIPROFLOXACIN 






























































































198.8 148.7 9.6 33.1 622.0 90.
5 









155.5 124.3 5.9 35.4 601.5 95.
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CV 0.2   0.3 0.2   0.1 0.0   0.1 0.1   0.1 0.4   0.3 0.2   0.2 0.2   0.2 
DESETHYLENE-CIPROFLOXACIN 





























































11.4 60.7 1.5 13.5 66.5 2.1 18.6 78.5 6.4 12.0 50.5 2.1 21.8 59.5 0.7 32.3 68.5 3.5 14.2 
T 51.0 0.0 22.2 57.5 0.7 13.3 71.5 0.7 20.3 76.0 1.4 11.3 52.0 0.0 20.4 0.0 0.0 0.0 66.0 1.4 14.8 
W 91.5 4.9 52.6 53.3 2.1 12.0 69.0 1.4 19.1 65.5 4.9 10.4 26.0 36.
8 
10.0 0.0 0.0 0.0 66.0 1.4 18.3 
T 40.5 57.
3 
21.5 53.7 1.5 12.0 73.5 7.8 20.0 75.0 0.0 11.3 51.0 0.0 20.0 0.0 0.0 0.0 69.5 6.4 18.9 
F 30.0 42.
4 




9.5 69.0 1.4 16.7 
S 50.0 1.4 22.1 53.0 1.7 13.2 70.0 0.0 18.2 77.0 7.1 11.8 51.0 1.4 24.9 0.0 0.0 0.0 67.0 2.8 14.2 
S 53.0 0.0 22.9 53.3 1.5 11.6 71.5 2.1 18.5 72.0 4.2 11.3 50.5 0.7 29.9 55.0 2.8 21.1 65.0 1.4 13.4 
















CV 0.4   0.6 0.1   0.1 0.0   0.0 0.1   0.0 0.3   0.4 1.4   1.4 0.0   0.1 
NORFLOXACIN 

























































M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 39.5 54.
4 
17.1 16.0 1.4 8.7 109.0 39.
6 
22.6 













16.9 88.0 7.1 24.5 
T 0.0 0.0 0.0 7.7 13.
3 
1.7 0.0 0.0 0.0 0.0 0.0 0.0 175.5 30.
4 





F 0.0 0.0 0.0 9.3 11.
4 




20.3 113.0 4.2 27.3 













6.1 69.5 2.1 14.3 
















CV 1.3   1.4 1.2   1.3 #DIV/
0! 
  #DIV/0! #DIV/
0! 
  #DIV/0! 0.7   0.6 0.5   0.5 0.2   0.2 
NALIDIXIC ACID 

























































M 4.5 0.7 2.0 5.3 0.6 1.2 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.7 0.6 0.0 0.0 0.0 1.0 0.0 0.2 
T 4.5 0.7 2.0 2.0 1.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.4 7.0 9.9 2.7 1.5 0.7 0.3 
W 14.0 9.9 8.0 1.0 0.0 0.2 0.0 0.0 0.0 1.0 1.4 0.2 0.0 0.0 0.0 0.5 0.7 0.2 2.5 0.7 0.7 
T 4.5 0.7 2.4 0.5 0.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.7 1.5 0.7 0.4 
F 1.0 0.0 0.5 1.0 0.0 0.3 0.0 0.0 0.0 1.5 0.7 0.2 0.0 0.0 0.0 0.5 0.7 0.2 1.0 1.4 0.2 
S 2.0 0.0 0.9 1.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.4 0.2 
S 4.0 0.0 1.7 1.0 0.0 0.2 0.0 0.0 0.0 2.0 0.0 0.3 1.5 0.7 0.9 1.0 0.0 0.4 0.0 0.0 0.0 
















CV 0.9   1.0 1.0   0.9 #DIV/
0! 
  #DIV/0! 1.3   1.3 1.3   1.4 1.6   1.6 0.6   0.7 
LOMEFLOXACIN 



























































M 1.5 2.1 0.7 2.7 0.6 0.6 3.5 0.7 1.0 3.5 0.7 0.5 1.5 2.1 0.6 3.0 0.0 1.6 1.5 2.1 0.3 
T 3.0 1.4 1.3 2.5 0.7 0.6 1.5 2.1 0.4 1.5 2.1 0.2 0.0 0.0 0.0 14.0 14.
1 
5.4 1.0 1.4 0.2 
W 11.0 5.7 6.3 2.3 0.6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 1.1 6.5 0.7 2.4 3.5 2.1 1.0 
T 0.0 0.0 0.0 2.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.5 0.7 3.2 1.5 0.7 0.4 
F 0.0 0.0 0.0 3.0 0.0 0.9 0.0 0.0 0.0 0.5 0.7 0.1 0.0 0.0 0.0 5.0 0.0 1.8 1.5 2.1 0.4 
S 0.5 0.7 0.2 1.3 0.6 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.5 0.7 1.6 4.0 0.0 0.8 
S 2.0 2.8 0.9 2.0 1.0 0.4 1.5 2.1 0.4 1.0 1.4 0.2 0.0 0.0 0.0 5.5 2.1 2.1 2.0 0.0 0.4 
















CV 1.5   1.7 0.2   0.3 1.4   1.5 1.4   1.4 1.8   1.8 0.5   0.5 0.5   0.6 
MOXI-SULPHATE 





























































53.8 0.0 0.0 0.0 505.5 17.
7 
104.8 






30.6 84.0 7.1 32.3 484.5 9.2 108.5 






51.1 23.5 0.7 8.6 379.0 50.
9 
105.4 
























16.6 105.0 8.5 51.2 0.0 0.0 0.0 1053.5 30.
4 
223.3 





























  #DIV/0! #DIV/
0! 
  #DIV/0! 0.9   0.9 0.5   0.5 0.3   0.3 1.4   1.4 0.3   0.3 
 
S-(-)-OFLOXACIN 
























































































































AV 36.1   17.2 40.8   9.6 23.0   6.3 23.5   3.6 255.
6 
  110.0 1861
.3 
  727.4 2743
.3 





























































































M 6.0 1.4 2.6 13.3 0.6 3.0 0.0 0.0 0.0 6.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
T 9.5 3.5 4.1 12.3 1.2 2.8 0.0 0.0 0.0 4.0 1.4 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
W 9.5 9.2 5.5 15.3 1.2 3.4 9.5 7.8 2.6 4.0 1.4 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
T 7.0 2.8 3.7 10.3 1.2 2.3 0.0 0.0 0.0 1.5 2.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
F 7.0 0.0 3.3 10.3 1.2 2.9 0.0 0.0 0.0 3.5 0.7 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
S 8.5 2.1 3.8 14.3 3.2 3.6 4.0 0.0 1.0 5.5 2.1 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
S 6.0 1.4 2.6 13.7 2.9 3.0 4.5 0.7 1.2 4.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 


















































































































































































































































M 2.5 0.7 1.1 2.0 0.0 0.4 2.0 0.0 0.6 2.0 0.0 0.3 0.0 0.0 0.0 20.5 0.7 11.1 11.0 1.4 2.3 
T 2.5 0.7 1.1 0.0 0.0 0.0 1.0 1.4 0.3 2.0 0.0 0.3 2.0 0.0 0.8 9.0 12.7 3.5 10.0 1.4 2.2 
W 0.0 0.0 0.0 2.5 0.7 0.6 1.0 1.4 0.3 2.5 0.7 0.4 4.0 0.0 1.5 22.5 0.7 8.2 10.0 1.4 2.8 
T 5.0 1.4 2.7 2.0 0.0 0.4 0.0 0.0 0.0 2.0 0.0 0.3 4.0 0.0 1.6 21.0 1.4 7.9 15.5 3.5 4.2 
F 4.0 0.0 1.9 2.0 0.0 0.6 1.0 1.4 0.3 2.0 0.0 0.3 2.0 0.0 0.8 19.5 0.7 7.1 19.0 0.0 4.6 
S 2.5 0.7 1.1 2.0 0.0 0.5 2.0 0.0 0.5 2.0 0.0 0.3 5.5 0.7 2.7 18.0 1.4 6.6 16.5 2.1 3.5 
S 3.0 1.4 1.3 2.0 0.0 0.4 0.0 0.0 0.0 2.0 0.0 0.3 2.5 0.7 1.5 19.0 2.8 7.3 14.0 1.4 2.9 
















CV 0.6   0.6 0.5   0.5 0.8   0.8 0.1   0.1 0.6   0.7 0.2   0.3 0.3   0.3 
R-(+)-OFLOXACIN-N-OXIDE 









































































M 2.0 0.0 0.9 2.0 0.0 0.4 1.0 1.4 0.3 1.0 1.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
T 2.0 0.0 0.9 0.7 1.2 0.2 0.0 0.0 0.0 1.0 1.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
W 0.0 0.0 0.0 2.0 0.0 0.4 1.0 1.4 0.3 1.0 1.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
T 2.5 0.7 1.3 2.0 0.0 0.4 1.0 1.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
F 0.0 0.0 0.0 2.0 0.0 0.6 2.0 0.0 0.5 1.0 1.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
S 0.0 0.0 0.0 2.0 0.0 0.5 2.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
S 2.0 0.0 0.9 2.0 0.0 0.4 1.0 1.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 





































































































M 4.5 2.0 0.4 4.0 0.9 0.5 3.0 0.8 0.3 3.0 0.5 0.3 0.0 0.0   20.5 11.1 0.0 11.0 2.3 0.0 
T 4.5 2.0 0.4 0.7 0.2 1.0 1.0 0.3 0.0 3.0 0.4 0.3 2.0 0.8 0.0 9.0 3.5 0.0 10.0 2.2 0.0 
W 0.0 0.0   4.5 1.0 0.4 2.0 0.6 0.5 3.5 0.6 0.3 4.0 1.5 0.0 22.5 8.2 0.0 10.0 2.8 0.0 
T 7.5 4.0 0.3 4.0 0.9 0.5 1.0 0.3 1.0 2.0 0.3 0.0 4.0 1.6 0.0 21.0 7.9 0.0 15.5 4.2 0.0 
F 4.0 1.9 0.0 4.0 1.1 0.5 3.0 0.8 0.7 3.0 0.5 0.3 2.0 0.8 0.0 19.5 7.1 0.0 19.0 4.6 0.0 
S 2.5 1.1 0.0 4.0 1.0 0.5 4.0 1.0 0.5 2.0 0.3 0.0 5.5 2.7 0.0 18.0 6.6 0.0 16.5 3.5 0.0 
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S 5.0 2.2 0.4 4.0 0.9 0.5 1.0 0.3 1.0 2.0 0.3 0.0 2.5 1.5 0.0 19.0 7.3 0.0 14.0 2.9 0.0 
AV 4.0 1.9 0.3 3.6 0.9 0.6 2.1 0.6 0.6 2.6 0.4 0.2 2.9 1.3 0.0 18.5 7.4 0.0 13.7 3.2 0.0 
SD 2.3 1.2 0.2 1.3 0.3 0.2 1.2 0.3 0.4 0.6 0.1 0.2 1.8 0.8 0.0 4.4 2.3 0.0 3.5 0.9 0.0 














































































M 6.5 0.7 2.8 12.3 4.2 2.7 17.5 0.7 4.9 10.0 2.8 1.5 8.5 7.8 3.7 17.5 2.1 9.5 39.0 1.4 8.1 
T 8.5 0.7 3.7 5.7 4.9 1.3 15.5 3.5 4.4 11.0 0.0 1.6 11.5 0.7 4.5 28.5 12.0 11.0 46.5 6.4 10.4 
W 2.5 3.5 1.4 7.7 1.2 1.7 12.0 0.0 3.3 5.0 5.7 0.8 10.0 0.0 3.8 33.5 7.8 12.3 32.5 0.7 9.0 
T 3.5 4.9 1.9 7.7 2.3 1.7 13.5 2.1 3.7 13.5 0.7 2.0 10.5 2.1 4.1 37.5 4.9 14.1 46.0 1.4 12.5 
F 6.5 0.7 3.1 6.0 1.0 1.7 16.0 4.2 4.4 12.0 0.0 2.0 7.0 1.4 2.8 27.5 3.5 10.1 54.0 2.8 13.1 
S 3.0 1.4 1.3 6.7 2.5 1.7 15.0 0.0 3.9 8.5 0.7 1.3 9.0 4.2 4.4 26.0 1.4 9.5 46.5 4.9 9.9 
S 4.5 0.7 1.9 7.3 1.2 1.6 16.5 2.1 4.3 10.0 5.7 1.6 6.5 3.5 3.9 29.0 4.2 11.1 44.0 0.0 9.1 
















CV 0.4   0.4 0.3   0.3 0.1   0.1 0.3   0.3 0.2   0.2 0.2   0.1 0.2   0.2 
R-(+)-DESMETHYL-OFLOXACIN 









































































M 2.0 0.0 0.9 2.3 1.2 0.5 0.0 0.0 0.0 2.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
T 2.5 0.7 1.1 3.0 1.0 0.7 0.5 0.7 0.1 1.0 1.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
W 12.0 17.0 6.9 3.0 0.0 0.7 0.0 0.0 0.0 0.5 0.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
T 2.5 3.5 1.3 3.7 0.6 0.8 0.0 0.0 0.0 2.5 0.7 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
F 2.0 2.8 1.0 2.3 0.6 0.7 0.0 0.0 0.0 2.5 0.7 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
S 1.0 1.4 0.4 2.7 0.6 0.7 0.5 0.7 0.1 2.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
S 1.0 1.4 0.4 2.0 0.0 0.4 1.0 1.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 





































































































M 8.5 3.7 0.2 14.7 3.3 0.2 17.5 4.9 0.0 12.0 1.8 0.2 8.5 3.7 0.0 17.5 9.5 0.0 39.0 8.1 0.0 
T 11.0 4.8 0.2 8.7 2.0 0.3 16.0 4.5 0.0 12.0 1.8 0.1 11.5 4.5 0.0 28.5 11.0 0.0 46.5 10.4 0.0 
W 14.5 8.3 0.8 10.7 2.4 0.3 12.0 3.3 0.0 5.5 0.9 0.1 10.0 3.8 0.0 33.5 12.3 0.0 32.5 9.0 0.0 
T 6.0 3.2 0.4 11.3 2.5 0.3 13.5 3.7 0.0 16.0 2.4 0.2 10.5 4.1 0.0 37.5 14.1 0.0 46.0 12.5 0.0 
F 8.5 4.1 0.2 8.3 2.4 0.3 16.0 4.4 0.0 14.5 2.4 0.2 7.0 2.8 0.0 27.5 10.1 0.0 54.0 13.1 0.0 
S 4.0 1.8 0.3 9.3 2.3 0.3 15.5 4.0 0.0 10.5 1.6 0.2 9.0 4.4 0.0 26.0 9.5 0.0 46.5 9.9 0.0 
S 5.5 2.4 0.2 9.3 2.0 0.2 17.5 4.5 0.1 10.0 1.6 0.0 6.5 3.9 0.0 29.0 11.1 0.0 44.0 9.1 0.0 
AV 8.3 4.0 0.3 10.3 2.4 0.3 15.4 4.2 0.0 11.5 1.8 0.1 9.0 3.9 0.0 28.5 11.1 0.0 44.1 10.3 0.0 
SD 3.6 2.1 0.2 2.2 0.4 0.1 2.0 0.5 0.0 3.4 0.5 0.1 1.8 0.6 0.0 6.3 1.6 0.0 6.8 1.9 0.0 
















































































M 0.0 0.0 0.0 0.0 0.0 0.0 9.0 0.0 2.5 0.0 0.0 0.0 10.0 1.4 4.3 6.0 0.0 3.3 74.5 13.4 15.4 
T 0.0 0.0 0.0 0.0 0.0 0.0 8.0 1.4 2.3 0.0 0.0 0.0 14.5 0.7 5.7 6.5 9.2 2.5 84.5 2.1 18.9 
W 0.0 0.0 0.0 0.0 0.0 0.0 9.5 0.7 2.6 0.0 0.0 0.0 21.0 0.0 8.0 10.0 0.0 3.7 69.0 12.7 19.2 
T 0.0 0.0 0.0 0.0 0.0 0.0 8.0 1.4 2.2 0.0 0.0 0.0 19.0 1.4 7.5 8.5 0.7 3.2 85.0 7.1 23.1 
F 0.0 0.0 0.0 0.0 0.0 0.0 6.0 1.4 1.6 0.0 0.0 0.0 7.5 0.7 3.0 7.0 0.0 2.6 121.
5 
6.4 29.4 
S 0.0 0.0 0.0 0.0 0.0 0.0 7.5 2.1 1.9 0.0 0.0 0.0 17.0 1.4 8.3 9.0 2.8 3.3 127.
0 
9.9 26.9 
S 0.0 0.0 0.0 0.0 0.0 0.0 5.0 0.0 1.3 0.0 0.0 0.0 10.5 0.7 6.2 7.5 0.7 2.9 87.5 2.1 18.0 
















CV -   - -   - 0.2   0.2 -   - 0.4   0.3 0.2   0.1 0.2   0.2 
(±)-MOXIFLOXACIN 








































































M 0.0 0.0 - 0.0 0.0 - 9.0 2.5 1.0 0.0 0.0 - 10.0 4.3 1.0 6.0 3.3 1.0 74.5 15.4 1.0 
T 0.0 0.0 - 0.0 0.0 - 8.0 2.3 1.0 0.0 0.0 - 14.5 5.7 1.0 6.5 2.5 1.0 84.5 18.9 1.0 
W 0.0 0.0 - 0.0 0.0 - 9.5 2.6 1.0 0.0 0.0 - 21.0 8.0 1.0 10.0 3.7 1.0 69.0 19.2 1.0 
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T 0.0 0.0 - 0.0 0.0 - 8.0 2.2 1.0 0.0 0.0 - 19.0 7.5 1.0 8.5 3.2 1.0 85.0 23.1 1.0 
F 0.0 0.0 - 0.0 0.0 - 6.0 1.6 1.0 0.0 0.0 - 7.5 3.0 1.0 7.0 2.6 1.0 121.
5 
29.4 1.0 
S 0.0 0.0 - 0.0 0.0 - 7.5 1.9 1.0 0.0 0.0 - 17.0 8.3 1.0 9.0 3.3 1.0 127.
0 
26.9 1.0 
S 0.0 0.0 - 0.0 0.0 - 5.0 1.3 1.0 0.0 0.0 - 10.5 6.2 1.0 7.5 2.9 1.0 87.5 18.0 1.0 
AV 0.0 0.0 - 0.0 0.0 - 7.6 2.1 1.0 0.0 0.0 - 14.2 6.1 1.0 7.8 3.1 1.0 92.7 21.6 1.0 









- 0.2 0.2 0.0 - - - 0.4 0.3 0.0 0.2 0.1 0.0 0.2 0.2 0.0 
ULIFLOXACIN-E1 







































































M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 49.5 9.2 26.9 0.0 0.0 0.0 
T 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.5 3.5 8.3 0.0 0.0 0.0 
W 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 27.0 14.1 9.9 0.0 0.0 0.0 
T 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 41.5 16.3 15.6 0.0 0.0 0.0 
F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 29.5 6.4 10.8 0.0 0.0 0.0 
S 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 43.0 1.4 15.8 0.0 0.0 0.0 
S 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 31.0 4.2 11.9 0.0 0.0 0.0 
















CV -   - -   - -   - -   - -   - 0.3   0.4 -   - 
ULIFLOXACIN-E2 









































































M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 25.0 7.1 13.6 0.0 0.0 0.0 
T 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.0 15.6 4.2 0.0 0.0 0.0 
W 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.0 1.4 7.7 0.0 0.0 0.0 
T 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.5 2.1 8.4 0.0 0.0 0.0 
F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.0 4.9 5.1 30.0 2.8 7.3 
S 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.5 2.1 8.2 15.0 3.5 3.2 
S 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 26.0 8.5 10.0 0.0 3.5 0.0 
















CV -   - -   - -   - -   - -   - 0.3   0.4 1.8   1.9 
(±)-ULIFLOXACIN 








































































M 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 74.5 40.5 0.7 0.0 0.0 - 
T 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 32.5 12.5 0.7 0.0 0.0 - 
W 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 48.0 17.6 0.6 0.0 0.0 - 
T 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 64.0 24.0 0.6 0.0 0.0 - 
F 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 43.5 15.9 0.7 30.0 7.3 - 
S 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 65.5 24.0 0.7 15.0 3.2 0.0 
S 0.0 0.0  0.0 0.0  0.0 0.0  0.0 0.0  0.0 0.0  57.0 21.9 0.5 0.0 0.0  
Appendix 5 
 345 
AV 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 55.0 22.3 0.6 6.4 1.5 - 
SD 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 0.0 0.0 - 14.5 9.1 0.1 11.8 2.8 - 
CV - - - - - - - - - - - - - - - 0.3 0.4 0.1 1.8 1.9 - 
KETOCONAZOLE-D1 







































































M 19.5 0.7 8.5 8.0 1.0 1.8 42.5 3.5 11.9 8.0 0.0 1.2 13.5 0.7 5.8 7.0 0.0 3.8 20.0 0.0 4.1 
T 18.5 0.7 8.1 9.0 1.7 2.1 27.0 1.4 7.7 7.0 0.0 1.0 26.0 0.0 10.2 15.0 4.2 5.8 15.0 0.0 3.4 
W 23.5 4.9 13.5 10.0 1.0 2.2 27.5 0.7 7.6 7.0 0.0 1.1 28.0 1.4 10.7 11.5 0.7 4.2 9.5 0.7 2.6 
T 22.5 0.7 11.9 6.7 0.6 1.5 48.5 2.1 13.2 17.5 0.7 2.6 22.0 1.4 8.6 10.0 0.0 3.7 20.5 0.7 5.6 
F 24.5 0.7 11.7 5.7 0.6 1.6 37.5 0.7 10.3 8.5 0.7 1.4 12.0 0.0 4.7 10.5 0.7 3.8 21.5 0.7 5.2 
S 26.0 0.0 11.5 9.3 0.6 2.3 32.5 0.7 8.4 10.0 0.0 1.5 23.5 0.7 11.5 10.0 0.0 3.7 28.5 0.7 6.0 
S 22.0 2.8 9.5 10.7 0.6 2.3 36.0 1.4 9.3 11.0 1.4 1.7 18.0 0.0 10.7 11.0 0.0 4.2 17.5 0.7 3.6 
















CV 0.1   0.2 0.2   0.2 0.2   0.2 0.4   0.4 0.3   0.3 0.2   0.2 0.3   0.3 
KETOCONAZOLE-D2 







































































M 12.0 0.0 5.3 5.3 0.6 1.2 26.0 1.4 7.3 5.5 0.7 0.8 9.5 0.7 4.1 4.5 0.7 2.4 12.0 0.0 2.5 
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T 11.5 0.7 5.0 5.3 0.6 1.2 15.0 0.0 4.3 5.0 0.0 0.7 18.0 0.0 7.1 11.0 2.8 4.2 9.5 0.7 2.1 
W 18.0 2.8 10.3 6.0 0.0 1.3 16.0 0.0 4.4 4.5 0.7 0.7 20.0 0.0 7.7 7.5 0.7 2.7 6.5 0.7 1.8 
T 16.5 0.7 8.8 4.0 0.0 0.9 33.0 1.4 9.0 10.5 0.7 1.6 15.5 0.7 6.1 7.0 0.0 2.6 13.0 1.4 3.5 
F 16.5 0.7 7.9 4.0 0.0 1.1 20.0 0.0 5.5 6.0 0.0 1.0 7.0 1.4 2.8 8.0 0.0 2.9 12.0 1.4 2.9 
S 17.5 2.1 7.7 6.0 0.0 1.5 16.5 0.7 4.3 6.5 0.7 1.0 16.0 0.0 7.8 7.0 0.0 2.6 16.0 0.0 3.4 
S 14.0 1.4 6.0 6.0 0.0 1.3 20.0 1.4 5.2 7.0 0.0 1.1 12.0 0.0 7.1 7.5 0.7 2.9 11.5 0.7 2.4 
















CV 0.2   0.3 0.2   0.2 0.3   0.3 0.3   0.3 0.3   0.3 0.3   0.2 0.3   0.2 
(±)-KETOCONAZOLE 








































































M 31.5 13.8 0.6 13.3 3.0 0.6 68.5 19.2 0.6 13.5 2.1 0.6 23.0 9.9 0.6 11.5 6.2 0.6 32.0 6.6 0.6 
T 30.0 13.1 0.6 14.3 3.3 0.6 42.0 11.9 0.6 12.0 1.8 0.6 44.0 17.3 0.6 26.0 10.0 0.6 24.5 5.5 0.6 
W 41.5 23.8 0.6 16.0 3.6 0.6 43.5 12.1 0.6 11.5 1.8 0.6 48.0 18.4 0.6 19.0 7.0 0.6 16.0 4.4 0.6 
T 39.0 20.7 0.6 10.7 2.4 0.6 81.5 22.2 0.6 28.0 4.2 0.6 37.5 14.7 0.6 17.0 6.4 0.6 33.5 9.1 0.6 
F 41.0 19.6 0.6 9.7 2.8 0.6 57.5 15.7 0.7 14.5 2.4 0.6 19.0 7.5 0.6 18.5 6.8 0.6 33.5 8.1 0.6 
S 43.5 19.2 0.6 15.3 3.8 0.6 49.0 12.7 0.7 16.5 2.5 0.6 39.5 19.3 0.6 17.0 6.2 0.6 44.5 9.4 0.6 
S 36.0 15.5 0.6 16.7 3.6 0.6 56.0 14.5 0.6 18.0 2.8 0.6 30.0 17.8 0.6 18.5 7.1 0.6 29.0 6.0 0.6 
AV 37.5 18.0 0.6 13.7 3.2 0.6 56.9 15.5 0.6 16.3 2.5 0.6 34.4 15.0 0.6 18.2 7.1 0.6 30.4 7.0 0.6 
SD 5.2 3.9 0.0 2.7 0.5 0.0 14.2 3.9 0.0 5.7 0.8 0.0 10.8 4.6 0.0 4.3 1.3 0.0 8.8 1.9 0.0 











































































M 1.0 0.0 0.4 0.7 0.6 0.1 1.5 0.7 0.4 1.5 0.7 0.2 1.0 0.0 0.4 0.0 0.0 0.0 1.5 0.7 0.3 
T 1.0 0.0 0.4 1.7 0.6 0.4 1.0 0.0 0.3 2.0 0.0 0.3 3.5 0.7 1.4 3.0 2.8 1.2 2.0 0.0 0.4 
W 2.5 2.1 1.4 1.0 0.0 0.2 1.0 0.0 0.3 1.5 0.7 0.2 1.0 0.0 0.4 1.0 0.0 0.4 1.5 0.7 0.4 
T 1.0 0.0 0.5 0.3 0.6 0.1 1.0 0.0 0.3 3.5 0.7 0.5 1.0 0.0 0.4 1.0 0.0 0.4 3.5 0.7 1.0 
F 1.0 0.0 0.5 1.0 0.0 0.3 1.0 0.0 0.3 1.5 0.7 0.2 1.0 0.0 0.4 1.0 0.0 0.4 1.0 0.0 0.2 
S 1.0 0.0 0.4 1.0 0.0 0.2 2.0 0.0 0.5 1.5 0.7 0.2 3.0 0.0 1.5 1.0 0.0 0.4 1.0 0.0 0.2 
S 1.0 0.0 0.4 1.0 0.0 0.2 1.0 0.0 0.3 1.5 0.7 0.2 1.0 0.0 0.6 0.0 0.0 0.0 1.5 0.7 0.3 
















CV 0.5   0.6 0.4   0.4 0.3   0.3 0.4   0.4 0.7   0.7 1.0   1.0 0.5   0.6 
FLUMEQUINE-E2 







































































M 0.0 0.0 0.0 0.3 0.6 0.1 0.5 0.7 0.1 1.0 0.0 0.2 0.5 0.7 0.2 0.0 0.0 0.0 0.5 0.7 0.1 
T 0.0 0.0 0.0 1.7 0.6 0.4 0.0 0.0 0.0 1.0 0.0 0.1 3.0 0.0 1.2 4.5 4.9 1.7 1.0 0.0 0.2 
W 3.0 2.8 1.7 0.3 0.6 0.1 0.0 0.0 0.0 1.0 0.0 0.2 0.5 0.7 0.2 0.0 0.0 0.0 0.5 0.7 0.1 
T 1.0 0.0 0.5 0.3 0.6 0.1 0.0 0.0 0.0 3.0 0.0 0.5 1.0 0.0 0.4 0.5 0.7 0.2 2.5 0.7 0.7 
F 0.5 0.7 0.2 0.3 0.6 0.1 0.0 0.0 0.0 1.0 0.0 0.2 0.5 0.7 0.2 0.5 0.7 0.2 0.5 0.7 0.1 
S 1.0 0.0 0.4 1.0 0.0 0.2 1.0 0.0 0.3 1.0 0.0 0.2 2.5 0.7 1.2 0.0 0.0 0.0 0.0 0.0 0.0 
Appendix 5 
 348 
S 0.0 0.0 0.0 1.0 0.0 0.2 0.0 0.0 0.0 1.0 0.0 0.2 0.5 0.7 0.3 0.0 0.0 0.0 0.5 0.7 0.1 
















CV 1.4   1.5 0.7   0.7 1.8   1.8 0.6   0.6 0.9   0.9 2.1   2.1 1.0   1.1 
(±)-FLUMEQUINE 








































































M 1.0 0.4 1.0 1.0 0.2 0.7 2.0 0.6 0.8 2.5 0.4 0.6 1.5 0.6 0.7 0.0 0.0   2.0 0.0 0.8 
T 1.0 0.4 1.0 3.3 0.8 0.5 1.0 0.3 1.0 3.0 0.4 0.7 6.5 2.6 0.5 7.5 2.9 0.4 3.0 0.0 0.7 
W 5.5 3.2 0.5 1.3 0.3 0.8 1.0 0.3 1.0 2.5 0.4 0.6 1.5 0.6 0.7 1.0 0.4 1.0 2.0 0.0 0.8 
T 2.0 1.1 0.5 0.7 0.1 0.5 1.0 0.3 1.0 6.5 1.0 0.5 2.0 0.8 0.5 1.5 0.6 0.7 6.0 0.0 0.6 
F 1.5 0.7 0.7 1.3 0.4 0.8 1.0 0.3 1.0 2.5 0.4 0.6 1.5 0.6 0.7 1.5 0.5 0.7 1.5 0.0 0.7 
S 2.0 0.9 0.5 2.0 0.5 0.5 3.0 0.8 0.7 2.5 0.4 0.6 5.5 2.7 0.5 1.0 0.4 1.0 1.0 0.0 1.0 
S 1.0 0.4 1.0 2.0 0.4 0.5 1.0 0.3 1.0 2.5 0.4 0.6 1.5 0.9 0.7 0.0 0.0   2.0 0.0 0.8 
AV 2.0 1.0 0.7 1.7 0.4 0.6 1.4 0.4 0.9 3.1 0.5 0.6 2.9 1.2 0.6 1.8 0.7 0.7 2.5 0.0 0.7 
SD 1.6 1.0 0.3 0.9 0.2 0.1 0.8 0.2 0.1 1.5 0.2 0.0 2.2 0.9 0.1 2.6 1.0 0.3 1.7 0.0 0.1 









Figure S1 Test “dry run on non-selective media” performed by using 100 μL (on the left) and 200 
μL (on the right) of refrigerated wastewater Bristolian samples for day 6th and 7th. 
 
   
Figure S2 Growth of different colonies from an incubated Bristolian wastewater sample (on the 
left), result of the incubation for colony no. 7 and no.8 (on the centre), pointing of the single colony 





1st Day: single colony from 1 to 8 1st Day: single colony from 9 to 16 
  
2nd Day: single colony from 1 to 8 2nd Day: single colony from 9 to 16 
 
 
3rd Day: single colony from 1 to 8 3rd Day: single colony from 9 to 16 
  




5th Day: single colony from 1 to 8 5th Day: single colony from 9 to 16 
  
6th Day: single colony from 1 to 6 6th Day: single colony from 7 to 16 
 
 









1st and 2nd Day: single colony from 1 
to 4 
3rd and 4th Day: single colony from 1 to 
4 
  
5th and 6th Day: single colony from 1 
to 4 








5th and 7th Day From 5th Day to 7th Day 
  
MILAN UTRECHT 
From 1st Day to 3rd Day From 1st Day to 4th Day 
  





1st, 2nd, 6th and 7th Day 
 
Figure S4 Result of the incubation for the colonies found from every day of the sampling campaign 
in Oslo, Castellon, Lyngby, Milan, Utrecht and Zurich. 
Table S2 Results on colony morphology assessment for the selected cities in the study. 
City COLONY MORPHOLOGY ON CLED AGAR 










1st Day 1, 3 2, 4    
2nd Day 1, 4 2, 3    
3rd Day 3, 4 1, 2    
4th Day 2, 3 1, 4    
5th Day 4 1, 2, 3    
6th Day 3, 4 1, 2    
7th Day 2, 3 1, 4    
BRISTOL 
1st Day 1, 2, 3, 4, 5, 8, 10, 
11 
12, 13, 14, 15 6, 7 9, 16  
2nd Day 1, 2, 3, 11, 12, 13, 
14, 15 
4, 5, 6, 7, 8, 9, 10 - 16  
3rd Day 1, 3, 4, 5, 6, 10, 
11, 12 
2, 7, 8, 9, 13, 14 15, 16 -  
4th Day 1, 2, 3, 4, 5, 6, 7, 
10, 11, 12, 13, 14 
16 15 8, 9  
5th Day 1, 2, 3, 4, 14, 15, 
16 
6, 9, 10, 11, 12, 13 - 5, 7, 8  









1st Day 2, 4 1, 3, 5 - - 5 
2nd Day 6, 4, 5 - - 1, 2, 3 - 
3rd Day 4, 5, 6 2, 3 - - 1 
4th Day 3, 5 4, 6 - 1, 2 - 
5th Day 2, 3, 4 5, 6 1 - - 
6th Day 1, 6, 3 2 - 5, 4 - 
7th Day 1, 2, 4 5, 6 - - 3 
UTRECHT 
1st Day - - - - - 
2nd Day 1, 2, 3, 4 - - - - 
3rd Day 1, 2, 3, 4, 5 - - - - 
Appendix 5 
 355 
4th Day 2, 4 1, 3 - - - 
5th Day 1, 2, 3, 4 - - - - 
6th Day 1, 4 2, 3 - - - 
7th Day - - - - - 
ZURICH 
1st Day 1, 2, 4, 5 - - 3 6 
2nd Day 3, 4, 5 - - 1, 2 6 
6th Day 1, 3, 6 - - - 2, 4, 5 
7th Day 1, 2, 3 5 - - 4, 6 
MILAN 
1st Day 1, 2, 3 - - - - 
2nd Day 1, 2, 4, 5 - - - 3 
3rd Day 2, 3 6, 7 4 - 1, 5, 8 
4th Day 3, 4, 5, 6, 7, 8 - - - 1, 2 
5th Day 2, 3, 4, 6 1 - - 5 
6th Day 1, 2, 3, 4, 5 - - - - 
7th Day 1, 2, 3, 4 - - - - 
CASTELLON 
1st Day 1, 2, 5, 6, 7 3 - 4, 8 - 
2nd Day - 5, 6, 7, 8 - - 1, 2, 3, 4 
3rd Day 1, 2 5, 6 - 7, 8 3, 4 
4th Day 2, 3, 4, 8 5, 6 - 7 1 
5th Day 4, 5, 7, 8 1, 2, 3, 6 - - - 
6th Day 1, 2, 3, 5 4, 8 - - 7, 6 
7th Day 7, 8, 10 1, 2, 4 5, 6 - 3, 9 
 
 





Figure S6 qPCR-Standard curve. 
 
